Document:

EX-10.13

 Exhibit 10.13 

***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

COLLABORATION AGREEMENT 

dated June 15, 2010 

by and between 
 Abbott
International Luxembourg S.à r.l. 
 and 

Neurocrine Biosciences, Inc. 

 EXHIBIT INDEX 

 

	
	 A – Elagolix

	
	 B – Follow-on Compounds

	
	 C – Neurocrine Patent Rights

	
	 D – Third Party Development Contracts

	
	 E – Third Party Manufacturing Contracts

	
	 F – Transition Plan

	
	 G – Collaborative Development Plan

	
	 H – Alternative Dispute Resolution

	
	 I – Press Release

 COLLABORATION AGREEMENT 

COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) dated as of June 15, 2010 (“Effective
Date”) by and between Abbott International Luxembourg S.à r.l., a corporation organized and existing under the laws of Luxembourg, with offices at 26, Boulevard Royal, L-2449 Luxembourg (“Abbott”) and
Neurocrine Biosciences, Inc., a corporation organized and existing under the laws of Delaware with offices at 12780 El Camino Real, San Diego, California 92130 (“Neurocrine”). 

WHEREAS, Neurocrine has a proprietary research and development program in the field of Non-peptide GnRH Antagonists (as
defined below) and in connection therewith has identified proprietary drug candidates for development and commercialization. 

WHEREAS, Abbott is engaged in research, development and commercialization of pharmaceuticals and would like to
collaborate with Neurocrine in the field of Non-peptide GnRH Antagonists. 
 WHEREAS, the Parties would like to set
forth the terms and conditions pursuant to which the Parties will collaborate in connection with the research, development and commercialization of Products in the Territory (as both terms are defined below), and with respect to certain other
matters as described herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
herein contained, the Parties agree as follows: 
 ARTICLE ONE - DEFINITIONS 

Capitalized terms not otherwise defined herein will have the definitions set forth below. 

 

	1.1	 “Abbott Patent Rights” means the Patent Rights covering Abbott Technology. 

 

	1.2	 “Abbott Quarter” means the calendar quarters ending March 31, June 30, September 30 and
December 31 each year. 

  

	1.3	 “Abbott Technology” means Technology reasonably necessary or directly useful to research, develop, make, have made, use,
sell, offer for sale, import and/or otherwise exploit Compounds and Products in the Field of Use, including synthetic processes to manufacture Compounds and all related chemical and biological data: (i) Controlled by Abbott during the Term but,
excluding Program Technology, and is actually utilized by Abbott, in Abbott’s sole discretion, in the Development or Commercialization of Compounds or Products. 

 

	1.4	 “Abbott Year” means the twelve (12) month period commencing on January 1 of any calendar year.

  

	1.5	 “[...***...]” means [...***...]. 

 

	1.6	 “Affiliate” means any entity directly or indirectly controlled by, controlling, able to control, or under common control
with, a Party to this Agreement, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under
common control with”) means possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of an entity 

  
 *** Confidential Treatment
Requested 

	 	 
(whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least fifty percent (50%) of the voting securities (whether
directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States,
the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign
investor has the power to direct the management and policies of such entity. Neither of the Parties to this Agreement shall be deemed to be an “Affiliate” of the other solely as a result of their entering into this Agreement.

  

	1.7	 “Assigned Third Party Development Contracts” means those contracts set forth on Exhibit D assigned to Abbott as set forth
in Section 6.5 (Assignment of Third Party Development Contracts). 

  

	1.8	 “Assigned Third Party Manufacturing Contracts” means those contracts set forth on Exhibit E assigned to Abbott as set forth
in Section 6.6 (Assignment of Third Party Manufacturing Contracts). 

  

	1.9	 “Bankruptcy Code” means 11 U.S.C. §§ 101-1532, as amended. 

 

	1.10	 “[...***...]” means [...***...]. 

 

	1.11	 “Change of Control” means (i) a merger, consolidation or reorganization of Neurocrine with a Third Party which results
in the voting securities of Neurocrine outstanding immediately prior thereto ceasing to represent more than fifty percent (50%) of the voting power of the then combined entity, (ii) a Third Party(ies) becoming the beneficial owner(s) of
more than fifty percent (50%) of the combined voting power of the outstanding securities of Neurocrine or (iii) the sale or transfer to a Third Party of all or substantially all of the assets of Neurocrine. Notwithstanding the foregoing,
the merger, consolidation or reorganization of Neurocrine with another entity in which [...***...] is the surviving entity and with respect to which [...***...], will not constitute a Change of Control. 

 

	1.12	 “Collaboration” means the collaboration between Neurocrine and Abbott related to the Transition Program and Collaborative
Development Program. 

  

	1.13	 “Collaborative Development Program” means the collaborative development program to be conducted by Abbott and Neurocrine as
set forth in Article Seven, as further described in the Collaborative Development Plan. 

  

	1.14	 “Collaborative Development Plan” means the plan describing the overall plan, budget, goals and activities to be undertaken
by the Parties in the Collaborative Development Program, as agreed to by the Parties in writing concurrently with the execution of this Agreement and set forth on Exhibit G, and as may be updated from time to time pursuant to Section 7.2(b)
(Collaborative Development Plan and Budget, Amendments). 

  

	1.15	 “Combination Product(s)” means any product which contains, in addition to a Product, one or more other therapeutically
active ingredients that are proprietary to Abbott and not within the scope of the Neurocrine Patent Rights and/or Program Patent Rights. 

  

	1.16	 “Commercialization” or “Commercialize” means any and all activities directed to the offering for
sale and sale of a Product, after Regulatory Approval has been obtained, including activities related to marketing, promoting, distributing, importing, selling and offering to sell Product and/or conducting post-marketing human clinical studies with
respect to any Indication with respect to 

  
 *** Confidential Treatment
Requested 

	 	 
which Regulatory Approval has been received or for a use that is subject of an investigator-initiated study program, and interacting with Regulatory Authorities regarding the foregoing. When used
as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

 

	1.17	 “Commercially Reasonable Efforts” means with respect to activities of a Party in the discovery, Development or the
Commercialization of a particular Product, the efforts and resources typically used by that Party in the development of product candidates or the commercialization of products of comparable market potential taking into account all relevant factors
including, as applicable and without limitations, stage of development, mechanism of action, efficacy and safety relative to competitive products in the marketplace, actual or anticipated labeling, the nature and extent of market exclusivity
(including patent coverage and regulatory exclusivity), cost, actual or projected profitability (provided [...***...]) and likelihood of obtaining marketing approval. Commercially Reasonable Efforts will be determined on a market-by-market and
indication-by-indication basis, and it is anticipated that the level of effort will be different for different markets and will change over time reflecting changes in the status of the Product and the markets involved. 

 

	1.18	 “Compound(s)” means (a) Elagolix, (b) the Follow-on Compounds, (c) all complexes, mixtures or other
combinations, prodrugs, esters, metabolites, solvates, enantiomers, salt forms, polymorphs, racemates and stereoisomers of the foregoing; and (d) all derivatives of the foregoing containing one or more atoms substituted with an isotope.

  

	1.19	 “Confidential Information” means with respect to each Party, all materials, trade secrets or other information or data in
connection with and pursuant to this Agreement, including without limitation, any data, proprietary information and materials (whether or not patentable, or protectable as a trade secret) regarding a Party’s Technology, products, business
information or objectives, which is disclosed orally, visually in writing or other form by a Party to the other Party. Confidential Information does not include such materials, trade secrets or other information or data which the receiving Party can
demonstrate by competent evidence: 

  

	 	a)	 was known by the receiving Party or its Affiliates or Sublicensees prior to its date of disclosure to the receiving Party; or

  

	 	b)	 is in the public domain by use and/or publication before its receipt from the disclosing Party or thereafter enters the public domain through no
fault of the receiving Party or its Affiliates or Sublicensees; or 

  

	 	c)	 either before or after the date of the disclosure to the receiving Party or its Affiliates or Sublicensees is lawfully disclosed to the receiving
Party by a Third Party(ies) not in violation of any obligation to the disclosing Party; or 

  

	 	d)	 is independently developed by or for the receiving Party or its Affiliates or Sublicensees without reference to` or reliance upon the Confidential
Information. 

 All confidential information disclosed prior to the Effective Date by one Party to the
other Party under or pursuant to the confidentiality agreements between the Parties dated [...***...], that is not excluded by subsections (a)-(d) above shall be deemed “Confidential Information” of the disclosing Party. 

 

	1.20	 “Control” or “Controlled” means with respect to Technology or Patent Rights, ownership by the
applicable Party or possession (whether by license, covenant not to sue or otherwise) of the ability 

  
 *** Confidential Treatment
Requested 

	 	 
to grant licenses, sublicenses or access, other than pursuant to this Agreement, without [...***...] the violation of the terms of any agreement or other arrangement with, or rights of, any
Third Party existing on or after the Effective Date and during the Term. 

  

	1.21	 “Default” means with respect to a Party that (i) any representation or warranty of such Party set forth herein shall
have been untrue in any material respect when made or (ii) such Party shall have failed to perform any material obligation set forth in this Agreement. 

  

	1.22	 “Development” or “Develop” means, with respect to each Product, all non-clinical and clinical
activities designed to obtain Regulatory Approval of such Product in accordance with this Agreement up to and including the obtaining of Regulatory Approval of such Product, including regulatory toxicology studies, statistical analysis and report
writing, clinical trial design and operations, preparing and filing Regulatory Filings, and all regulatory affairs related to the foregoing. When used as a verb, “Developing” means to engage in Development and “Developed” has a
corresponding meaning. 

  

	1.23	 “Diagnostic Use” means use solely for diagnosis, prediction, detection or imaging of any disease, disorder, state, or
condition where: the Product (i) is packaged, labeled and sold solely for diagnosis, prediction, detection or imaging of any disease, disorder, state or condition and (ii) does not on its own or in combination with another product(s) rely
on the pharmacodynamic effect of a Non-peptide GnRH Antagonist for its use or application. 

  

	1.24	 “Effective Date” means the date first written above. 

 

	1.25	 “Elagolix” means the compound known as NBI-56418, as further described and set forth on Exhibit A.

  

	1.26	 “EMA” means European Medicines Agency or any successor agency(ies) or authority having substantially the same function.

  

	1.27	 “End of Phase II Meeting(s)” means the meeting(s) between the sponsor of an investigational drug and the FDA following
completion of a key set of Phase II clinical studies in which it is determined whether it is safe to proceed to Phase III, Phase III program and protocols are evaluated and additional information necessary to support a marketing application for the
uses under investigation are decided. 

  

	1.28	 “Endometriosis” means the condition in which endometrial glands and stroma are present in a location outside of the uterus,
including its signs and symptoms, which include, but are not limited to, pain associated with such condition. 

  

	1.29	 “FDA” means the U.S. Food and Drug Administration of the United States Department of Health and Human Services or any
successor agency(ies) or authority having substantially the same function. 

  

	1.30	 “Field of Use” means all Therapeutic Uses and Diagnostic Uses. 

 

	1.31	 “First Commercial Sale” means with respect to each Product granted Regulatory Approval for commercial sale by applicable
Regulatory Authorities, the first transfer by Abbott, its Affiliates or Sublicensees of the Product to a Third Party in exchange for cash or some equivalent to which value can be assigned. A sale by Abbott to an Affiliate or Sublicensee will not
constitute a First Commercial Sale unless the Affiliate or Sublicensee is the last entity in the distribution chain and 

  
 *** Confidential Treatment
Requested 

	 	 
provided further that any sale on a cost reimbursement basis for use in a clinical trial will not constitute a First Commercial Sale. 

 

	1.32	 “Follow-on Compound” means any of (i) [...***...], and [...***...] as set forth on Exhibit B (ii) and
all non-peptide synthetic organic chemical compounds which are encompassed, generically or specifically, by (a) [...***...]. 

  

	1.33	 “Force Majeure” means any occurrence beyond the reasonable control of a Party that prevents or substantially interferes
with the performance by the Party of any of its obligations hereunder, if such occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute, casualty or accident; or war, revolution, civil commotion, acts of
terrorism, acts of public enemies, blockage or embargo; or any injunction, Law, order, proclamation, regulation, ordinance, demand or requirement of any Governmental Authority; or breakdown of plant, inability to procure or use materials, labor,
equipment, transportation, or energy sufficient to meet manufacturing needs without the necessity of allocation; or any other cause whatsoever, whether similar or dissimilar to those above enumerated, beyond the reasonable control of such Party, if
and only if the Party affected shall have used reasonable efforts to avoid such occurrence and to remedy it promptly if it shall have occurred. 

  

	1.34	 “FTE” means a full time equivalent Neurocrine employee consisting of a total of approximately [...***...] hours per
year of work in accordance with Neurocrine’s time allocation practices (including normal vacations, sick-days and holidays for Neurocrine employees). 

  

	1.35	 “Generic Product(s)” means any pharmaceutical product that (i) is sold by a Third Party that is not a licensee or
Sublicensee of Abbott or its Affiliates, or any of their licensees or Sublicensees under a marketing authorization granted by a Regulatory Authority to such Third Party, and (ii) contains the same Compound as an active pharmaceutical ingredient
as the relevant Product and (x) for purposes of the United States, is approved in reliance on the prior approval of a Product as determined by the FDA, or (y) for purposes of a country outside the United States, is approved in reliance on
the prior approval of a Product as determined by the applicable Regulatory Authority. On a country by country basis, a Product licensed or produced by Abbott (e.g. an authorized generic product) will not constitute a Generic Product.

  

	1.36	 “Generic Competition” means, on a country by country and Product by Product basis, that the following conditions are met:
(x) one or more Third Parties is selling a Generic Product in a country during [...***...], and (y) the [...***...] of such Generic Products sold in such country by the Third Party(ies) in such [...***...] is
[...***...] sold in that country by Abbott, its Affiliates and Sublicensees. Unless otherwise agreed by the Parties, the [...***...] of each Generic Product sold during [...***...] shall be deemed to be the volume of sales of
the Generic Product in such country in that [...***...] as reported by IMS America Ltd. of Plymouth Meeting, Pennsylvania (“IMS”) or any successor to IMS or any other independent sales auditing firm reasonably agreed
upon by the Parties. 

  

	1.37	 “GnRH Receptor” means [...***...]. 

 

	1.38	 “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state,
county, city or other political subdivision. 

  

	1.39	 “IND” means an investigational new drug application filed with the FDA pursuant to 21 CFR 312 or the foreign equivalent for
authorization to commence human clinical trials of a product, including all supplements and amendments that may be filed with respect to the foregoing. 

  
 *** Confidential Treatment
Requested 

	1.40	 “Indication” means an individual, separate and distinct disease or clinical condition with respect to which at least one
adequate and well controlled study is required to support inclusion of such disease or condition in the indication statement of a Regulatory Authority approved package insert for a Product. The Parties agree that: (i) prevention of a disease or
medical condition shall not be a separate indication from treatment of the same disease or medical condition; (ii) the treatment and prevention of separate varieties of the same disease or medical condition shall not be a separate indication;
and (iii) the treatment or prevention of the same disease or medical condition in a different population shall not be a separate indication (e.g., adult and pediatric) unless in each of (i)-(iii) above, at least one adequate and
well controlled study is required to support inclusion of such disease or condition in the indication statement of a Regulatory Authority approved package insert for a Product. Furthermore, a label enhancement or elaboration or expansion of an
approved Indication is not a separate Indication even if one or more studies are performed to receive such enhancement or elaboration. 

  

	1.41	 “Initiation” means, with respect to a human clinical trial, dosing of the first subject in a Phase I, Phase II or Phase III
clinical study, as applicable, pursuant to a clinical protocol of the specified clinical trial. 

  

	1.42	 “Invention” means any information, composition of matter, or article of manufacture that is discovered, developed,
generated, made, conceived and/or reduced to practice by or on behalf of a Party (or its Affiliate) through performance of activities conducted pursuant to the Collaboration. Inventorship of Inventions will be determined in accordance with United
States patent laws and ownership shall be determined in accordance with this Agreement. 

  

	1.43	 “Law” or “Laws” means all laws, statutes, rules, codes, regulations, orders, decrees, judgments
and/or ordinances of any Governmental Authority. 

  

	1.44	 “MAA” means a Marketing Authorization Application covering a Product filed with the EMA, required for marketing approval of
a pharmaceutical product. 

  

	1.45	 “Major European Country” means [...***...]. 

 

	1.46	 “Milestones” means those payments to be made by Abbott to Neurocrine upon the occurrence of certain events as set forth in
Article Four. 

  

	1.47	 “NDA” means a New Drug Application covering a Product filed with the FDA pursuant to 21 CFR 314, required for marketing
approval of a pharmaceutical product and/or a supplemental NDA (sNDA). 

  

	1.48	 “Net Sales” means the total amount billed or invoiced on sales of Product by Abbott, its Affiliates and/or Sublicensees in
the Territory to Third Parties (for example, wholesalers or distributors) in bona fide arm’s length transactions, less the following deductions (specifically excluding any royalty payments made by Abbott, its Affiliates and/or Sublicensees to
Licensor), in each case related specifically to the Product and actually allowed and taken by such Third Parties and not otherwise recovered by or reimbursed to Abbott, its Affiliates and/or Sublicensees: 

 

	 	a)	 trade, cash and quantity discounts; 

  

	 	b)	 price reductions or rebates, retroactive or otherwise, imposed by, negotiated with or otherwise paid to Governmental Authorities;

  
 *** Confidential Treatment
Requested 

	 	c)	 taxes on sales (such as sales, value added or use taxes) to the extent added to the sale price and set forth separately as such in the total amount
invoiced; 

  

	 	d)	 freight, insurance and other transportation charges to the extent added to the sale price and set forth separately as such in the total amount
invoiced, as well as any fees for services provided by wholesalers and warehousing chains related to the distribution of the Product; 

  

	 	e)	 amounts repaid or credited by reason of rejections, defects, one percent (1%) return goods allowance, recalls or returns, or because of
retroactive price reductions, including, but not limited to, rebates or wholesaler charge backs; 

  

	 	f)	 the portion of administrative fees paid during the relevant time period to group purchasing organizations, pharmaceutical benefit managers and/or
Medicare Prescription Drug Plans relating specifically to the Product; and 

  

	 	g)	 any consideration actually paid or payable for any Delivery System related to a billed or invoiced sale of a Product, where for purposes of this
Net Sales definition, a “Delivery System” means any delivery system comprising equipment, instrumentation, one or more devices or other components designed to assist in the administration of a Product. 

Net Sales shall include the amount or fair market value of all other consideration received by Abbott, its Affiliates and/or
Sublicensees in respect of the Product, whether such consideration is in cash, payment in kind, exchange or other form. For purposes of determining Net Sales, Net Sales shall not include transfers or dispositions for charitable, promotional,
pre-clinical, clinical, regulatory or governmental purposes. Net sales shall not include sales between or among Abbott, its Affiliates and/or Sublicensees. 

Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and procedures of Abbott,
its Affiliates and/or Sublicensees, which must be in accordance with generally accepted accounting principles (“GAAP”). 

For purposes of calculating Net Sales, all Net Sales shall be converted into United States Dollars using Abbott, its Affiliates
and/or Sublicensees’ standard conversion methodology consistent with GAAP. The standard conversion methodology is based on monthly averages (the spot rate at the end of the month immediately prior to the reporting month plus the spot rate at
the end of the reporting month, divided by two) using open market rates. 
 In the event that a Product is sold in the form
of a Combination Product, the Net Sales for such Combination Product will be [...***...]: 
  

	 	a)	 [...***...]. 

  

	 	b)	 [...***...]. 

  

	 	c)	 [...***...]. 

  

	 	d)	 [...***...]. 

  

	1.49	 “Neurocrine Patent Rights” means the Patent Rights covering Neurocrine Technology, as set forth on Exhibit C.

  
 *** Confidential Treatment
Requested 

	1.50	 “Neurocrine Technology” means all Technology Controlled by Neurocrine: (i) on the Effective Date or during the Term,
that is reasonably necessary or directly useful to research, develop, make, have made, use, sell, offer for sale, import and/or otherwise exploit Compounds (including Compounds contained in Product(s)) in the Field of Use, including synthetic
processes to manufacture Compounds and all related chemical and biological data and/or (ii) on the Effective Date, that is reasonably necessary or directly useful to research, develop, make, have made, use, sell, offer for sale, import and/or
otherwise exploit Products in the Field of Use that is not otherwise covered by (i). Neurocrine Technology will specifically not include Neurocrine’s rights under the Receptor License. 

 

	1.51	 “Non-peptide GnRH Antagonists” means [...***...]. “Non-peptide GnRH Antagonists” excludes
[...***...]. 

  

	1.52	 “Patent Rights” means the rights and interest in and to all issued patents and pending patent applications in any country,
including, all divisionals, continuations, renewals, continuations-in-part, patents of addition, substitutions, reexaminations, supplementary protection certificates and the like, extensions, registration or confirmation patents and reissues
thereof. 

  

	1.53	 “Phase I” means a human clinical trial in any country of a product in any country, the principal purpose of which is a
preliminary determination of safety or pharmacokinetics in healthy individuals or patients or similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to applicable law or otherwise, including for example the
trials referred to in 21 C.F.R. §312.21(a). 

  

	1.54	 “Phase II” means a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b) conducted to
study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including Phase IIa studies. 

 

	1.55	 “Phase IIb” means a Phase II study in any country, the principal purpose of which is to explore the dose relationship of a
Product against some efficacy measure for the Indication in patients with the disease or Indication under study. 

  

	1.56	 “Phase III” means an expanded human clinical study in any country on a sufficient number of subjects that is designated to
establish that such product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions, if any, that are associated with such product in the dosage range to be prescribed, which trial is designed to
result in Regulatory Approval of such product, including all tests, studies, or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to applicable law or otherwise, including for example the trials referred
to in 21 C.F.R.§312.21(c). 

  

	1.57	 “PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency or any successor agency(ies) or authority having
substantially the same function. 

  

	1.58	 “Product(s)” means a product or product candidate that contains one or more Compounds, including all formulations and
dosages of such Compound, all processes and delivery systems that incorporate such Compound, and any Combination Product. For the purposes of this Agreement, [...***...] will constitute a single Product. 

 

	1.59	 “Program Patent Rights” means the Patent Rights covering the Program Technology. 

  
 *** Confidential Treatment
Requested 

	1.60	 “Program Technology” means any and all Technology conceived, reduced to practice, made or developed, [...***...], by
employees of [...***...] and/or others acting on behalf of [...***...] in performance of the Collaborative Development Program or Transition Program that is necessary or useful to research, develop, make, have made, use, sell, offer for
sale, import and/or otherwise exploit Compounds and Products in the Field of Use. 

  

	1.61	 “Receptor License” means Non-exclusive License Agreement dated August 27, 1999, by and between Neurocrine and The
Mount Sinai School of Medicine of the City University of New York regarding the human GnRH receptor. 

  

	1.62	 “Regulatory Approval” means all the technical, medical and scientific licenses, registrations, authorizations and approvals
(including, approvals of NDAs and equivalents, supplements and amendments, pre- and post- approvals, pricing and third party reimbursement approvals where required, and labeling approvals) of any national, supra-national, regional, state or local
regulatory agency, department, bureau, commission, council or other Governmental Authority, necessary for the manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Product(s) in a regulatory jurisdiction.

  

	1.63	 “Regulatory Authorities” means any applicable government regulatory authority involved in granting approvals for the
manufacturing, marketing, reimbursement and/or pricing of a product in the Territory, including the FDA, EMA and PMDA. 

  

	1.64	 “Regulatory Filings” means, collectively, INDs, MAAs, NDAs and/or any other related, equivalent or comparable filings as
may be required by Regulatory Authorities to obtain Regulatory Approvals relating to the Products. 

  

	1.65	 “Royalties” means those royalties payable by Abbott to Neurocrine pursuant to Article Four of this Agreement.

  

	1.66	 “Rest of World Territory” means worldwide excluding the United States Territory. 

 

	1.67	 “[...***...]” means [...***...]. 

 

	1.68	 “Sublicensee” means any Third Party to whom Abbott has granted a sublicense of the license rights granted to Abbott under
this Agreement. 

  

	1.69	 “Technology” means all proprietary data, information, and materials (including Inventions, know-how, trade secrets,
experimental data, formula, market research data, expert opinions, experimental procedures, pre-clinical and clinical data, regulatory data and filings and other confidential and/or proprietary information, molecules, assays, reagents, compounds,
compositions, human or animal tissue, samples or specimens). 

  

	1.70	 “Territory” means United States Territory and Rest of World Territory. 

 

	1.71	 “Therapeutic Use” means use(s) for any disease, disorder, state or condition in humans or animals, other than a Diagnostic
Use. 

  

	1.72	 “Third Party(ies)” means any person or party other than Neurocrine, Abbott and their respective Affiliates.

  
 *** Confidential Treatment
Requested 

	1.73	 “Third Party Development Contracts” means all contracts in effect on the Effective Date between Neurocrine and Third Party
contractors pursuant to which Neurocrine has contracted for pre-clinical and/or clinical services for Products as set forth on Exhibit D, true and complete copies of which have been made available to Abbott prior to the date hereof.

  

	1.74	 “Third Party License Payments” means [...***...] payments payable by Abbott, its Affiliates or Sublicensees to a
Third Party (or multiple Third Parties) [...***...] to obtain rights under the Third Party Patent Rights to make, have made, use, offer for sale, sell and/or import such Products. 

 

	1.75	 “Third Party Manufacturing Contracts” means all contracts in effect on the Effective Date between Neurocrine and Third
Party contract manufacturers pursuant to which Neurocrine has contracted for manufacturing services for Products as set forth on Exhibit E, true and complete copies of which have been made available to Abbott prior to the date hereof.

  

	1.76	 “Trademarks” means any proprietary names selected by Abbott for commercialization of Products in the Territory.

  

	1.77	 “Transition Plan” means the plan describing the Development activities to be conducted by Neurocrine including (i) the
timetable for transferring to Abbott various assets related to the Compounds and the Products, including the Development and manufacture thereof, and (ii) the activities to be undertaken by Neurocrine in the Transition Program, as agreed to by
the Parties in writing concurrently with the execution of this Agreement and set forth on Exhibit F as may be updated from time to time pursuant to Section 6.1(c) (Transition Program; Transition Plan). 

 

	1.78	 “Transition Program” means the Product development, regulatory and manufacturing activities to be conducted by Neurocrine
pursuant to Article Six, as described in further detail in the Transition Plan. 

  

	1.79	 “United States Territory” means the United States of America. 

 

	1.80	 “Uterine Fibroids” means the condition in which a benign (non-cancerous) tumor originates from the smooth muscle layer
(myometrium) and the accompanying connective tissue of the uterus, including its signs and symptoms, which include, but are not limited to, heavy bleeding during menstruation, dysmenorrhea, dyspareunia, pressure related symptoms, and urinary
frequency and urgency. 

  

	1.81	 “Valid Claim” means a claim of any issued and unexpired patent included within the Neurocrine Patent Rights and/or Program
Patent Rights whose enforceability has not been effected by one or more of any of the following: (1) irretrievable lapse, revocation or abandonment and/or (2) holding of unenforceability or invalidity by a decision of a court or other
appropriate body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and/or (3) disclaimer or admission of invalidity or unenforceability through reissue or re-examination or opposition, nullity action or
invalidation suit response or otherwise. 

  
 *** Confidential Treatment
Requested 

	1.82	 Additional Definitions. Each of the following definitions is set forth in the Section of this Agreement indicated below:

  

			
	 DEFINITION
	 	 SECTION

	Agreement	 	Preamble
	Abbott	 	Preamble
	Neurocrine	 	Preamble
	GAAP	 	“Net Sales”
	Exclusivity Period	 	2.3
	License Fee	 	4.1
	JDC	 	5.3
	Alliance Manager	 	5.5
	Assigned Third Party Development Contracts	 	6.5
	Assigned Third Party Manufacturing Contracts	 	6.6
	Manufacturing Technology Transfer	 	8.4
	Paragraph IV Notice	 	12.5
	Neurocrine Indemnified Party	 	10.1
	Liability	 	10.1
	Abbott Indemnified Party	 	10.2
	Indemnified Party	 	10.3
	Indemnifying Party	 	10.3
	Term	 	11.1(a)
	Notifying Party	 	11.4(a)
	Adverse Ruling	 	11.4(a)(1)
	Insolvent Party	 	11.5

  

	1.83	 Construction. In construing this Agreement, unless expressly specified otherwise: 

 

	 	(a)	 references to Articles, Sections, Exhibits and Schedules are to articles and sections of, and exhibits and schedules to, this Agreement;

  

	 	(b)	 except where the context otherwise requires, use of either gender includes the other gender, and use of the singular includes the plural and
vice versa; 

  

	 	(c)	 any list or examples following the word “including” shall be interpreted without limitation to the generality of the preceding
words; 

	 	(d)	 except where the context otherwise requires, the word “or” is used in the inclusive sense; and 

 

	 	(e)	 all references to “dollars” or “$” herein means United States of America Dollars. 

ARTICLE TWO - REPRESENTATIONS AND WARRANTIES AND COVENANTS 

2.1 Mutual Representations and Warranties. Neurocrine and Abbott each hereby represents and warrants, to the other as of the
Effective Date of this Agreement, as follows: 
  

	 	a)	 Organization. It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its
incorporation and has all requisite power and authority, corporate and otherwise, to execute, deliver and perform this Agreement. 

  

	 	b)	 Authorization. The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action and will not violate (a) such Party’s certificate of incorporation or by-laws, (b) any agreement, instrument or contractual obligation to which such Party is bound in any material respect,
(c) any requirement of applicable Law, or (d) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party. 

 

	 	c)	 Binding Agreement. Assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal,
valid and binding obligation of such Party, enforceable against such Party in accordance with its respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar Laws relating to or
affecting creditors generally or by general equitable principles (regardless of whether such enforceability is considered in a proceeding in equity or at Law). 

 

	 	d)	 No Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Third Party that conflict with or is
inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 

2.2 Additional Neurocrine Representations and Warranties. Neurocrine hereby represents and warrants as of the Effective Date as
follows: 
  

	 	a)	 The status of all Neurocrine Patent Rights listed on Exhibit C are properly stated as to their filing status or issuance and, to Neurocrine’s
knowledge, no issued patents which are part of Neurocrine Patent Rights listed on Exhibit C are invalid or unenforceable. All Neurocrine Patent Rights that (a) contain one or more claims that cover any Compound or Product (including its
manufacture or its formulation or a method of its delivery or of its use); and (b) to the best of Neurocrine’s knowledge are necessary for Abbott to exercise the licenses granted to it pursuant to Article Three and (c) that are
existing on the Effective Date, are listed on Exhibit C. 

	 	b)	 There are no claims, judgment or settlements against Neurocrine pending, or to Neurocrine’s knowledge, threatened that invalidate or seek to
invalidate the Neurocrine Patent Rights. 

  

	 	c)	 Except as required [...***...], Neurocrine has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and
interest in the Neurocrine Patent Rights in manner inconsistent with the terms hereof. 

  

	 	d)	 Except as required by [...***...], to Neurocrine’s knowledge, it is the sole and exclusive owner of the Neurocrine Patent Rights all of
which are free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever with respect to the
Neurocrine Patent Rights. 

  

	 	e)	 To Neurocrine’s knowledge and except [...***...], Neurocrine has complied with all requirements of [...***...], where applicable,
with respect to Neurocrine Patent Rights. 

  

	 	f)	 Neurocrine has disclosed or made available to Abbott all material information known to Neurocrine regarding the Neurocrine Patent Rights and
Neurocrine Technology. 

  

	 	g)	 To Neurocrine’s knowledge, Neurocrine has sufficient legal and/or beneficial title under the Neurocrine Patent Rights and Neurocrine
Technology necessary to grant the rights contained in and to carry out its obligations under this Agreement. 

  

	 	h)	 Subject to Sections 6.2(b) and 7.3(b), Neurocrine shall maintain all Third Party Development Contracts, Third Party Manufacturing Contracts, and
the [...***...] in full force and effect and will not, without Abbott’s prior written consent, terminate or otherwise modify the terms of such Third Party Development Contracts, Third Party Manufacturing Contracts, or the
[...***...]. 

  

	2.3	 Exclusive Collaborative Effort. Subject to Abbott’s sublicensing rights hereunder, and except where the Parties shall mutually
agree otherwise (in which event, for avoidance of doubt, such activities to which the Parties shall have agreed will be considered part of the Collaboration), Neurocrine and Abbott shall not, and shall cause their respective Affiliates and
Sublicensees not to, other than pursuant to this Agreement, independently, or in collaboration with any Third Parties, engage in [...***...] prior to the earlier of (a) [...***...] or (b) [...***...] (the
“Exclusivity Period”); provided, however, that nothing in this Agreement shall (i) restrict [...***...], or (ii) preclude either Party [...***...], provided that the Party making such [...***...].
If either Party (or its Affiliates) breaches this Section 2.3 due to an acquisition of or merger with all or substantially all of the business or assets of a Third Party, such acquiring Party shall not be in breach of this Section 2.3 so
long as such acquiring Party (or its Affiliate) [...***...] after the closing of such acquisition or merger. 

 2.4
Commercially Reasonable Efforts. Abbott will use Commercially Reasonable Efforts to Develop and Commercialize [...***...]. Neurocrine and Abbott shall each use Commercially Reasonable Efforts to perform their respective
obligations hereunder. In addition, Abbott agrees to comply with the [...***...], if and as applicable, in relation to this Agreement. 

2.5 Conduct of Activities. Each Party will conduct, and shall use Commercially Reasonable Efforts to cause its Affiliates to
conduct, those activities allocated to such Party under this Agreement in 

  
 *** Confidential Treatment
Requested 

 
compliance in all material respects with applicable Laws of the country in which such activities are conducted. 

2.6 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY HEREBY DISCLAIMS, ANY OTHER
REPRESENTATION OR WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT, INCLUDING WITHOUT
LIMITATION NEUROCRINE PATENT RIGHTS AND NEUROCRINE TECHNOLOGY. ADDITIONALLY, EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEUROCRINE MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT THE MANUFACTURE, USE OR SALE OF ANY PRODUCT WILL NOT
INFRINGE THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 
 ARTICLE THREE - LICENSE GRANTS; RETAINED RIGHTS 

3.1 License. Subject to the terms of this Agreement, Neurocrine and its Affiliates hereby grants to Abbott, and Abbott hereby
accepts, an exclusive worldwide license, with the right to sublicense through multiple tiers, under the Neurocrine Technology and Neurocrine Patent Rights, in each case, to research, develop, make, have made, use, sell, offer for sale, import and/or
otherwise exploit Compounds and Products in the Field of Use in the Territory. 
 3.2 License Grant to Neurocrine for the
Collaboration. Abbott hereby grants to Neurocrine a non-exclusive license, without the right to sublicense, under Patent Rights and Technology Controlled by Abbott solely for use in connection with Neurocrine’s conduct of the
Collaboration. Nothing set forth herein will limit Abbott’s right to use for all purposes, any Abbott Technology or Abbott Patent Rights. 

3.3 Retention of Rights. Notwithstanding the exclusive licenses granted to Abbott pursuant to Section 3.1 (License),
Neurocrine retains the right to practice under the Neurocrine Technology and Neurocrine Patent Rights to perform (and to sublicense Third Parties to perform) its obligations under this Agreement (including the manufacture and supply of Compound and
Product to Abbott). Subject to Section 2.3, Neurocrine also retains: (i) a [...***...] license in the [...***...], to use the Neurocrine Technology (including Neurocrine Patent Rights) for [...***...] and
(ii) exclusive rights for all purposes outside the scope of the licenses granted in Section 3.1; provided that any activity Neurocrine would undertake in relation to the retention of rights hereunder that [...***...], shall require
Abbott’s prior written consent before undertaking such activity. 
 3.4 License Grant to Neurocrine under Program Technology.
Subject to Section 2.3, Abbott grants Neurocrine a [...***...] license [...***...], to use the Program Technology (including Program Patent Rights) [...***...] for: (i) [...***...] and (ii) for any purpose
outside the scope of the licenses granted in Section 3.1; provided that any activity Neurocrine would undertake in relation to the grant of rights hereunder that [...***...], shall require Abbott’s prior written consent before
undertaking such activity. 
 3.5 No Implied Licenses. Except as expressly set forth in this Agreement, neither Party grants
any license under its intellectual property rights to the other Party. 

  
 *** Confidential Treatment
Requested 

 3.6 Exclusions. For avoidance of doubt, the licenses granted to Abbott under this
Agreement shall not include any rights for Abbott to research, develop, make, have made, use, sell, offer for sale and/or import any proprietary compound of Neurocrine that is not a Compound. Notwithstanding anything to the contrary in this
Agreement, for the Term of Royalty set forth in Section 4.6, Neurocrine shall not, alone or with or through (i) its Affiliates or (ii) any Third Party: Develop, Commercialize, offer for sale, sell and/or otherwise commercially exploit
Compounds or Products in the Field of Use in the Territory. 
 ARTICLE FOUR - ROYALTIES, MILESTONES AND PAYMENT PROVISIONS 

4.1 License Fee. In consideration of the licenses granted to Abbott hereunder and the disclosure to Abbott of Neurocrine
Technology, Abbott shall pay to Neurocrine a non-refundable, non-creditable license fee equal to seventy five million dollars ($75 MM) ( “License Fee”). The License Fee shall be paid to Neurocrine within [...***...]
days after the Effective Date of this Agreement. 
 4.2 Milestones. Abbott will pay to Neurocrine [...***...] Milestones
for achievement of the events set forth below. Abbott will notify Neurocrine within [...***...] days of achievement of each Milestone event and the related Milestone payment will be made to Neurocrine within [...***...] days of
achievement of the event. 
  

	 	a)	 Elagolix. In consideration for the license rights granted by Neurocrine to Abbott, on an [...***...], Abbott will pay to
Neurocrine the Milestones set forth below for Elagolix: 

  

					
	 ELAGOLIX EVENT*
	  	 [...***...]
	  	 [...***...]

	 Acceptance of SPA by FDA following agreement on protocols during the End of Phase II Meeting(s) with the FDA
	  	$20 MM	  	N/A
			
	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Initiation of first Phase IIa study
	  	N/A	  	$10 MM
			
	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Acceptance of [...***...]
	  	[...***...]	  	[...***...]

  
 *** Confidential Treatment
Requested 

					
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]
			
	 First filing of [...***...]
	  	[...***...]	  	[...***...]
			
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]
			
	 First filing of [...***...]
	  	[...***...]	  	[...***...]
			
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]

 Total Milestones payable under this Section 4.2(a) shall not exceed [...***...].

 In the event that a Product is discontinued in the course of development for [...***...], only those Milestones that
have not been paid at the time the Product has been discontinued shall be payable for a future Product achieving the Milestone Event. 

* Once a Product achieves a Milestone for [...***...], it will be deemed to have achieved all earlier Milestones
[...***...] and any Milestone payment for such earlier Milestone will become due and payable to the extent it has not already been paid. Specifically, (i) should the Initiation of [...***...] be achieved prior to or in the absence
of the Acceptance of [...***...], the Acceptance of [...***...] shall be paid when the Initiation of [...***...] is achieved and (ii) should a [...***...] not be required or a previously conducted clinical study be
accepted in place of such a study, the Initiation of [...***...] will be paid upon the earlier of (A) receipt of [...***...] or (B) first filing of [...***...]. 

** Should another [...***...] as the [...***...] to advance through Development, the Milestone events enumerated in
the [...***...] stream above shall apply to that [...***...] [...***...] shall apply to [...***...]. 

*** If Regulatory approval of a MAA [...***...] is granted, such Milestone event shall be paid [...***...]. If
approved by [...***...], without regard to order or combination. 
  

	 	b)	 Follow-On Compounds. On the first occurrence of the events set forth below for a Follow-on Compound, Abbott shall pay Neurocrine the
following Milestones for Follow-on Compounds on [...***...] (each Milestone stream would be payable one time only regardless of how many Products advance through development): 

  
 *** Confidential Treatment
Requested 

					
	 FOLLOW-ON EVENT*
	  	 [...***...]
	  	 [...***...]

	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Initiation of [...***...]
	  	[...***...]	  	[...***...]
			
	 Acceptance of [...***...]
	  	[...***...]	  	[...***...]
			
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]
			
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]
			
	 First Regulatory Approval of [...***...]
	  	[...***...]	  	[...***...]

 Total Milestones payable under this Section 4.2(b) shall not exceed [...***...].

 In the event that a Product is discontinued in the course of development for [...***...], only those Milestones that
have not been paid at the time the Product has been discontinued would be payable for a future Product achieving the Milestone Event. 

* Once a product achieves a Milestone for a [...***...], it will be deemed to have achieved all earlier Milestones
[...***...] and any Milestone payment for such earlier Milestone will become due and payable to the extent it has not already been paid. 

** In the event that Follow-on Compound [...***...] is the same Follow-on Compound [...***...], the
[...***...] Milestone shall be paid upon the achievement of the Initiation of [...***...]. 
 *** If Regulatory
Approval of a MAA [...***...] is granted, such Milestone event shall be paid [...***...]. If approved by a [...***...], without regard to order or combination. 

4.3 Royalties. Subject to Section 4.4 (Royalty Adjustments) and Section 4.6 (Royalty Term), Abbott will
pay to Neurocrine Royalties on Net Sales in an Abbott Year, of each Product [...***...] containing Elagolix and the Follow-on Compounds, on a Product [...***...] by Product [...***...] and United States

  
 *** Confidential Treatment
Requested 

 
Territory and Rest of World Territory basis (as the case may be), commencing upon the First Commercial Sale in the United States Territory or Rest of World Territory, as applicable, as follows:

 For Products containing [...***...]: 
  

					
	 Abbott Year Net Sales
	 	United States
Territory
Royalty
(% Net Sales)	 	Rest of World
Territory
Royalty
(% Net Sales)
	 Less than [...***...]
	 	[...***...]	 	[...***...]
			
	 Greater than or equal to [...***...] and less than [...***...]
	 	[...***...]	 	[...***...]
			
	 Greater than or equal [...***...]
	 	[...***...]	 	[...***...]

 For Products containing [...***...]: 

 

					
	 Abbott Year Net Sales
	  	United States
Territory
Royalty
(% Net Sales)	 	Rest of World
Territory
Royalty
(% Net Sales)
	 Less than [...***...]
	  	[...***...]	 	[...***...]
			
	 Greater than or equal to [...***...]
	  	[...***...]	 	[...***...]

 The Royalties set forth above are marginal rates and shall only apply to that portion of Net
Sales opposite each applicable Royalty rate. For the purposes of Royalty payments, [...***...] will be considered to be the same Product, regardless of the indications for which such Product [...***...] may be used. 

Notwithstanding anything to the contrary in this Agreement, the Parties shall, prior [...***...] negotiate in good faith
on commercially reasonable terms, and execute an amendment to this Agreement duly executed by authorized representatives of both Parties, setting forth [...***...] of the applicable [...***...] sold by Abbott or its Affiliates or
Sublicensees. If the Parties are unable to agree [...***...] after good faith negotiations, then the Parties shall submit the issue under Section 13.2 (Dispute Resolution). 

4.4 Royalty Adjustments. Except as otherwise set forth in this Agreement, Royalties due hereunder are subject to adjustment on a
Product by Product, [...***...] basis as a result of the events set forth below (such adjustments to be prorated for the then-current [...***...] in which the reduction becomes 

  
 *** Confidential Treatment
Requested 

 
applicable) provided, however, that the Royalties payable under Section 4.3 (Royalties) shall not be reduced by more than [...***...] of the amounts set forth in
Section 4.3 (Royalties) by reason of the adjustments set forth below. 
  

	 	a)	 Royalty Adjustment for Third Party License Payments. Neurocrine shall be responsible for and pay all amounts due under the
[...***...]. If Abbott, its Affiliates or Sublicensees, in their reasonable judgment, is required to pay any Third Party License Payments, then the amount of Royalties payable under Section 4.3 (Royalties) shall be reduced by
[...***...] of the amount of such Third Party License Payments paid to such Third Party. 

  

	 	b)	 Royalty Adjustment for Non-Patent Products. If the making, having made, using, offering for sale, sale, and/or importation of a Product
would not infringe a Valid Claim within the [...***...], Royalties payable to Neurocrine will be reduced by [...***...] of the Royalty rate(s) set forth in Section 4.3 (Royalties). 

 

	 	c)	 Royalty Adjustment for Generic Competition. If there is Generic Competition, the Royalties payable to Neurocrine shall be reduced by
[...***...] of the Royalty rates set forth in Section 4.3 (Royalties). 

 4.5 Sales
Milestones. Within [...***...] days following the last day of the Abbott Year of the first achievement of each event of annual combined Net Sales of all Products as detailed below, Abbott shall make the following one-time payments:

  

			
	 Event
	  	 Sales Milestone

	 Abbott Year Net Sales of Product(s) exceeds [***]
	  	[...***...]
	 Abbott Year Net Sales of Product(s) exceeds [***]
	  	[...***...]
	 Abbott Year Net Sales of Product(s) exceeds [***]
	  	[...***...]

 4.6 Term of Royalty. Notwithstanding the foregoing, Abbott’s Royalty obligations pursuant
to Section 4.3 (Royalties) shall expire, on a Product by Product and country by country basis, following the later of: (i) the last to expire of all Valid Claims in the Neurocrine Patent Rights or Program Patent Rights covering the
making, having made, using, offering to sell, selling, and importing of Product in such country or (ii) [...***...] following the First Commercial Sale in such country. Notwithstanding the foregoing, if, after the aforementioned Royalty
term, Neurocrine is required to make royalty payments [...***...]. 
  

	4.7	 Reports and Payments. 

  

	 	a)	 Inter-Company Sales. Sales between or among Abbott, its Affiliates or Sublicensees shall not be subject to Royalties under this
Section 4. Abbott shall be responsible for the payment of Royalties on Net Sales by its Affiliates or Sublicensees. 

  

	 	b)	 Cumulative Royalties. The obligation to pay Royalties under this Article 4 shall be imposed only once (i) with respect to any sale of
the same unit of Product and (ii) with respect to a single unit of Product, in each case, regardless of how many Valid Claims in the Neurocrine Patent Rights or Program Patent Rights cover the Compound included in such Product.

  

	 	c)	 Statements and Payments. Following commencement of Abbott’s obligation to pay Royalties pursuant to Section 4.3, Abbott shall
deliver to Neurocrine (a) within [...***...] days after the end of each [...***...] report setting forth [...***...] and (b) within [...***...] days after

  
 *** Confidential Treatment
Requested 

	 	 
the end of each [...***...], a report certified by Abbott as accurate to the best of its ability based on information then available to Abbott, setting forth for such [...***...] the
following information on a Product by Product basis [...***...]. The total Royalty due for the sale of Products during [...***...] shall be remitted within [...***...] days after the end of each [...***...].

  

	 	d)	 Taxes and Withholding. 

  

	 	1)	 VAT. It is understood and agreed between the Parties that any payments made by Abbott under this Agreement are inclusive of any value added
or similar tax imposed upon such payments. 

  

	 	2)	 Tax Cooperation. Where any sum due to be paid to either Party hereunder is subject to any withholding or similar tax, the Parties shall use
their commercially reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation
agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the payor shall pay such withholding or similar tax to the appropriate government authority, deduct the
amount paid from the amount due to payee and secure and send to payee the best available evidence of such payment. On the Effective Date, each Party shall provide the other with a completed and signed Form W-8BEN. 

 

	 	3)	 Withholding Tax Matters. In addition, in the event any of the payments made by Abbott to Neurocrine under this Agreement become subject to
withholding taxes under the Laws of any jurisdiction, Abbott shall deduct and withhold the amount of such taxes for the account of Neurocrine to the extent required by Law, such payment to Neurocrine shall be reduced by the amount of taxes deducted
and withheld, and Abbott shall pay the amount of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Neurocrine an official tax certificate or other evidence of such tax obligations, together with proof of
payment from the relevant Governmental Authority of all amounts deducted and withheld sufficient to enable Neurocrine to claim such payment of taxes. Any such withholding taxes required under applicable Law to be paid or withheld shall be an expense
of, and borne solely by, Neurocrine. Abbott will provide Neurocrine with reasonable assistance, at Neurocrine’s expense, to enable Neurocrine to recover such taxes as permitted by Law. 

 

	 	e)	 Currency. All amounts payable and calculations hereunder shall be in United States dollars. Conversion of sales recorded in local currencies
to U.S. dollars will be at the monthly rate of exchange used by Abbott in its worldwide accounting system prevailing on the third to last business day of the month preceding the month in which such sales are recorded by Abbott. If governmental
regulations prevent remittances from a foreign country with respect to sales made in that country, the Royalties shall continue to accrue but the obligation of Abbott to pay Royalties on sales in that country shall be delayed until such remittances
are possible. Neurocrine shall have the right, upon giving written notice to Abbott, to receive payment in that country in local currency. 

  

	 	f)	 Late Payments. If Neurocrine does not receive payment of any sum due it hereunder on or before the due date set forth herein, simple
interest thereon shall accrue on the sum from the due date until the date of payment at the rate equal to [...***...]; provided, that with respect to any disputed payments, no interest payment shall be due until such dispute is
resolved and 

  
 *** Confidential Treatment
Requested 

	 	 
the interest which shall be payable thereon shall be based on the finally-resolved amount of such payment, calculated from the original date on which the disputed payment was due through the date
on which payment is actually made. 

  

	 	g)	 Maintenance of Records; Audit. For a period [...***...], Abbott shall maintain and shall cause its Affiliates and Sublicensees to
maintain complete and accurate books and records in connection with the sale of Products hereunder, as necessary to allow the accurate calculation of Royalties due hereunder including any records required to calculate any Royalty adjustments
hereunder. Once per calendar year, Neurocrine shall have the right to engage an registered public accounting firm of nationally recognized standing selected by Neurocrine and reasonably acceptable to Abbott, at Neurocrine’s expense, which shall
have the right to examine in confidence the relevant Abbott records as may be reasonably necessary to determine and/or verify the amount of Royalty payments due hereunder for any year ending not more than [...***...] months prior to the date
of such request. Such examination shall be conducted during Abbott’s normal business hours, after at least [...***...] days prior written notice to Abbott and shall take place at the Abbott facility(ies) where such records are maintained.
In the event the report reflects an under-payment by Abbott hereunder, Abbott shall promptly (but in no event later than [...***...] days after Abbott’s receipt of the independent auditor’s report) make payment to Neurocrine of any
short-fall. In the event that there was an over-payment by Abbott hereunder, Neurocrine shall promptly (but in no event later than [...***...] days after Neurocrine’s receipt of the independent auditor’s report so correctly
concluding) refund to Abbott the excess amount. In the event any payment by Abbott shall prove to have been incorrect by more than [...***...] to Neurocrine’s detriment, Abbott will pay the reasonable fees and costs of Neurocrine’s
independent auditor for conducting the audit. 

  

	 	h)	 No Other Compensation. Each party hereby agrees that the terms of this Agreement, fully define all consideration, compensation and benefits,
monetary or otherwise, to be paid, granted or delivered by one party to the other Party in connection with the transactions contemplated herein. Neither Party previously has paid or entered into any other commitment to pay, whether orally or in
writing, any of the other Party’s employees, directly or indirectly, any consideration, compensation or benefits, monetary or otherwise, in connection with the transaction contemplated herein. 

ARTICLE FIVE - MANAGEMENT OF COLLABORATION 

5.1 Goal of the Collaboration. The goals of the Collaboration are to conduct the Transition Program in accordance with the
Transition Program Plan and conduct the Collaborative Development Program in accordance with the Collaborative Development Plan. 
 5.2
Meetings of Senior Executives. Upon agreement of the JDC for the necessity of a meeting(s) with senior executives, the Chief Executive Officer of Neurocrine and Senior Vice President, Pharmaceuticals Research &
Development of Abbott shall meet and review the progress of the Collaboration and shall discuss any current issues of the Collaboration with the intent of proposing resolutions for such issues. Meetings may be in person or may be held
telephonically or by videoconference. 
  

	5.3	 Joint Development Committee. 

  
 *** Confidential Treatment
Requested 

	 	a)	 Formation. Within thirty (30) days following the Effective Date, the Parties shall establish a joint development committee (the
“JDC”). The JDC shall consist of senior representatives from each Party with decision making authority in such number as mutually agreed on by the Parties not to exceed [...***...] from each Party. Each Party shall have
the right at any time to substitute individuals, on a permanent or temporary basis, for any of its previously designated representatives to the JDC by giving written notice to the other Party. The JDC shall be chaired by a representative member from
Abbott. 

  

	 	b)	 Responsibility. The JDC will be responsible for coordination and oversight of all activities conducted under the Transition Program and the
Collaborative Development Program in accordance with this Agreement. The Parties shall cause their respective representatives on the JDC to use diligent efforts, acting in good faith, to resolve all matters presented to them as expeditiously as
possible. 

  

	 	c)	 Decision Making and Dispute Resolution. All decisions of the JDC will be by consensus whereby each of Neurocrine and Abbott shall have one
(1) vote on all matters before the JDC. If for any reason the JDC cannot resolve any matter properly before it, the matter shall be [...***...]. 

  

	 	d)	 Withdrawal; Disbandment. Subject to Neurocrine’s other obligations herein, Neurocrine may irrevocably withdraw from participation in
the JDC upon written notice to Abbott and subject to Abbott’s consent, not to be unreasonably withheld, conditioned or delayed. The JDC shall disband upon completion of the Transition Program and Collaborative Development Program.

 5.4 JDC Meetings. The JDC chairperson shall call meetings [...***...], or as otherwise mutually
agreed. Meetings may be held in person, by telephone, or by video conference call, and the location of each meeting shall be selected by the chairperson, unless otherwise agreed. In addition to the foregoing, either Party may call a special meeting
of the JDC up to [...***...] per year upon [...***...] days notice to the other Party. Meetings will be minuted and signed by the chairperson and distributed the both Parties. Upon the other Party’s consent, additional participants
of a Party may be invited by any representative to attend meetings when and where appropriate. If feasible, prior to each JDC meeting, the Parties will distribute to each other written copies (or corresponding electronic files) of materials intended
to be discussed at such meeting. In the event that after receipt of any such report, either Party shall request additional data or information, the Party to whom such request is made shall use reasonable efforts to promptly provide to the other
Party such data or information. 
 5.5 Alliance Managers. In addition to the JDC set forth above, Neurocrine and Abbott each
acknowledge and agree that it would be beneficial to the Collaboration for each to have a senior representative with a general understanding of the non-clinical and pharmaceutical development (API and drug product), clinical, regulatory, and
manufacturing issues relating to Products to act as an alliance manager (“Alliance Manager”), and will appoint such a person to the extent each Party in its sole discretion determines it is practical. It is envisioned that
the Alliance Managers will serve as a single point of contact within each Party with responsibility for facilitating communication and collaboration between the Parties. The Alliance Managers may attend JDC meetings as appropriate and will be
provided access to decision making representatives of both Parties. 
 5.6 Abbott Authority. Subject to the oversight of the
JDC as provided in Section 5.3 (Joint Development Committee) and except as provided elsewhere herein, Abbott shall have sole responsibility and authority with regard to (a) Development activities related to Products, including the
timing and staging of Development work on the various Indications and the determination of which Indications to 

  
 *** Confidential Treatment
Requested 

 
pursue, (b) manufacturing and commercial supply of Products, including holding title to commercial inventory and responsibility for invoicing, credit and collection, and
(c) Commercialization of Products, including pricing of Products, all pricing and reimbursement approvals and all other terms of sale. 

5.7 Reporting. After the JDC has been disbanded, on [...***...] basis until [...***...], Abbott will provide to
Neurocrine a written report setting forth [...***...]; provided however, in the event of a Change of Control, Abbott will provide to Neurocrine, on [...***...] basis, a written report setting forth [...***...] only. If following
receipt of [...***...] report or [...***...], Neurocrine shall reasonably request additional information about [...***...], Neurocrine may make such request through the Alliance Managers of the Parties and Abbott will provide such
information within a reasonable time after the request; provided however, in the event of a Change of Control, Abbott shall not be obligated to provide any such information. 

ARTICLE SIX - TRANSITION PROGRAM 
  

	6.1	 Transition Program.  

  

	 	a)	 Term. The activities under the Transition Program as outlined in the Transition Plan will terminate on the date set forth in the Transition
Plan, provided that, prior to the end of the Transition Term, (i) all Regulatory Filings in existence on the Effective Date will have been assigned to, and accepted by, Abbott, (ii) all Assigned Third Party Development Contracts will have
been assigned to, and accepted by Abbott, and (iii) all Assigned Third Party Manufacturing Contracts will have been assigned to, and accepted by, Abbott. The Parties shall use Commercially Reasonable Efforts to perform the activities set forth
in the Transition Plan and complete the Transition Program, in accordance with the timelines set forth in the Transition Plan. The Parties currently agree that the Transition Program will be initiated on [...***...] and will be substantially
completed and will terminate on [...***...], it being understood that such date is an estimate based on the current state of the Transition Program and may be changed by the JDC even if the Parties are exerting Commercially Reasonable Efforts
to complete the Transition Program by such date. 

  

	 	b)	 Goal; Diligence. The goal of the Transition Program will be to (1) [...***...] and (2) [...***...]. Specifically, the
Transition Program may include, but is not limited to, all activities under the Third Party Development Contracts and Third Party Manufacturing Contracts during the term of the Transition Program. Each Party shall use Commercially Reasonable Efforts
in carrying out its activities under the Transition Program and Transition Plan and shall conduct the Transition Program in compliance with all applicable Laws. 

 

	 	c)	 Transition Plan. Subject to oversight of the JDC, Neurocrine shall (i) perform Product manufacturing, clinical, and regulatory
activities set forth in the Transition Plan, in accordance with the terms of the Transition Plan, and (ii) transfer to Abbott the data and other assets set forth in the Transition Plan, in accordance with the terms of the Transition Plan. The
Transition Plan will be updated by the JDC as needed and will specifically include detailed plans for staffing levels and activities, timelines and transition dates. In particular, the Transition Plan will address the timelines for the transfer of
data and Technology to Abbott, and for the assignment to Abbott of Regulatory Filings, Third Party Manufacturing Contracts and Third Party Development Contracts, and the specific Development activities

  
 *** Confidential Treatment
Requested 

	 	 
(and corresponding timelines) to be performed by Neurocrine. Each amendment and update to the Transition Plan shall be prepared jointly by the Parties through the JDC in accordance with the
limitations on total numbers of FTEs in any given period and allocation across functional areas set forth on Exhibit F. The Transition Plan may be amended by the JDC to accelerate, decelerate, add or remove activities thereunder including reducing
or eliminating Neurocrine’s responsibilities for an activity thereunder provided that, the number of Neurocrine FTEs funded and the allocation of Neurocrine FTEs across functional areas (e.g., CMC, pre-clinical, clinical) may not be reduced or
increased or altered without Neurocrine’s consent. 

  

	 	d)	 Transfer of Data, Information, Technology and Assets. From and after the Effective Date, all data, information, Technology and assets
related to the Compounds and Products that are reasonably requested by Abbott shall be made available to Abbott through a secure electronic document sharing service. Additionally, hardcopy forms of data, information, Technology and assets related to
the Compounds and Products that are reasonably requested by Abbott shall be transferred to a site selected by Abbott, and electronic forms of data, information, Technology and assets related to the Compounds that are reasonably requested by Abbott
shall be transferred to an Abbott electronic system per Abbott’s instructions. These transfers of data, information, Technology and assets shall occur at scheduled intervals as mutually agreed upon by the Parties and will be categorized as high
priority, low priority and upon request to determine the expedience of such transfer. The Parties agree that the method of transfer of such data, information, Technology and assets will be of a secure nature, with an agreed upon applied data
integrity method (such as a checksum utility), if applicable. 

 6.2 Transition Budget. Notwithstanding
anything to the contrary in this Agreement, Abbott’s total funding responsibility for the Transition Program shall not exceed [...***...] without Abbott’s prior written permission. 

 

	 	a)	 Internal Costs. Abbott will initially provide funding for Neurocrine FTEs devoted to the conduct of the Transition Program in accordance
with the Transition Plan, at a rate of [...***...] per FTE per year (such rate will be prorated for any partial year), and provided such funding shall not exceed [...***...] without Abbott’s prior written permission. The
contemplated allocation of Neurocrine FTEs devoted to the conduct of the Transition Program in accordance with the Transition Plan, as of the Effective Date, is [...***...]. Neurocrine FTEs in [...***...] will be allocated by the JDC in
accordance with the Transition Plan and Section 6.1(c) from time to time based on the progress of the activities under the Transition Plan. Within [...***...] days after the end of each Abbott Quarter after the Effective Date, Neurocrine
will provide to Abbott an invoice setting forth the amount of funding for Neurocrine FTEs allocated to Transition Plan activities in such preceding Abbott Quarter as well as a FTE report for the preceding Abbott Quarter, which FTE report details the
FTEs committed to the Transition Program by department and/or functional area, and a brief summary of the work performed (which summary may be limited to references to the reports to the JDC). Invoices will be payable by Abbott within
[...***...] days of receipt of the invoice. 

  

	 	b)	 External and Third Party Costs. 

  

	 	1)	 Abbott agrees that Abbott will be responsible for all Third Party and external costs and expenses for the activities set forth on Exhibit F on or
after [...***...] and accrued and properly expensed under generally accepted accounting principles for activities undertaken on or after [...***...], as set forth in the Transition Plan, or otherwise

  
 *** Confidential Treatment
Requested 

	 	 
approved by the JDC, provided such amounts do not exceed the budget set forth in the Transition Plan by more than [...***...] without Abbott’s prior written permission. Within
[...***...] days after the end of each Abbott Quarter during the term of the Transition Program, Neurocrine will provide to Abbott a report and invoice setting forth the external and Third Party costs arising out of the Transition Program in
such Abbott Quarter, including copies of original invoices for such Third Party costs. Neurocrine’s quarterly invoice to Abbott will be payable by Abbott within [...***...] days of receipt of the report. 

 

	 	2)	 All expenses under the Third Party Development Contracts and Third Party Manufacturing Contracts relating to activities conducted by Neurocrine
pursuant to the Transition Plan on or after [...***...] (including termination fees, if applicable, as contemplated by the Transition Plan) are included in the budget in the Transition Plan and will be reimbursed by Abbott as Third Party
external costs and expenses hereunder. 

  

	 	3)	 The budget included in the Transition Plan sets forth all the expenditures that will be incurred in the course of the Transition Program with
respect to activities performed by Neurocrine and Third Parties. The Parties acknowledge and agree that, notwithstanding the Parties’ efforts to fully budget all cost items of the Transition Program, costs may change over time and/or unbudgeted
items may be identified. As such, the JDC will review the Transition Program budget on a quarterly basis and reforecast such budget based on the then current costs and expenses on the basis of whether such expenditure is reasonably necessary to
maintain timelines and beyond the reasonable control of the Parties. 

 6.3 Regulatory Filings. In
accordance with the Transition Plan, Neurocrine will assign to Abbott all Regulatory Filings and thereafter all Regulatory Filings shall be the property of Abbott and Abbott shall be responsible for, and pay all cost and expenses relating to,
Regulatory Filings in the Territory. Each of the Parties shall take all reasonable steps to ensure an orderly transfer of the Regulatory Filings to Abbott as provided herein and in the Transition Plan, and in accordance with the timelines for
transfer set forth in the Transition Plan. 
 6.4 Adverse Events and Safety Information. Within ninety (90) days after
the date of this Agreement, the Parties shall enter into an agreement to initiate a process for the exchange of adverse event safety data in a mutually agreed format, including but not limited to, postmarketing spontaneous reports received by the
Party or its Affiliates in order to monitor the safety of the product and to meet reporting requirements with any applicable regulatory authority. 

6.5 Assignment of Third Party Development Contracts. If and to the extent applicable, Neurocrine will use Commercially
Reasonable Efforts to obtain necessary consents from Third Parties to assign to Abbott all Third Party Development Contracts the JDC requests be assigned to Abbott. Neurocrine will assign to Abbott, and Abbott will accept assignment of, the
assignable Third Party Development Contracts identified by the JDC prior to the end of the Transition Program (the “Assigned Third Party Development Contracts”). Upon assignment to Abbott of each Assigned Third Party
Development Contract, Abbott will be responsible for all future performance under such Assigned Third Party Development Contract and will make all decisions regarding such Assigned Third Party Development Contract and any other future Development
contracts Abbott elects. Subject to Section 6.2(b), Neurocrine remains responsible for all rights, duties and obligations of such Assigned Third Party Development Contracts prior to the date of assignment to Abbott. Any Third Party Development
Contracts not included in the Assigned Third Party Development Contracts will not be assigned to Abbott and Abbott shall have no rights or obligations under such unassigned Third Party Development Contracts

  
 *** Confidential Treatment
Requested 

 
(it being understood that Abbott has certain obligations to Neurocrine with respect to such unassigned Third Party Development Contracts pursuant to Section 6.2(b)). 

6.6 Assignment of Third Party Manufacturing Contracts. If and to the extent applicable, Neurocrine will use Commercially
Reasonable Efforts to obtain necessary consents from Third Parties to assign to Abbott all Third Party Manufacturing Contracts the JDC requests be assigned to Abbott. Neurocrine will assign to Abbott, and Abbott will accept assignment of, all
assignable Third Party Manufacturing Contracts identified by the JDC prior to the end of the Transition Program (the “Assigned Third Party Manufacturing Contracts”). Upon assignment to Abbott of each Assigned Third Party
Manufacturing Contract, Abbott will be responsible for all future performance under such Assigned Third Party Manufacturing Contract and will make all decisions regarding such Assigned Third Party Manufacturing Contract and any future manufacturing
or Product supply contracts Abbott elects. Subject to Section 6.2(b), Neurocrine remains responsible for all rights, duties and obligations of such Assigned Third Party Development Contracts prior to the date of assignment to Abbott. Any Third
Party Manufacturing Contracts not included in the Assigned Third Party Manufacturing Contracts will not be assigned to Abbott and Abbott shall have no rights or obligations under such unassigned Third Party Manufacturing Contracts (it being
understood that Abbott has certain obligations to Neurocrine with respect to such unassigned Third Party Manufacturing Contracts pursuant to Section 6.2(b)). 

6.7 Use of Third Parties. Neurocrine shall be entitled to utilize the services of Third Parties to perform its share of
Transition Program activities, only upon Abbott’s prior written consent, which [...***...]. Notwithstanding the foregoing, Neurocrine shall remain at all times fully liable for its responsibilities under the Transition Program and this
Agreement; provided, further, that Neurocrine shall not subcontract any such obligations unless the written agreement pursuant to which it engages any Third Party: (i) is consistent in all material respects with this Agreement, and
(ii) contains terms obligating such Third Party to comply with the confidentiality, intellectual property, and all other relevant provisions no less stringent than those set forth in this Agreement. 

ARTICLE SEVEN - COLLABORATIVE DEVELOPMENT PROGRAM 
  

	7.1	 Collaborative Development Program. 

  

	 	a)	 Goal. The Parties will collaborate in a Collaborative Development Program to achieve [...***...], as more expressly set forth in the
Collaborative Development Plan. 

  

	 	b)	 Term. The term of the Collaborative Development Program will begin on [...***...] and will end [...***...], unless otherwise
agreed by the Parties. 

  

	 	c)	 Efforts. The Parties will use Commercially Reasonable Efforts to perform the activities set forth in the Collaborative Development Plan in
accordance with the timelines set forth in the Collaborative Development Plan. Both parties will participate in [...***...] and, as appropriate, [...***...] as Transition Program or Collaborative Development Program activities, as the
case may be. 

  

	7.2	 Collaborative Development Plan and Budget.  

 

	 	a)	 Activities. The Collaborative Development Program, subject to JDC approval and oversight, may include any of the types of activities
contemplated in the Collaborative Development Plan set forth as Exhibit G. The Parties understand and agree that Exhibit G is not intended 

  
 *** Confidential Treatment
Requested 

	 	 
to represent a final Collaborative Development Plan. In addition, while Exhibit G includes estimated numbers of Neurocrine FTEs that will be required to conduct development activities, it is
understood that these numbers are estimates only and may change depending on timing of the activities and final study designs for selected activities. Within [...***...] days following the Effective Date, the JDC will finalize a Collaborative
Development Plan for the term of the Collaborative Development Program. The Collaborative Development Plan will allocate to Neurocrine activities equivalent to the Neurocrine FTE Funding Commitment (as defined in Section 7.3(a) in accordance
with the limitations on total numbers of FTEs in any given period and allocation across functional areas set forth on Exhibit G. The initial Collaborative Development Plan will focus on the activities to be conducted in the [...***...].
Thereafter the Collaborative Development Plan will be updated by the JDC quarterly as needed and will specifically include detailed plans for staffing levels and activities, timelines and transition dates and outline all Neurocrine FTE funding and
external costs and expenses. The Parties acknowledge and agree that, notwithstanding the Parties’ efforts to fully budget all cost items of the Collaborative Development Program, costs may change over time and/or unbudgeted items may be
identified. As such, the JDC will review the budget set forth in the Collaborative Development Plan on a quarterly basis and reforecast such budget based on the then current costs and expenses on the basis of whether such expenditure is reasonably
necessary to maintain timelines and beyond the reasonable control of the Parties. 

  

	 	b)	 Amendments. The Collaborative Development Plan and each amendment and update thereto shall be prepared jointly by the Parties through the
JDC. The JDC shall have the authority to amend the Collaborative Development Plan with [...***...] days prior written notice to Neurocrine, including accelerating, decelerating, extending, adding or removing activities thereunder; provided
that, (i) the amendment is consistent with the goals of the Collaborative Development Program and (ii) the number of Neurocrine FTEs funded pursuant to Section 7.3(a), the limitations on total numbers of FTEs in any given period and
the allocation of Neurocrine FTEs across functional areas (e.g., CMC, pre-clinical, clinical) may not be decreased or extended or activities added that result in an increase, in either case except as set forth in Section 7.3(a) or with
Neurocrine’s written approval, (iii) the Third Party activities set forth in the Third Party Development Contracts and Third Party Manufacturing Contracts will not be terminated except in accordance with their terms (and any associated
expenses being payable pursuant to Section 7.3(b)). 

  

	7.3	 Collaborative Development Program Funding. 

 

	 	a)	 Internal Costs. Abbott will provide funding for Neurocrine FTEs devoted to the conduct of the Collaborative Development Program in
accordance with the Collaborative Development Plan at a rate of [...***...] per year (such rate will be prorated for any partial year), in an amount equal to [...***...] over the term of the Collaborative Development Program (the
“Neurocrine FTE Funding Commitment”). The Neurocrine FTE Funding Commitment will not exceed [...***...] without Abbott’s prior written permission. 

 

	 	b)	 External and Third Party Costs. Abbott will be responsible for all Third Party and external costs and expenses approved in advance by Abbott
for the Collaborative Development Program activities. 

  

	 	c)	 Invoices. During the term of the Collaborative Development Program, within [...***...] days after the end of each Abbott Quarter,
Neurocrine will provide to Abbott an invoice 

  
 *** Confidential Treatment
Requested 

	 	 
setting forth the amount of funding for Neurocrine FTEs allocated to Collaborative Development Plan activities and Third Party external costs and expenses incurred by Neurocrine pursuant to the
Collaborative Development Plan for such preceding Abbott Quarter, as well as a FTE report for the preceding Abbott Quarter, which FTE report details the FTEs committed to the Collaborative Development Program by department and/or functional area,
and a brief summary of the work performed (which summary may be limited to references to the reports to the JDC). Invoices will be payable by Abbott within [...***...] days of receipt of the invoice. 

7.4 Use of Third Parties. The provisions set forth in Section 6.7 (Use of Third Parties) apply mutatis
mutandis for the Collaborative Development Program. 
 ARTICLE EIGHT – MANUFACTURING 

8.1 Manufacturing Responsibility. Product manufacturing shall be the responsibility of Abbott and Abbott, at its sole
discretion, may (1) modify or terminate Assigned Third Party Manufacturing Agreements, subject to the terms of such agreements; (2) negotiate with Neurocrine or its designee an agreement for the manufacture and supply Compound or Product
to Abbott, its Affiliates or Sublicensees which agreement will contain standard manufacturing commercial terms, conditions and payments mutually acceptable to Neurocrine and Abbott (for avoidance of doubt Neurocrine will not be obligated to enter
into such a manufacturing agreement if it mutually acceptable terms cannot be negotiated); (3) transfer some or all of the manufacture of the Product to locations selected by Abbott, (4) modify the manufacturing process for Products,
(5) modify the quality assurance process for the manufacture or release of Product, and (5) take such other actions related to the manufacture of Products that Abbott deems appropriate. 

8.2 Clinical Supply. Neurocrine will arrange for the transfer to Abbott of all Elagolix clinical trial material owned by
Neurocrine on the Effective Date. Neurocrine will invoice Abbott for all costs incurred by Neurocrine in the manufacture, testing, formulation, packaging, storage, and release of the Elagolix clinical trial material as well as shipment costs
to Abbott, provided however such cost shall not exceed [...***...] without Abbott’s prior written consent. Abbott shall only be responsible to pay for such clinical trial material that conforms to the applicable Product specifications in
effect on the Effective Date, and (b) which has been manufactured in compliance with cGMP and all applicable laws and regulations; and (c) which is not adulterated or misbranded within the meaning of the U.S. Food, Drug &
Cosmetics Act or other applicable law. Abbott may request that Neurocrine assume responsibility for Elagolix clinical supply production after the Effective Date as a Collaborative Development Program activity. 

8.3 Inspections. Abbott shall be responsible for the management of any governmental or regulatory review, audit or inspection of
facilities or processes relating to the manufacture of Products and all communications to governmental or regulatory authorities on such matters shall be made by Abbott. 

8.4 Manufacturing Technology Transfer. All manufacturing Neurocrine Technology transfer activities will be Transition Program or
Collaborative Development Program activities, as the case may be. Upon receipt of written notice from Abbott, Neurocrine shall use Commercially Reasonable Efforts to make available or to cause to be made available to Abbott or its designee, all
manufacturing Neurocrine Technology, including, product manufacturing, packaging and sterilization specifications, utilities and process equipment information, and other technical information, relating to the manufacture of the

  
 *** Confidential Treatment
Requested 

 
Products, then within Neurocrine’s possession or Control, and shall thereafter render such assistance to Abbott or its designee as would allow Abbott or its designee to manufacture the
Products (such transfer, the “Manufacturing Technology Transfer”). If any manufacturing Neurocrine Technology is within the control or possession of a Third Party pursuant to a Third Party Manufacturing Contract, Neurocrine
shall use Commercially Reasonable Efforts to obtain the cooperation and assistance of such Third Party in such Manufacturing Technology Transfer. The Manufacturing Technology Transfer shall include the successful completion of installation
qualification, operational qualification, performance qualification and process validation of the manufacturing process at the facility designated by Abbott. In connection with the Manufacturing Technology Transfer, Neurocrine and/or its Third Party
manufacturer shall (i) deliver a comprehensive manual in English setting forth in detail the techniques, processes, documentation and know-how that are reasonably necessary or directly useful in the manufacture of Products then within either
Neurocrine’s possession or control and (ii) make available to Abbott at a site designated by Abbott the services of such personnel of Neurocrine’s as Abbott may reasonably request in order to assist Abbott in establishing the
manufacturing facility. 
 ARTICLE NINE - CONFIDENTIAL INFORMATION 

9.1 Treatment of Confidential Information. During the Term and for a period of [...***...] years thereafter, each Party
shall maintain Confidential Information of the other Party in confidence, and shall not disclose, divulge or otherwise communicate such Confidential Information to any Third Party, or use it for any purpose other than as permitted under this
Agreement or in connection with the development, manufacture, marketing, promotion, distribution or sale of the Products pursuant to this Agreement, and each Party agrees to exercise its reasonable efforts to prevent and restrain the unauthorized
disclosure of such Confidential Information by any of its directors, officers, employees, or permitted Third Parties. 
 If, in the opinion
of the receiving Party’s counsel, any of the disclosing Party’s Confidential Information is required to be disclosed pursuant to law, regulation, or court order, the receiving Party shall give the disclosing Party prompt, written notice
and, to the extent practical and consistent with the receiving Party’s legal obligations (as determined in good faith by counsel to the receiving Party) withhold disclosure to allow the disclosing Party to take whatever action it reasonably
deems necessary to protect its Confidential Information. In the event that (i) no protective order or other remedy is obtained, or (ii) the disclosing Party waives compliance with the terms of this Article 9 (Confidential
Information), or (iii) in the good faith opinion of counsel to the receiving Party, disclosure of the disclosing Party’s Confidential information can or should not be withheld to allow (i) or (ii) above, then in each case the
receiving Party will furnish only that portion of the Confidential Information which receiving Party is advised by counsel is legally required. 

Notwithstanding the foregoing, the receiving Party may disclose the disclosing Party’s Confidential Information to the extent that such:

  

	 	a)	 is disclosed to governmental or other regulatory agencies in order to obtain and/or maintain patents pursuant to and in accordance with Article 12
(Intellectual Property) or to gain or maintain Regulatory Approvals in accordance with a Party’s rights to do so under this Agreement, but such disclosure, in each case, may only be to the extent reasonably necessary to obtain and/or
maintain patents or Regulatory Approvals and reasonable measures shall be taken to assure confidential treatment of such information; 

  

	 	b)	 is deemed reasonably necessary by a Party to be disclosed to agents, consultants, Sublicensees and/or other Third Parties for the research,
development, manufacturing and/or marketing of 

  
 *** Confidential Treatment
Requested 

	 	 
Products (or for such entities to determine their interest in entering into applicable agreements to perform such activities with or for such Party) in accordance with this Agreement provided
such Third Parties agree to be bound by confidentiality and non-use provisions no less stringent that those contained in this Agreement for terms of not less than [...***...] years; or 

 

	 	c)	 is deemed necessary by counsel to the receiving Party to be disclosed to (1) such Party’s directors, attorneys, auditors and advisors for
the sole purpose of enabling such parties to provide advice to the receiving Party, or (2) to [...***...], provided such Third Parties agree to be bound by confidentiality and non-use provisions no less stringent that those contained in
this Agreement for terms of not less than [...***...] years; or 

  

	 	d)	 is required to be disclosed by the receiving Party defend or prosecute litigation pursuant to and in accordance with Article 12 (Intellectual
Property), provided that the receiving Party provides prior notice of such disclosure to the other Party and takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure; or 

 

	 	e)	 is required to be disclosed by the receiving Party to comply with applicable Laws including disclosure required by the U.S. Securities and Exchange
Commission, subject to the second paragraph above and Section 9.3. 

 9.2 Publications. The Parties,
through the JDC, will develop a publication plan for the Collaboration, as well as a Joint Publication Practices, Processes, and Policies document that is consistent with the Parties’ respective policies and procedures for publication and
disclosure of results of clinical trials. During the term of the Transition Program and Collaborative Development Program, each Party will submit to the other Party through the JDC for review and approval all peer-reviewed academic, scientific and
medical publications relating to the Development of Compounds or Products. The submitting Party will also provide all data (eg, final protocol, statistical analysis plan, relevant statistical tables generated from the plan, figures, and reports)
needed to prepare the publication. Neurocrine agrees that it will, and will cause its Affiliates to, not publish any such publications without the prior written consent of Abbott. The non-publishing Party shall have at least [...***...] days
to review each proposed publication. The review period may be extended for up to [...***...] days in the event the non-publishing Party can demonstrate to the JDC a reasonable need for such extension including, but not limited to, the
preparation and filing of patent applications. Such period may be further extended by the JDC. In the event that the two Parties differ in their opinion or interpretation of data in the publication, the parties shall resolve such differences in good
faith through appropriate scientific debate. The Parties agree to, and will cause their respective Affiliates to, comply with the ICMJE criteria for authorship of scientific publications and acknowledgement of contributions of other Parties in any
publications relating to research or Development of Products. Notwithstanding the foregoing, the Parties shall endeavor as far as possible, for ease and convenience, to agree on a universal basis joint authorship in respect of such publications.
After the expiration of the Transition Program and Collaborative Development Program, Neurocrine agrees that it will, and will cause its Affiliates to, not publish any such publications relating to the Compounds or Products without the prior written
consent of Abbott. 
  

	9.3	 Public Announcements. 

  

	 	a)	 Coordination. The Parties agree on the importance of coordinating their public announcements respecting this Agreement and the subject
matter thereof (other than academic, scientific or medical publications that are subject to the publication provision set forth above). Neurocrine and Abbott will, from time to time, and at the request of the other Party discuss and agree on the
general information content relating to this Agreement and/or Products which may be publicly disclosed. 

  
 *** Confidential Treatment
Requested 

	 	b)	 Announcements. The Parties agree that the public announcement of the execution of this Agreement shall be in the form of the press release
attached as Exhibit I. Any other publication, news release or other public announcement relating to this Agreement or to the performance hereunder, may only be made by Neurocrine or Abbott with the review and prior written approval of the other
Party, [...***...]. The party wishing to make a publication, news release or other public announcement hereunder shall provide written notice to the other Party regarding the same. If a publication, news release or other public
announcement is agreed upon by both Parties, the other Party shall be allowed to review and comment on the publication, news release or other public announcement. The aforementioned approval procedure and review period in total shall not exceed
[...***...] days. In no event shall such statements or disclosures disclose, if previously undisclosed, the stage of development of Products and/or the financial terms of the transaction; provided, however, that any disclosure which is
required by applicable law, including disclosures required by the U.S. Securities and Exchange Commission or made pursuant to the requirements of the national securities exchange or other recognized stock market on which such Party’s securities
are traded, as advised by the disclosing Party’s counsel, may be made without the prior consent of the other Party, although, to the extent practicable and in opinion of counsel to the disclosing Party consistent with such Party’s
disclosure obligations, the other Party shall, as far in advance as reasonably practicable but in no event less than [...***...] days provide advance notice of any such legally required disclosure to comment and reasonably consider such
comments provided by such Party on the proposed disclosure. Notwithstanding the foregoing, with respect to [...***...], and is thus [...***...], the Parties agree: [...***...]. 

 

	 	c)	 Notwithstanding anything to the contrary in this Agreement, but subject to the provisions of Article 9 (Confidential Information) and
Section 13.19 (Use Of Names, Logos Or Symbols), Abbott shall have the right to publicly disclose research, development and commercial information regarding the Compound(s) and Product(s). 

ARTICLE TEN – INDEMNIFICATION AND INSURANCE 

10.1 Indemnification by Abbott. Abbott will indemnify, defend and hold harmless Neurocrine, its licensees, sublicensees and
Affiliates, and each of its and their respective employees, officers, directors and agents (each, a “Neurocrine Indemnified Party”) from and against any and all liability, loss, damage, expense (including reasonable
attorneys’ fees and expenses) and cost (collectively, a “Liability”) which the Neurocrine Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: (i) any claims of any
nature arising out of (y) the conduct of the Product Development or Commercialization by, on behalf of or under authority of, Abbott (other than by a Neurocrine Indemnified Party) or (z) research, Development and/or Commercialization of
Products by, on behalf of or under authority of, Abbott (other than by Neurocrine Indemnified Party) and/or (ii) any Abbott representation or warranty set forth herein being untrue in any material respect when made; except in each case, to the
extent caused by the negligence or willful misconduct of Neurocrine or any Neurocrine Indemnified Party. Notwithstanding the foregoing, Abbott shall have no obligation to defend, indemnify or hold harmless any Neurocrine Indemnified Party from and
against any Liability arising out of or resulting from the infringement of a Third Party Patent Right provided such indemnify does fall within the foregoing indemnification requirements. 

10.2 Indemnification by Neurocrine. Neurocrine will indemnify, defend and hold harmless Abbott, its licensees, Sublicensees and
Affiliates, and each of its and their respective employees, officers, directors and agents (each, a “Abbott Indemnified Party”) from and against and all Liability which the 

  
 *** Confidential Treatment
Requested 

 
Abbott Indemnified Party may be required to pay to one or more Third Parties arising out of (i) any claims of any nature arising out of (x) the conduct of Product Development or
Commercialization of by, on behalf of or under authority of, Neurocrine (other than by an Abbott Indemnified Party) or (y) research, Development and/or Commercialization of Products by, on behalf of or under authority of, Neurocrine (other than
by an Abbott Indemnified Party) and/or (ii) any Neurocrine representation or warranty set forth herein being untrue in any material respect when made; except in each case, to the extent caused by the negligence or willful misconduct of Abbott
or any Abbott Indemnified Party. Notwithstanding the foregoing, Neurocrine shall have no obligation to defend, indemnify or hold harmless any Abbott Indemnified Party from and against any Liability arising out of or resulting from the infringement
of a Third Party Patent Right provided such indemnify does fall within the foregoing indemnification requirements. 
 10.3
Procedure. Each Party will provide prompt written notice to the other in the event it becomes aware of a claim for which indemnification may be sought hereunder. In case any proceeding (including any governmental investigation) shall
be instituted involving any Party in respect of which indemnity may be sought pursuant to this Article 10, such Party (the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying
Party”) in writing. Within [...***...] days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party claim with
counsel reasonably satisfactory to the Indemnified Party and control the disposition or settlement thereof (including all decisions relative to litigation, appeal, and settlement subject to this Article). The Indemnified Party shall cooperate fully
with the Indemnifying Party in such defense. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense. The Party not controlling such defense may participate therein at its own expense;
provided the Indemnified Party shall bear the expense if the named parties to any such proceeding (including any impleaded parties) include both the Indemnifying Party and the Indemnified Party and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. All such fees and expenses shall be reimbursed as they are incurred, and provided reasonable documentation along with an invoice is provided. The Indemnifying Party
shall not be liable for any settlement of any proceeding effected without its prior written consent, but if settled with such prior written consent or if there be a final judgment for the plaintiff, the Indemnifying Party agrees to indemnify the
Indemnified Party from and against any Liability by reason of such settlement or judgment. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, effect any settlement of any pending or threatened proceeding in
respect of which the Indemnified Party is, or arising out of the same set of facts could have been, a party and indemnity could have been sought hereunder by the Indemnified Party, unless [...***...]. 

10.4 Insurance. Each Party acknowledges that they each maintain and shall, maintain adequate insurance for liability insurance
adequately covering such Party’s obligations under this Agreement. During the Term Abbott shall maintain comprehensive general liability insurance, including products liability insurance, with reputable and financially secure insurance
carriers, or shall provide an explanation of self insurance, in a minimum amount of $[...***...] per occurrence and $[...***...] aggregate prior to first commercial sale and $[...***...] aggregate on and after first commercial sale
(exclusive of deductible amounts) as respects personal injury, bodily injury and property damage arising out of a Abbott’s Development and Commercialization of Products. Abbott shall provide Neurocrine with evidence of such insurance, upon
request. Such insurance shall include Neurocrine as a named insured and shall require prior notice to the Neurocrine before cancellation. Notwithstanding the foregoing, either Party may self-insure in whole or in part the insurance requirements
described above, provided such Party continues to be investment grade determined by reputable and accepted financial rating agencies. This Section shall apply mutatis mutandis to Neurocrine, in the event Neurocrine obtains a license to
Compounds and Products pursuant to Section 11.2(b), 11.3, 11.4, 11.5 and 11.7. 

  
 *** Confidential Treatment
Requested 

 10.5 Survival. All obligations of indemnification and insurance imposed under this
Article 10 (Indemnification and Insurance) shall expire [...***...] years following the longer of termination or expiration of this Agreement or, with respect to a particular Party, last sale of a Product sold under this Agreement by a
Party. 
 ARTICLE ELEVEN - TERM AND TERMINATION 
  

	11.1	 Term; Effect of Expiration. 

a) Unless earlier terminated by mutual agreement of the Parties, or pursuant to the provisions of this Article 11, this
Agreement shall commence on the Effective Date and will continue in full force and effect, on a country by country and Product by Product basis, until the final obligation to pay Royalties with respect to the sale of such Product in a country
expires as provided in Article 4 and Abbott’s obligations [...***...] expire, at which time this Agreement shall expire in its entirety in such country for such Product (“Term”). 

b) On a country by country and Product by Product basis, upon expiration of this Agreement with respect to a Product in a
country pursuant to this Section 11.1(a) (Term), the license set forth in Section 3.1 (License) shall be deemed to be irrevocable, unrestricted, perpetual and fully paid-up with respect to such Product in such country. 

 

	11.2	 Termination for Convenience; Effects. 

  

	 	a)	 Termination for Convenience. Notwithstanding anything contained herein to the contrary, Abbott shall have the right to terminate this
Agreement at any time in its sole discretion by giving Neurocrine one hundred eighty (180) days prior written notice. 

  

	 	b)	 Effects of Termination. If Abbott terminates this Agreement pursuant to Section 11.2(a), (i) Abbott will pay all amounts due and
owing to Neurocrine as of the termination effective date; and (ii) Abbott shall continue to be obligated during the termination notice period to perform all of its obligations under this Agreement, including its obligation to pay all expenses
associated with the Transition Program and Collaborative Development Program. In addition, if Abbott terminates this Agreement pursuant to Section 11.2(a): 

 

	 	1)	 All of Abbott’s licenses and rights to the Neurocrine Technology and Neurocrine Patent Rights will terminate; 

 

	 	2)	 All Neurocrine Confidential Information provided to Abbott in tangible form and all substances or compositions provided by Neurocrine to Abbott
will be returned to Neurocrine or destroyed, except that Abbott may retain one copy of the Neurocrine Confidential Information solely for legal archive purposes; 

 

	 	3)	 All Abbott Confidential Information provided to Neurocrine in tangible form and all substances or compositions delivered or provided to Neurocrine
by Abbott shall be returned to Abbott or destroyed, except that Neurocrine may retain one copy of the Abbott Confidential Information solely for legal archive purposes; 

  
 *** Confidential Treatment
Requested 

	 	4)	 Abbott will transfer to Neurocrine such [...***...] and information reasonably necessary to allow Neurocrine to [...***...], including,
at Neurocrine’s option, exercisable within [...***...] days following the effective date of such termination, transfer to Neurocrine of any [...***...]; 

 

	 	5)	 Abbott will transfer to Neurocrine any [...***...]; 

 

	 	6)	 Abbott will transfer and assign ownership to Neurocrine of all [...***...] as well as (1) a copy of the [...***...],
(2) copies of [...***...], and access to the [...***...], (3) copies of all documents [...***...], (4) access to [...***...] (5) copies of correspondence with [...***...] and (6) access to
information Abbott determines is relevant to [...***...]; 

  

	 	7)	 At Abbott’s option, Abbott will either [...***...], provided, if Abbott [...***...]; and 

 

	 	8)	 Abbott will grant to Neurocrine an [...***...] license under the Abbott Technology, Abbott Patent Rights, [...***...] and
[...***...] to make, have made, use, import, offer for sale and sell Compounds and Products. 

  

	 	9)	 The [...***...] pursuant to subsections 7 and 8 above, shall be [...***...]. Subject to [...***...], if there is a termination
[...***...] pursuant to [...***...], then the parties shall negotiate in good faith [...***...], whereby the Parties shall take into consideration: [...***...]. 

 

	11.3	 Termination if Abbott [...***...]. In the event Abbott, Abbott’s Affiliates or Sublicensees [...***...], Neurocrine
shall have the right to terminate this Agreement upon [...***...] days written notice to Abbott. Any such termination shall only become effective if Abbott or its Affiliate or Sublicensees, as applicable, has not [...***...] before the
end of the above notice period and the provisions of Section 11.2(b) shall apply mutatis mutandis to termination pursuant to this Section. 

  

	11.4	 Termination for Cause.  

  

	 	a)	 Termination for Cause. If either Party (the “Notifying Party”) believes that the other Party (the “Other
Party”) is in Default of this Agreement, then the Notifying Party may deliver notice of such breach to the Other Party. 

  

	 	1)	 If the Other Party disputes that it is in Default of this Agreement, the matter shall be handled pursuant to Section 13.2 (Dispute
Resolution). If the neutral renders a ruling that the Other Party is in Default of this Agreement (the “Adverse Ruling”), such ruling shall also specify the actions to be taken by the Other Party to cure such Default,
which actions must be completed within [...***...] days after such ruling (or [...***...] days if such Default relates [...***...]). If the Other Party has failed to comply with the terms of the Adverse Ruling within such
[...***...] or [...***...] day period, as applicable, or if such compliance cannot be fully achieved within such [...***...] day or [...***...] day period, the Other Party has failed to commence compliance and/or has failed
to use diligent efforts to achieve full compliance as soon thereafter as is reasonably possible, then the Notifying Party shall have the following rights: 

  
 *** Confidential Treatment
Requested 

	 	a)	 where [...***...] is the Other Party and where the basis for such Default is [...***...] failure to abide by a material obligation
under this Agreement with respect to [...***...] may terminate this Agreement with respect [...***...] by delivering written notice to [...***...] of such termination; and 

 

	 	b)	 notwithstanding (A) above, where [...***...] is the Other Party and where the basis for such breach is [...***...] may terminate
this Agreement by delivering written notice to [...***...] of such termination; and 

  

	 	c)	 where [...***...] is the Other Party, [...***...] may terminate this Agreement by delivering written notice to [...***...] of
such termination. 

  

	 	2)	 If the Other Party does not dispute that it has committed a material breach of this Agreement, then if the Other Party fails to cure such breach,
or take steps as would be considered reasonable to effectively cure such breach, within [...***...] (or [...***...] days if such Default relates to [...***...]), after receipt of notice as provided above, the the provisions of
Section 11.4(1)(a)(b) or (c) shall apply. 

 b) Effect of Termination for Cause. If a
Party terminates this Agreement pursuant to Section 11.4(a), the Parties shall have the rights set forth below, each measured from the date written notice of such termination is given to the Other Party. 

(i) Neurocrine. Where Neurocrine is the Other Party and Abbott terminated [...***...] pursuant to
11.4(a), Abbott may in its sole discretion: (i) [...***...] and (ii) [...***...]. Except as set forth in this clause (a): all rights and obligations under this Agreement shall survive such termination and continue unaffected ,
subject to [...***...], as determined in accordance with Section 13.2 (Dispute Resolution). 

(ii) Abbott. Where Abbott is the Other Party and Neurocrine terminated [...***...] pursuant to
11.4(a), the provisions of Section 11.2(b) shall apply provided however, that if this Agreement is terminated only with respect to [...***...], the provisions of Section 11.2(b) shall apply mutatis mutandis to termination by
Neurocrine pursuant to this Section but only with respect to [...***...]. 
  

	11.5	 Bankruptcy. Each Party may, in addition to any other remedies available to it by Law or in equity, exercise the rights set forth
below by written notice to the other Party (the “Insolvent Party”), in the event the Insolvent Party shall have become insolvent or bankrupt, or shall cease conducting business in the ordinary course, or shall have made an
assignment for the benefit of its creditors, or there shall have been appointed a trustee or receiver of the Insolvent Party or for all or a substantial part of its property, or any case or proceeding shall have been commenced or other action taken
by or against the Insolvent Party in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other
similar act or Law of any jurisdiction now or hereafter in effect, or there shall have been issued a warrant of attachment, execution, distraint or similar process against any substantial part of the property of the Insolvent Party, and any such
event shall have continued for sixty (60) days undismissed, unbonded and undischarged. 

 All rights
and licenses granted under or pursuant to this Agreement by Neurocrine and Abbott are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code or its foreign equivalent, licenses of rights to
“intellectual property” as defined under Section 101 

  
 *** Confidential Treatment
Requested 

 
of the Bankruptcy Code or its foreign equivalent. The Parties agree that the Parties as licensees of such rights under this Agreement shall retain and may fully exercise all of their rights and
elections under the Bankruptcy Code or its foreign equivalent. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the Bankruptcy Code or its foreign equivalent, the other
Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in the other Party’s possession, shall be
promptly delivered to other Party (i) upon any such commencement of a bankruptcy proceeding upon its written request therefore, unless the Party subject to such proceeding elects to continue to perform all of their obligations under this
Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefore by the other Party. 

 

	 	a)	 Neurocrine. In the event Neurocrine is the Insolvent Party, in addition to any other remedies available to Abbott at Law or in equity,
Abbott may in its sole discretion (i) [...***...]. Except as set forth in this clause (a), all rights and obligations under this Agreement shall survive such termination and continue unaffected upon Neurocrine becoming an Insolvent Party,
unless this Agreement is terminated by Abbott pursuant to Section 11.2(a). 

  

	 	b)	 Abbott. In the event Abbott is the Insolvent Party, in addition to any other remedies available to Neurocrine at Law or in equity,
Neurocrine may terminate this Agreement and the provisions of Section 11.2(b) shall apply to termination by Neurocrine pursuant to this Section. 

  

	11.6	 Change of Control. In the event of a Change of Control of Neurocrine, Abbott may in its discretion within [...***...] days
following the Change of Control elect some or all of the following: 

  

	 	a)	 with no less than [...***...] prior written notice [...***...] and thereafter [...***...]; 

 

	 	b)	 with no less than [...***...] prior written notice, terminate [...***...]; 

 

	 	c)	 Abbott may elect to require Neurocrine and the Change of Control party to adopt [...***...]; 

 

	 	d)	 Abbott may elect to terminate the [...***...]; 

  

	 	e)	 All other rights and obligations under this Agreement shall continue unaffected upon a Change of Control, unless this Agreement is terminated
pursuant to this Agreement. 

  

	11.7	 Divestiture by [...***...]. If in connection with any proposed acquisition, merger, or agreement, [...***...]
determines that in order to [...***...], it would be advisable, in [...***...] business judgment, [...***...] shall notify [...***...] thereof [...***...]. 

If [...***...] in good faith believes, based on a determination made by [...***...], that it is capable of
[...***...] shall have [...***...] days from [...***...] to (i) [...***...] and (ii) [...***...]. Upon receipt of [...***...] notice hereunder, [...***...] shall [...***...].
[...***...] shall be free at any and all times to [...***...]; provided however, [...***...] shall provide to [...***...] notice of [...***...] and [...***...] shall have [...***...] days following receipt
of such notice to [...***...]. 

  
 *** Confidential Treatment
Requested 

	11.8	 Debarment and Exclusion.  

  

	 	a)	 Neurocrine represents and warrants that prior to the Effective Date neither it, nor any of its employees, nor [...***...] each of its
consultants, or independent contractors or any other person working on its behalf that provided services in connection with an NDA for a Product, were at the time the services were performed a Debarred Entity or Debarred Individual, an Excluded
Entity or Excluded Individual or a Convicted Entity or Convicted Individual, or after the services were performed, [...***...] became a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or
Convicted Individual due to actions related to the services in connection with an NDA for a Product. 

  

	 	b)	 Neurocrine covenants that with respect to work conducted pursuant to the Transition Plan and Collaborative Development Plan neither it, nor
any of its employees, nor [...***...] each of its consultants, or independent contractors and any other person working on its behalf that provide services in connection with an NDA for a Product (i) will be at the time services are
performed a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual or (ii) [...***...] are currently the subject of a proceeding that could lead to it or such
employees, consultants, independent contractors, becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual. 

 

	 	c)	 Abbott covenants that neither it, nor any of its employees, nor [...***...] each of its consultants, or independent contractors or any
other person working on its behalf that provide services in connection with an NDA for a Product, (i) will be at the time services are performed a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted
Entity or Convicted Individual or (ii) [...***...] are currently the subject of a proceeding that could lead to it or such employees, consultants, independent contractors, becoming, as applicable, a Debarred Entity or Debarred Individual,
an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual. 

  

	 	d)	 Each Party covenants, represents and warrants that if, during the Term, it, or any of its employees, consultants, independent contractors,
or any other person working on its behalf that provided services or are providing services in connection with an NDA for a Product becomes, as applicable, a Debarred Entity, or Debarred Individual, an Excluded Entity or Excluded Individual, a
Convicted Entity, or Convicted Individual, it shall immediately notify the other Party. The parties shall serve said written notice in accordance with Section 13.4 (Notices). 

 

	 	e)	 Upon breach of this Section 11.7, the [...***...]. 

For purposes of this provision, the following definitions shall apply 

 

	 	a)	 A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from
providing services in any capacity to a person that has an approved or pending drug or biological product application. 

  

	 	b)	 A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a
(a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or affiliate of a Debarred Entity. 

  
 *** Confidential Treatment
Requested 

	 	c)	 An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who has been excluded,
debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (ii) is an
individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration
(GSA). 

  

	 	d)	 A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal
offense that falls within the ambit of 21 U.S.C. §335a (a) or 42 U.S.C. §1320a - 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

 

	11.9	 Liabilities. Termination of this Agreement shall not release either Party from any obligation or liability which shall have accrued
at the time of termination, or preclude either Party from pursuing all rights at Law and in equity with respect to any Default under this Agreement. 

  

	11.10	 LIMITATION ON LIABILITY. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, EXCEPT FOR THE WILLFUL MISCONDUCT OF A PARTY OR ITS
AFFILIATES, OR A MATERIAL BREACH OF THE CONFIDENTIALITY AND INTELLECTUAL PROPERTY PROVISIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER CONTRACT, NEGLIGENCE, STRICT LIABILITY OR
OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES EXCEPT SUCH DAMAGES OWED TO THIRD PARTIES EXPRESSLY PROVIDED IN THIS AGREEMENT. 

 

	11.11	 Survival. Upon expiration or termination of this Agreement the following provisions shall expressly survive any such expiration or
termination: Articles 1, 12, and 13 and Sections 2.6, 3.5, 3.6, 11.1(c), 11.2(b), 11.4(b), 11.5(a) and 11.5(b), 11.8, 11.9, 11.10, and this 11.11 and the following provisions shall expressly survive any such expiration or termination for the period
stated therein: Articles 9, 10, and Section 4.7(g). 

 ARTICLE TWELVE - INTELLECTUAL PROPERTY 

 

	12.1	 Ownership, Filing, Prosecution and Maintenance. 

 

	 	a)	 Abbott Patent Rights. Abbott shall solely own and shall, at its expense, be solely responsible for the preparation, filing, all prosecution
matters, including all inter parte and ex parte patent office submissions, procedural decisions and patent office adversarial proceedings, for example, requests for, or filing or declaration of, interference or opposition, or reexamination
(collectively, “Prosecution”) and maintenance of Abbott Patent Rights. Abbott shall have no obligation to continue the Prosecution and/or maintenance of any Abbott Patent Right in any country and shall be free to abandon such Abbott Patent
Rights at its sole discretion. 

  
 *** Confidential Treatment
Requested 

	 	b)	 Program Patent Rights. Abbott shall solely own and shall, at its expense, be solely responsible for the preparation, filing, Prosecution and
maintenance of Program Patent Rights. Neurocrine agrees that it will, and will cause its Affiliates to, (i) execute and file those notices and other filings as Abbott shall request be made, from time to time, with the United States Patent and
Trademark Office (or any successor agency) or any analogous patent office in the Territory with respect to the rights granted under this Agreement, and (ii) execute and deliver to Abbott all assignments and other instruments as Abbott shall
request to effect the ownership, filing, Prosecution and maintenance of Program Patent Rights. Abbott will keep Neurocrine reasonably informed of the status of the Program Patent Rights and will provide Neurocrine with copies of all substantive
documentation submitted to, or received from, the patent offices in connection therewith. With respect to any substantive submissions that Abbott is required to or otherwise intends to submit to a patent office, Abbott shall provide a draft of such
submission to Neurocrine at least [...***...] days prior to the deadline or intended filing date, whichever is earlier, for submission of such documentation. Neurocrine shall have the right to review and comment upon any such submission by
Abbott to a patent office, and will provide such comments, if any, no later than [...***...] days prior to the applicable deadline or intended filing date provided that Abbott shall not be obligated to incorporate comments provided by
Neurocrine. Abbott shall have the right to cease the Prosecution and/or maintenance of, or not to pursue, or cease to pay the expenses of Prosecution or maintenance of, any Program Patent Right in any country in which such Program Patent Right has
been filed. In all cases, Abbott shall have final decision-making authority with respect to the filing, Prosecution, and maintenance of Program Patent Rights. 

 

	 	c)	 Neurocrine Patents. 

(i) Neurocrine shall solely own the Neurocrine Patent Rights and shall be responsible for, through [...***...] counsel
reasonably acceptable to Abbott, the preparation, filing, Prosecution (except as provided in Article 12.1(c)(ii)) and maintenance of Neurocrine Patent Rights. [...***...]. Neurocrine will keep Abbott fully informed of all significant steps to
be taken in the preparation and Prosecution of all patent applications and any subsequent actions to be taken with respect to issued patents within the Neurocrine Patents and Neurocrine shall furnish Abbott with copies of any such applications,
amendments thereto and other related [...***...] correspondence to and from patent offices and patent associates to allow for review by and consultation with Abbott reasonably in advance of any submission to a patent office which could
[...***...] affect the scope or validity of the patent coverage that may result. Copies of all such applications filed prior to the Effective Date shall be provided to Abbott promptly after the Effective Date. With respect to any substantive
submissions that Neurocrine is required to or otherwise intends to submit to a patent office, Neurocrine shall provide a draft of such submission to Abbott at least [...***...] days prior to the deadline or intended filing date, whichever is
earlier, for submission of such documentation. Abbott shall have the right to review and comment upon any such submission by Neurocrine to a patent office, and will provide such comments, if any, no later than [...***...] days prior to the
applicable deadline or intended filing date. Neurocrine shall also act on recommendations Abbott may make with respect to issued patents within the Neurocrine Patent Rights. 

(ii) Notwithstanding the foregoing, Neurocrine shall promptly inform Abbott of any adversarial patent office proceeding,
including, but not limited to a request for, or filing or declaration of, any interference, opposition, or reexamination relating to Neurocrine Patent Rights. Abbott and Neurocrine shall thereafter consult and cooperate fully to determine a course
of action with respect to any such proceeding and Neurocrine shall incorporate all comments provided by Abbott. Neurocrine shall not initiate any reexamination, interference 

  
 *** Confidential Treatment
Requested 

 
or reissue proceeding relating to Neurocrine Patent Rights without the prior written consent of Abbott. 

(iii) In the event that Neurocrine disagrees with any comment or suggestion provided by Abbott under Section 12.1(i) or
Section 12.1(ii), Neurocrine shall provide Abbott with a written explanation detailing the basis for such disagreement. If Abbott does not accept Neurocrine’s explanation, Abbott shall have final decision-making authority with respect to
the matter in dispute. 
  

	 	d)	 Abandonment of Patent Rights. Abbott may elect to discontinue payment for the costs and expenses of preparation, filing, Prosecution,
validation or maintenance of any Program Patent Right pursuant to Section 12.1(b) or Neurocrine Patent Right pursuant to Section 12.1(c) on a country-by-country and application-by-application or patent-by-patent basis, at any time and in
its sole discretion. If Neurocrine thereafter chooses to resume the preparation, filing, Prosecution, validation or maintenance of any Program Patent Rights [...***...] or Neurocrine Patent Right, the licenses to Abbott hereunder with respect
to such applications or patents shall terminate and Neurocrine will own sole right, title and interest in and to such applications or patents. 

  

	 	e)	 Trademarks. Abbott shall solely own and shall, at its expense, be solely responsible for the development, selection, filing prosecution,
enforcement, and maintenance of the Trademarks. Abbott shall have no obligation to continue the prosecution and/or maintenance of any Trademark in any country and shall be free to abandon such Trademark at its sole discretion. Neurocrine agrees, at
its own expense, to cooperate with Abbott in the protection of the Trademarks by executing documents, and by taking any other action reasonably requested by Abbott to effectuate the intent of this Section 12.1(e). Neurocrine also agrees not to
take any action detrimental to Abbott’s interest in the Trademarks. Neurocrine agrees to notify Abbott immediately if Neurocrine becomes aware of any infringement of the Trademarks. Abbott shall have the sole right but no obligation to initiate
any legal proceedings alleging infringement of the Trademarks. 

  

	12.2	 Extension of Patent Rights. At the time of the granting of approval of an NDA or equivalent in any country in respect of a Product,
Abbott shall have the exclusive right, but not the obligation, to seek, in Neurocrine’s name if so required, patent term extensions or supplemental patent protection in any country in the Territory in respect of a Neurocrine Patent Right,
Program Patent Right or Abbott Patent Right. Abbott shall use Commercially Reasonable Efforts to obtain such patent term extensions or supplement protection, where applicable. Neurocrine and Abbott shall cooperate in connection with all such
activities, and Abbott, its agents and attorneys will give due consideration to all suggestions and comments of Neurocrine regarding any such activities, but in the event of a disagreement between the parties, Abbott will have the final
decision-making authority. In the case where Abbott determines to seek such patent term extensions or supplement patent protection in respect of a Neurocrine Patent Right, Neurocrine shall appoint Abbott or its designee as Neurocrine’s agent
for the sole purpose of submitting an application to extend the term of such patent, an application for a Supplementary Protection Certificate, or an equivalent thereof. Neurocrine shall co-operate with Abbott or its designee in connection with any
such application. 

  

	12.3	 Enforcement and Defense of Patent Rights. 

 

	 	a)	 Notification. Each Party shall promptly notify each other of any infringement, alleged infringement or non-patent office adverserial
proceeding challenging the validity or enforceability of the Neurocrine Patent Rights or Program Patent Rights. In the event of a 

  
 *** Confidential Treatment
Requested 

	 	 
notification under 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii) (IV) concerning Neurocrine Patent Rights or Program Patent Rights, then the Party receiving the notice shall provide a
copy of such notice to the other Party within [...***...] days after its receipt thereof. 

  

	 	b)	 Abbott shall have the sole right, but not the obligation, in its own name, to (i) enforce Neurocrine Patent Rights and Program Patent Rights
against any Third Party suspected of infringing a claim of such a Patent Right in the Territory, and (ii) defend Neurocrine Patent Rights and Program Patent Rights against any Third Party asserting that a claim of such a Patent Right is invalid
or unenforceable. Neurocrine, upon request of Abbott, shall reasonably cooperate with Abbott in any such litigation, or file such action in Neurocrine’s name, if required, at Abbott’s expense and shall join in any such litigation at
Abbott’s request and expense. Abbott shall have exclusive control over the conduct of any such proceedings, including the right to not bring an action, settle or compromise such proceedings. Any award or recovery paid to Abbott by a Third Party
as a result of such patent infringement or defense proceedings (whether by way of settlement or otherwise) shall first be applied toward reimbursement of legal fees, costs and expenses incurred by Abbott, and from the remainder, if any,
[...***...]. Any excess shall be [...***...]. 

  

	 	c)	 In the event Abbott shall not elect to enforce or defend any such Patent Right in the Territory pursuant to 12.3(b), it may grant, in its sole
discretion, such right to Neurocrine and Neurocrine shall have the sole right, but not the obligation, in its own name, to (i) enforce Neurocrine Patent Rights and Program Patent Rights against any Third Party suspected of infringing a claim of
such a Patent Right in the Territory, and (ii) defend Neurocrine Patent Rights and Program Patent Rights against any Third Party asserting that a claim of such a Patent Right is invalid or unenforceable. Abbott, upon request of Neurocrine,
shall reasonably cooperate with Neurocrine in any such litigation, or file such action in Abbott’s name, if required, at Neurocrine’s expense and shall join in any such litigation at Neurocrine’s request and expense. Neurocrine shall
have exclusive control over the conduct of any such proceedings, including the right to not bring an action, settle or compromise such proceedings. Any award or recovery paid to Neurocrine by a Third Party as a result of such patent infringement
proceedings (whether by way of settlement or otherwise) shall first be applied toward reimbursement of legal fees, costs and expenses incurred by Neurocrine, and the excess, if any shall be [...***...]. 

  
 *** Confidential Treatment
Requested 

	12.4	 Infringement Defense. Abbott will be responsible for defending and controlling any suit against any of Abbott, Abbott’s
Affiliates or Sublicensees, alleging infringement of any patent or other intellectual property right of a Third Party arising out of the manufacture, use, sale, offer to sell or importation of a Product by Abbott, Abbott’s Affiliates or
Sublicensees in the Territory. Abbott shall be responsible for the costs and expenses, including legal fees and costs, associated with any suit or action. Upon Abbott’s request, Neurocrine will consult with Abbott and co-operate in the defense
of any such action. If Abbott finds it necessary or desirable to join Neurocrine as a party to any such action, Neurocrine will execute all papers and perform such acts as shall be reasonably required, at Abbott expense. 

 

	12.5	 Inventorship. Inventorship with respect to all Patent Rights under this Agreement shall be determined according to United States Law.

  

	12.6	 Hold Harmless. The Parties hereby agree to hold each other harmless in respect of their good faith activities hereunder to file,
prosecute, maintain, enforce and defend Patent Rights under this Article 12.6.13. 

 ARTICLE THIRTEEN –
MISCELLANEOUS 
  

	13.1	 Governing Law. This Agreement (and any claims or disputes arising out of or related thereto or to the transactions contemplated
thereby or to the inducement of a Party to enter therein, whether for breach of contract, tortious conduct, or otherwise and whether predicated on common law, statute or otherwise) shall be governed by and interpreted in accordance with the internal
laws of [...***...], including all matters of construction, validity and performance, and in each case without regard to its conflicts of laws rules that might lead to the application of the laws of any other jurisdiction. Notwithstanding the
foregoing, questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. 

 

	13.2	 ADR. If a dispute arises between the Parties, the Parties will follow the procedures set forth in Exhibit H.

  

	13.3	 Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but
no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party or Parties waiving such term or condition. Neither the waiver by any Party of any term or condition of this Agreement nor the
failure on the part of any Party, on one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall be deemed or construed to be a waiver of such term or condition for any similar instance in
the future or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation
or agreement. 

  

	13.4	 Notices. All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent to
the address below and shall be: (a) delivered personally; (b) sent by registered or certified mail, return receipt requested, postage prepaid; (c) sent via a reputable nationwide overnight courier service; or (d) sent by
facsimile transmission. Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if 

  
 *** Confidential Treatment
Requested 

	 	 
delivered by hand, three (3) business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1) business day after it is sent via a
reputable nationwide overnight courier service, or when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a business day; otherwise, on the next business day following such transmission).

 Notices to Abbott shall be addressed to: 

Abbott International Luxembourg S.à r.l. 

26, Boulevard Royal 

L-2449 Luxembourg 

Luxembourg 

Attention: Treasurer, Logistics 

With a copy to: 

Abbott International Luxembourg S.à r.l 

c/o Abbott Laboratories 

Pharmaceutical Products Group 

100 Abbott Park Road 

Abbott Park, IL 60064-3500 

Attention: Executive Vice President 

Facsimile No.: [...***...] 

Abbott Laboratories 

Pharmaceutical Products Group Legal Operations 

Bldg. AP6A-2 

100 Abbott Park Road 

Abbott Park, IL 60064-3500 

Attention: DVP & Associate General Counsel 

Fax: [...***...] 

Notices to Neurocrine shall be addressed to: 

Neurocrine Biosciences, Inc. 

12780 El Camino Real 

San Diego, California 92130 

Attention: Chief Executive Officer and President 

Fax: [...***...] 

with a copy to: General Counsel 

Fax: [...***...] 

Either Party may change its address by giving notice to the other Party in the manner provided above. 

 

	13.5	 Entire Agreement. This Agreement (including Exhibits and Schedules), contains the complete understanding of the Parties with respect
to the subject matter hereof and supersedes all prior agreements or understandings between the Parties with respect to the subject matter hereof, including the Confidential Disclosure Agreement between the Parties, dated [...***...]. None of
the terms of this Agreement shall be amended, supplemented or modified except in writing signed by duly authorized representatives of the Parties hereto. 

  
 *** Confidential Treatment
Requested 

	13.6	 Headings; References. Headings in this Agreement are for convenience of reference only and shall not be considered in construing this
Agreement. References to Articles, Sections, Exhibits and Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement unless otherwise specified. 

 

	13.7	 Severability. If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render
this entire Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not effect the validity of the remainder of this Agreement or any of its provisions; provided, however, the Parties shall
use their respective reasonable efforts to renegotiate the offending provisions to best accomplish the original intentions of the Parties. 

  

	13.8	 Registration and Filing of the Agreement. To the extent, if any, that counsel of a Party concludes in good faith that it is required
under applicable Laws to file or register this Agreement or a notification thereof with any Governmental Authority, including without limitation the US Securities and Exchange Commission, or the US Federal Trade Commission, in accordance with
applicable Laws, such Party may do so and shall provide the other Party to this Agreement with a written copy of all proposed filings or registrations to allow for a reasonably sufficient time for review and comment by the other Party. The other
Party shall cooperate in such filing or notification and shall execute all documents reasonably required in connection therewith. If confidential treatment of sensitive provisions of the Agreement is available, the Parties will request such
treatment and file a redacted copy of this Agreement mutually agreed to promptly following the Effective Date. The Parties shall promptly inform each other as to the activities or inquiries of any such Governmental Authority relating to this
Agreement, and shall cooperate to respond to any request for further information therefrom. 

  

	13.9	 Assignment. Except as expressly set forth herein, this Agreement may not be assigned or transferred, nor may any right or obligation
hereunder be assigned or transferred without the prior written consent of the other Party. 

  

	 	a)	 Abbott may assign this Agreement, in whole or in part, to an Affiliate of Abbott or in whole to a Third Party in connection with the transfer or
sale of all or substantially all of business unit which relates to this Agreement, or to a Third Party in the event of its merger, consolidation, change in control or similar transaction. 

 

	 	b)	 Neurocrine may assign this Agreement to the surviving entity in a merger, consolidation, reorganization or similar transaction of Neurocrine with
another person that does not constitute a Change of Control, provided the management and Board of Directors of the surviving entity are predominantly comprised of the Neurocrine management and Board of Directors immediately preceding the
transaction. 

  

	 	c)	 Subject to Section 11.6 (Change of Control), Neurocrine may assign this Agreement to a Change of Control party. 

Any attempted assignment not in accordance with this Section 13.9 shall be void. 

 

	13.10	 Successors and Assigns. This Agreement will be binding on and inure to the benefit of successors and permitted assigns.

	13.11	 Counterparts. This Agreement may be executed in any number of counterparts, each of which, when executed, shall be deemed an original
and all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures.

  

	13.12	 Force Majeure. The Parties agree that, if either of them find themselves wholly or partially unable to fulfill their respective
obligations in this Agreement by reasons of Force Majeure, the Party affected will advise the other Party in writing of its inability to perform giving a detailed explanation of the occurrence of the event which excuses performance as soon as
possible after the cause or event has occurred. If said notice is given, the performance of the Party giving the notification, except for the payment of funds and except as otherwise expressly provided in this Agreement, shall be abated, and any
time deadlines shall be extended, for so long as performance may be prevented by such event of Force Majeure. Except as otherwise expressly provided in this Agreement and except for the payment of funds that are due and payable, neither Party shall
be required to make up any performance that was prevented by Force Majeure. 

  

	13.13	 Non-Solicitation of Employees. Commencing on the Effective Date and for a period of [...***...] thereafter, neither Party
shall, directly or indirectly, actively recruit, or solicit any employee of the other Party with whom such Party has come into contact or interacted for the purposes of performing this Agreement, without the prior consent of the other Party For
purposes of this Section, “solicit” shall be deemed not to include: (a) circumstances where an employee of one Party or any of its Affiliates initially contacts the other Party, or any of such Party’s Affiliates, seeking
employment or (b) general solicitations of employment not specifically targeted at such employees. 

  

	13.14	 Third Party Beneficiaries. Except as provided in Article 10 (Indemnification and Insurance), None of the provisions of this
Agreement shall be for the benefit of or enforceable by any Third Party, including, any creditor of either Party hereto. Except as provided in Article 10 (Indemnification and Insurance), no such Third Party shall obtain any right under any
provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto. 

 

	13.15	 Relationship of the Parties. Each Party shall bear its own costs incurred in the performance of its obligations hereunder without
charge or expense to the other except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party’s employees or for any employee compensation or benefits
of the other Party’s employees. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractual or other
liability on the other Party without said Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party’s legal relationship under this Agreement to the other Party shall be that
of independent contractor. Nothing in this Agreement shall be construed to establish a relationship of partners or joint venturers between the Parties. 

  

	13.16	 Further Assurances. Following the date hereof, Neurocrine and Abbott shall, and shall cause each of their respective Affiliates to,
from time to time, execute and deliver such additional instruments, documents, conveyances or assurances and take such other actions as shall be 

  
 *** Confidential Treatment
Requested 

	 	 necessary or otherwise reasonably requested by Abbott or Neurocrine, to confirm and assure the rights and obligations provided for in this
Agreement, and render effective the consummation of the transactions contemplated thereby provided however that neither Party will be required under this Section 13.16 to deliver instruments, documents, conveyances or assurances of any third
Party. 

  

	13.17	 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting
and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	13.18	 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in
addition to any other remedy referred to in this Agreement or otherwise available under Law. 

  

	13.19	 Use Of Names, Logos Or Symbols. No Party shall use the name, trademarks, logos, physical likeness, employee names or owner symbol of
the other Party for any promotional or publicity purpose without the other Party’s prior written consent. The restrictions imposed by this Section 13.19 shall not prohibit either Party from making any disclosure identifying the other Party
that is required by Law or the requirements of a national securities exchange or similar regulatory body, provided the procedures set forth in Section 9.3(b) (Announcements) are followed. Nothing contained in this Agreement shall be
construed as granting either Party any rights or license to use any of the other Party’s trademarks or trade names without separate, express written permission of the owner of such trademark or trade name or name. 

 

	13.20	 Exhibits; Schedules. In the event of inconsistencies between this Agreement and any exhibits, schedules or attachments hereto, the
terms of this Agreement shall control. 

 [The remainder of this page is intentionally blank] 

 IN WITNESS WHEREOF, the Parties have signed this Agreement as of the date first written above.

 ABBOTT INTERNATIONAL LUXEMBOURG S.À R.L 
  

			
	 /s/ William J. Chase

	By:	 	William J. Chase
	Title:	 	Vice President, Corporate Licensing and Acquisitions

  

			
	NEUROCRINE BIOSCIENCES, INC.
	
	 /s/ Kevin C. Gorman

	By:	 	Kevin C. Gorman
	Title:	 	President and Chief Executive Officer

 Exhibit A 

Elagolix 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit B 

Follow-On Compounds 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit C 

Neurocrine Patent Rights 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit D 

Third Party Development Contracts 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit E 

Third Party Manufacturing Contracts 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit F 

Transition Plan 
 [...***...]

  
 *** Confidential
Treatment Requested 

 Exhibit G 

Collaborative Development Plan 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit H 

ALTERNATIVE DISPUTE RESOLUTION 

[...***...] 

  
 *** Confidential
Treatment Requested 

 Exhibit I 

PRESS RELEASE 
 ABBOTT PARK, Ill.
and SAN DIEGO, June 16 /PRNewswire-FirstCall/ — Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the
treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be
evaluated for the treatment of uterine fibroids. 
 “Extensive preclinical and clinical experience with elagolix suggests this drug
could be an important advance for women with endometriosis and uterine fibroids, highly prevalent conditions where there is a need for new treatments,” said John Leonard, M.D., senior vice president, pharmaceuticals, research and development,
Abbott. “This agreement enhances Abbott’s late stage pipeline, with the potential for additional compounds in earlier stage development.” 

Under the terms of the agreement, Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women’s and men’s health. Abbott will make an upfront payment of $75 million and will fund all ongoing development activities. Neurocrine is eligible to receive
additional milestone payments of approximately $500 million from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future
product sales. 
 “We are pleased to have one of the world’s most admired companies as our partner in developing our entire GnRH
portfolio for both women’s and men’s health indications,” said Kevin Gorman, president and chief executive officer, Neurocrine Biosciences. “Abbott shares our long-term vision for elagolix, and, together, we look forward to
bringing this important new treatment option to endometriosis and uterine fibroid sufferers.” 
 About GnRH and Elagolix 

Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels.
Elagolix has a unique profile that allows partial estrogen suppression. It maintains estradiol in the low-normal range, providing symptom reduction while avoiding significant bone loss or other adverse effects that can sometimes be associated with
excessive suppression of estrogen. In Phase II studies, elagolix has been found to be effective in reducing the pain associated with endometriosis. To date, elagolix has been studied in 18 clinical trials totaling more than 1,000 subjects. 

About Endometriosis and Uterine Fibroids 

Endometriosis is associated with a multitude of symptoms, some of the most common of which include pain related both to menstruation
(dysmenorrhea) as well as chronic pelvic pain 

 
throughout the menstrual cycle, and infertility. The World Endometriosis Research Foundation estimates that there are approximately 100 million women worldwide who suffer from endometriosis.
With annual healthcare costs and endometriosis-related productivity losses of approximately $4,000 per patient, the annual direct and indirect costs of endometriosis are estimated to exceed $20 billion in the United States alone. 

Uterine fibroids are benign tumors that form on the wall of the uterus. They are the most common type of growth found in a woman’s pelvis
and are most common in women aged 30-40 years. While many women do not have symptoms, depending on the size, location and number, uterine fibroids can cause heavy menstrual bleeding, can put pressure on the bladder and rectum, and can cause pain and
nausea. Symptoms can also include miscarriages and infertility. Depending on the symptoms, treatment sometimes requires surgery. 
 About Neurocrine
Biosciences 
 Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our
product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders.
Neurocrine Biosciences news releases are available through the Company’s website at http://www.neurocrine.com. 
 About Abbott Laboratories

 Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries. Abbott’s news releases and other information are
available on the company’s website at www.abbott.com 
 Neurocrine Biosciences Forward Looking Statement 

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties.
Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine’s business and finances in general, as well as risks and
uncertainties associated with the Company’s GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company’s GnRH program include, but are not limited to, risk that the elagolix
clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to Phase III clinical trials; risk associated with the Company’s dependence on Abbott for Phase III development, commercial
manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the
Company’s dependence on contract manufacturers for clinical drug supply; risks associated with the Company’s dependence on corporate collaborators for commercial manufacturing and marketing and sales

 
activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that
may limit demand for the Company’s products; and the other risks described in the Company’s report on Form 10-K for the year ended December 31, 2009 and reports on Form 10-Q for the quarter ended March 31, 2010. Neurocrine
undertakes no obligation to update the statements contained in this press release after the date hereof. 
 Abbott Forward Looking Statement 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental,
technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in
Item 1A, “Risk Factors,” to our Quarterly Report on Securities and Exchange Commission Form 10-Q for the period ended March 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any
revisions to forward-looking statements as a result of subsequent events or developments.EX-10.1

 Exhibit 10.1 

EXECUTION COPY 
  

 
  

CREDIT AGREEMENT 
 Dated
as of February 8, 2016 
 among 

NUVASIVE, INC., 
 as the
Borrower, 
 CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, 

as the Guarantors, 
 BANK
OF AMERICA, N.A., 
 as Administrative Agent, Swingline Lender and L/C Issuer, 

and 
 THE LENDERS PARTY
HERETO 
 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED, 

as Sole Lead Arranger and Sole Bookrunner 
  

 
  

 TABLE OF CONTENTS 
  

							
	 	 	 	  	Page	 
	 ARTICLE I
	 	 DEFINITIONS AND ACCOUNTING TERMS
	  	 	1	  
			
	 1.01
	 	 Defined Terms
	  	 	1	  
	 1.02
	 	 Other Interpretive Provisions
	  	 	35	  
	 1.03
	 	 Accounting Terms
	  	 	35	  
	 1.04
	 	 Rounding
	  	 	36	  
	 1.05
	 	 Times of Day
	  	 	36	  
	 1.06
	 	 Letter of Credit Amounts
	  	 	36	  
	 1.07
	 	 UCC Terms
	  	 	36	  
	 1.08
	 	 Exchange Rates; Currency Equivalents
	  	 	36	  
	 1.09
	 	 Additional Alternative Currencies
	  	 	37	  
	 1.10
	 	 Change of Currency
	  	 	38	  
			
	 ARTICLE II
	 	 COMMITMENTS AND CREDIT EXTENSIONS
	  	 	38	  
			
	 2.01
	 	 Loans
	  	 	38	  
	 2.02
	 	 Borrowings, Conversions and Continuations of Loans
	  	 	39	  
	 2.03
	 	 Letters of Credit
	  	 	40	  
	 2.04
	 	 Swingline Loans
	  	 	48	  
	 2.05
	 	 Prepayments
	  	 	51	  
	 2.06
	 	 Termination or Reduction of Commitments
	  	 	52	  
	 2.07
	 	 Repayment of Loans
	  	 	53	  
	 2.08
	 	 Interest and Default Rate
	  	 	53	  
	 2.09
	 	 Fees
	  	 	54	  
	 2.10
	 	 Computation of Interest and Fees; Retroactive Adjustments of Applicable Rate
	  	 	54	  
	 2.11
	 	 Evidence of Debt
	  	 	55	  
	 2.12
	 	 Payments Generally; Administrative Agent’s Clawback
	  	 	56	  
	 2.13
	 	 Sharing of Payments by Lenders
	  	 	58	  
	 2.14
	 	 Cash Collateral
	  	 	58	  
	 2.15
	 	 Defaulting Lenders
	  	 	59	  
	 2.16
	 	 Increase in Commitments
	  	 	62	  
			
	 ARTICLE III
	 	 TAXES, YIELD PROTECTION AND ILLEGALITY
	  	 	65	  
			
	 3.01
	 	 Taxes
	  	 	65	  
	 3.02
	 	 Illegality and Designated Lenders
	  	 	70	  
	 3.03
	 	 Inability to Determine Rates
	  	 	70	  
	 3.04
	 	 Increased Costs; Reserves on Eurocurrency Rate Loans
	  	 	71	  
	 3.05
	 	 Compensation for Losses
	  	 	72	  
	 3.06
	 	 Mitigation Obligations; Replacement of Lenders
	  	 	73	  
	 3.07
	 	 Survival
	  	 	73	  
			
	 ARTICLE IV
	 	 CONDITIONS PRECEDENT TO CREDIT EXTENSIONS
	  	 	73	  
			
	 4.01
	 	 Conditions of Initial Credit Extension
	  	 	73	  
	 4.02
	 	 Conditions to all Credit Extensions
	  	 	75	  
			
	 ARTICLE V
	 	 REPRESENTATIONS AND WARRANTIES
	  	 	76	  
			
	 5.01
	 	 Existence, Qualification and Power
	  	 	76	  
	 5.02
	 	 Authorization; No Contravention
	  	 	76	  
	 5.03
	 	 Governmental Authorization; Other Consents
	  	 	76	  
	 5.04
	 	 Binding Effect
	  	 	77	  

  
 i 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 5.05
	 	 Financial Statements; No Material Adverse Effect
	  	 	77	  
	 5.06
	 	 Litigation
	  	 	77	  
	 5.07
	 	 No Default
	  	 	77	  
	 5.08
	 	 Ownership of Property
	  	 	78	  
	 5.09
	 	 Environmental Compliance
	  	 	78	  
	 5.10
	 	 Insurance
	  	 	78	  
	 5.11
	 	 Taxes
	  	 	78	  
	 5.12
	 	 ERISA Compliance
	  	 	79	  
	 5.13
	 	 Margin Regulations; Investment Company Act
	  	 	79	  
	 5.14
	 	 Disclosure
	  	 	80	  
	 5.15
	 	 Compliance with Laws
	  	 	80	  
	 5.16
	 	 Solvency
	  	 	80	  
	 5.17
	 	 Reserved
	  	 	80	  
	 5.18
	 	 Sanctions Concerns and Anti-Corruption Laws
	  	 	80	  
	 5.19
	 	 Reserved.
	  	 	80	  
	 5.20
	 	 Subsidiaries; Equity Interests; Loan Parties
	  	 	80	  
	 5.21
	 	 Healthcare Regulatory Matters
	  	 	81	  
	 5.22
	 	 Intellectual Property; Licenses, Etc.
	  	 	82	  
	 5.23
	 	 EEA Financial Institutions
	  	 	82	  
			
	 ARTICLE VI
	 	 AFFIRMATIVE COVENANTS
	  	 	83	  
			
	 6.01
	 	 Financial Statements
	  	 	83	  
	 6.02
	 	 Certificates; Other Information
	  	 	84	  
	 6.03
	 	 Notices
	  	 	86	  
	 6.04
	 	 Payment of Obligations
	  	 	86	  
	 6.05
	 	 Preservation of Existence, Etc.
	  	 	87	  
	 6.06
	 	 Maintenance of Properties
	  	 	87	  
	 6.07
	 	 Maintenance of Insurance
	  	 	87	  
	 6.08
	 	 Compliance with Laws
	  	 	88	  
	 6.09
	 	 Books and Records
	  	 	88	  
	 6.10
	 	 Inspection Rights
	  	 	88	  
	 6.11
	 	 Use of Proceeds
	  	 	88	  
	 6.12
	 	 Material Contracts
	  	 	88	  
	 6.13
	 	 Covenant to Guarantee Obligations
	  	 	89	  
	 6.14
	 	 Covenant to Give Security
	  	 	89	  
	 6.15
	 	 Further Assurances
	  	 	90	  
	 6.16
	 	 Compliance with Environmental Laws
	  	 	91	  
	 6.17
	 	 Anti-Corruption Laws
	  	 	91	  
	 6.18
	 	 Post-Closing Covenants
	  	 	91	  
			
	 ARTICLE VII
	 	 NEGATIVE COVENANTS
	  	 	91	  
			
	 7.01
	 	 Liens
	  	 	91	  
	 7.02
	 	 Indebtedness
	  	 	94	  
	 7.03
	 	 Investments
	  	 	95	  
	 7.04
	 	 Fundamental Changes
	  	 	97	  
	 7.05
	 	 Dispositions
	  	 	97	  
	 7.06
	 	 Restricted Payments
	  	 	98	  
	 7.07
	 	 Change in Nature of Business
	  	 	99	  
	 7.08
	 	 Transactions with Affiliates
	  	 	100	  
	 7.09
	 	 Burdensome Agreements
	  	 	100	  

  
 ii 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 7.10
	 	 Use of Proceeds
	  	 	100	  
	 7.11
	 	 Financial Covenants
	  	 	101	  
	 7.12
	 	 Amendments of Organization Documents; Fiscal Year; Legal Name, State of Formation; Form of Entity and Accounting
Changes
	  	 	101	  
	 7.13
	 	 Sale and Leaseback Transactions
	  	 	101	  
	 7.14
	 	 Amendment, Etc.
	  	 	101	  
	 7.15
	 	 Sanctions
	  	 	102	  
	 7.16
	 	 Anti-Corruption Laws
	  	 	102	  
			
	 ARTICLE VIII
	 	 EVENTS OF DEFAULT AND REMEDIES
	  	 	102	  
			
	 8.01
	 	 Events of Default
	  	 	102	  
	 8.02
	 	 Remedies upon Event of Default
	  	 	104	  
	 8.03
	 	 Application of Funds
	  	 	105	  
			
	 ARTICLE IX
	 	 ADMINISTRATIVE AGENT
	  	 	106	  
			
	 9.01
	 	 Appointment and Authority
	  	 	106	  
	 9.02
	 	 Rights as a Lender
	  	 	107	  
	 9.03
	 	 Exculpatory Provisions
	  	 	107	  
	 9.04
	 	 Reliance by Administrative Agent
	  	 	108	  
	 9.05
	 	 Delegation of Duties
	  	 	108	  
	 9.06
	 	 Resignation of Administrative Agent
	  	 	109	  
	 9.07
	 	 Non-Reliance on Administrative Agent and Other Lenders
	  	 	109	  
	 9.08
	 	 No Other Duties, Etc.
	  	 	110	  
	 9.09
	 	 Administrative Agent May File Proofs of Claim; Credit Bidding
	  	 	110	  
	 9.10
	 	 Collateral and Guaranty Matters
	  	 	111	  
	 9.11
	 	 Secured Cash Management Agreements and Secured Hedge Agreements
	  	 	112	  
			
	 ARTICLE X
	 	 CONTINUING GUARANTY
	  	 	112	  
			
	 10.01
	 	 Guaranty
	  	 	112	  
	 10.02
	 	 Rights of Lenders
	  	 	113	  
	 10.03
	 	 Certain Waivers
	  	 	113	  
	 10.04
	 	 Obligations Independent
	  	 	113	  
	 10.05
	 	 Subrogation
	  	 	113	  
	 10.06
	 	 Termination; Reinstatement
	  	 	114	  
	 10.07
	 	 Stay of Acceleration
	  	 	114	  
	 10.08
	 	 Condition of Borrower
	  	 	114	  
	 10.09
	 	 Appointment of Borrower
	  	 	114	  
	 10.10
	 	 Right of Contribution
	  	 	114	  
	 10.11
	 	 Keepwell
	  	 	115	  
			
	 ARTICLE XI
	 	 MISCELLANEOUS
	  	 	115	  
			
	 11.01
	 	 Amendments, Etc.
	  	 	115	  
	 11.02
	 	 Notices; Effectiveness; Electronic Communications
	  	 	117	  
	 11.03
	 	 No Waiver; Cumulative Remedies; Enforcement
	  	 	118	  
	 11.04
	 	 Expenses; Indemnity; Damage Waiver
	  	 	119	  
	 11.05
	 	 Payments Set Aside
	  	 	121	  
	 11.06
	 	 Successors and Assigns
	  	 	121	  
	 11.07
	 	 Treatment of Certain Information; Confidentiality
	  	 	126	  
	 11.08
	 	 Right of Setoff
	  	 	127	  

  
 iii 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 11.09
	 	 Interest Rate Limitation
	  	 	127	  
	 11.10
	 	 Counterparts; Integration; Effectiveness
	  	 	128	  
	 11.11
	 	 Survival of Representations and Warranties
	  	 	128	  
	 11.12
	 	 Severability
	  	 	128	  
	 11.13
	 	 Replacement of Lenders
	  	 	129	  
	 11.14
	 	 Governing Law; Jurisdiction; Etc.
	  	 	129	  
	 11.15
	 	 Waiver of Jury Trial
	  	 	130	  
	 11.16
	 	 Subordination
	  	 	131	  
	 11.17
	 	 No Advisory or Fiduciary Responsibility
	  	 	131	  
	 11.18
	 	 Electronic Execution
	  	 	132	  
	 11.19
	 	 USA PATRIOT Act Notice
	  	 	132	  
	 11.20
	 	 Judgment Currency
	  	 	132	  
	 11.21
	 	 Acknowledgement and Consent to Bail-In of EEA Financial Institutions
	  	 	133	  

  
 iv 

 SCHEDULES AND EXHIBITS 

 

			
	 SCHEDULES
	  	
		
	 Schedule 1.01(a)
	  	 Certain Addresses for Notices

	 Schedule 1.01(b)
	  	 Initial Commitments and Applicable Percentages

		
	 EXHIBITS
	  	
		
	 Exhibit A
	  	 Form of Administrative Questionnaire

	 Exhibit B
	  	 Form of Assignment and Assumption

	 Exhibit C
	  	 Form of Compliance Certificate

	 Exhibit D
	  	 Form of Joinder Agreement

	 Exhibit E
	  	 Form of Loan Notice

	 Exhibit F
	  	 Form of Permitted Acquisition Certificate

	 Exhibit G
	  	 Form of Revolving Note

	 Exhibit H
	  	 Form of Secured Party Designation Notice

	 Exhibit I
	  	 Form of Solvency Certificate

	 Exhibit J
	  	 Form of Swingline Loan Notice

	 Exhibit L
	  	 Form of Officer’s Certificate

	 Exhibit M
	  	 Forms of U.S. Tax Compliance Certificates

	 Exhibit N
	  	 Form of Notice of Loan Prepayment

  
 v 

 CREDIT AGREEMENT 

This CREDIT AGREEMENT is entered into as of February 8, 2016, among NUVASIVE, INC., a Delaware corporation (the
“Borrower”), the Guarantors (defined herein), the Lenders (defined herein), and BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and L/C Issuer. 

PRELIMINARY STATEMENTS: 

WHEREAS, the Loan Parties (as hereinafter defined) have requested that the Lenders, the Swingline Lender and the L/C Issuer
make loans and other financial accommodations to the Loan Parties in an aggregate amount of up to $150,000,000. 
 WHEREAS,
the Lenders, the Swingline Lender and the L/C Issuer have agreed to make such loans and other financial accommodations to the Loan Parties on the terms and subject to the conditions set forth herein. 

NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree
as follows: 
 ARTICLE I 

DEFINITIONS AND ACCOUNTING TERMS 
  

	 1.01
	 Defined Terms. 

As used in this Agreement, the following terms shall have the meanings set forth below: 

“Acquired EBITDA” means, with respect to any Target acquired during the applicable Measurement Period,
Consolidated EBITDA for such Target (determined as if references to the Borrower and the Subsidiaries in the definition of Consolidated EBITDA were references to such Target and its Subsidiaries) for the most recent four (4) fiscal quarter
period preceding the acquisition thereof, as adjusted (without duplication) by verifiable expense reductions and other add-backs described in clause (b)(ix) of the definition of Consolidated EBITDA, including excess owner compensation, if any, which
are expected to be realized, in each case of such adjustments (if any) calculated on a quarter by quarter basis by the Loan Parties. 

“Acquisition” means the acquisition, whether through a single transaction or a series of related
transactions, of (a) a majority of the Voting Stock or other controlling ownership interest in another Person (including the purchase of an option, warrant or convertible or similar type security to acquire such a controlling interest at the
time it becomes exercisable by the holder thereof), whether by purchase of such equity or other ownership interest or upon the exercise of an option or warrant for, or conversion of securities into, such equity or other ownership interest, or
(b) assets of another Person which constitute all or substantially all of the assets of such Person or of a division, line of business or other business unit of such Person. 

“Additional Secured Obligations” means all obligations arising under Secured Cash Management Agreements and
Secured Hedge Agreements, in each case whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the
commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such
proceeding; provided that Additional Secured Obligations of a Guarantor shall exclude any Excluded Swap Obligations with respect to such Guarantor. 

  
 1 

 “Administrative Agent” means Bank of America in its capacity as
administrative agent under any of the Loan Documents, or any successor administrative agent. 
 “Administrative
Agent’s Office” means, with respect to any currency, the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 1.01(a) with respect to such currency, or such other address or account with
respect to such currency as the Administrative Agent may from time to time notify the Borrower and the Lenders. 

“Administrative Questionnaire” means an Administrative Questionnaire in substantially the form of Exhibit
A or any other form approved by the Administrative Agent. 
 “Affiliate” means, with respect to a
specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 

“Aggregate Commitments” means the Commitments of all the Lenders. 

“Agreement” means this Credit Agreement. 

“Agreement Currency” has the meaning specified in Section 11.22. 

“Alternative Currency” means each of the following currencies: (a) Euro, (b) Australian Dollar,
(c) Yen and (d) Sterling, together with each other currency (other than Dollars) that is approved in accordance with Section 1.09. 

“Alternative Currency Equivalent” means, at any time, with respect to any amount denominated in Dollars, the
equivalent amount thereof in the applicable Alternative Currency as determined by the Administrative Agent at such time on the basis of the Spot Rate (determined in respect of the most recent Revaluation Date) for the purchase of such Alternative
Currency with Dollars. 
 “Alternative Currency Sublimit” means an amount equal to the lesser of the
Aggregate Commitments and $50,000,000. The Alternative Currency Sublimit is part of, and not in addition to, the Aggregate Commitments. 

“Applicable Percentage” means, with respect to any Lender at any time, the percentage (carried out to the
ninth decimal place) of the Aggregate Commitments represented by such Lender’s Commitment at such time, subject to adjustment as provided in Section 2.15. If the Commitment of all of the Lenders to make Loans and the obligation of
the L/C Issuer to make L/C Credit Extensions have been terminated pursuant to Section 8.02, or if the Commitments have expired, then the Applicable Percentage of each Lender shall be determined based on the Applicable Percentage of such
Lender most recently in effect, giving effect to any subsequent assignments. The Applicable Percentage of each Lender is set forth opposite the name of such Lender on Schedule 1.01(b) or in the Assignment and Assumption pursuant to which such
Lender becomes a party hereto, as applicable. 

  
 2 

 
“Applicable Rate” means, for any day, the rate per annum set forth below opposite the applicable Level then in effect (based on the Consolidated Leverage Ratio), it being
understood that the Applicable Rate for (a) Base Rate Loans shall be the percentage set forth under the column “Base Rate”, (b) Eurocurrency Rate Loans shall be the percentage set forth under the column “Eurocurrency Rate
& Letter of Credit Fee”, (c) the Letter of Credit Fee shall be the percentage set forth under the column “Eurocurrency Rate & Letter of Credit Fee”, and (d) the Commitment Fee shall be the percentage set forth
under the column “Commitment Fee”: 
  

									
	 Applicable Rate

	 Level
	 	 Consolidated Leverage Ratio
	 	Eurocurrency Rate &
Letter of Credit Fee	 	Base
Rate	 	Commitment
Fee
	 1
	 	 Less than 1.00 to 1.00
	 	1.00%	 	0.00%	 	0.20%
	 2
	 	 Greater than or equal to 1.00 to 1.00 but less than 2.00 to 1.00
	 	1.50%	 	0.50%	 	0.30%
	 3
	 	 Greater than or equal to 2.00 to 1.00 but less than 3.00 to 1.00
	 	1.75%	 	1.00%	 	0.40%
	 4
	 	 Greater than or equal to 3.00 to 1.00
	 	2.00%	 	1.25%	 	0.40%

 Any increase or decrease in the Applicable Rate resulting from a change in the Consolidated Leverage Ratio
shall become effective as of the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to Section 6.02(a); provided, however, that if a Compliance Certificate is not delivered when
due in accordance with such Section, then, upon the request of the Required Lenders, Pricing Level 4 shall apply, in each case as of the first Business Day after the date on which such Compliance Certificate was required to have been delivered and
in each case shall remain in effect until the first Business Day following the date on which such Compliance Certificate is delivered. 

Notwithstanding anything to the contrary contained in this definition, (a) the determination of the Applicable Rate for any period shall
be subject to the provisions of Section 2.10(b) and (b) the initial Applicable Rate shall be set forth in Level 2 until the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to
Section 6.02(a) to the Administrative Agent for the fiscal quarter of the Borrower ending September 30, 2016. Any adjustment in the Applicable Rate shall be applicable to all Credit Extensions then existing or subsequently made or
issued. 
 The Applicable Rate set forth above shall be increased as, and to the extent, required by Section 2.16. 

“Applicable Time” means, with respect to any borrowings and payments in any Alternative Currency, the local
time in the place of settlement for such Alternative Currency as may be determined by the Administrative Agent or the L/C Issuer, as the case may be, to be necessary for timely settlement on the relevant date in accordance with normal banking
procedures in the place of payment. 
 “Appropriate Lender” means, at any time, (a) a Lender that has
a Commitment or holds a Loan under the Aggregate Commitments at such time, (b) with respect to the Letter of Credit Sublimit, (i) the L/C Issuer and (ii) if any Letters of Credit have been issued pursuant to Section 2.03, the
Lenders and (c) with respect to the Swingline Sublimit, (i) the Swingline Lender and (ii) if any Swingline Loans are outstanding pursuant to Section 2.04(a), the Lenders. 

“Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of
a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. 

“Arranger” means Merrill Lynch, Pierce, Fenner & Smith Incorporated, in its capacity as sole lead
arranger and sole bookrunner. 

  
 3 

 “Assignment and Assumption” means an assignment and assumption
entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 11.06(b)), and accepted by the Administrative Agent, in substantially the form of Exhibit B or any other form
(including an electronic documentation form generated by use of an electronic platform) approved by the Administrative Agent. 

“Attributable Indebtedness” means, on any date, (a) in respect of any Capitalized Lease of any Person,
the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b) in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining lease or similar
payments under the relevant lease or other applicable agreement or instrument that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease or other agreement or instrument were accounted for as a
Capitalized Lease. 
 “Audited Financial Statements” means the audited Consolidated balance sheet of the
Borrower and its Subsidiaries for the fiscal year ended December 31, 2014, and the related Consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year of the Borrower and its Subsidiaries,
including the notes thereto. 
 “Australian Dollar” means the lawful currency of Australia. 

“Auto-Extension Letter of Credit” has the meaning set forth in Section 2.03(b). 

“Availability Period” means the period from and including the Closing Date to the earliest of (i) the
Maturity Date, (ii) the date of termination of the Commitments pursuant to Section 2.06, and (iii) the date of termination of the Commitment of each Lender to make Loans and of the obligation of the L/C Issuer to make L/C Credit
Extensions pursuant to Section 8.02. 
 “Bail-In Action” means the exercise of any Write-Down and
Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution. 

“Bail-In Legislation” means, with respect to any EEA Member Country implementing Article 55 of Directive
2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule. 

“Bank of America” means Bank of America, N.A. and its successors. 

“Base Rate” means for any day a fluctuating rate of interest per annum equal to the highest of (a) the
Federal Funds Rate plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate,” and (c) the Eurocurrency Rate plus 1.00%; and if the Base Rate
shall be less than zero, such rate shall be deemed zero for purposes of this Agreement. The “prime rate” is a rate set by Bank of America based upon various factors including Bank of America’s costs and desired return, general
economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate. Any change in such prime rate announced by Bank of America shall take effect at the opening
of business on the day specified in the public announcement of such change. 
 “Base Rate Loan” means a
Revolving Loan that bears interest based on the Base Rate. 
 “Borrower” has the meaning specified in the
introductory paragraph hereto. 

  
 4 

 “Borrower Materials” has the meaning specified in
Section 6.02. 
 “Borrowing” means a Revolving Borrowing or a Swingline Borrowing, as the
context may require. 
 “Business Day” means any day other than a Saturday, Sunday or other day on which
commercial banks are authorized to close under the Laws of, or are in fact closed in, the state where the Administrative Agent’s Office is located and: 

(a) if such day relates to any interest rate settings as to a Eurocurrency Rate Loan denominated in Dollars,
any fundings, disbursements, settlements and payments in Dollars in respect of any such Eurocurrency Rate Loan, or any other dealings in Dollars to be carried out pursuant to this Agreement in respect of any such Eurocurrency Rate Loan, means any
such day that is also a London Banking Day; 
 (b) if such day relates to any interest rate settings as to a
Eurocurrency Rate Loan denominated in Euro, any fundings, disbursements, settlements and payments in Euro in respect of any such Eurocurrency Rate Loan, or any other dealings in Euro to be carried out pursuant to this Agreement in respect of any
such Eurocurrency Rate Loan, means a TARGET Day; 
 (c) if such day relates to any interest rate settings as
to a Eurocurrency Rate Loan denominated in a currency other than Dollars or Euro, means any such day on which dealings in deposits in the relevant currency are conducted by and between banks in the London or other applicable offshore interbank
market for such currency; and 
 (d) if such day relates to any fundings, disbursements, settlements and
payments in a currency other than Dollars or Euro in respect of a Eurocurrency Rate Loan denominated in a currency other than Dollars or Euro, or any other dealings in any currency other than Dollars or Euro to be carried out pursuant to this
Agreement in respect of any such Eurocurrency Rate Loan (other than any interest rate settings), means any such day on which banks are open for foreign exchange business in the principal financial center of the country of such currency. 

“Capitalized Leases” means all leases that have been or should be, in accordance with GAAP, recorded as
capitalized leases. 
 “Cash Collateralize” means, to pledge and deposit with or deliver to the
Administrative Agent, for the benefit of one or more of the L/C Issuers or Swingline Lender (as applicable) or the Lenders, as collateral for L/C Obligations, the Obligations in respect of Swingline Loans, or obligations of the Lenders to fund
participations in respect of either thereof (as the context may require), (a) cash or deposit account balances, (b) backstop letters of credit entered into on terms and from issuers satisfactory to the Administrative Agent and the
applicable L/C Issuer and in amounts equal to the outstanding L/C Obligations, and/or (c) if the Administrative Agent and the applicable L/C Issuer or Swingline Lender shall agree, in their sole discretion, other credit support, in each case,
in Dollars and pursuant to documentation in form and substance satisfactory to the Administrative Agent and such L/C Issuer or Swingline Lender (as applicable). “Cash Collateral” shall have a meaning correlative to the foregoing and
shall include the proceeds of such cash collateral and other credit support. 

  
 5 

 “Cash Equivalents” means any of the following types of
Investments, to the extent owned by the Borrower or any of its Subsidiaries free and clear of all Liens (other than Permitted Liens): 

(a) readily marketable obligations issued or directly and fully guaranteed or insured by the United States or
any agency or instrumentality thereof having maturities of not more than three hundred sixty five days (365) days from the date of acquisition thereof; provided that the full faith and credit of the United States is pledged in support
thereof; 
 (b) time deposits with, or insured certificates of deposit or bankers’ acceptances of, any
commercial bank that (i) (A) is a Lender or (B) is organized under the laws of the United States, any state thereof or the District of Columbia or is the principal banking subsidiary of a bank holding company organized under the laws
of the United States, any state thereof or the District of Columbia, and is a member of the Federal Reserve System, (ii) issues (or the parent of which issues) commercial paper rated as described in clause (c) of this definition and
(iii) has combined capital and surplus of at least $500,000,000, in each case with maturities of not more than three hundred sixty five (365) days from the date of acquisition thereof; 

(c) commercial paper issued by any Person organized under the laws of any state of the United States and rated
at least “Prime-1” (or the then equivalent grade) by Moody’s or at least “A-1” (or the then equivalent grade) by S&P, in each case with maturities of not more than three hundred sixty five (365) days from the date
of acquisition thereof; 
 (d) Investments, classified in accordance with GAAP as current assets of the
Borrower or any of its Subsidiaries, in money market investment programs registered under the Investment Company Act of 1940, which are administered by financial institutions that have the highest rating obtainable from either Moody’s or
S&P, and the portfolios of which are limited solely to Investments of the character, quality and maturity described in clauses (a), (b) and (c) of this definition; 

(e) fully collateralized repurchase agreements with a term of not more than thirty (30) days for
securities described in clauses (a) and (b) above and entered into with financial institutions satisfying the criteria described in clause (b) above; 

(f) other comparable short-term investments of a Foreign Subsidiary in the ordinary course of business utilized
by Foreign Subsidiaries or by the Borrower in connection with its foreign operations; and 
 (g) investments
in the ordinary course of business in accordance with the investment policy of the Borrower in the form delivered to the Administrative Agent prior to the Closing Date. 

“Cash Management Agreement” means any agreement that is not prohibited by the terms hereof to provide
treasury or cash management services, including deposit accounts, overnight draft, credit cards, debit cards, p-cards (including purchasing cards and commercial cards), funds transfer, automated clearinghouse, zero balance accounts, returned check
concentration, controlled disbursement, lockbox, account reconciliation and reporting and trade finance services and other cash management services. 

“Cash Management Bank” means any Person in its capacity as a party to a Cash Management Agreement that,
(a) at the time it enters into a Cash Management Agreement with a Loan Party or any Subsidiary, is a Lender or an Affiliate of a Lender, or (b) at the time it (or its Affiliate) becomes a Lender on the Closing Date, is a party to a Cash
Management Agreement with a Loan Party or any Subsidiary, in each case in its capacity as a party to such Cash Management Agreement (even if such Person ceases to be a Lender or such Person’s Affiliate ceases to be a Lender); provided,
however, that for any of the foregoing to be included as a “Secured Cash Management Agreement” on any date of determination by the Administrative Agent, the applicable Cash Management Bank (other than the Administrative Agent or an
Affiliate of the Administrative Agent) must have delivered a Secured Party Designation Notice to the Administrative Agent prior to such date of determination. 

  
 6 

 “CFC” means a Person that is a controlled foreign corporation
under Section 957 of the Code. 
 “Change in Law” means the occurrence, after the Closing Date, of any
of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any
Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary,
(i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank
for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a
“Change in Law”, regardless of the date enacted, adopted or issued. 
 “Change of Control” means
an event or series of events by which: 
 (a) any “person” or “group” (as such terms are
used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or
administrator of any such plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to have “beneficial ownership” of all
securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of thirty-five percent (35)% or more
of the Equity Interests of the Borrower entitled to vote for members of the board of directors or equivalent governing body of the Borrower on a fully-diluted basis (and taking into account all such securities that such “person” or
“group” has the right to acquire pursuant to any option right); or 
 (b) during any period of
twelve (12) consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Borrower cease to be composed of individuals (i) who were members of that board or equivalent governing body on
the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a
majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time
of such election or nomination at least a majority of that board or equivalent governing body. 
 “Closing
Date” means the date hereof. 
 “Code” means the Internal Revenue Code of 1986. 

“Collateral” means all of the “Collateral” referred to in the Collateral Documents and all
of the other property that is or is intended under the terms of the Collateral Documents to be subject to Liens in favor of the Administrative Agent for the benefit of the Secured Parties. 

  
 7 

 “Collateral Documents” means, collectively, the Security
Agreement, the Disclosure Letter to Security Agreement, each Joinder Agreement, each of the mortgages, collateral assignments, security agreements, pledge agreements or other similar agreements delivered to the Administrative Agent pursuant to
Section 6.14, and each of the other agreements, instruments or documents that creates or purports to create a Lien in favor of the Administrative Agent for the benefit of the Secured Parties. 

“Commitment” means, as to each Lender, its obligation to (a) make Revolving Loans to the Borrower
pursuant to Section 2.01, (b) purchase participations in L/C Obligations, and (c) purchase participations in Swingline Loans, in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite
such Lender’s name on Schedule 1.01(b) under the caption “Commitment” or opposite such caption in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted
from time to time in accordance with this Agreement. The Commitment of all of the Lenders on the Closing Date shall be $150,000,000. 

“Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.), as amended from
time to time, and any successor statute. 
 “Compliance Certificate” means a certificate substantially in
the form of Exhibit C. 
 “Connection Income Taxes” means Other Connection Taxes that are
imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes. 

“Consolidated” means, when used with reference to financial statements or financial statement items of the
Borrower and its Subsidiaries or any other Person, such statements or items on a consolidated basis in accordance with the consolidation principles of GAAP. 

“Consolidated EBITDA” means, for any period, the sum of the following determined on a Consolidated basis,
without duplication, for the Borrower and its Subsidiaries in accordance with GAAP, (a) Consolidated Net Income for the most recently completed Measurement Period plus (b) the following to the extent deducted in calculating such
Consolidated Net Income (without duplication): (i) Consolidated Interest Charges, (ii) the provision for federal, state, local and foreign income taxes payable, (iii) depreciation and amortization expense, (iv) all losses (less
gains) in respect of Swap Contracts, (v) fees and expenses incurred in connection with the negotiation, execution and delivery on the Closing Date of the Loan Documents to the extent such fees and expenses in the aggregate do not exceed
$500,000 and were incurred on or prior to the Closing Date or within 60 days after the Closing Date, (vi) (A) fees and expenses incurred in connection with any Acquisition and Disposition permitted hereunder, whether or not consummated,
(B) fees and expenses incurred in connection with severance costs, relocation costs, integration and facilities opening and closing costs, signing costs, retention or completion bonuses, transition costs and restructuring charges or reserves
(including restructuring costs related to Acquisitions after the date hereof and to closure and/or consolidation of facilities) and (C) fees, costs, expenses, charges and losses (including, without limitation, settlement amounts and judgment
amounts) paid in connection with litigation involving a Loan Party, including, without limitation, all reasonable out-of-pocket legal fees and expenses (other than any such fees, costs, expenses charges and losses incurred in connection with the
Medtronic Litigation), in each case of clauses (A), (B) and (C), to the extent all such fees, costs and expenses under clauses (A), (B) and (C) do not exceed 15% of Consolidated EBITDA in the aggregate for such Measurement Period,
(vii) fees, costs, expenses, charges and losses incurred in connection with the Medtronic Litigation, including, without limitation, reasonable out-of-pocket legal fees and expenses, provided that the aggregate amount added back pursuant to
this clause (vii) shall not exceed $85,000,000 in the aggregate; (viii) fees and expenses related to the issuance of Equity Interests or Indebtedness or any other capital markets transactions, including the termination, repurchase,
redemption or refinancing of any of the foregoing, (ix) without duplication of any amounts included in calculating Acquired EBITDA, “run rate” synergies, operating expense reductions and other operating improvements and cost savings
in Acquisitions that are reasonably identifiable, factually supportable, expected to have a continuing impact on the operations of the Borrower and its Subsidiaries and certified by a Responsible Officer of the Borrower as having been determined in
good faith to be reasonably anticipated to be realizable within twelve (12) months following any such Acquisition, net of actual benefits realized; provided that the aggregate amount added back pursuant to this clause (ix) shall not exceed
10% of Consolidated EBITDA in the aggregate for such Measurement Period, ix) proceeds of business interruption insurance actually received in cash during such period, (xi) charges, losses and expenses to the extent indemnified or insured or
reimbursed by a third party to the extent such indemnification, insurance or reimbursement is actually received in cash for such period, (xii) non-cash charges and losses, including, without limitation, any non-cash loss or expense (or income
or gain) due to the application of FASB ASC 815-10 regarding hedging activity, FASB ASC-350 regarding impairment of goodwill, FASB ASC 480-10 regarding accounting for financial instruments with debt and equity characteristics, non-cash foreign
currency exchange losses (or minus gains), the refinancing of convertible indebtedness and non-cash expenses deducted as a result of any grant of Equity Interests to employees, officers or directors (excluding any such non-cash charges or losses to
the extent there were cash charges with respect to such charges and losses in past accounting periods) less (c) without duplication and to the extent reflected as a gain or otherwise included in the calculation of Consolidated Net Income
for such period (i) non-cash gains (excluding any such non-cash gains to the extent (A) there were cash gains with respect to such gains in past accounting periods or (B) there is a reasonable expectation that there will be cash gains
with respect to such gains in future accounting periods), or (ii) all cash charges and losses incurred in such Measurement Period to the extent that such charges and losses were included in the calculation of Consolidated EBITDA under clause
(xii) above in a prior Measurement Period. 

  
 8 

 There shall be included in determining Consolidated EBITDA for any Measurement Period, without
duplication, (i) the Acquired EBITDA of any Target owned, directly or indirectly, by the Loan Parties for which the total consideration paid or payable (including without limitation, all transaction costs, assumed Indebtedness and liabilities
incurred, assumed or reflected on a consolidated balance sheet of the Loan Parties and their Subsidiaries after giving effect to such Acquisition and the maximum amount of all deferred payments, including earnouts but excluding any Equity Interests
of the Borrower) was greater than or equal to $15,000,000 (each, a “Material Acquisition”) and for which the Administrative Agent has received financial statements pursuant to Section 6.01(b) for less than four
(4) fiscal quarters, Acquired EBITDA allocated to each quarter prior to the acquisition thereof included in the trailing four (4) fiscal quarter period for which Acquired EBITDA is being calculated minus (ii) with respect to
any Material Disposition consummated within the Measurement Period, Consolidated EBITDA (if any) attributable to the Subsidiary, profit centers or other asset which is the subject of such Material Disposition from the beginning of such period until
the date of consummation of such Material Disposition. 
 “Consolidated Funded Indebtedness” means, as of
any date of determination, for the Borrower and its Subsidiaries on a Consolidated basis, the sum of (a) the outstanding principal amount of all obligations, whether current or long-term, for borrowed money (including the principal amount of
the Obligations hereunder) and all obligations evidenced by bonds, debentures, notes, loan agreements or other similar instruments; (b) all purchase money Indebtedness; (c) the face amount of all letters of credit issued (including standby
and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments; (d) all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course
of business); (e) all Attributable Indebtedness; (f) all obligations to purchase, redeem, retire, defease or otherwise make any payment prior to the Maturity Date in respect of any Equity Interest or any warrant, right or option to acquire
such Equity Interest, valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends; (g) without duplication, all Guarantees with respect
to outstanding Indebtedness of the types specified in clauses (a) through (f) above of Persons other than the Borrower or any Subsidiary; and (h) all Indebtedness of the types referred to in clauses (a) through (g) above of
any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which the Borrower or a Subsidiary is a general partner or joint venturer, unless such Indebtedness is expressly made
non-recourse to the Borrower or such Subsidiary. 

  
 9 

 “Consolidated Interest Charges” means, for any Measurement
Period, the sum of (a) all interest, premium payments, debt discount, fees, charges and related expenses in connection with borrowed money (including capitalized interest) or in connection with the deferred purchase price of assets, in each
case to the extent treated as interest in accordance with GAAP, (b) all interest paid or payable with respect to discontinued operations and (c) the portion of rent expense under Capitalized Leases that is treated as interest in accordance
with GAAP, in each case, of or by the Borrower and its Subsidiaries on a Consolidated basis for the most recently completed Measurement Period. 

For purposes of calculating Consolidated Interest Charges for any Measurement Period, (i) if during such Measurement Period the Loan
Parties shall have made a Material Acquisition or a Material Disposition, Consolidated Interest Charges for such Measurement Period shall be calculated after giving Pro Forma Effect thereto. 

“Consolidated Interest Coverage Ratio” means, as of any date of determination, the ratio of
(a) Consolidated EBITDA for the most recently completed Measurement Period to (b) Consolidated Interest Charges for the most recently completed Measurement Period. 

“Consolidated Leverage Ratio” means, as of any date of determination, the ratio of (a) Consolidated
Funded Indebtedness as of such date to (b) Consolidated EBITDA for the most recently completed Measurement Period. 

“Consolidated Net Income” means, at any date of determination, the net income (or loss) of the Borrower and
its Subsidiaries on a Consolidated basis for the most recently completed Measurement Period; provided that Consolidated Net Income shall exclude (a) gains and losses from unusual or infrequently occurring events for such Measurement
Period, (b) the net income of any Subsidiary during such Measurement Period to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary of such income is not permitted by operation of the terms of its
Organization Documents or any agreement, instrument or Law applicable to such Subsidiary during such Measurement Period, and (c) any income (or loss) for such Measurement Period of any Person if such Person is not a Subsidiary, except that the
equity of the Borrower or any of its Subsidiaries in the net income of any such Person for such Measurement Period shall be included in Consolidated Net Income up to the aggregate amount of cash actually distributed by such Person during such
Measurement Period to the Borrower or a Subsidiary as a dividend or other distribution (and in the case of a dividend or other distribution to a Subsidiary, such Subsidiary is not precluded from further distributing such amount to the Borrower as
described in clause (b) of this proviso). 
 “Contractual Obligation” means, as to any Person, any
provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound. 

“Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 

  
 10 

 “Convertible Indebtedness Documents” means, collectively, the
Convertible Note Indenture and the Convertible Notes. 
 “Convertible Note Indenture” means that certain
Indenture, dated June 28, 2011, between the Borrower and U.S. Bank National Association, as trustee. 

“Convertible Notes” means the 2.75% Senior Convertible Notes issued by the Borrower pursuant to the
Convertible Note Indenture. 
 “Cost of Acquisition” means, with respect to any Acquisition, as at the date
of entering into any agreement therefor, the sum of the following (without duplication): (a) the value of the Equity Interests of the Borrower or any Subsidiary to be transferred in connection with such Acquisition, (b) the amount of any
cash and fair market value of other property (excluding property described in clause (a) and the unpaid principal amount of any debt instrument) given as consideration in connection with such Acquisition, (c) the amount (determined by
using the face amount or the amount payable at maturity, whichever is greater) of any Indebtedness incurred, assumed or acquired by the Borrower or any Subsidiary in connection with such Acquisition, (d) all additional purchase price amounts in
the form of earnouts and other contingent obligations that should be recorded on the financial statements of the Borrower and its Subsidiaries in accordance with GAAP in connection with such Acquisition, (e) all amounts paid in respect of
covenants not to compete and consulting agreements (other than customary employment agreements in the ordinary course of business consistent with past practice) that should be recorded on the financial statements of the Borrower and its Subsidiaries
in accordance with GAAP, and (f) the aggregate fair market value of all other consideration given by the Borrower or any Subsidiary in connection with such Acquisition. For purposes of determining the Cost of Acquisition for any transaction,
the Equity Interests of the Borrower shall be valued in accordance with GAAP. 
 “Credit Extension” means
each of the following: (a) a Borrowing and (b) an L/C Credit Extension. 
 “Debtor Relief Laws”
means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of
the United States or other applicable jurisdictions from time to time in effect. 
 “Default” means any
event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default. 

“Default Rate” means (a) with respect to any Obligation for which a rate is specified, a rate per annum
equal to two percent (2%) in excess of the rate otherwise applicable thereto and (b) with respect to any Obligation for which a rate is not specified or available, a rate per annum equal to the Base Rate plus the Applicable Rate for
Revolving Loans that are Base Rate Loans plus two percent (2%), in each case, to the fullest extent permitted by applicable Law. 

  
 11 

 “Defaulting Lender” means, subject to Section 2.15(b), any
Lender that (a) has failed to (i) fund all or any portion of its Loans within two (2) Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in
writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing)
has not been satisfied, or (ii) pay to the Administrative Agent, the L/C Issuer, the Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or
Swingline Loans) within two (2) Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent, the L/C Issuer or the Swingline Lender in writing that it does not intend to comply with its funding obligations
hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such position is based on such Lender’s determination that a
condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) Business Days
after written request by the Administrative Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder (provided that such Lender shall
cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the
subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its
business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity or (iii) become the subject of a Bail-in Action; provided that a Lender shall not be a
Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide
such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or
disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above, and the effective date of such status,
shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.15(b)) as of the date established therefor by the Administrative Agent in a written notice of such
determination, which shall be delivered by the Administrative Agent to the Borrower, the L/C Issuer, the Swingline Lender and each other Lender promptly following such determination. 

“Designated Jurisdiction” means any country or territory to the extent that such country or territory itself
is the subject of any Sanctions. 
 “Disclosure Letter” means the Disclosure Schedule Letter to the Credit
Agreement, dated as of the Closing Date, executed by the Loan Parties in favor of the Administrative Agent and the Lenders. 

“Disclosure Letter to Security Agreement” means the Disclosure Schedule Letter to the Security Agreement,
dated as of the Closing Date, executed by the Loan Parties in favor of the Administrative Agent and the Lenders. 

“Disposition” or “Dispose” means the sale, transfer, license, lease or other disposition
(including any Sale and Leaseback Transaction) of any property by any Loan Party or Subsidiary (or, following the Closing Date, the granting of any option or other right to do any of the foregoing), including any sale, assignment, transfer or other
disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith, but excluding any Involuntary Disposition; provided that “Disposition” or “Dispose” shall not mean the
issuance of any Equity Interests of the Borrower or the granting of any option or right with respect thereto. 

“Disqualified Stock” has the meaning specified in clause (g) of the definition of Indebtedness. 

“Dollar” and “$” mean lawful money of the United States. 

  
 12 

 “Dollar Equivalent” means, at any time, (a) with respect to
any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in any Alternative Currency, the equivalent amount thereof in Dollars as determined by the Administrative Agent at such time on the basis of the Spot
Rate (determined in respect of the most recent Revaluation Date) for the purchase of Dollars with such Alternative Currency. 

“Domestic Subsidiary” means any Subsidiary that is organized under the laws of the United States, any state
thereof or the District of Columbia. 
 “EEA Financial Institution” means (a) any credit institution
or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of
this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its
parent. 
 “EEA Member Country” means any of the member states of the European Union, Iceland,
Liechtenstein, and Norway. 
 “EEA Resolution Authority” means any public administrative authority or any
person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution. 

“Eligible Assignee” means any Person that meets the requirements to be an assignee under Section 11.06
(subject to such consents, if any, as may be required under Section 11.06(b)(iii)). 
 “Ellipse
Acquisition” means the acquisition by the Borrower, directly or indirectly, of Ellipse Technologies, Inc., a Delaware corporation (“Ellipse”), pursuant to and in accordance with that certain Agreement and Plan of Merger,
dated as of January 4, 2016 among Borrower, Magneto Acquisition Corporation, a Delaware corporation, Ellipse and the Equityholders’ Representative (as defined therein). 

“Environmental Laws” means all Requirements of Law and Permits imposing liability or standards of conduct for
or relating to Hazardous Materials or the regulation and protection of the environment or natural resources, and including public notification requirements and environmental transfer of ownership, notification or approval statutes. 

“Environmental Liability” means any liability, contingent or otherwise (including any liability for damages,
costs of environmental remediation, fines, penalties or indemnities), of the Borrower, any other Loan Party or any of their respective Subsidiaries directly or indirectly resulting from, or related to, any claim, suit, action, investigation,
proceeding or demand by any Person, whether based in contract, tort, implied or express warranty, strict liability, criminal or civil statute or common law or otherwise, arising out of (a) violation of any Environmental Law, (b) the
generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or
(e) any contract or agreement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 

“Environmental Permit” means any permit, approval, identification number, license or other authorization
required under any Environmental Law. 

  
 13 

 “Equity Interests” means, with respect to any Person, all of the
shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests
in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such
shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or
other interests are outstanding on any date of determination. 
 “ERISA” means the Employee Retirement
Income Security Act of 1974. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated)
under common control with the Borrower within the meaning of Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code). 

“ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) the withdrawal of
the Borrower or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which such entity was a “substantial employer” as defined in Section 4001(a)(2) of ERISA or a cessation of operations
that is treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial withdrawal by the Borrower or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization;
(d) the filing of a notice of intent to terminate, the treatment of a Pension Plan amendment as a termination under Section 4041 or 4041A of ERISA; (e) the institution by the PBGC of proceedings to terminate a Pension Plan;
(f) any event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan; (g) the determination that any Pension Plan is considered an
at-risk plan or a plan in endangered or critical status within the meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (h) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums
due but not delinquent under Section 4007 of ERISA, upon the Borrower or any ERISA Affiliate or (i) a failure by the Borrower or any ERISA Affiliate to meet all applicable requirements under the Pension Funding Rules in respect of a
Pension Plan, whether or not waived, or the failure by the Borrower or any ERISA Affiliate to make any required contribution to a Multiemployer Plan. 

“EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market
Association (or any successor person), as in effect from time to time. 
 “Euro” and
“€” mean the single currency of the Participating Member States. 
 “Eurocurrency
Rate” means: 
 (a) for any Interest Period, with respect to any Credit Extension: 

(i) denominated in a LIBOR Quoted Currency, the rate per annum equal to the London Interbank Offered Rate
(“LIBOR”), or a comparable or successor rate which rate is approved by the Administrative Agent, as published on the applicable Bloomberg screen page (or such other commercially available source providing such quotations as may be
designated by the Administrative Agent from time to time) (in such case, the “LIBOR Rate”) at or about 11:00 a.m. (London time) on the Rate Determination Date, for deposits in the relevant currency, with a term equivalent to such
Interest Period; 
 (ii) denominated in Australian Dollars, the rate per annum equal to the Bank Bill Swap Reference Bid
Rate (“BBSY”), or a comparable or successor rate which rate is approved by the Administrative Agent, as published on the applicable Bloomberg screen page (or such other commercially available source providing such quotations as may
be designated by the Administrative Agent from time to time) at or about 10:30 a.m. (Melbourne, Australia time) on the Rate Determination Date with a term equivalent to such Interest Period; 

  
 14 

 (iii) with respect to any Credit Extension denominated in any Non-LIBOR
Quoted Currency other than those currencies listed above, the rate per annum as designated with respect to such Alternative Currency at the time such Alternative Currency is approved by the Administrative Agent and the relevant Lenders pursuant to
Section 1.09(a); and 
 (b) for any interest rate calculation with respect to a Base Rate Loan on any date, the
rate per annum equal to the LIBOR Rate, at or about 11:00 a.m. (London time) determined two (2) Business Days prior to such date for Dollar deposits being delivered in the London interbank market for deposits in Dollars with a term of one
(1) month commencing that day; 
 provided that (i) to the extent a comparable or successor rate is
approved by the Administrative Agent in connection with any rate set forth in this definition, the approved rate shall be applied in a manner consistent with market practice; provided, further that to the extent such market practice is
not administratively feasible for the Administrative Agent, such approved rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent and (ii) if the Eurocurrency Rate shall be less than zero, such rate
shall be deemed zero for purposes of this Agreement. 
 “Eurocurrency Rate Loan” means a Loan that bears
interest at a rate based on clause (a) of the definition of “Eurocurrency Rate”. Eurocurrency Rate Loans may be denominated in Dollars or in an Alternative Currency. 

“Event of Default” has the meaning specified in Section 8.01. 

“Excluded Foreign Subsidiary” means any subsidiary of the Borrower that is (a) a CFC, (b) any
subsidiary of a CFC or (c) a disregarded entity or a partnership for U.S. federal income tax purposes substantially all of the assets of which consist of Equity Interests in one or more CFCs, in each case, that has not guaranteed or pledged any
of its assets or suffered a pledge of more than 65% of its Voting Stock to secure, directly or indirectly, any Indebtedness (other than the Obligations) of the Borrower or any Loan Party that is a Domestic Subsidiary. 

“Excluded Property” has the meaning specified in the Security Agreement. 

“Excluded Subsidiary” means (a) any Subsidiary that is not a Wholly-Owned Subsidiary of the Borrower or
a Guarantor, (b) any Subsidiary that is prohibited by applicable Law from guaranteeing the Secured Obligations or if guaranteeing the Secured Obligations would require governmental (including regulatory) consent, approval or could result in
adverse tax consequences as reasonably determined by the Borrower, (c) any Excluded Foreign Subsidiary and (d) Immaterial Subsidiaries. 

“Excluded Swap Obligation” means, with respect to any Guarantor, any Swap Obligation if, and to the extent
that, all or a portion of the Guaranty of such Guarantor of, or the grant by such Guarantor of a Lien to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order
of the Commodity Futures Trading Commission (or the application or official interpretation thereof) by virtue of such Guarantor’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity
Exchange Act (determined after giving effect to Section 10.11 and any other “keepwell, support or other agreement for the benefit of such Guarantor and any and all guarantees of such Guarantor’s Swap Obligations by other Loan Parties)
at the time the Guaranty of such Guarantor, or grant by such Guarantor of a Lien, becomes effective with respect to such Swap Obligation. If a Swap Obligation arises under a Master Agreement governing more than one Swap Contract, such exclusion
shall apply only to the portion of such Swap Obligation that is attributable to Swap Contracts for which such Guaranty or Lien is or becomes excluded in accordance with the first sentence of this definition. 

  
 15 

 “Excluded Taxes” means any of the following Taxes imposed on or
with respect to any Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed
as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that
are Other Connection Taxes, (b) in the case of a Lender, withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on
which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under Section 11.13) or (ii) such Lender changes its Lending Office, except in each case to the
extent that, pursuant to Section 3.01(a)(ii), (a)(iii) or (c), amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it
changed its Lending Office, (c) Taxes attributable to such Recipient’s failure to comply with Section 3.01(e) and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA. 

“Existing Term Loan” has the meaning set forth in Section 2.16(c)(ii). 

“Facility Termination Date” means the date as of which all of the following shall have occurred: (a) the
Aggregate Commitments have terminated, (b) all Obligations have been paid in full (other than contingent indemnification obligations), and (c) all Letters of Credit have terminated or expired (other than Letters of Credit as to which other
arrangements with respect thereto satisfactory to the Administrative Agent and the L/C Issuer shall have been made). 

“FASB ASC” means the Accounting Standards Codification of the Financial Accounting Standards Board. 

“FATCA” means (i) Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any
amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to the foregoing and
(ii) any similar law adopted by any non-U.S. Governmental Authority pursuant to an intergovernmental agreement between such non-U.S. jurisdiction and the United States. 

“FDA” means the United States Food and Drug Administration and any successor thereto. 

“FDA Permits” has the meaning set forth in Section 5.21(a). 

“Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on
overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that
(a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so
published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to Bank of America on such day on such transactions as
determined by the Administrative Agent. 

  
 16 

 “First Tier Foreign Subsidiary” means a Foreign Subsidiary or
Excluded Foreign Subsidiary, in each case, held directly by a Loan Party. 
 “Foreign Lender” means
(a) if the Borrower is a U.S. Person, a Lender that is not a U.S. Person, and (b) if the Borrower is not a U.S. Person, a Lender that is resident or organized under the laws of a jurisdiction other than that in which the Borrower is
resident for tax purposes. For purposes of this definition, the United States, each state thereof and the District of Columbia shall be deemed to constitute a single jurisdiction. 

“Foreign Obligor” means a Loan Party that is a Foreign Subsidiary. 

“Foreign Subsidiary” means any Subsidiary that is not a Domestic Subsidiary. 

“FRB” means the Board of Governors of the Federal Reserve System of the United States. 

“Fronting Exposure” means, at any time there is a Defaulting Lender that is a Lender, (a) with respect
to the L/C Issuer, such Defaulting Lender’s Applicable Percentage of the outstanding L/C Obligations other than L/C Obligations as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash
Collateralized in accordance with the terms hereof, and (b) with respect to the Swingline Lender, such Defaulting Lender’s Applicable Percentage of Swingline Loans other than Swingline Loans as to which such Defaulting Lender’s
participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof. 

“Fund” means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing,
holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities. 

“GAAP” means generally accepted accounting principles in the United States set forth from time to time in the
opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable
stature and authority within the accounting profession) including, without limitation, the FASB Accounting Standards Codification, that are applicable to the circumstances as of the date of determination, consistently applied and subject to
Section 1.03. 
 “Governmental Authority” means the government of the United States or any other
nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or
administrative powers or functions of or pertaining to government (including, without limitation, any supra-national bodies such as the European Union or the European Central Bank). 

  
 17 

 “Guarantee” means, as to any Person, (a) any obligation,
contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness of the kind described in clauses (a) through (g) of the definition thereof or other obligation payable or performable by
another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or
payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such
Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such
Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss
in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness of the kind described in clauses (a) through (g) of the definition thereof or other obligation of any other Person,
whether or not such Indebtedness or other obligation is assumed or expressly undertaken by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien). The amount of any Guarantee shall be deemed
to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect
thereof as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning. 

“Guaranteed Obligations” has the meaning set forth in Section 10.01. 

“Guarantors” means, collectively, (a) the Subsidiaries of the Borrower as are or may from time to time
become parties to this Agreement pursuant to Section 6.13, in each case other than any Excluded Subsidiary, and (b) with respect to Additional Secured Obligations owing by any Loan Party or any of its Subsidiaries and any Swap Obligation
of a Specified Loan Party (determined before giving effect to Sections 10.01 and 10.11) under the Guaranty, the Borrower. 

“Guaranty” means, collectively, the Guarantee made by the Guarantors under Article X in favor of the Secured
Parties, together with each other guaranty delivered pursuant to Section 6.13. 
 “Hazardous Material”
means any substance, material or waste that is classified, regulated or otherwise characterized under any Requirement of Law as hazardous, toxic, a contaminant or a pollutant or by other words of similar meaning or regulatory effect, including
without limitation, petroleum or any fraction thereof, asbestos, polychlorinated biphenyls and radioactive substances. 

“Hedge Bank” means any Person in its capacity as a party to a Swap Contract that, (a) at the time it
enters into a Swap Contract not prohibited under Article VI or VII, is a Lender or an Affiliate of a Lender, or (b) at the time it (or its Affiliate) becomes a Lender on the Closing Date, is a party to a Swap Contract not prohibited under
Article VI or VII, in each case, in its capacity as a party to such Swap Contract (even if such Person ceases to be a Lender or such Person’s Affiliate ceased to be a Lender); provided, in the case of a Secured Hedge Agreement with a
Person who is no longer a Lender (or Affiliate of a Lender), such Person shall be considered a Hedge Bank only through the stated termination date (without extension or renewal) of such Secured Hedge Agreement and provided further that for any of
the foregoing to be included as a “Secured Hedge Agreement” on any date of determination by the Administrative Agent, the applicable Hedge Bank (other than the Administrative Agent or an Affiliate of the Administrative Agent) must have
delivered a Secured Party Designation Notice to the Administrative Agent prior to such date of determination. 

“Healthcare Laws” means, collectively, all local, state, federal, national, and supranational, and foreign
healthcare laws, manual provisions, policies and administrative guidance relating to the regulation of the Loan Parties including, without limitation, the U.S. Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the federal Anti-kickback
Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. § 1320a- 7a(a)(5)), the Health
Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (§§ 13400-13424 of the American Recovery and Reinvestment
Act of 2009), the Stark Law (42 U.S.C. § 1395nn), the exclusion laws (42 U.S.C. § 1320a-7), Social Security Act § 1128 (42 U.S.C. § 1320a-7), Medicare (Title XVIII of the Social Security Act), and Medicaid (Title XIX of the
Social Security Act), comparable state Laws, and all regulations promulgated pursuant to such Laws. 

  
 18 

 “Honor Date” has the meaning set forth in
Section 2.03(c). 
 “Immaterial Subsidiary” means any Subsidiary that, together with its
Subsidiaries and all other Immaterial Subsidiaries, collectively, account for less than 6.0% of Consolidated EBITDA or Total Assets of the Borrower and its Subsidiaries for the Measurement Period ended on the last day of the most recently ended
fiscal quarter of the Borrower for which financial statements have been delivered pursuant to Section 6.01(b). 

“Increase Effective Date” has the meaning set forth in Section 2.16(a). 

“Increase Joinder” has the meaning set forth in Section 2.16(c)(v). 

“Incremental Commitments” means Incremental Revolving Commitments and/or the Incremental Term Loan
Commitments. 
 “Incremental Revolving Commitment” has the meaning set forth in
Section 2.16(a). 
 “Incremental Term Loan Commitment” has the meaning set forth in
Section 2.16(a). 
 “Incremental Term Loan Maturity Date” has the meaning set forth in
Section 2.16(c)(iii). 
 “Incremental Term Loans” means any loans made pursuant to any
Incremental Term Loan Commitments. 
 “Indebtedness” means, as to any Person at a particular time, without
duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP: 

(a) all obligations of such Person for borrowed money and all obligations of such Person evidenced by bonds,
debentures, notes, loan agreements or other similar instruments; 
 (b) the maximum amount of all direct or
contingent obligations of such Person arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments; 

(c) net obligations of such Person under any Swap Contract; 

(d) all obligations (including, without limitation, earnout obligations) of such Person to pay the deferred
purchase price of property or services (other than trade accounts payable in the ordinary course of business); 

(e) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by
such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; 

  
 19 

 (f) all Attributable Indebtedness in respect of Capitalized
Leases and Synthetic Lease Obligations of such Person and all Synthetic Debt of such Person; 
 (g) all
obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any of its own Equity Interests (or any Equity Interests of a direct or indirect parent entity thereof) prior to the date that is 180 days after the
Maturity Date (any such Equity Interest, “Disqualified Stock”), valued at, in the case of redeemable preferred Equity Interests, the greater of the voluntary liquidation preference of such Equity Interests plus accrued and unpaid
dividends; and 
 (h) all Guarantees of such Person in respect of any of the foregoing. 

For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture
(other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any net
obligation under any Swap Contract on any date shall be deemed to be the Swap Termination Value thereof as of such date. 

“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any
payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a), Other Taxes. 

“Indemnitees” has the meaning specified in Section 11.04(b). 

“Information” has the meaning specified in Section 11.07. 

“Intellectual Property” has the meaning set forth in the Security Agreement. 

“Intercompany Debt” has the meaning specified in Section 7.02. 

“Interest Payment Date” means, (a) as to any Eurocurrency Rate Loan, the last day of each Interest
Period applicable to such Loan and the Maturity Date; provided, however, that if any Interest Period for a Eurocurrency Rate Loan exceeds three (3) months, the respective dates that fall every three (3) months after the
beginning of such Interest Period shall also be Interest Payment Dates; and (b) as to any Base Rate Loan or Swingline Loan, the last Business Day of each March, June, September and December and the Maturity Date. 

“Interest Period” means, as to each Eurocurrency Rate Loan, the period commencing on the date such
Eurocurrency Rate Loan is disbursed or converted to or continued as a Eurocurrency Rate Loan and ending on the date one (1), two (2), three (3) or six (6) months thereafter in each case with respect to an Alternative Currency, subject to
availability for the interest rate applicable to the relevant currency, as selected by the Borrower in its Loan Notice; provided that: 

(a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the
next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day; 

(b) any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there
is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and 

  
 20 

 (c) no Interest Period shall extend beyond the Maturity Date.

 “Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person,
whether by means of (a) the purchase or other acquisition of Equity Interests of another Person, (b) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or
interest in, another Person (including any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor guaranties Indebtedness of such other Person), or (c) the purchase or other acquisition (in
one transaction or a series of transactions) of assets of another Person which constitute all or substantially all of the assets of such Person or of a division, line of business or other business unit of such Person. For purposes of covenant
compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment. 

“Involuntary Disposition” means any loss of, damage to or destruction of, or any condemnation or other taking
for public use of, any property of any Loan Party or any Subsidiary. 
 “IRS” means the United States
Internal Revenue Service. 
 “ISP” means, with respect to any Letter of Credit, the “International
Standby Practices 1998” published by the Institute of International Banking Law & Practice, Inc. (or such later version thereof as may be in effect at the time of issuance). 

“Issuer Documents” means with respect to any Letter of Credit, the Letter of Credit Application, and any
other document, agreement and instrument entered into by the L/C Issuer and the Borrower (or any Subsidiary) or in favor of the L/C Issuer and relating to such Letter of Credit. 

“Joinder Agreement” means a joinder agreement substantially in the form of Exhibit D executed and
delivered in accordance with the provisions of Section 6.13. 
 “Judgment Currency” has the meaning
specified in Section 11.22. 
 “Laws” means, collectively, all international, foreign, federal, state
and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the
enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having
the force of law. 
 “L/C Advance” means, with respect to each Lender, such Lender’s funding of its
participation in any L/C Borrowing in accordance with its Applicable Percentage. All L/C Advances shall be denominated in Dollars. 

“L/C Borrowing” means an extension of credit resulting from a drawing under any Letter of Credit which has
not been reimbursed on the date when made or refinanced as a Revolving Borrowing. All L/C Borrowings shall be denominated in Dollars. 

“L/C Credit Extension” means, with respect to any Letter of Credit, the issuance thereof or extension of the
expiry date thereof, or the increase of the amount thereof. 

  
 21 

 “L/C Issuer” means Bank of America, through itself or through
one of its designated Affiliates or branch offices, in its capacity as issuer of Letters of Credit hereunder, or any successor issuer of Letters of Credit hereunder. 

“L/C Obligations” means, as at any date of determination, the aggregate amount available to be drawn under
all outstanding Letters of Credit plus the aggregate of all Unreimbursed Amounts (including all L/C Borrowings). For purposes of computing the amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be
determined in accordance with Section 1.06. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of
the ISP, such Letter of Credit shall be deemed to be “outstanding” in the amount so remaining available to be drawn. 

“Lender” means each of the Persons identified as a “Lender” on the signature pages hereto, each
other Person that becomes a “Lender” in accordance with this Agreement and, their successors and permitted assigns and, unless the context requires otherwise, includes the Swingline Lender. 

“Lending Office” means, as to the Administrative Agent, the L/C Issuer or any Lender, the office or offices
of such Person described as such in such Person’s Administrative Questionnaire, or such other office or offices as such Person may from time to time notify the Borrower and the Administrative Agent; which office may include any Affiliate of
such Person or any domestic or foreign branch of such Person or such Affiliate. 
 “Letter of Credit” means
any standby letter of credit issued hereunder. Letters of Credit shall be issued in Dollars. 
 “Letter of Credit
Application” means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the L/C Issuer. 

“Letter of Credit Expiration Date” means the day that is seven (7) days prior to the Maturity Date (or,
if such day is not a Business Day, the next preceding Business Day). 
 “Letter of Credit Fee” has the
meaning specified in Section 2.03(h). 
 “Letter of Credit Sublimit” means an amount equal to the
lesser of (a) $15,000,000 and (b) the Aggregate Commitments. The Letter of Credit Sublimit is part of, and not in addition to, the Aggregate Commitments. 

“LIBOR” has the meaning specified in the definition of Eurocurrency Rate. 

“LIBOR Quoted Currency” means Dollars, Euro, Sterling and Yen, in each case as long as there is a published
LIBOR rate with respect thereto. 
 “Lien” means any mortgage, pledge, hypothecation, assignment, deposit
arrangement, encumbrance, lien (statutory or otherwise), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or
other title retention agreement and any financing lease having substantially the same economic effect as any of the foregoing). 

“Loan” means an extension of credit by a Lender to the Borrower under Article II in the form of a Revolving
Loan or a Swingline Loan. 

  
 22 

 “Loan Documents” means, collectively, (a) this Agreement,
(b) the Notes, (c) the Guaranty, (d) the Collateral Documents, (e) the Disclosure Letter, (f) each Issuer Document, (g) each Joinder Agreement and (h) any agreement creating or perfecting rights in Cash Collateral
pursuant to the provisions of Section 2.14, (but specifically excluding any Secured Hedge Agreement or any Secured Cash Management Agreement). 

“Loan Notice” means a notice of (a) a Borrowing, (b) a conversion of Loans from one Type to the
other, or (c) a continuation of Eurocurrency Rate Loans, pursuant to Section 2.02(a), which shall be substantially in the form of Exhibit E or such other form as may be approved by the Administrative Agent (including any form on an
electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the Borrower. 

“Loan Parties” means, collectively, the Borrower and each Guarantor. 

“London Banking Day” means any day on which dealings in Dollar deposits are conducted by and between banks in
the London interbank eurodollar market. 
 “Master Agreement” has the meaning set forth in the definition
of “Swap Contract.” 
 “Material Acquisition” has the meaning set forth in the definition of
“Consolidated EBITDA.” 
 “Material Adverse Effect” means (a) a material adverse change in,
or a material adverse effect upon, the operations, business, assets, liabilities (actual or contingent), condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole; (b) a material impairment of the rights and
remedies of the Administrative Agent or any Lender under any Loan Document, or of the ability of any Loan Party to perform its obligations under any Loan Document to which it is a party; or (c) a material adverse effect upon the legality,
validity, binding effect or enforceability against any Loan Party of any Loan Document to which it is a party. 

“Material Contract” means, with respect to any Person, each contract or agreement (a) material to the
business, condition (financial or otherwise), operations, performance or properties of such Person or (b) any other contract, agreement, permit or license, written or oral, of the Borrower and its Subsidiaries as to which the breach,
nonperformance, cancellation or failure to renew by any party thereto, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 

“Material Disposition” means any Disposition for which the total consideration received by the Borrower or
any of its Subsidiaries (including, without limitation, all transaction costs, transferred Indebtedness and liabilities repaid, transferred or no longer reflected on a consolidated balance sheet of the Loan Parties and their Subsidiaries after
giving effect to such Disposition and the maximum amount of all deferred payments, including earnouts) exceeds $15,000,000. 

“Maturity Date” means February 6, 2021; provided, however, that if such date is not a
Business Day, the Maturity Date shall be the next preceding Business Day. 
 “Measurement Period” means, at
any date of determination, the most recently completed four (4) fiscal quarters of the Borrower. 
 “Medtronic
Litigation” means the patent infringement lawsuit filed by Warsaw Orthopedic, Inc., Medtronic Sofamor Danek USA, Inc. and other Medtronic related entities (collectively, “Medtronic”), on August 18, 2008, against the Borrower
in the United States District Court for the Southern District of California, alleging that certain of the Borrower’s products or methods, including the XLIF® procedure, infringe, or
contribute to the infringement of, twelve U.S. patents. Three of the patents were later withdrawn by Medtronic leaving the following nine patents in the lawsuit: Nos. 5,860,973; 5,772,661; 6,936,051; 6,936,050; 6,916,320; 6,945,933; 6,969,390;
6,428,542; 6,592,586 assigned or licensed to Medtronic. 

  
 23 

 “Minimum Collateral Amount” means, at any time, (a) with
respect to Cash Collateral consisting of cash or deposit account balances provided to reduce or eliminate Fronting Exposure during any period when a Lender constitutes a Defaulting Lender, an amount equal to 103% of the Fronting Exposure of the L/C
Issuer with respect to Letters of Credit issued and outstanding at such time, (b) with respect to Cash Collateral consisting of cash or deposit account balances provided in accordance with the provisions of Section 2.14(a)(i), (a)(ii) or
(a)(iii), an amount equal to 103% of the Outstanding Amount of all L/C Obligations, and (c) otherwise, an amount determined by the Administrative Agent and the L/C Issuer in their sole discretion. 

“Moody’s” means Moody’s Investors Service, Inc. and any successor thereto. 

“Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of
ERISA, to which the Borrower or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five (5) plan years, has made or been obligated to make contributions. 

“Multiple Employer Plan” means a Plan which has two or more contributing sponsors (including the Borrower or
any ERISA Affiliate) at least two of whom are not under common control, as such a plan is described in Section 4064 of ERISA. 

“Non-Consenting Lender” means any Lender that does not approve any consent, waiver or amendment that
(a) requires the approval of all Lenders or all affected Lenders in accordance with the terms of Section 11.01 and (b) has been approved by the Required Lenders. 

“Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time. 

“Non-Extension Notice Date” has the meaning set forth in Section 2.03(b). 

“Non-LIBOR Quoted Currency” means any currency other than a LIBOR Quoted Currency. 

“Note” means a promissory note made by the Borrower in favor of a Lender evidencing Revolving Loans or
Swingline Loans, as the case may be, made by such Lender, substantially in the form of Exhibit G. 
 “Notice
of Loan Prepayment” means a notice of prepayment with respect to a Loan, which shall be substantially in the form of Exhibit N or such other form as may be approved by the Administrative Agent (including any form on an electronic
platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer. 

“Obligations” means (a) all advances to, and debts, liabilities, obligations, covenants and duties of,
any Loan Party arising under any Loan Document or otherwise with respect to any Loan, or Letter of Credit and (b) all costs and expenses incurred in connection with enforcement and collection of the foregoing, including the fees, charges and
disbursements of counsel, in each case whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the
commencement by or against any Loan Party or any Affiliate thereof pursuant to any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such
proceeding; provided that Obligations of a Guarantor shall exclude any Excluded Swap Obligations with respect to such Guarantor. 

  
 24 

 “OFAC” means the Office of Foreign Assets Control of the United
States Department of the Treasury. 
 “Officer’s Certificate” means a certificate substantially the
form of Exhibit L or any other form approved by the Administrative Agent. 
 “Organization
Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to
any limited liability company, the certificate or articles of formation or organization and operating agreement or limited liability company agreement (or equivalent or comparable documents with respect to any non-U.S. jurisdiction); (c) with
respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization (or equivalent or comparable documents with respect to any non-U.S.
jurisdiction) and (d) with respect to all entities, any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its
formation or organization (or equivalent or comparable documents with respect to any non-U.S. jurisdiction). 

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or
former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or
perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). 

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or
similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any
such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.06). 

“Outstanding Amount” means (a) with respect to Revolving Loans and Swingline Loans on any date, the
Dollar Equivalent amount of the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of Revolving Loans and Swingline Loans, as the case may be, occurring on such date; and (b) with
respect to any L/C Obligations on any date, the amount of such L/C Obligations on such date after giving effect to any L/C Credit Extension occurring on such date and any other changes in the aggregate amount of the L/C Obligations as of such date,
including as a result of any reimbursements by the Borrower of Unreimbursed Amounts. 
 “Overnight Rate”
means, for any day, (a) with respect to any amount denominated in Dollars, the greater of (i) the Federal Funds Rate and (ii) an overnight rate determined by the Administrative Agent, the L/C Issuer or the Swingline Lender, as the
case may be, in accordance with banking industry rules on interbank compensation, and (b) with respect to any amount denominated in an Alternative Currency, the rate of interest per annum at which overnight deposits in the applicable
Alternative Currency, in an amount approximately equal to the amount with respect to which such rate is being determined, would be offered for such day by a branch or Affiliate of Bank of America in the applicable offshore interbank market for such
currency to major banks in such interbank market. 

  
 25 

 “Participant” has the meaning specified in
Section 11.06(d). 
 “Participant Register” has the meaning specified in Section 11.06(d). 

“Participating Member State” means any member state of the European Union that adopts or has adopted the Euro
as its lawful currency in accordance with legislation of the European Union relating to Economic and Monetary Union. 

“PBGC” means the Pension Benefit Guaranty Corporation. 

“Pension Act” means the Pension Protection Act of 2006. 

“Pension Funding Rules” means the rules of the Code and ERISA regarding minimum required contributions
(including any installment payment thereof) to Pension Plans and set forth in, with respect to plan years ending prior to the effective date of the Pension Act, Section 412 of the Code and Section 302 of ERISA, each as in effect prior to
the Pension Act and, thereafter, Section 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA. 

“Pension Plan” means any employee pension benefit plan (including a Multiple Employer Plan or a Multiemployer
Plan) that is maintained or is contributed to by the Borrower and any ERISA Affiliate and is either covered by Title IV of ERISA or is subject to the minimum funding standards under Section 412 of the Code. 

“Permits” means, with respect to any Person, any permit, approval, authorization, license, registration,
certificate, concession, grant, franchise, variance or permission from, and any other Contractual Obligations with, any Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or
any of its property is subject. 
 “Permitted Acquisition” means (x) the Ellipse Acquisition and
(y) an Acquisition by a Loan Party (the Person or division, line of business or other business unit of the Person to be acquired in such Acquisition shall be referred to herein as the “Target”), in each case of this clause
(y) that is a type of business (or assets used in a type of business) permitted to be engaged in by the Borrower and its Subsidiaries pursuant to the terms of this Agreement, in each case of this clause (y) so long as: 

(a) no Default or Event of Default shall then exist or would exist after giving effect thereto; 

(b) the Loan Parties shall demonstrate to the reasonable satisfaction of the Administrative Agent that, after
giving effect to the Acquisition on a Pro Forma Basis, the Loan Parties are in Pro Forma Compliance; 
 (c)
the Administrative Agent, on behalf of the Secured Parties, shall have received (or shall receive in connection with the closing of such Acquisition) a security interest in all property (including, without limitation, Equity Interests) acquired with
respect to the Target in accordance with the terms of Section 6.14 subject, with respect to perfection of Liens in the case of an Acquisition being financed with proceeds of an Incremental Term Loan, to customary “Funds Certain
Provisions”, and the Target, if a Person, shall have executed a Joinder Agreement in accordance with the terms of Section 6.13; 

  
 26 

 (d) the Target is engaged in lines of business substantially
similar (or complementary) to those lines of businesses conducted by the Borrower and its Subsidiaries on the date such Acquisition is consummated; 

(e) with respect to any Permitted Acquisition with a purchase price in excess of $25,000,000, the
Administrative Agent and the Lenders shall have received not less than ten (10) Business Days (or such shorter period as may be agreed to by the Administrative Agent in writing in its reasonable discretion) prior to the consummation of any such
Acquisition (A) a description of the material terms of such Acquisition, (B) at the request of the Administrative Agent, audited financial statements (or, if unavailable, management-prepared financial statements) of the Target for its two
most recent fiscal years and for any fiscal quarters ended within the fiscal year to date, (C) at the request of the Administrative Agent, Consolidated projected income statements of the Borrower and its Subsidiaries (giving effect to such
Acquisition), and (D) not less than five (5) Business Days (or such shorter period as may be agreed to by the Administrative Agent in writing in its reasonable discretion) prior to the consummation of such Permitted Acquisition, a
Permitted Acquisition Certificate, executed by a Responsible Officer of the Borrower certifying that such Permitted Acquisition complies with the requirements of this Agreement; 

(f) the Target shall have Acquired EBITDA in an amount greater than $0, provided, however, that
the Target may have an Acquired EBITDA that is $0 or less (each a “Negative EBITDA Target”) so long as (i) such Negative EBITDA Target’s Acquired EBITDA is not less than negative $10,000,000 and (ii) the aggregate
Acquired EBITDA for all Negative EBITDA Targets acquired shall not be less than negative $15,000,000; 
 (g)
such Acquisition shall not be a “hostile” Acquisition and shall have been approved by the board of directors (or equivalent) and/or shareholders (or equivalent) of the applicable Loan Party and the Target; 

(h) after giving effect to such Acquisition and any Borrowings made in connection therewith, the aggregate
principal amount of Revolving Loans available to be borrowed under Section 2.01 hereof shall be at least $5,000,000; and 

(i) the Cost of Acquisition paid by the Loan Parties and their Subsidiaries (i) in connection with any
single Acquisition shall not exceed 50% of Consolidated EBITDA and (ii) for all Acquisitions made during the term of this Agreement shall not exceed 125% of Consolidated EBITDA. 

“Permitted Acquisition Certificate” means a certificate substantially the form of Exhibit F or any
other form approved by the Administrative Agent. 
 “Permitted Convertible Note Refinancing” means
Indebtedness constituting a refinancing or extension of the Convertible Notes that (a) does not have a maturity date prior to the Maturity Date or require any payment of principal in respect thereof in any manner materially different from the
repayment requirements set forth in the Convertible Notes, (b) does not require or permit any cash payment of interest in respect thereof at a rate in excess of 1.5% per annum of the Convertible Notes, (c) is not supported by
guaranties that are more favorable than the guaranties supporting the Obligations, (d) does not require representations, warranties, covenants or events of default that are more restrictive, taken as a whole, than those set forth herein,
(e) does not contain a cross-default to any Loan Document and (f) is unsecured. 
 “Permitted
Liens” has the meaning set forth in Section 7.01. 

  
 27 

 “Permitted Transfers” means (a) Dispositions of inventory
in the ordinary course of business; (b) Dispositions of property to the Borrower or any Subsidiary; provided, that if the transferor of such property is a Loan Party then the transferee thereof must be a Loan Party; (c) Dispositions
of accounts receivable in connection with the collection or compromise thereof; (d) licenses, sublicenses, leases or subleases granted to others not interfering in any material respect with the business of the Borrower and its Subsidiaries; and
(e)(i) Dispositions of cash or Cash Equivalents in the ordinary course of business or (ii) conversions of cash or Cash Equivalents into cash or other Cash Equivalents. 

“Person” means any natural person, corporation, limited liability company, trust, joint venture, association,
company, partnership, Governmental Authority or other entity. 
 “Plan” means any employee benefit plan
within the meaning of Section 3(3) of ERISA (including a Pension Plan), maintained for employees of the Borrower or any ERISA Affiliate or any such Plan to which the Borrower or any ERISA Affiliate is required to contribute on behalf of any of
its employees. 
 “Platform” has the meaning specified in Section 6.02. 

“Pledged Equity” has the meaning specified in the Security Agreement. 

“Pro Forma Basis” and “Pro Forma Effect” means, for any applicable Disposition of all or
substantially all of a division or a line of business or for any applicable Acquisition, whether actual or proposed, for purposes of determining compliance with the financial covenants set forth in Section 7.11, each such transaction or
proposed transaction shall be deemed to have occurred on and as of the first day of the relevant Measurement Period, and the following pro forma adjustments shall be made: 

(a) in the case of an actual or proposed Disposition, all income statement items (whether positive or negative)
attributable to the line of business or the Person subject to such Disposition shall be excluded from the results of the Borrower and its Subsidiaries for such Measurement Period; 

(b) in the case of an actual or proposed Acquisition, income statement items (whether positive or negative)
attributable to the property, line of business or the Person subject to such Acquisition shall be included in the results of the Borrower and its Subsidiaries for such Measurement Period; 

(c) interest accrued during the relevant Measurement Period on, and the principal of, any Indebtedness repaid
or to be repaid or refinanced in such transaction shall be excluded from the results of the Borrower and its Subsidiaries for such Measurement Period; and 

(d) any Indebtedness actually or proposed to be incurred or assumed in such transaction shall be deemed to have
been incurred as of the first day of the applicable Measurement Period, and interest thereon shall be deemed to have accrued from such day on such Indebtedness at the applicable rates provided therefor (and in the case of interest that does or would
accrue at a formula or floating rate, at the rate in effect at the time of determination) and shall be included in the results of the Borrower and its Subsidiaries for such Measurement Period.  

“Pro Forma Compliance” means, with respect to any transaction, that such transaction does not cause, create
or result in a Default after giving Pro Forma Effect, based upon the results of operations for the most recently completed Measurement Period to (a) such transaction and (b) all other transactions which are contemplated or required to be
given Pro Forma Effect hereunder that have occurred on or after the first day of the relevant Measurement Period. 

  
 28 

 “Public Lender” has the meaning specified in
Section 6.02. 
 “Qualified ECP Guarantor” means, at any time, each Loan Party with total
assets exceeding $10,000,000 or that qualifies at such time as an “eligible contract participant” under the Commodity Exchange Act and can cause another Person to qualify as an “eligible contract participant” at such time under
Section 1a(18)(A)(v)(II) of the Commodity Exchange Act. 
 “Qualifying Control Agreement” means an
agreement, among a Loan Party, a depository institution or securities intermediary and the Administrative Agent, which agreement is in form and substance reasonably acceptable to the Administrative Agent and which provides the Administrative Agent
with “control” (as such term is used in Article 9 of the UCC) over the deposit account(s) or securities account(s) described therein. 

“Recipient” means the Administrative Agent, any Lender, the L/C Issuer or any other recipient of any payment
to be made by or on account of any obligation of any Loan Party hereunder. 
 “Register” has the meaning
specified in Section 11.06(c). 
 “Related Parties” means, with respect to any Person, such
Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates. 

“Reportable Event” means any of the events set forth in Section 4043(c) of ERISA, other than events for
which the thirty (30) day notice period has been waived. 
 “Request for Credit Extension” means
(a) with respect to a Borrowing, conversion or continuation of Revolving Loans, a Loan Notice, (b) with respect to an L/C Credit Extension, a Letter of Credit Application, and (c) with respect to a Swingline Loan, a Swingline Loan
Notice. 
 “Required Lenders” means, at any time, Lenders having Total Credit Exposures representing more
than 50% of the Total Credit Exposures of all Lenders. The Total Credit Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time; provided that, the amount of any participation in any Swingline Loan
and Unreimbursed Amounts that such Defaulting Lender has failed to fund that have not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the Swingline Lender or L/C Issuer, as the case may be, in making
such determination. 
 “Requirement of Law” means, with respect to any Person, the common law and any
federal, state, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents
or authorities) and the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in each case that are applicable to or binding upon such Person or any of its
property or to which such Person or any of its property is subject. 
 “Resignation Effective Date” has the
meaning set forth in Section 9.06. 

  
 29 

 “Responsible Officer” means the chief executive officer,
president, chief financial officer, treasurer, assistant treasurer or controller of a Loan Party, solely for purposes of the delivery of incumbency certificates pursuant to Section 4.01, the secretary or any assistant secretary of a Loan Party
and, solely for purposes of notices given pursuant to Article II, any other officer or employee of the applicable Loan Party so designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of
the applicable Loan Party designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively
presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party. To the extent
reasonably requested by the Administrative Agent, each Responsible Officer will provide an incumbency certificate and to the extent reasonably requested by the Administrative Agent, appropriate authorization documentation, in form and substance
satisfactory to the Administrative Agent. 
 “Restricted Payment” means any (a) dividend payment or
other distribution of assets, properties, cash, rights, obligations or securities on account of any Equity Interests, (b) purchase, redemption or other acquisition for value of any Equity Interests now or hereafter outstanding or (c) any
payment or prepayment of principal of, premium, if any, interest, fees, redemption, exchange, purchase, retirement, defeasance sinking fund or similar payment with respect to, Subordinated Debt or the Convertible Notes or any Permitted Convertible
Note Refinancings that are Subordinated Debt, convertible Indebtedness or other similar subordinated or convertible instruments (collectively, “Junior Debt”). 

“Revaluation Date” means with respect to any Loan, each of the following: (i) each date of a Borrowing
of a Eurocurrency Rate Loan denominated in an Alternative Currency, (ii) each date of a continuation of a Eurocurrency Rate Loan denominated in an Alternative Currency pursuant to Section 2.02, and (iii) such additional dates
as the Administrative Agent shall reasonably determine or the Required Lenders shall reasonably require. 

“Revolving Borrowing” means a borrowing consisting of simultaneous Revolving Loans of the same Type and, in
the case of Eurocurrency Rate Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.01. 

“Revolving Exposure” means, as to any Lender at any time, the aggregate principal amount at such time of its
outstanding Revolving Loans and such Lender’s participation in L/C Obligations and Swingline Loans at such time. 

“Revolving Loan” has the meaning specified in Section 2.01. 

“S&P” means Standard & Poor’s Financial Services LLC, a subsidiary of The McGraw-Hill
Companies, Inc., and any successor thereto. 
 “Safety Notices” has the meaning set forth in
Section 5.21(e). 
 “Sale and Leaseback Transaction” means, with respect to any Loan Party or
any Subsidiary, any arrangement, directly or indirectly, with any Person whereby such Loan Party or such Subsidiary shall sell or transfer any property used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or
lease such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold or transferred. 

“Same Day Funds” means (a) with respect to disbursements and payments in Dollars, immediately available
funds, and (b) with respect to disbursements and payments in an Alternative Currency, same day or other funds as may reasonably be determined by the Administrative Agent to be customary in the place of disbursement or payment for the settlement
of international banking transactions in the relevant Alternative Currency. 

  
 30 

 “Sanction(s)” means any sanction administered or enforced by the
United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union, Her Majesty’s Treasury (“HMT”) or other relevant sanctions authority. 

“SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its
principal functions. 
 “Secured Cash Management Agreement” means any Cash Management Agreement between the
any Loan Party and any Cash Management Bank. 
 “Secured Hedge Agreement” means any interest rate,
currency, foreign exchange, or commodity Swap Contract permitted under Article VI or VII between any Loan Party and any Hedge Bank. 

“Secured Obligations” means all Obligations and all Additional Secured Obligations. 

“Secured Parties” means, collectively, the Administrative Agent, the Lenders, the L/C Issuer, the Hedge
Banks, the Cash Management Banks, the Indemnitees and each co-agent or sub-agent appointed by the Administrative Agent from time to time pursuant to Section 9.05. 

“Secured Party Designation Notice” means a notice from any Lender or an Affiliate of a Lender substantially
in the form of Exhibit H. 
 “Securities Act” means the Securities Act of 1933, including all
amendments thereto and regulations promulgated thereunder. 
 “Security Agreement” means the security and
pledge agreement, dated as of the Closing Date, executed in favor of the Administrative Agent by each of the Loan Parties. 

“Solvency Certificate” means a solvency certificate in substantially in the form of Exhibit I.

 “Solvent” and “Solvency” mean, with respect to any Person on any date of determination,
that on such date (a) the fair value of the property of such Person is greater than the total amount of liabilities, including contingent liabilities, of such Person, (b) the present fair saleable value of the assets of such Person is not
less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond
such Person’s ability to pay such debts and liabilities as they mature, (d) such Person is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person’s property would
constitute an unreasonably small capital, and (e) such Person is able to pay its debts and liabilities, contingent obligations and other commitments as they mature in the ordinary course of business. The amount of contingent liabilities at any
time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability. 

“Special Notice Currency” means at any time an Alternative Currency, other than the currency of a country
that is a member of the Organization for Economic Cooperation and Development at such time located in North America or Europe. 

“Specified Loan Party” means any Loan Party that is not then an “eligible contract participant”
under the Commodity Exchange Act (determined prior to giving effect to Section 10.11). 

  
 31 

 “Spot Rate” for a currency means the rate determined by the
Administrative Agent to be the rate quoted by the Person acting in such capacity as the spot rate for the purchase by such Person of such currency with another currency through its principal foreign exchange trading office at approximately 11:00
a.m. on the date two (2) Business Days prior to the date as of which the foreign exchange computation is made; provided that the Administrative Agent may obtain such spot rate from another financial institution designated by the
Administrative Agent if the Person acting in such capacity does not have as of the date of determination a spot buying rate for any such currency. 

“Sterling” and “£” mean the lawful currency of the United Kingdom. 

“Subordinated Debt” means Indebtedness incurred by any Loan Party, which (i) by its terms is
subordinated in right and time of payment to the prior payment of the Obligations and as to other rights and remedies thereunder, including, without limitation, standstill, interest rate, maturity and amortization, and insolvency-related provisions
(collectively, the “Subordination Terms”), which Subordination Terms shall be on terms that are reasonably acceptable to the Administrative Agent, (ii) is not supported by guaranties that are more favorable than the guaranties
supporting the Obligations, (iii) does not require representations, warranties, covenants or events of default that are more restrictive, taken as a whole, than those set forth herein, and (iv) does not contain a cross-default to any Loan
Document. 
 “Subordinated Debt Documents” means all agreements (including without limitation intercreditor
agreements, instruments and other documents) pursuant to which Subordinated Debt has been or will be issued or otherwise setting forth the terms of any Subordinated Debt. 

“Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other
business entity of which a majority of the shares of Voting Stock is at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person. Unless
otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Borrower. 

“Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit derivative
transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward
bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or
any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all
transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign
Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations or liabilities under any Master Agreement. 

“Swap Obligations” means with respect to any Guarantor any obligation to pay or perform under any agreement,
contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act. 

“Swap Termination Value” means, in respect of any one or more Swap Contracts, after taking into account the
effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination
value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations
provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender). 

  
 32 

 “Swingline Borrowing” means a borrowing of a Swingline Loan
pursuant to Section 2.04. 
 “Swingline Lender” means Bank of America in its capacity as provider of
Swingline Loans, or any successor swingline lender hereunder. 
 “Swingline Loan” has the meaning specified
in Section 2.04(a). 
 “Swingline Loan Notice” means a notice of a Swingline Borrowing pursuant to
Section 2.04(b), which shall be substantially in the form of Exhibit J or such other form as approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved
by the Administrative Agent pursuant), appropriately completed and signed by a Responsible Officer of the Borrower. 

“Swingline Sublimit” means an amount equal to the lesser of (a) $5,000,000 and (b) the Aggregate
Commitments. The Swingline Sublimit is part of, and not in addition to, the Aggregate Commitments. 
 “Synthetic
Debt” means, with respect to any Person as of any date of determination thereof, all obligations of such Person in respect of transactions entered into by such Person that are intended to function primarily as a borrowing of funds but are
not otherwise included in the definition of “Indebtedness” or as a liability on the Consolidated balance sheet of such Person and its Subsidiaries in accordance with GAAP. 

“Synthetic Lease Obligation” means the monetary obligation of a Person under (a) a so-called synthetic,
off-balance sheet or tax retention lease, or (b) an agreement for the use or possession of property (including Sale and Leaseback Transactions), in each case, creating obligations that do not appear on the balance sheet of such Person but
which, upon the application of any Debtor Relief Laws to such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment). 

“Target” has the meaning set forth in the definition of “Permitted Acquisition.” 

“TARGET2” means the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which
utilizes a single shared platform and which was launched on November 19, 2007. 
 “TARGET Day” means
any day on which TARGET2 (or, if such payment system ceases to be operative, such other payment system, if any, determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro. 

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including
backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 

“Threshold Amount” means $25,000,000. 

  
 33 

 “Total Assets” means the total assets of the Borrower and its
Subsidiaries on a consolidated basis in accordance with GAAP, as shown on the most recent balance sheet of the Borrower delivered pursuant to Section 6.01(a) or (b). 

“Total Credit Exposure” means, as to any Lender at any time, the unused Commitments and Revolving Exposure of
such Lender at such time. 
 “Total Outstandings” means the aggregate Outstanding Amount of all Revolving
Loans, Swingline Loans and L/C Obligations. 
 “Type” means, with respect to a Loan, its character as a
Base Rate Loan or a Eurocurrency Rate Loan. 
 “UCC” means the Uniform Commercial Code as in effect in the
State of New York; provided that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the
State of New York, “UCC” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or
priority. 
 “UCP” means, with respect to any Letter of Credit, the Uniform Customs and Practice for
Documentary Credits, International Chamber of Commerce (“ICC”) Publication No. 600 (or such later version thereof as may be in effect at the time of issuance). 

“United States” and “U.S.” mean the United States of America. 

“Unreimbursed Amount” has the meaning specified in Section 2.03(c)(i). 

“U.S. Person” means any Person that is a “United States Person” as defined in
Section 7701(a)(30) of the Code. 
 “U.S. Tax Compliance Certificate” has the meaning specified in
Section 3.01(e)(ii)(B)(3). 
 “Voting Stock” means, with respect to any Person, Equity Interests
issued by such Person the holders of which are ordinarily entitled to vote for the election of directors (or persons performing similar functions) of such Person. 

“Wholly-Owned Subsidiary” of a Person means any Subsidiary of such Person, all of the Equity Interests of
which (other than directors’ qualifying shares required by law or shares in a Foreign Subsidiary held by nationals of the country in which such Foreign Subsidiary is organized, in each case, as required by law) are owned by such Person, either
directly or through one or more Wholly-Owned Subsidiaries of such Person. 
 “Write-Down and Conversion
Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and
conversion powers are described in the EU Bail-In Legislation Schedule. 
 “Yen” and
“¥” mean the lawful currency of Japan. 

  
 34 

	 1.02
	 Other Interpretive Provisions. 

With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan
Document: 
 (a) The definitions of terms herein shall apply equally to the singular and plural forms of the
terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followed by the
phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Unless the context requires otherwise, (i) any definition of or reference to any agreement,
instrument or other document (including the Loan Documents and any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, modified, extended, restated, replaced or
supplemented from time to time (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such
Person’s successors and permitted assigns, (iii) the words “hereto,” “herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, shall be construed to refer to
such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Preliminary Statements, Exhibits and Schedules shall be construed to refer to Articles and Sections
of, and Preliminary Statements, Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory rules, regulations, orders and provisions consolidating,
amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified, extended, restated, replaced or supplemented from time to time, and
(vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract
rights. 
 (b) In the computation of periods of time from a specified date to a later specified date, the
word “from” means “from and including;” the words “to” and “until” each mean “to but excluding;” and the word “through” means “to and including.” 

(c) Section headings herein and in the other Loan Documents are included for convenience of reference only and
shall not affect the interpretation of this Agreement or any other Loan Document. 
  

	 1.03
	 Accounting Terms. 

(a) Generally. All accounting terms not specifically or completely defined herein shall be construed in
conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from
time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein. Notwithstanding the foregoing, for purposes of determining compliance with any covenant
(including the computation of any financial covenant) contained herein, Indebtedness of the Borrower and its Subsidiaries shall be deemed to be carried at 100% of the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC
470-20 on financial liabilities shall be disregarded. 

  
 35 

 (b) Changes in GAAP. If at any time any change in GAAP
would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith
to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended, (i) such ratio or requirement shall continue
to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably
requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. Without limiting the foregoing, leases shall continue to be classified and accounted for
on a basis consistent with that reflected in the Audited Financial Statements for all purposes of this Agreement, notwithstanding any change in GAAP relating thereto, unless the parties hereto shall enter into a mutually acceptable amendment
addressing such changes, as provided for above. 
  

	 1.04
	 Rounding. 

Any financial ratios required to be maintained by the Borrower pursuant to this Agreement shall be calculated by dividing the
appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest
number). 
  

	 1.05
	 Times of Day. 

Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as
applicable). 
  

	 1.06
	 Letter of Credit Amounts. 

Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such
Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated
amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time. 

 

	 1.07
	 UCC Terms. 

Terms defined in the UCC in effect on the Closing Date and not otherwise defined herein shall, unless the context otherwise
indicates, have the meanings provided by those definitions. Subject to the foregoing, the term “UCC” refers, as of any date of determination, to the UCC then in effect. 

 

	 1.08
	 Exchange Rates; Currency Equivalents. 

(a) The Administrative Agent shall determine the Spot Rates as of each Revaluation Date to be used for
calculating Dollar Equivalent amounts of Credit Extensions and Outstanding Amounts denominated in Alternative Currencies. Such Spot Rates shall become effective as of such Revaluation Date and shall be the Spot Rates employed in converting any
amounts between the applicable currencies until the next Revaluation Date to occur. Except for purposes of financial statements delivered by Loan Parties hereunder or calculating financial covenants hereunder or except as otherwise provided herein,
the applicable amount of any currency (other than Dollars) for purposes of the Loan Documents shall be such Dollar Equivalent amount as so determined by the Administrative Agent. 

  
 36 

 (b) Wherever in this Agreement in connection with a Borrowing,
conversion, continuation or prepayment of a Eurocurrency Rate Loan or the issuance, amendment or extension of a Letter of Credit, an amount, such as a required minimum or multiple amount, is expressed in Dollars, but such Borrowing or Eurocurrency
Rate Loan is denominated in an Alternative Currency, such amount shall be the relevant Alternative Currency Equivalent of such Dollar amount (rounded to the nearest unit of such Alternative Currency, with 0.5 of a unit being rounded upward), as
determined by the Administrative Agent. 
 (c) The Administrative Agent does not warrant, nor accept
responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to the rates in the definition of “Eurocurrency Rate” or with respect to any comparable or
successor rate thereto. 
  

	 1.09
	 Additional Alternative Currencies. 

(a) The Borrower may from time to time request that Eurocurrency Rate Loans be made in a currency other than
those specifically listed in the definition of “Alternative Currency”; provided that such requested currency is a lawful currency (other than Dollars) that is readily available and freely transferable and convertible into Dollars. In the
case of any such request with respect to the making of Eurocurrency Rate Loans, such request shall be subject to the approval of the Administrative Agent and the Lenders. 

(b) Any such request shall be made to the Administrative Agent not later than 1:00 p.m., twenty
(20) Business Days prior to the date of the desired Credit Extension (or such other time or date as may be agreed by the Administrative Agent). In the case of any such request pertaining to Eurocurrency Rate Loans, the Administrative Agent
shall promptly notify each Lender thereof. Each Lender (in the case of any such request pertaining to Eurocurrency Rate Loans) shall notify the Administrative Agent, not later than 1:00 p.m., ten (10) Business Days after receipt of such request
whether it consents, in its sole discretion, to the making of Eurocurrency Rate Loans in such requested currency. 

(c) Any failure by a Lender to respond to such request within the time period specified in the preceding
sentence shall be deemed to be a refusal by such Lender to permit Eurocurrency Rate Loans to be made in such requested currency. If the Administrative Agent and all the Lenders consent to making Eurocurrency Rate Loans in such requested currency,
the Administrative Agent shall so notify the Borrower and such currency shall thereupon be deemed for all purposes to be an Alternative Currency hereunder for purposes of any Borrowings of Eurocurrency Rate Loans. If the Administrative Agent shall
fail to obtain consent to any request for an additional currency under this Section 1.09, the Administrative Agent shall promptly so notify the Borrower. 

  
 37 

	 1.10
	 Change of Currency. 

(a) Each obligation of the Borrower to make a payment denominated in the national currency unit of any member
state of the European Union that adopts the Euro as its lawful currency after the date hereof shall be redenominated into Euro at the time of such adoption. If, in relation to the currency of any such member state, the basis of accrual of interest
expressed in this Agreement in respect of that currency shall be inconsistent with any convention or practice in the London interbank market for the basis of accrual of interest in respect of the Euro, such expressed basis shall be replaced by such
convention or practice with effect from the date on which such member state adopts the Euro as its lawful currency; provided that if any Borrowing in the currency of such member state is outstanding immediately prior to such date, such replacement
shall take effect, with respect to such Borrowing, at the end of the then current Interest Period. 
 (b)
Each provision of this Agreement shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect the adoption of the Euro by any member state of the European Union
and any relevant market conventions or practices relating to the Euro. 
 (c) Each provision of this
Agreement also shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect a change in currency of any other country and any relevant market conventions or
practices relating to the change in currency. 
 ARTICLE II 

COMMITMENTS AND CREDIT EXTENSIONS 
  

	 2.01
	 Loans. 

Subject to the terms and conditions set forth herein, each Lender severally agrees to make loans (each such
loan, a “Revolving Loan”) to the Borrower, in Dollars or in one or more Alternative Currencies, from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed at any time outstanding the
amount of such Lender’s Commitment; provided, however, that after giving effect to any Revolving Borrowing, (i) the Total Outstandings shall not exceed the Aggregate Commitments, (ii) the Revolving Exposure of any Lender
shall not exceed such Lender’s Commitment, and (iii) the aggregate Outstanding Amount of all Loans denominated in Alternative Currencies shall not exceed the Alternative Currency Sublimit. Within the limits of each Lender’s
Commitment, and subject to the other terms and conditions hereof, the Borrower may borrow Revolving Loans, prepay under Section 2.05, and reborrow under this Section 2.01. Revolving Loans may be Base Rate Loans or Eurocurrency Rate Loans,
as further provided herein; provided, however, any Borrowings made on the Closing Date or any of the three (3) Business Days following the Closing Date shall be made as Base Rate Loans unless the Borrower delivers a funding indemnity letter, in
form and substance satisfactory to Administrative Agent, not less than three (3) Business Days prior to the date of such Revolving Borrowing. 

  
 38 

	 2.02
	 Borrowings, Conversions and Continuations of Loans. 

(a) Notice of Borrowing. Each Borrowing, each conversion of Loans from one Type to the other, and each
continuation of Eurocurrency Rate Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent, which may be given by: (A) telephone or (B) a Loan Notice; provided that any telephonic notice must be
confirmed immediately by delivery to the Administrative Agent of a Loan Notice. Each such Loan Notice must be received by the Administrative Agent not later than 1:00 p.m. (i) three (3) Business Days prior to the requested date of any
Borrowing of, conversion to or continuation of Eurocurrency Rate Loans denominated in Dollars or of any conversion of Eurocurrency Rate Loans denominated in Dollars to Base Rate Loans, (ii) four (4) Business Days (or five (5) Business
Days in the case of a Special Notice Currency) prior to the requested date of any Borrowing or continuation of Eurocurrency Rate Loans denominated in Alternative Currencies and (iii) on the requested date of any Borrowing of Base Rate Loans.
Each Borrowing of, conversion to or continuation of Eurocurrency Rate Loans shall be in a principal amount of the Dollar Equivalent of $1,000,000 or a whole multiple of the Dollar Equivalent of $1,000,000 in excess thereof. Except as provided in
Sections 2.03(c) and 2.04(c), each Borrowing of or conversion to Base Rate Loans shall be in a principal amount of the Dollar Equivalent of $500,000 or a whole multiple of the Dollar Equivalent of $100,000 in excess thereof. Each Loan Notice
and each telephonic notice shall specify (A) whether the Borrower is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of Loans, as the case may be, (B) the requested date of the Borrowing,
conversion or continuation, as the case may be (which shall be a Business Day), (C) the principal amount of Loans to be borrowed, converted or continued, (D) the Type of Loans to be borrowed or to which existing Loans are to be converted,
(E) if applicable, the duration of the Interest Period with respect thereto and (F) the currency of the Loans to be borrowed. If the Borrower fails to specify a currency in a Loan Notice requesting a Borrowing, then the Loans so requested
shall be made in Dollars. If the Borrower fails to specify a Type of Loan in a Loan Notice or if the Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base
Rate Loans; provided, however, that in the case of a failure to timely request a continuation of Loans denominated in an Alternative Currency, such Loans shall be continued as Eurocurrency Rate Loans in their original currency with an
Interest Period of one (1) month. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Eurocurrency Rate Loans. If the Borrower requests a
Borrowing of, conversion to, or continuation of Eurocurrency Rate Loans in any such Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one (1) month. Notwithstanding anything to the
contrary herein, a Swingline Loan may not be converted to a Eurocurrency Rate Loan. Except as provided pursuant to Section 2.20(c), no Loan may be converted into or continued as a Loan denominated in a different currency, but instead must be
repaid in the original currency of such Loan and reborrowed in the other currency. 
 (b) Advances.
Following receipt of a Loan Notice, the Administrative Agent shall promptly notify each Appropriate Lender of the amount and currency of its Applicable Percentage of the applicable Loans, and if no timely notice of a conversion or continuation is
provided by the Borrower, the Administrative Agent shall notify each Appropriate Lender of the details of any automatic conversion to Base Rate Loans or continuation of Loans denominated in a currency other than Dollars, in each case as described in
Section 2.02(a). In the case of a Borrowing, each Appropriate Lender shall make the amount of its Loan available to the Administrative Agent in Same Day Funds at the Administrative Agent’s Office for the applicable currency not
later than 3:00 p.m., in the case of any Loan denominated in Dollars, and not later than the Applicable Time specified by the Administrative Agent in the case of any Loan in an Alternative Currency, in each case on the Business Day specified in
the applicable Loan Notice. Upon satisfaction of the applicable conditions set forth in Section 4.02 (and, if such Borrowing is the initial Credit Extension, Section 4.01), the Administrative Agent shall make all funds so received
available to the Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the Borrower on the books of Bank of America with the amount of such funds or (ii) wire transfer of such funds, in each
case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower; provided, however, that if, on the date a Loan Notice with respect to a Revolving Borrowing denominated in
Dollars is given by the Borrower, there are L/C Borrowings outstanding, then the proceeds of such Revolving Borrowing, first, shall be applied to the payment in full of any such L/C Borrowings, and second, shall be made available to
the Borrower as provided above. 

  
 39 

 (c) Eurocurrency Rate Loans. Except as otherwise provided
herein, a Eurocurrency Rate Loan may be continued or converted only on the last day of an Interest Period for such Eurocurrency Rate Loan. During the existence of an Event of Default, no Loans may be requested as, converted to or continued as
Eurocurrency Rate Loans (whether in Dollars or any Alternative Currency) without the consent of the Required Lenders, and Required Lenders may demand that any or all of the then outstanding Eurocurrency Rate Loans denominated in an Alternative
Currency be prepaid, or redenominated into Dollars in the amount of the Dollar Equivalent thereof, on the last day of the then current Interest Period with respect thereto. 

(d) Notice of Interest Rates. The Administrative Agent shall promptly notify the Borrower and the
Lenders of the interest rate applicable to any Interest Period for Eurocurrency Rate Loans upon determination of such interest rate. At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrower and the Lenders
of any change in Bank of America’s prime rate used in determining the Base Rate promptly following the public announcement of such change. 

(e) Interest Periods. After giving effect to all Revolving Borrowings, all conversions of Revolving
Loans from one Type to the other, and all continuations of Revolving Loans as the same Type, there shall not be more than ten (10) Interest Periods. 

(f) Cashless Settlement Mechanism. Notwithstanding anything to the contrary in this Agreement, any
Lender may exchange, continue or rollover all or the portion of its Loans in connection with any refinancing, extension, loan modification or similar transaction permitted by the terms of this Agreement, pursuant to a cashless settlement mechanism
approved by the Borrower, the Administrative Agent and such Lender. 
  

	 2.03
	 Letters of Credit. 

(a) The Letter of Credit Commitment. 

(i) Subject to the terms and conditions set forth herein, (A) the L/C Issuer agrees, in reliance upon the
agreements of the Lenders set forth in this Section, (1) from time to time on any Business Day during the period from the Closing Date until the Letter of Credit Expiration Date, to issue Letters of Credit denominated in Dollars for the account
of the Borrower or its Subsidiaries, and to amend or extend Letters of Credit previously issued by it, in accordance with Section 2.03(b), and (2) to honor drawings under the Letters of Credit; and (B) the Lenders severally agree to
participate in Letters of Credit issued for the account of the Borrower or its Subsidiaries and any drawings thereunder; provided that after giving effect to any L/C Credit Extension with respect to any Letter of Credit, (x) the Total
Outstandings shall not exceed the Aggregate Commitments, (y) the Revolving Exposure of any Lender shall not exceed such Lender’s Commitment, and (z) the Outstanding Amount of the L/C Obligations shall not exceed the Letter of Credit
Sublimit. Each request by the Borrower for the issuance or amendment of a Letter of Credit shall be deemed to be a representation by the Borrower that the L/C Credit Extension so requested complies with the conditions set forth in the proviso to the
preceding sentence. Within the foregoing limits, and subject to the terms and conditions hereof, the Borrower’s ability to obtain Letters of Credit shall be fully revolving, and accordingly the Borrower may, during the foregoing period, obtain
Letters of Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed. 

  
 40 

 (ii) The L/C Issuer shall not issue any Letter of Credit if:

 (A) the expiry date of the requested Letter of Credit would occur more than twelve (12) months after
the date of issuance or last extension, unless the Required Lenders have approved such expiry date; or 

(B) the expiry date of the requested Letter of Credit would occur after the Letter of Credit Expiration Date,
unless (x) all the Lenders have approved such expiry date or (y) such Letter of Credit is Cash Collateralized on terms and pursuant to arrangements satisfactory to the L/C Issuer; 

(iii) The L/C Issuer shall not be under any obligation to issue any Letter of Credit if: 

(A) any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to
enjoin or restrain the L/C Issuer from issuing the Letter of Credit, or any Law applicable to the L/C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the L/C Issuer
shall prohibit, or request that the L/C Issuer refrain from, the issuance of letters of credit generally or the Letter of Credit in particular or shall impose upon the L/C Issuer with respect to the Letter of Credit any restriction, reserve or
capital requirement (for which the L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon the L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date and
which the L/C Issuer in good faith deems material to it; 
 (B) the issuance of the Letter of Credit would
violate one or more policies of the L/C Issuer applicable to letters of credit generally; 
 (C) except as
otherwise agreed by the Administrative Agent and the L/C Issuer, the Letter of Credit is in an initial stated amount less than $250,000; 

(D) the Letter of Credit is to be denominated in a currency other than Dollars; 

(E) any Lender is at that time a Defaulting Lender, unless the L/C Issuer has entered into arrangements,
including the delivery of Cash Collateral, satisfactory to the L/C Issuer (in its sole discretion) with the Borrower or such Lender to eliminate the L/C Issuer’s actual or potential Fronting Exposure (after giving effect to
Section 2.15(a)(iv)) with respect to the Defaulting Lender arising from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L/C Obligations as to which the L/C Issuer has actual or potential Fronting
Exposure, as it may elect in its sole discretion; or 
 (iv) The L/C Issuer shall not amend any Letter of
Credit if the L/C Issuer would not be permitted at such time to issue the Letter of Credit in its amended form under the terms hereof. 

  
 41 

 (v) The L/C Issuer shall be under no obligation to amend any
Letter of Credit if (A) the L/C Issuer would have no obligation at such time to issue such Letter of Credit in its amended form under the terms hereof, or (B) the beneficiary of such Letter of Credit does not accept the proposed amendment
to the Letter of Credit. 
 (vi) The L/C Issuer shall act on behalf of the Lenders with respect to any
Letters of Credit issued by it and the documents associated therewith, and the L/C Issuer shall have all of the benefits and immunities (A) provided to the Administrative Agent in Article IX with respect to any acts taken or omissions suffered
by the L/C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and Issuer Documents pertaining to such Letters of Credit as fully as if the term “Administrative Agent” as used in Article IX included the
L/C Issuer with respect to such acts or omissions, and (B) as additionally provided herein with respect to the L/C Issuer. 

(b) Procedures for Issuance and Amendment of Letters of Credit; Auto-Extension Letters of Credit. 

(i) Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the Borrower
delivered to the L/C Issuer (with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Responsible Officer of the Borrower. Such Letter of Credit Application may be sent by fax
transmission, by United States mail, by overnight courier, by electronic transmission using the system provided by the L/C Issuer, by personal delivery or by any other means acceptable to the L/C Issuer. Such Letter of Credit Application must be
received by the L/C Issuer and the Administrative Agent not later than 1:00 p.m. at least three (3) Business Days (or such later date and time as the Administrative Agent and the L/C Issuer may agree in a particular instance in their sole
discretion) prior to the proposed issuance date or date of amendment, as the case may be. In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the
L/C Issuer: (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day); (B) the amount thereof; (C) the expiry date thereof; (D) the name and address of the beneficiary thereof; (E) the
documents to be presented by such beneficiary in case of any drawing thereunder; (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder; (G) the purpose and nature of the requested Letter
of Credit; and (H) such other matters as the L/C Issuer may require. In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L/C
Issuer (1) the Letter of Credit to be amended; (2) the proposed date of amendment thereof (which shall be a Business Day); (3) the nature of the proposed amendment; and (4) such other matters as the L/C Issuer may require.
Additionally, the Borrower shall furnish to the L/C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as the L/C Issuer or
the Administrative Agent may require. 

  
 42 

 (ii) Promptly after receipt of any Letter of Credit Application,
the L/C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the Borrower and, if not, the L/C Issuer will provide the
Administrative Agent with a copy thereof. Unless the L/C Issuer has received written notice from any Lender, the Administrative Agent or any Loan Party, at least one (1) Business Day prior to the requested date of issuance or amendment of the
applicable Letter of Credit, that one or more applicable conditions contained in Article IV shall not then be satisfied, then, subject to the terms and conditions hereof, the L/C Issuer shall, on the requested date, issue a Letter of Credit for the
account of the Borrower or enter into the applicable amendment, as the case may be, in each case in accordance with the L/C Issuer’s usual and customary business practices. Immediately upon the issuance of each Letter of Credit, each Lender
shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the L/C Issuer a risk participation in such Letter of Credit in an amount equal to the product of such Lender’s Applicable Percentage times the amount of
such Letter of Credit. 
 (iii) Promptly after its delivery of any Letter of Credit or any amendment to a
Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the L/C Issuer will also deliver to the Borrower and the Administrative Agent a true and complete copy of such Letter of Credit or amendment. 

(iv) If the Borrower so requests in any applicable Letter of Credit Application, the L/C Issuer may, in its
sole discretion, agree to issue a standby Letter of Credit that has automatic extension provisions (each an “Auto-Extension Letter of Credit”); provided that any such Auto-Extension Letter of Credit must permit the L/C Issuer to
prevent any such extension at least once in each twelve (12) month period (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice
Date”) in each such twelve (12) month period to be agreed upon at the time such Letter of Credit is issued. Unless otherwise directed by the L/C Issuer, the Borrower shall not be required to make a specific request to the L/C Issuer
for any such extension. Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not
later than the Letter of Credit Expiration Date; provided that the L/C Issuer shall not permit any such extension if (A) the L/C Issuer has determined that it would have no obligation at such time to issue such Letter of Credit in its revised
form (as extended) under the terms hereof (by reason of the provisions of clause (ii) or (iii) of Section 2.03(a) or otherwise) or (B) it has received notice (which may be by telephone, followed promptly in
writing, or in writing) on or before the day that is thirty (30) days before the Non-Extension Notice Date (1) from the Administrative Agent that the Required Lenders have elected not to permit such extension or (2) from the
Administrative Agent, any Lender or the Borrower that one or more of the applicable conditions specified in Section 4.02 is not then satisfied, and in each such case directing the L/C Issuer not to permit such extension. 

(c) Drawings and Reimbursements; Funding of Participations. 

(i) Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of
Credit, the L/C Issuer shall notify the Borrower and the Administrative Agent thereof. Not later than 1:00 p.m. on the date of any payment by the L/C Issuer under a Letter of Credit (each such date, an “Honor Date”), the Borrower
shall reimburse the L/C Issuer through the Administrative Agent in an amount equal to the amount of such drawing. If the Borrower fails to so reimburse the L/C Issuer by such time, the Administrative Agent shall promptly notify each Lender of the
Honor Date, the amount of the unreimbursed drawing (the “Unreimbursed Amount”), and the amount of such Lender’s Applicable Percentage thereof. In such event, the Borrower shall be deemed to have requested a Revolving Borrowing
of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in Section 2.02 for the principal amount of Base Rate Loans, but subject to the amount of
the unutilized portion of the Commitments and the conditions set forth in Section 4.02 (other than the delivery of a Loan Notice). Any notice given by the L/C Issuer or the Administrative Agent pursuant to this Section 2.03(c)(i) may be
given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice. 

  
 43 

 (ii) Each Lender shall upon any notice pursuant to
Section 2.03(c)(i) make funds available (and the Administrative Agent may apply Cash Collateral provided for this purpose) for the account of the L/C Issuer at the Administrative Agent’s Office in an amount equal to its Applicable
Percentage of the Unreimbursed Amount not later than 3:00 p.m. on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.03(c)(iii), each Lender that so makes funds available
shall be deemed to have made a Base Rate Loan to the Borrower in such amount. The Administrative Agent shall remit the funds so received to the L/C Issuer. 

(iii) With respect to any Unreimbursed Amount that is not fully refinanced by a Revolving Borrowing of Base
Rate Loans because the conditions set forth in Section 4.02 cannot be satisfied or for any other reason, the Borrower shall be deemed to have incurred from the L/C Issuer an L/C Borrowing in the amount of the Unreimbursed Amount that is not so
refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate. In such event, each Lender’s payment to the Administrative Agent for the account of the L/C Issuer pursuant
to Section 2.03(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such Lender in satisfaction of its participation obligation under this Section. 

(iv) Until each Lender funds its Revolving Loan or L/C Advance pursuant to this Section 2.03(c) to
reimburse the L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lender’s Applicable Percentage of such amount shall be solely for the account of the L/C Issuer. 

(v) Each Lender’s obligation to make Revolving Loans or L/C Advances to reimburse the L/C Issuer for
amounts drawn under Letters of Credit, as contemplated by this Section 2.03(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right
which such Lender may have against the L/C Issuer, the Borrower, any Subsidiary or any other Person for any reason whatsoever; (B) the occurrence or continuance of a Default; or (C) any other occurrence, event or condition, whether or not
similar to any of the foregoing; provided, however, that each Lender’s obligation to make Revolving Loans pursuant to this Section 2.03(c) is subject to the conditions set forth in Section 4.02 (other than delivery by
the Borrower of a Loan Notice). No such making of an L/C Advance shall relieve or otherwise impair the obligation of the Borrower to reimburse the L/C Issuer for the amount of any payment made by the L/C Issuer under any Letter of Credit, together
with interest as provided herein. 

  
 44 

 (vi) If any Lender fails to make available to the Administrative
Agent for the account of the L/C Issuer any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.03(c) by the time specified in Section 2.03(c)(ii), then, without limiting the other provisions of
this Agreement, the L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such
payment is immediately available to the L/C Issuer at a rate per annum equal to the applicable Overnight Rate from time to time in effect, plus any administrative, processing or similar fees customarily charged by the L/C Issuer in connection with
the foregoing. If such Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s Revolving Loan included in the relevant Revolving Borrowing or L/C Advance in respect of the relevant L/C
Borrowing, as the case may be. A certificate of the L/C Issuer submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this Section 2.03(c)(vi) shall be conclusive absent manifest error. 

(d) Repayment of Participations. 

(i) At any time after the L/C Issuer has made a payment under any Letter of Credit and has received from any
Lender such Lender’s L/C Advance in respect of such payment in accordance with Section 2.03(c), if the Administrative Agent receives for the account of the L/C Issuer any payment in respect of the related Unreimbursed Amount or interest
thereon (whether directly from the Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Lender its Applicable Percentage thereof in the same funds
as those received by the Administrative Agent. 
 (ii) If any payment received by the Administrative Agent
for the account of the L/C Issuer pursuant to Section 2.03(c)(i) is required to be returned under any of the circumstances described in Section 11.05 (including pursuant to any settlement entered into by the L/C Issuer in its discretion),
each Lender shall pay to the Administrative Agent for the account of the L/C Issuer its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by
such Lender, at a rate per annum equal to the applicable Overnight Rate from time to time in effect. The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement. 

(e) Obligations Absolute. The obligation of the Borrower to reimburse the L/C Issuer for each drawing
under each Letter of Credit and to repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following: 

(i) any lack of validity or enforceability of such Letter of Credit, this Agreement, or any other Loan
Document; 
 (ii) the existence of any claim, counterclaim, setoff, defense or other right that the Borrower
or any Subsidiary may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), the L/C Issuer or any other Person, whether in connection
with this Agreement or by such Letter of Credit, the transactions contemplated hereby or any agreement or instrument relating thereto, or any unrelated transaction; 

  
 45 

 (iii) any draft, demand, endorsement, certificate or other
document presented under or in connection with such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the
transmission or otherwise of any document required in order to make a drawing under such Letter of Credit; 

(iv) waiver by the L/C Issuer of any requirement that exists for the L/C Issuer’s protection and not the
protection of the Borrower or any waiver by the L/C Issuer which does not in fact materially prejudice the Borrower; 

(v) honor of a demand for payment presented electronically even if such Letter of Credit requires that demand
be in the form of a draft; 
 (vi) any payment made by the L/C Issuer in respect of an otherwise complying
item presented after the date specified as the expiration date of, or the date by which documents must be received under, such Letter of Credit if presentation after such date is authorized by the UCC, the ISP or the UCP, as applicable; 

(vii) any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate
that does not strictly comply with the terms of such Letter of Credit; or any payment made by the L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of
creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law; or 

(viii) any other circumstance or happening whatsoever, whether or not similar to any of the foregoing,
including any other circumstance that might otherwise constitute a defense available to, or a discharge of, the Borrower or any of its Subsidiaries. 

The Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in
the event of any claim of noncompliance with the Borrower’s instructions or other irregularity, the Borrower will immediately notify the L/C Issuer. The Borrower shall be conclusively deemed to have waived any such claim against the L/C Issuer
and its correspondents unless such notice is given as aforesaid. 
 (f) Role of L/C Issuer. Each
Lender and the Borrower agree that, in paying any drawing under a Letter of Credit, the L/C Issuer shall not have any responsibility to obtain any document (other than any sight or time draft, certificates and documents expressly required by the
Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document. None of the L/C Issuer, the Administrative Agent, any of their respective
Related Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Required
Lenders, as applicable; (ii) any action taken or omitted in the absence of gross negligence or willful misconduct; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of
Credit or Issuer Document. The Borrower hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to its use of any Letter of Credit; provided, however, that this assumption is not intended to, and
shall not, preclude the Borrower’s pursuing such rights and remedies as it may have against the beneficiary or transferee at law or under any other agreement. None of the L/C Issuer, the Administrative Agent, any of their respective Related
Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable or responsible for any of the matters described in Section 2.03(e); provided, however, that anything in such clauses to the contrary
notwithstanding, the Borrower may have a claim against the L/C Issuer, and the L/C Issuer may be liable to the Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by the Borrower
which the Borrower proves, as determined by a final nonappealable judgment of a court of competent jurisdiction, were caused by the L/C Issuer’s willful misconduct or gross negligence or the L/C Issuer’s willful failure to pay under any
Letter of Credit after the presentation to it by the beneficiary of a sight or time draft and certificate(s) strictly complying with the terms and conditions of a Letter of Credit. In furtherance and not in limitation of the foregoing, the L/C
Issuer may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuer shall not be responsible for the validity or
sufficiency of any instrument transferring, endorsing or assigning or purporting to transfer, endorse or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or
ineffective for any reason. The L/C Issuer may send a Letter of Credit or conduct any communication to or from the beneficiary via the Society for Worldwide Interbank Financial Telecommunication (“SWIFT”) message or overnight
courier, or any other commercially reasonable means of communicating with a beneficiary. 

  
 46 

 (g) Applicability of ISP and UCP; Limitation of Liability.
Unless otherwise expressly agreed by the L/C Issuer and the Borrower when a Letter of Credit is issued, the rules of the ISP shall apply to each standby Letter of Credit. Notwithstanding the foregoing, the L/C Issuer shall not be responsible to
the Borrower for, and the L/C Issuer’s rights and remedies against the Borrower shall not be impaired by, any action or inaction of the L/C Issuer required or permitted under any law, order, or practice that is required or permitted to be
applied to any Letter of Credit or this Agreement, including the Law or any order of a jurisdiction where the L/C Issuer or the beneficiary is located, the practice stated in the ISP or UCP, as applicable, or in the decisions, opinions, practice
statements, or official commentary of the ICC Banking Commission, the Bankers Association for Finance and Trade - International Financial Services Association (BAFT-IFSA), or the Institute of International Banking Law & Practice, whether or
not any Letter of Credit chooses such law or practice. 
 (h) Letter of Credit Fees. The
Borrower shall pay to the Administrative Agent for the account of each Lender in accordance, subject to Section 2.15, with its Applicable Percentage a Letter of Credit fee (the “Letter of Credit Fee”) for each Letter of
Credit equal to the Applicable Rate times the daily amount available to be drawn under such Letter of Credit. Letter of Credit Fees shall be (1) due and payable on the first Business Day following each fiscal quarter end, commencing with
the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand and (2) computed on a quarterly basis in arrears. If there is any change in the Applicable Rate during
any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect. 

(i) Documentary and Processing Charges Payable to L/C Issuer. The Borrower shall pay directly to the L/C
Issuer for its own account, in Dollars the customary issuance, presentation, amendment and other processing fees, and other standard costs and charges, of the L/C Issuer relating to letters of credit as from time to time in effect. Such customary
fees and standard costs and charges are due and payable on demand and are nonrefundable. 

  
 47 

 (j) Conflict with Issuer Documents. In the event of any
conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control. 

(k) Letters of Credit Issued for Subsidiaries. Notwithstanding that a Letter of Credit issued or
outstanding hereunder is in support of any obligations of, or is for the account of, a Subsidiary, the Borrower shall be obligated to reimburse the L/C Issuer hereunder for any and all drawings under such Letter of Credit. The Borrower hereby
acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Borrower, and that the Borrower’s business derives substantial benefits from the businesses of such Subsidiaries. 

 

	 2.04
	 Swingline Loans. 

(a) The Swingline. Subject to the terms and conditions set forth herein, the Swingline Lender, in
reliance upon the agreements of the other Lenders set forth in this Section, may in its sole discretion make loans to the Borrower (each such loan, a “Swingline Loan”). Each such Swingline Loan may be made, subject to the terms and
conditions set forth herein, to the Borrower, in Dollars, from time to time on any Business Day. During the Availability Period in an aggregate amount not to exceed at any time outstanding the amount of the Swingline Sublimit, notwithstanding the
fact that such Swingline Loans, when aggregated with the Applicable Percentage of the Outstanding Amount of Revolving Loans and L/C Obligations of the Lender acting as Swingline Lender, may exceed the amount of such Lender’s Commitment;
provided, however, that (i) after giving effect to any Swingline Loan, (A) the Total Outstandings shall not exceed the Aggregate Commitments at such time, and (B) the Revolving Exposure of any Lender at such time shall
not exceed such Lender’s Commitment, (ii) the Borrower shall not use the proceeds of any Swingline Loan to refinance any outstanding Swingline Loan, and (iii) the Swingline Lender shall not be under any obligation to make any
Swingline Loan if it shall determine (which determination shall be conclusive and binding absent manifest error) that it has, or by such Credit Extension may have, Fronting Exposure. Within the foregoing limits, and subject to the other terms and
conditions hereof, the Borrower may borrow under this Section, prepay under Section 2.05, and reborrow under this Section. Each Swingline Loan shall bear interest only at a rate based on the Base Rate plus the Applicable Rate. Immediately upon
the making of a Swingline Loan, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the Swingline Lender a risk participation in such Swingline Loan in an amount equal to the product of such
Lender’s Applicable Percentage times the amount of such Swingline Loan. 
 (b) Borrowing
Procedures. 
 (i) Each Swingline Borrowing shall be made upon the Borrower’s irrevocable notice to
the Swingline Lender and the Administrative Agent, which may be given by: (A) telephone or (B) a Swingline Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Swingline Lender and the
Administrative Agent of a Swingline Loan Notice. Each such Swingline Loan Notice must be received by the Swingline Lender and the Administrative Agent not later than 1:00 p.m. on the requested borrowing date, and shall specify (i) the amount to
be borrowed, which shall be a minimum of $100,000, and (ii) the requested date of the Borrowing (which shall be a Business Day). Promptly after receipt by the Swingline Lender of any Swingline Loan Notice, the Swingline Lender will confirm with
the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Swingline Loan Notice and, if not, the Swingline Lender will notify the Administrative Agent (by telephone or in writing) of the contents
thereof. Unless the Swingline Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any Lender) prior to 2:00 p.m. on the date of the proposed Swingline Borrowing (A) directing the
Swingline Lender not to make such Swingline Loan as a result of the limitations set forth in the first proviso to the first sentence of Section 2.04(a), or (B) that one or more of the applicable conditions specified in Article IV is not
then satisfied, then, subject to the terms and conditions hereof, the Swingline Lender will, not later than 3:00 p.m. on the borrowing date specified in such Swingline Loan Notice, make the amount of its Swingline Loan available to the Borrower at
its office by crediting the account of the Borrower on the books of the Swingline Lender in Same Day Funds. 

  
 48 

 (c) Refinancing of Swingline Loans. 

(i) The Swingline Lender at any time in its sole discretion may request, on behalf of the Borrower (which
hereby irrevocably authorizes the Swingline Lender to so request on its behalf), that each Lender make a Eurocurrency Rate Loan in an amount equal to such Lender’s Applicable Percentage of the amount of Swingline Loans then outstanding. Such
request shall be made in writing (which written request shall be deemed to be a Loan Notice for purposes hereof) and in accordance with the requirements of Section 2.02, without regard to the minimum and multiples specified therein for the
principal amount of Base Rate Loans, but subject to the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.02. The Swingline Lender shall furnish the Borrower with a copy of the applicable Loan Notice
promptly after delivering such notice to the Administrative Agent. Each Lender shall make an amount equal to its Applicable Percentage of the amount specified in such Loan Notice available to the Administrative Agent in Same Day Funds (and the
Administrative Agent may apply Cash Collateral available with respect to the applicable Swingline Loan) for the account of the Swingline Lender at the Administrative Agent’s Office for Dollar-denominated payments not later than 1:00 p.m. on the
day specified in such Loan Notice, whereupon, subject to Section 2.04(c)(ii), each Lender that so makes funds available shall be deemed to have made a Base Rate Loan to the Borrower in such amount. The Administrative Agent shall remit the funds
so received to the Swingline Lender. 
 (ii) If for any reason any Swingline Loan cannot be refinanced by
such a Revolving Borrowing in accordance with Section 2.04(c)(i), the request for Base Rate Loans submitted by the Swingline Lender as set forth herein shall be deemed to be a request by the Swingline Lender that each of the Lenders fund its
risk participation in the relevant Swingline Loan and each Lender’s payment to the Administrative Agent for the account of the Swingline Lender pursuant to Section 2.04(c)(i) shall be deemed payment in respect of such participation. 

(iii) If any Lender fails to make available to the Administrative Agent for the account of the Swingline
Lender any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.04(c) by the time specified in Section 2.04(c)(i), the Swingline Lender shall be entitled to recover from such Lender (acting
through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the Swingline Lender at a rate per annum equal to the
applicable Overnight Rate from time to time in effect, plus any administrative, processing or similar fees customarily charged by the Swingline Lender in connection with the foregoing. If such Lender pays such amount (with interest and fees as
aforesaid), the amount so paid shall constitute such Lender’s Revolving Loan included in the relevant Revolving Borrowing or funded participation in the relevant Swingline Loan, as the case may be. A certificate of the Swingline Lender
submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (iii) shall be conclusive absent manifest error. 

  
 49 

 (iv) Each Lender’s obligation to make Revolving Loans or to
purchase and fund risk participations in Swingline Loans pursuant to this Section 2.04(c) shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or
other right which such Lender may have against the Swingline Lender, the Borrower or any other Person for any reason whatsoever, (B) the occurrence or continuance of a Default or (C) any other occurrence, event or condition, whether or not
similar to any of the foregoing; provided however, that each Lender’s obligation to make Revolving Loans pursuant to this Section 2.04(c) is subject to the conditions set forth in Section 4.02 (other than delivery by the
Borrower of a Loan Notice). No such funding of risk participations shall relieve or otherwise impair the obligation of the Borrower to repay Swingline Loans, together with interest as provided herein. 

(d) Repayment of Participations. 

(i) At any time after any Lender has purchased and funded a risk participation in a Swingline Loan, if the
Swingline Lender receives any payment on account of such Swingline Loan, the Swingline Lender will distribute to such Lender its Applicable Percentage thereof in the same funds as those received by the Swingline Lender. 

(ii) If any payment received by the Swingline Lender in respect of principal or interest on any Swingline Loan
is required to be returned by the Swingline Lender under any of the circumstances described in Section 11.05 (including pursuant to any settlement entered into by the Swingline Lender in its discretion), each Lender shall pay to the Swingline
Lender its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the applicable Overnight Rate. The Administrative
Agent will make such demand upon the request of the Swingline Lender. The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement. 

(e) Interest for Account of Swingline Lender. The Swingline Lender shall be responsible for invoicing
the Borrower for interest on the Swingline Loans. Until each Lender funds its Base Rate Loan or risk participation pursuant to this Section to refinance such Lender’s Applicable Percentage of any Swingline Loan, interest in respect of such
Applicable Percentage shall be solely for the account of the Swingline Lender. 
 (f) Payments Directly to
Swingline Lender. The Borrower shall make all payments of principal and interest in respect of the Swingline Loans directly to the Swingline Lender. 

  
 50 

	 2.05
	 Prepayments. 

(a) Optional. 

(i) The Borrower may, upon notice to the Administrative Agent pursuant to delivery to the Administrative Agent
of a Notice of Loan Prepayment, at any time or from time to time voluntarily prepay Revolving Loans in whole or in part without premium or penalty subject to Section 3.05; provided that, unless otherwise agreed by the Administrative
Agent, (A) such notice must be received by the Administrative Agent not later than 1:00 p.m. (1) three (3) Business Days prior to any date of prepayment of Eurocurrency Rate Loans denominated in Dollars, (2) four
(4) Business Days (or five (5), in the case of prepayment of Loans denominated in Special Notice Currencies) prior to any date of prepayment of Eurocurrency Rate Loans denominated in Alternative Currencies, and (3) on the date of
prepayment of Base Rate Loans; (B) any prepayment of Eurocurrency Rate Loans shall be in a principal Dollar Equivalent amount of $1,000,000 or a whole multiple of the Dollar Equivalent amount of $1,000,000 in excess thereof; and (C) any
prepayment of Base Rate Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding. Each such notice shall specify the date, the
currency and amount of such prepayment and the Type(s) of Loans to be prepaid and, if Eurocurrency Rate Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will promptly notify each Lender of its receipt of each
such notice, and of the amount of such Lender’s ratable portion of such prepayment (based on such Lender’s Applicable Percentage). If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount
specified in such notice shall be due and payable on the date specified therein. Any prepayment of principal shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to
Section 3.05. Subject to Section 2.15, such prepayments shall be paid to the Lenders in accordance with their respective Applicable Percentages. 

(ii) The Borrower may, upon notice to the Swingline Lender pursuant to delivery to the Swingline Lender of a
Notice of Loan Prepayment (with a copy to the Administrative Agent), at any time or from time to time, voluntarily prepay Swingline Loans in whole or in part without premium or penalty; provided that, unless otherwise agreed by the Swingline
Lender, (A) such notice must be received by the Swingline Lender and the Administrative Agent not later than 1:00 p.m. on the date of the prepayment, and (B) any such prepayment shall be in a minimum principal amount of $100,000 or a whole
multiple of $100,000 in excess hereof (or, if less, the entire principal thereof then outstanding). Each such notice shall specify the date and amount of such prepayment. If such notice is given by the Borrower, the Borrower shall make such
prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. Any prepayment of principal shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts
required pursuant to Section 3.05. 
 (b) Mandatory. 

(i) Revolving Outstandings. In the event and on such occasion that the aggregate Total Outstandings
exceed (A) 105% of the Aggregate Commitments, solely as a result of currency fluctuations or (B) the Aggregate Commitments (other than as a result of currency fluctuations), the Borrower shall prepay (no later than one (1) Business
Day after written notice from the Administrative Agent to the Borrower) Revolving Loans and Swingline Loans (or, if no such Revolving Loans or Swingline Loans are outstanding, deposit cash collateral in an account with the Administrative Agent
pursuant to Section 2.14) in an aggregate amount equal to the amount by which the aggregate Total Outstandings exceed the aggregate Revolving Commitments. 

  
 51 

 (ii) Application of Other Payments. Except as otherwise
provided in Section 2.15, prepayments of the Aggregate Commitments made pursuant to this Section 2.05(b), first, shall be applied ratably to the L/C Borrowings and the Swingline Loans, second, shall be applied to the
outstanding Revolving Loans, and, third, shall be used to Cash Collateralize the remaining L/C Obligations. Upon the drawing of any Letter of Credit that has been Cash Collateralized, the funds held as Cash Collateral shall be applied
(without any further action by or notice to or from the Borrower or any other Loan Party or any Defaulting Lender that has provided Cash Collateral) to reimburse the L/C Issuer or the Lenders, as applicable. 

(iii) Alternative Currencies. If the Administrative Agent notifies the Borrower at any time that the
Outstanding Amount of all Loans denominated in Alternative Currencies at such time exceeds an amount equal to 105% of the Alternative Currency Sublimit then in effect, then, within two (2) Business Days after receipt of such notice, the
Borrower shall prepay Loans in an aggregate amount sufficient to reduce such Outstanding Amount as of such date of payment to an amount not to exceed 100% of the Alternative Currency Sublimit then in effect. 

Within the parameters of the applications set forth above, prepayments pursuant to this Section 2.05(b) shall be applied
first to Base Rate Loans and then to Eurocurrency Rate Loans in direct order of Interest Period maturities. All prepayments under this Section 2.05(b) shall be subject to Section 3.05, but otherwise without premium or penalty, and shall be
accompanied by interest on the principal amount prepaid through the date of prepayment. 
  

	 2.06
	 Termination or Reduction of Commitments. 

(a) Optional. The Borrower may, upon notice to the Administrative Agent, terminate the Aggregate
Commitments, the Letter of Credit Sublimit or the Swingline Sublimit, or from time to time permanently reduce the Aggregate Commitments, the Letter of Credit Sublimit or the Swingline Sublimit; provided that (i) any such notice shall be
received by the Administrative Agent not later than 1:00 p.m. three (3) Business Days prior to the date of termination or reduction, (ii) any such partial reduction shall be in an aggregate amount of $5,000,000 or any whole multiple of
$1,000,000 in excess thereof and (iii) the Borrower shall not terminate or reduce (A) the Aggregate Commitments if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Outstandings would exceed the Aggregate
Commitments, (B) the Letter of Credit Sublimit if, after giving effect thereto, the Outstanding Amount of L/C Obligations not fully Cash Collateralized hereunder would exceed the Letter of Credit Sublimit, or (C) the Swingline Sublimit if,
after giving effect thereto and to any concurrent prepayments hereunder, the Outstanding Amount of Swingline Loans would exceed the Letter of Credit Sublimit. 

(b) Mandatory. If after giving effect to any reduction or termination of Commitments under this
Section 2.06, the Letter of Credit Sublimit, the Alternative Currency Sublimit or the Swingline Sublimit exceeds the Aggregate Commitments at such time, the Letter of Credit Sublimit, the Alternative Currency Sublimit or the Swingline Sublimit,
as the case may be, shall be automatically reduced by the amount of such excess. 

  
 52 

 (c) Application of Commitment Reductions; Payment of Fees.
The Administrative Agent will promptly notify the Lenders of any termination or reduction of the Letter of Credit Sublimit, Swingline Sublimit, the Alternative Currency Sublimit or the Commitment under this Section 2.06. The amount of any such
reduction of the Revolving Commitments shall not be applied to the Alternative Currency Sublimit unless otherwise specified by the Borrower. Upon any reduction of the Commitments, the Commitment of each Lender shall be reduced by such Lender’s
Applicable Percentage of such reduction amount. All fees in respect of the Aggregate Commitments accrued until the effective date of any termination of the Aggregate Commitments shall be paid on the effective date of such termination. 

 

	 2.07
	 Repayment of Loans. 

(a) Revolving Loans. The Borrower shall repay to the Lenders on the Maturity Date the aggregate
principal amount of all Revolving Loans outstanding on such date. 
 (b) Swingline Loans. The Borrower
shall repay each Swingline Loan on the earlier to occur of (i) the date ten (10) Business Days after such Loan is made and (ii) the Maturity Date. 
  

	 2.08
	 Interest and Default Rate. 

(a) Interest. Subject to the provisions of Section 2.08(b), (i) each Eurocurrency Rate Loan
shall bear interest on the outstanding principal amount thereof for each Interest Period from the applicable borrowing date at a rate per annum equal to the Eurocurrency Rate for such Interest Period plus the Applicable Rate; (ii) each Base
Rate Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate; and (iii) each Swingline Loan shall bear interest on the
outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate. 

(b) Default Rate. 

(i) (A) During the continuance of an Event of Default under Sections 8.01(a) or (f), the
Borrower shall pay interest on overdue amounts (after giving effect to any applicable grace period) owing by it hereunder at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable
Laws, and (B) upon the request of the Required Lenders, while any other Event of Default exists, all outstanding Obligations (including Letter of Credit Fees) may accrue at a fluctuating interest rate per annum at all times equal to the Default
Rate to the fullest extent permitted by applicable Laws; provided that no interest at the Default Rate shall accrue or be payable to a Defaulting Lender so long as such Lender shall be a Defaulting Lender. 

(ii) Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due
and payable upon demand. 
 (c) Interest Payments. Interest on each Loan shall be due and payable in
arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the
commencement of any proceeding under any Debtor Relief Law. 

  
 53 

	 2.09
	 Fees. 

In addition to certain fees described in subsections (h) and (i) of Section 2.03: 

(a) Commitment Fee. The Borrower shall pay to the Administrative Agent for the account of each Lender in
accordance with its Applicable Percentage, a commitment fee equal to the Applicable Rate times the actual daily amount by which the Aggregate Commitments exceeds the sum of (i) the Outstanding Amount of Revolving Loans and (ii) the
Outstanding Amount of L/C Obligations, subject to adjustment as provided in Section 2.15. For the avoidance of doubt, the Outstanding Amount of Swingline Loans shall not be counted towards or considered usage of the Aggregate Commitments. The
commitment fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in Article IV is not met, and shall be due and payable quarterly in arrears on the last Business Day of each
March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the Maturity Date. The commitment fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Rate during
any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect. 

(b) Upfront Fee. The Borrower shall pay to the Administrative Agent, for its own account, an upfront fee
(the “Upfront Fee”) of 0.35% of the Aggregate Commitments in Dollars payable in full on the Closing Date in immediately available funds, free and clear of, and without deduction for, any and all present or future applicable taxes,
levies, imposts, deductions, charges or withholdings and all liabilities with respect thereto (with appropriate gross-up for withholding taxes). Once paid, such Upfront Fee shall not be subject to counterclaim, set off or otherwise affected, and
shall not be refundable for any reason whatsoever. Such Upfront Fee shall be in addition to any other fees, disbursements, charges and expenses payable hereunder or any other Loan Document. 

(c) Other Fees. The Borrower shall pay to the Lenders, in Dollars, such fees as shall have been
separately agreed in connection with the Loan Documents upon in writing in the amounts and at the times so specified. Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever. 

 

	 2.10
	 Computation of Interest and Fees; Retroactive Adjustments of Applicable Rate. 

(a) Computation of Interest and Fees. All computations of interest for Base Rate Loans (including Base
Rate Loans determined by reference to the Eurocurrency Rate) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest shall be made on the basis of a 360-day
year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365 day year), or, in the case of interest in respect of Loans denominated in Alternative Currencies as to which
market practice differs from the foregoing, in accordance with such market practice. Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or
such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to Section 2.12(a), bear interest for one (1) day. Each determination by the Administrative Agent of an interest rate or fee
hereunder shall be conclusive and binding for all purposes, absent manifest error. 

  
 54 

 (b) Financial Statement Adjustments or Restatements. If,
as a result of any restatement of or other adjustment to the financial statements of the Borrower and its Subsidiaries or for any other reason, the Borrower, or the Lenders determine that (i) the Consolidated Leverage Ratio as calculated by the
Borrower as of any applicable date was inaccurate and (ii) a proper calculation of the Consolidated Leverage Ratio would have resulted in higher pricing for such period, the Borrower shall immediately and retroactively be obligated to pay to
the Administrative Agent for the account of the applicable Lenders or the L/C Issuer, as the case may be, promptly on demand by the Administrative Agent (or, after the occurrence of an actual or deemed entry of an order for relief with respect to
the Borrower under the Bankruptcy Code of the United States, automatically and without further action by the Administrative Agent, any Lender or the L/C Issuer), an amount equal to the excess of the amount of interest and fees that should have been
paid for such period over the amount of interest and fees actually paid for such period. This paragraph shall not limit the rights of the Administrative Agent, any Lender or the L/C Issuer, as the case may be, under any provision of this Agreement
to payment of any Obligations hereunder at the Default Rate or under Article VIII. The Borrower’s obligations under this paragraph shall survive the termination of the Aggregate Commitments and the repayment of all other Obligations hereunder.

  

	 2.11
	 Evidence of Debt. 

(a) Maintenance of Accounts. The Credit Extensions made by each Lender shall be evidenced by one or more
accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business. The accounts or records maintained by the Administrative Agent and each Lender shall be conclusive absent manifest error of the amount
of the Credit Extensions made by the Lenders to the Borrower and the interest and payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any
amount owing with respect to the Obligations. In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the
Administrative Agent shall control in the absence of manifest error. Upon the request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) a Note, which shall
evidence such Lender’s Loans in addition to such accounts or records. Each Lender may attach schedules to its Note and endorse thereon the date, Type (if applicable), currency, amount and maturity of its Loans and payments with respect thereto.

 (b) Maintenance of Records. In addition to the accounts and records referred to in
Section 2.11(a), each Lender and the Administrative Agent shall maintain in accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit and Swingline Loans. In
the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the
absence of manifest error. 

  
 55 

	 2.12
	 Payments Generally; Administrative Agent’s Clawback. 

(a) General. All payments to be made by the Borrower shall be made free and clear of and without
condition or deduction for any counterclaim, defense, recoupment or setoff. Except as otherwise expressly provided herein and except with respect to principal of and interest on Loans denominated in an Alternative Currency, all payments by the
Borrower hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative Agent’s Office in Dollars and in Same Day Funds not later than 2:00 p.m. on the date
specified herein. Except as otherwise expressly provided herein, all payments by the Borrower hereunder with respect to principal and interest on Loans denominated in an Alternative Currency shall be made to the Administrative Agent, for the account
of the respective Lenders to which such payment is owed, at the applicable Administrative Agent’s Office in such Alternative Currency and in Same Day Funds not later than the Applicable Time specified by the Administrative Agent on the dates
specified herein. Without limiting the generality of the foregoing, the Administrative Agent may require that any payments due under this Agreement be made in the United States. If, for any reason, the Borrower is prohibited by any Law from making
any required payment hereunder in an Alternative Currency, the Borrower shall make such payment in Dollars in the Dollar Equivalent of the Alternative Currency payment amount. The Administrative Agent will promptly distribute to each Lender its
Applicable Percentage (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office. All payments received by the Administrative Agent (i) after 2:00 p.m., in the
case of payments in Dollars, or (ii) after the Applicable Time specified by the Administrative Agent, in the case of payments in an Alternative Currency, shall in each case be deemed received on the next succeeding Business Day and any
applicable interest or fee shall continue to accrue. Subject to Section 2.07(a) and as otherwise specifically provided for in this Agreement, if any payment to be made by the Borrower shall come due on a day other than a Business Day, payment
shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be. 

(b) (i) Funding by Lenders; Presumption by Administrative Agent. Unless the Administrative Agent shall
have received notice from a Lender prior to the proposed date of any Borrowing of Eurocurrency Rate Loans (or, in the case of any Borrowing of Base Rate Loans, prior to 12:00 noon on the date of such Borrowing) that such Lender will not make
available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.02 (or, in the case of a Borrowing of
Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.02) and may, in reliance upon such assumption, make available to the Borrower a corresponding amount. In such event, if a
Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount in
Same Day Funds with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such
Lender, the Overnight Rate, plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Borrower, the interest rate
applicable to Base Rate Loans. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid
by the Borrower for such period. If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s Loan included in such Borrowing. Any payment by the Borrower shall be
without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent. 

  
 56 

 (ii) Payments by Borrower; Presumptions by Administrative
Agent. Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L/C Issuer hereunder that the Borrower will not
make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Appropriate Lenders or the L/C Issuer, as the case may
be, the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Appropriate Lenders or the L/C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so
distributed to such Lender or the L/C Issuer, in Same Day Funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the Overnight Rate.

 A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this subsection
(b) shall be conclusive, absent manifest error. 
 (c) Failure to Satisfy Conditions Precedent.
If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent
because the conditions to the applicable Credit Extension set forth in Article IV are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such
Lender, without interest. 
 (d) Obligations of Lenders Several. The obligations of the Lenders
hereunder to make Revolving Loans, to fund participations in Letters of Credit and Swingline Loans and to make payments pursuant to Section 11.04(c) are several and not joint. The failure of any Lender to make any Loan, to fund any such
participation or to make any payment under Section 11.04(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other
Lender to so make its Loan, to purchase its participation or to make its payment under Section 11.04(c). 

(e) Funding Source. Nothing herein shall be deemed to obligate any Lender to obtain the funds for any
Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner. 

(f) Pro Rata Treatment. Except to the extent otherwise provided herein: (i) each Borrowing (other
than Swingline Borrowings) shall be made from the Appropriate Lenders, each payment of fees under Section 2.09 and 2.03(h) and (i) shall be made for account of the Appropriate Lenders, and each termination or reduction of the amount of the
Commitments shall be applied to the respective Commitments of the Lenders, pro rata according to the amounts of their respective Commitments; (ii) each Borrowing shall be allocated pro rata among the Lenders according to the amounts of their
respective Commitments (in the case of the making of Revolving Loans) or their respective Loans that are to be included in such Borrowing (in the case of conversions and continuations of Loans); (iii) each payment or prepayment of principal of
Loans by the Borrower shall be made for account of the Appropriate Lenders pro rata in accordance with the respective unpaid principal amounts of the Loans held by them; and (iv) each payment of interest on Loans by the Borrower shall be made
for account of the Appropriate Lenders pro rata in accordance with the amounts of interest on such Loans then due and payable to the respective Appropriate Lenders. 

  
 57 

	 2.13
	 Sharing of Payments by Lenders. 

If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of
(a) Obligations due and payable to such Lender hereunder and under the other Loan Documents at such time in excess of its ratable share (according to the proportion of (i) the amount of such Obligations due and payable to such Lender at
such time to (ii) the aggregate amount of the Obligations due and payable to all Lenders hereunder and under the other Loan Documents at such time) of payments on account of the Obligations due and payable to all Lenders hereunder and under the
other Loan Documents at such time obtained by all the Lenders at such time or (b) Obligations owing (but not due and payable) to such Lender hereunder and under the other Loan Documents at such time in excess of its ratable share (according to
the proportion of (i) the amount of such Obligations owing (but not due and payable) to such Lender at such time to (ii) the aggregate amount of the Obligations owing (but not due and payable) to all Lenders hereunder and under the other
Loan Documents at such time) of payments on account of the Obligations owing (but not due and payable) to all Lenders hereunder and under the other Loan Documents at such time obtained by all of the Lenders at such time, then, in each case under
clauses (a) and (b) above, the Lender receiving such greater proportion shall (A) notify the Administrative Agent of such fact, and (B) purchase (for cash at face value) participations in the Loans and subparticipations in L/C
Obligations and Swingline Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of Obligations then
due and payable to the Lenders or owing (but not due and payable) to the Lenders, as the case may be, provided that: 

(1) if any such participations or subparticipations are purchased and all or any portion of the payment giving
rise thereto is recovered, such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and 

(2) the provisions of this Section shall not be construed to apply to (x) any payment made by or on behalf
of the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) the application of Cash Collateral provided for in
Section 2.14, or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or subparticipations in L/C Obligations or Swingline Loans to any assignee or participant, other
than an assignment to any Loan Party or any Affiliate thereof (as to which the provisions of this Section shall apply). 

Each Loan Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable Law, that any
Lender acquiring a participation pursuant to the foregoing arrangements may exercise against such Loan Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Loan Party in
the amount of such participation. 
  

	 2.14
	 Cash Collateral. 

(a) Certain Credit Support Events. If (i) the L/C Issuer has honored any full or partial drawing
request under any Letter of Credit and such drawing has resulted in an L/C Borrowing, (ii) as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, (iii) the Borrower shall be required to provide
Cash Collateral pursuant to Section 2.05 or 8.02(c), or (iv) there shall exist a Defaulting Lender, the Borrower shall within one (1) Business Day following any request by the Administrative Agent or the L/C Issuer, provide Cash
Collateral in an amount not less than the applicable Minimum Collateral Amount (determined in the case of Cash Collateral provided pursuant to clause (iv) above, after giving effect to Section 2.15(a)(iv) and any Cash Collateral provided
by the Defaulting Lender). Additionally, if the Administrative Agent notifies the Borrower at any time that the Outstanding Amount of all L/C Obligations at such time exceeds 103% of the Letter of Credit Sublimit then in effect, then within two
(2) Business Days after receipt of such notice, the Borrower shall provide Cash Collateral for the Outstanding Amount of the L/C Obligations in an amount not less than the amount by which the Outstanding Amount of all L/C Obligations exceeds
the Letter of Credit Sublimit. 

  
 58 

 (b) Grant of Security Interest. The Borrower, and to the
extent provided by any Defaulting Lender, such Defaulting Lender, hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the L/C Issuer and the Lenders, and agrees to maintain, a
first priority security interest in all such cash, deposit accounts and all balances therein, and all other property so provided as collateral pursuant hereto, and in all proceeds of the foregoing, all as security for the obligations to which such
Cash Collateral may be applied pursuant to Section 2.14(c). If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent or the L/C Issuer as herein
provided, or that the total amount of such Cash Collateral is less than the Minimum Collateral Amount, the Borrower will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an
amount sufficient to eliminate such deficiency. All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in one or more blocked, non-interest bearing deposit accounts at Bank of America. The
Borrower shall pay on demand therefor from time to time all customary account opening, activity and other administrative fees and charges in connection with the maintenance and disbursement of Cash Collateral. 

(c) Application. Notwithstanding anything to the contrary contained in this Agreement, Cash Collateral
provided under any of this Section 2.14 or Sections 2.03, 2.05, 2.15 or 8.02 in respect of Letters of Credit shall be held and applied to the satisfaction of the specific L/C Obligations, obligations to fund participations therein (including,
as to Cash Collateral provided by a Lender that is a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may be provided
for herein. 
 (d) Release. Cash Collateral (or the appropriate portion thereof) provided to reduce
Fronting Exposure or to secure other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of
the applicable Lender (or, as appropriate, its assignee following compliance with Section 11.06(b)(vi))) or (ii) the determination by the Administrative Agent and the L/C Issuer that there exists excess Cash Collateral; provided,
however, (A) any such release shall be without prejudice to, and any disbursement or other transfer of Cash Collateral shall be and remain subject to, any other Lien conferred under the Loan Documents and the other applicable provisions
of the Loan Documents, and (B) the Person providing Cash Collateral and the L/C Issuer may agree that Cash Collateral shall not be released but instead held to support future anticipated Fronting Exposure or other obligations. 

 

	 2.15
	 Defaulting Lenders. 

(a) Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender
becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law: 

(i) Waivers and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment,
waiver or consent with respect to this Agreement shall be restricted as set forth in the definition of “Required Lenders” and Section 11.01. 

  
 59 

 (ii) Defaulting Lender Waterfall. Any payment of
principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article VIII or otherwise) or received by the Administrative Agent
from a Defaulting Lender pursuant to Section 11.08 shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the
Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the L/C Issuer or Swingline Lender hereunder; third, to Cash Collateralize the L/C Issuer’s Fronting
Exposure with respect to such Defaulting Lender in accordance with Section 2.14; fourth, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting
Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower, to be held in a deposit account and released pro
rata in order to (A) satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Agreement and (B) Cash Collateralize the L/C Issuer’s future Fronting Exposure with respect to such
Defaulting Lender with respect to future Letters of Credit issued under this Agreement, in accordance with Section 2.14; sixth, to the payment of any amounts owing to the Lenders, the L/C Issuer or Swingline Lender as a result of any
judgment of a court of competent jurisdiction obtained by any Lender, the L/C Issuer or the Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; seventh,
so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such
Defaulting Lender’s breach of its obligations under this Agreement; and eighth, to such Defaulting Lender or as otherwise as may be required under the Loan Documents in connection with any Lien conferred thereunder or directed by a court
of competent jurisdiction; provided that if (1) such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which such Defaulting Lender has not fully funded its appropriate share, and (2) such
Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in Section 4.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Obligations owed to, all
Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Obligations owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in L/C Obligations and Swingline
Loans are held by the Lenders pro rata in accordance with the Commitments hereunder without giving effect to Section 2.15(a)(v). Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay
amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.15(a)(ii) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto. 

(iii) Certain Fees. 

(A) Fees. No Defaulting Lender shall be entitled to receive any fee payable under Section 2.09(a)
for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender). 

  
 60 

 (B) Letter of Credit Fees. Each Defaulting Lender shall
be entitled to receive Letter of Credit Fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Applicable Percentage of the stated amount of Letters of Credit for which it has provided Cash Collateral
pursuant to Section 2.14. 
 (C) Defaulting Lender Fees. With respect to any Letter of Credit
Fee not required to be paid to any Defaulting Lender pursuant to clause (B) above, the Borrower shall (1) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such
Defaulting Lender’s participation in L/C Obligations that has been reallocated to such Non-Defaulting Lender pursuant to clause (iv) below, (2) pay to the L/C Issuer the amount of any such fee otherwise payable to such Defaulting
Lender to the extent allocable to such L/C Issuer’s Fronting Exposure to such Defaulting Lender, and (3) not be required to pay the remaining amount of any such fee. 

(iv) Reallocation of Applicable Percentages to Reduce Fronting Exposure. All or any part of such
Defaulting Lender’s participation in L/C Obligations and Swingline Loans shall be reallocated among the Non-Defaulting Lenders in accordance with their respective Applicable Percentages (calculated without regard to such Defaulting
Lender’s Commitment) but only to the extent that such reallocation does not cause the aggregate Revolving Exposure of any Non-Defaulting Lender to exceed such Non-Defaulting Lender’s Commitment. Subject to Section 11.21, no
reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of
such Non-Defaulting Lender’s increased exposure following such reallocation. 
 (v) Cash Collateral,
Repayment of Swingline Loans. If the reallocation described in clause (a)(v) above cannot, or can only partially, be effected, the Borrower shall, without prejudice to any right or remedy available to it hereunder or under applicable Law,
(A) first, prepay Swingline Loans in an amount equal to the Swingline Lender’s Fronting Exposure and (B) second, Cash Collateralize the L/C Issuer’s Fronting Exposure in accordance with the procedures set forth in
Section 2.14. 
 (b) Defaulting Lender Cure. If the Borrower, the Administrative Agent, Swingline
Lender and the L/C Issuer agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set
forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative
Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit and Swingline Loans to be held on a pro rata basis by the Lenders in accordance with their Applicable Percentages (without giving
effect to Section 2.15(a)(iv)), whereupon such Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that
Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim
of any party hereunder arising from that Lender’s having been a Defaulting Lender. 

  
 61 

	 2.16
	 Increase in Commitments. 

(a) The Borrower may by written notice to the Administrative Agent elect to request (x) prior to the
Maturity Date, an increase to the existing Aggregate Commitments (each, an “Incremental Revolving Commitment”) and/or (y) the establishment of one or more new term loan commitments (each, an “Incremental Term Loan
Commitment”); provided, that the Borrower may make a maximum of three (3) such requests. Each such notice shall specify the date (each, an “Increase Effective Date”) on which the Borrower proposes that the
Incremental Commitments shall be effective, which shall be a date not less than 10 Business Days (or such shorter period as may be agreed by the Administrative Agent) after the date on which such notice is delivered to the Administrative Agent;
provided that any existing Lender approached to provide all or a portion of the Incremental Commitments may elect or decline, in its sole discretion, to provide such Incremental Commitment. Each Incremental Commitment shall be in a minimum
aggregate amount of $10,000,000 or any whole multiple of $5,000,000 in excess thereof. 
 (b)
Conditions. The Incremental Commitments shall become effective as of the Increase Effective Date; provided that: 

(i) no Default or Event of Default shall have occurred and be continuing or would result from the borrowings
to be made on the Increase Effective Date or, solely with respect to an Incremental Term Loan Commitment the proceeds of which are intended to and shall be used to finance substantially contemporaneously a Permitted Acquisition or any other
Acquisition permitted by Section 7.03 which is subject to customary “Funds Certain Provisions”, unless the Persons holding not less than a majority of the commitments to provide such Incremental Term Loan waive the absence of a
Default or Event of Default as a condition to funding thereof, on the date on which the related acquisition agreement is executed and becomes effective (any such date, an “Permitted Acquisition Agreement Signing Date”); 

(ii) the representations and warranties contained in Article V and the other Loan Documents are true
and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty shall be true and correct in all respects) on and as of the Increase
Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall have been true and correct as of such earlier date, and except that for purposes of this
Section 2.16(b), the representations and warranties contained in Section 5.05(a) and Section 5.05(b) shall be deemed to refer to the most recent financial statements furnished pursuant to subsections (a) and
(b), respectively, of Section 6.01; provided, that with respect to Incremental Commitments the proceeds of which are intended to and shall be used to finance substantially contemporaneously a Permitted Acquisition or any other
Acquisition permitted by Section 7.03 which is subject to customary “Funds Certain Provisions”, (i) the representation and warranty in the second sentence of Section 5.07 shall be deemed to expressly relate to the applicable
Permitted Acquisition Signing Date and (ii) in the case of such Incremental Commitments that are Incremental Term Loan Commitments, the bring-down of such representations and warranties may be modified to reflect customary “Funds Certain
Provisions” as agreed to by Administrative Agent and the holders of such Incremental Term Loan Commitments; 

  
 62 

 (iii) on a Pro Forma Basis (assuming that such Incremental
Commitment is fully drawn and giving effect to any Acquisition being consummated with advances under such Incremental Commitments), (A) the Borrower shall be in compliance with each of the covenants set forth in Section 7.11, and
(B) the Consolidated Leverage Ratio shall be 0.50 to 1.0 less than the then applicable level set forth in Section 7.11, in each case, as of the end of the latest fiscal quarter for which internal financial statements are available;

 (iv) the Borrower shall make any breakage payments in connection with any adjustment of Revolving Loans
pursuant to Section 2.16(d); and 
 (v) the Borrower shall deliver or cause to be delivered
customary officer’s certificates and legal opinions to the extent reasonably requested by the Administrative Agent. 

(c) Terms of New Loans and Commitments. The terms and provisions of Loans made pursuant to Incremental
Commitments shall be as follows: 
 (i) the terms and provisions of Revolving Loans made pursuant to new
Commitments shall be identical to the Revolving Loans; 
 (ii) the weighted average life to maturity of any
Incremental Term Loans shall be no shorter than the remaining weighted average life to maturity of the then existing term loans, if any (the “Existing Term Loan”); 

(iii) the maturity date of Incremental Term Loans (the “Incremental Term Loan Maturity Date”)
shall not be earlier than the then latest applicable Maturity Date; 
 (iv) the Applicable Rate for
Incremental Term Loans shall be determined by the Borrower and the Lenders of the Incremental Term Loans; provided that in the event that the Applicable Rate for any Incremental Term Loan is greater than the Applicable Rate for the Existing
Term Loans by more than 50 basis points, then the Applicable Rate for the Existing Term Loans shall be increased to the extent necessary so that the Applicable Rate for the Incremental Term Loans is 50 basis points higher than the Applicable Rate
for the Existing Term Loans shall be increased by the same number of basis points as the Applicable Rate for the Existing Term Loan is increased; provided, further, that in determining the Applicable Rate applicable to the Existing
Term Loans and the Incremental Term Loans, (x) original issue discount (“OID”) or upfront fees (which shall be deemed to constitute like amounts of OID) payable by the Borrower to the Lenders of the Existing Term Loans or the
Incremental Term Loans in the primary syndication thereof shall be included (with OID being equated to interest based on an assumed four-year life to maturity), (y) customary arrangement or commitment fees payable to the Arranger (or its
respective affiliates) in connection with the Existing Term Loans or to one or more arrangers (or their affiliates) of the Incremental Term Loans shall be excluded; and (z) if the LIBOR or Base Rate “floor” for the Incremental Term
Loans is greater than the LIBOR or Base Rate “floor,” respectively, for the Existing Term Loans, the difference between such floor for the Incremental Term Loans and the Existing Term Loans shall be equated to an increase in the Applicable
Rate for purposes of this clause (iv); 

  
 63 

 (v) the mandatory prepayment provisions, covenants and events of
default of any Incremental Term Loans, if not consistent with the terms of this Agreement (or, in the case of mandatory prepayment provisions, consistent with the terms of any then outstanding Incremental Term Facility), shall be reasonably
satisfactory to the Administrative Agent (it being understood that covenants and events of default that are (A) not materially more restrictive to the Borrower, when taken as a whole, than the terms of this Agreement, or
(B) more-restrictive than the terms of this Agreement so long as (x) Lenders under this Agreement also receive the benefit of such more restrictive terms or (y) any such provisions apply after the Maturity Date, are in each case
reasonably satisfactory to the Administrative Agent); and 
 (vi) The Incremental Commitments shall be
effected by a joinder agreement (the “Increase Joinder”) executed by the Borrower, the Administrative Agent and each Lender making such Incremental Commitment, in form and substance reasonably satisfactory to each of them.
Notwithstanding the provisions of Section 11.01, the Increase Joinder may, without the consent of any other Lender, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate, in the
reasonable opinion of the Administrative Agent, to effect the provisions of this Section 2.16. In addition, unless otherwise specifically provided herein, all references in Loan Documents to Revolving Loans or, if applicable, term loans
shall be deemed, unless the context otherwise requires, to include references to Revolving Loans made pursuant to Incremental Revolving Commitments and Incremental Term Loans that are term loans, respectively, made pursuant to this Agreement. This
Section 2.16 shall supersede any provisions in Section 2.13 or Section 11.01 to the contrary. 

(d) Adjustment of Revolving Loans. To the extent the Commitments being increased on the relevant
Increase Effective Date are Incremental Revolving Commitments, then each Lender that is acquiring an Incremental Revolving Commitment on the Increase Effective Date shall make a Revolving Loan, the proceeds of which will be used to prepay the
Revolving Loans of the other Lenders immediately prior to such Increase Effective Date, so that, after giving effect thereto, the Revolving Loans outstanding are held by the Lenders pro rata based on their Commitments after giving effect to such
Increase Effective Date. If there is a new borrowing of Revolving Loans on such Increase Effective Date, the Lenders after giving effect to such Increase Effective Date shall make such Revolving Loans in accordance with Section 2.01.

 (e) Making of New Term Loans. On any Increase Effective Date on which Incremental Term Loan
Commitments are effective, subject to the satisfaction of the foregoing terms and conditions, each Lender of such new Commitment shall make a term loan to the Borrower in an amount equal to its new Commitment. 

(f) Equal and Ratable Benefit. The Loans and Commitments established pursuant to this paragraph shall
constitute Loans and Commitments under, and shall be entitled to all the benefits afforded by, this Agreement and the other Loan Documents, and shall, without limiting the foregoing, benefit equally and ratably from the Guarantees and security
interests created by the Collateral Documents, except that the new Loans may be subordinated in right of payment or the Liens securing the new Loans may be subordinated, in each case, to the extent set forth in the Increase Joinder. The Loan Parties
shall take any actions reasonably required by the Administrative Agent to ensure and/or demonstrate that the Lien and security interests granted by the Collateral Documents continue to be perfected under the UCC or otherwise after giving effect to
the establishment of any such new Commitments. 

  
 64 

 ARTICLE III 

TAXES, YIELD PROTECTION AND ILLEGALITY 
  

	 3.01
	 Taxes. 

(a) Payments Free of Taxes; Obligation to Withhold; Payments on Account of Taxes. 

(i) Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be
made without deduction or withholding for any Taxes, except as required by applicable Laws. If any applicable Laws (as determined in the good faith discretion of the Administrative Agent) require the deduction or withholding of any Tax from any such
payment by the Administrative Agent or a Loan Party, then the Administrative Agent or such Loan Party shall be entitled to make such deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to
subsection (e) below. 
 (ii) If any Loan Party or the Administrative Agent shall be required by the
Code to withhold or deduct any Taxes, including both United States federal backup withholding and withholding taxes, from any payment, then (A) the Administrative Agent shall withhold or make such deductions as are determined by the
Administrative Agent to be required based upon the information and documentation it has received pursuant to subsection (e) below, (B) the Administrative Agent shall timely pay the full amount withheld or deducted to the relevant
Governmental Authority in accordance with the Code, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any
required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the applicable Recipient receives an amount equal to the sum it would have received had no such
withholding or deduction been made. 
 (iii) If any Loan Party or the Administrative Agent shall be required
by any applicable Laws other than the Code to withhold or deduct any Taxes from any payment, then (A) such Loan Party or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as are determined by it to be
required based upon the information and documentation it has received pursuant to subsection (e) below, (B) such Loan Party or the Administrative Agent, to the extent required by such Laws, shall timely pay the full amount withheld or
deducted to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as
necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the applicable Recipient receives an amount equal to the sum it would
have received had no such withholding or deduction been made. 
 (b) Payment of Other Taxes by the Loan
Parties. Without limiting the provisions of subsection (a) above, the Loan Parties shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it
for the payment of, any Other Taxes. 

  
 65 

 (c) Tax Indemnifications. 

(i) Each of the Loan Parties shall, and does hereby, jointly and severally indemnify each Recipient, and shall
make payment in respect thereof within thirty (30) days after receipt of demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this
Section 3.01) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such
Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender or the L/C Issuer (with a copy to the
Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or the L/C Issuer, shall be conclusive absent manifest error. Each of the Loan Parties shall also, and does hereby, jointly and severally indemnify the
Administrative Agent, and shall make payment in respect thereof within thirty (30) days after demand therefor, for any amount which a Lender or the L/C Issuer for any reason fails to pay indefeasibly to the Administrative Agent as required
pursuant to Section 3.01(c)(ii) below. Upon making such payment to the Administrative Agent, within thirty (30) days after the request by the Borrower, the Administrative Agent shall assign to the applicable Loan Party its rights pursuant
to Section 3.01(c)(ii) below against the applicable Lender or the L/C Issuer, other than the right of set-off pursuant to the last sentence of Section 3.01(c)(ii), to the extent of the payments made by the Loan Parties to the
Administrative Agent pursuant to the preceding sentence. 
 (ii) Each Lender and the L/C Issuer shall, and
does hereby, severally indemnify and shall make payment in respect thereof within ten (10) days after demand therefor, (A) the Administrative Agent against any Indemnified Taxes attributable to such Lender or the L/C Issuer (but only to
the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Parties to do so), (B) the Administrative Agent and the Loan Parties, as applicable,
against any Taxes attributable to such Lender’s failure to comply with the provisions of Section 11.06(d) relating to the maintenance of a Participant Register and (C) the Administrative Agent and the Loan Parties, as applicable,
against any Excluded Taxes attributable to such Lender or the L/C Issuer, in each case, that are payable or paid by the Administrative Agent or a Loan Party in connection with any Loan Document, and any reasonable expenses arising therefrom or with
respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be
conclusive absent manifest error. Each Lender and the L/C Issuer hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender or the L/C Issuer, as the case may be, under this Agreement or any
other Loan Document against any amount due to the Administrative Agent under this clause (ii). 
 (d)
Evidence of Payments. As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority, as provided in this Section 3.01, the Borrower shall deliver to the Administrative Agent the original or a certified
copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. 

  
 66 

 (e) Status of Lenders; Tax Documentation. 

(i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments
made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested
by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver
such other documentation prescribed by applicable Law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup
withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in
Section 3.01(e)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would
materially prejudice the legal or commercial position of such Lender. 
 (ii) Without limiting the
generality of the foregoing, in the event that the Borrower is a U.S. Person, 
 (A) any Lender that is a
U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the
Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax; 

(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the
Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the
Borrower or the Administrative Agent), whichever of the following is applicable: 
 (1) in the case of a
Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an
exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN-E (or W-8BEN, as
applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty; 

  
 67 

 (2) executed originals of IRS Form W-8ECI; 

(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under
Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit M-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent
shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”)
and (y) executed copies of IRS Form W-8BEN-E (or W-8BEN, as applicable); or 
 (4) to the extent a
Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN-E (or W-8BEN, as applicable), a U.S. Tax Compliance Certificate substantially in the form of Exhibit M-2 or
Exhibit M-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are
claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit M-4 on behalf of each such direct and indirect partner; 

(C) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the
Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the
Borrower or the Administrative Agent), executed copies (or originals, as required) of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with
such supplementary documentation as may be prescribed by applicable Law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and 

(D) if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax
imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and
the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by
Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under
FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any
amendments made to FATCA after the date of this Agreement. 

  
 68 

 (iii) Each Lender agrees that if any form or certification it
previously delivered pursuant to this Section 3.01 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal
inability to do so. 
 (f) Treatment of Certain Refunds. Unless required by applicable Laws, at no
time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender or the L/C Issuer, or have any obligation to pay to any Lender or the L/C Issuer, any refund of Taxes withheld or deducted from funds paid
for the account of such Lender or the L/C Issuer, as the case may be. If any Recipient determines, in its sole discretion exercised in good faith, that it has received a refund (whether received in the form of a cash payment or in the form of a
credit against Taxes otherwise owed) of any Taxes as to which it has been indemnified by any Loan Party or with respect to which any Loan Party has paid additional amounts pursuant to this Section 3.01, it shall pay to such Loan Party an amount
equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by such Loan Party under this Section 3.01 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including
Taxes) incurred by such Recipient, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that such Loan Party, upon the request of the Recipient, agrees
to repay the amount paid over to such Loan Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Recipient in the event the Recipient is required to repay such refund to such Governmental
Authority. Notwithstanding anything to the contrary in this subsection, in no event will the applicable Recipient be required to pay any amount to such Loan Party pursuant to this subsection the payment of which would place the Recipient in a less
favorable net after-Tax position than such Recipient would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts
with respect to such Tax had never been paid. This subsection shall not be construed to require any Recipient to make available its tax returns (or any other information relating to its taxes that it deems confidential) to any Loan Party or any
other Person. 
 (g) Survival. Each party’s obligations under this Section 3.01 shall
survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender or the L/C Issuer, the termination of the Commitments and the repayment, satisfaction or discharge of all other
Obligations. 

  
 69 

	 3.02
	 Illegality and Designated Lenders. 

If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is
unlawful, for any Lender or its applicable Lending Office to perform any of its obligations hereunder or to make, maintain or fund or charge interest with respect to any Credit or to determine or charge interest rates based upon the Eurocurrency
Rate, or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars or any Alternative Currency in the applicable interbank market, then, on notice thereof by
such Lender to the Borrower through the Administrative Agent, (a) any obligation of such Lender to issue, make, maintain, fund or charge interest with respect to any such Credit Extension or continue Eurocurrency Rate Loans in the affected
currency or currencies or, in the case of Eurocurrency Rate Loans in Dollars, to convert Base Rate Loans to Eurocurrency Rate Loans shall be suspended, and (b) if such notice asserts the illegality of such Lender making or maintaining Base Rate
Loans the interest rate on which is determined by reference to the Eurocurrency Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the
Administrative Agent without reference to the Eurocurrency Rate component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist.
Upon receipt of such notice, (i) the Borrower shall, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable and such Loans are denominated in Dollars, convert all Eurocurrency Rate Loans of such Lender
to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurocurrency Rate component of the Base Rate), either on
the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Eurocurrency Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Eurocurrency Rate Loans and
(ii) if such notice asserts the illegality of such Lender determining or charging interest rates based upon the Eurocurrency Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such
Lender without reference to the Eurocurrency Rate component thereof until the Administrative Agent is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Eurocurrency
Rate. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted. 
  

	 3.03
	 Inability to Determine Rates. 

(a) If in connection with any request for a Eurocurrency Rate Loan or a conversion to or continuation thereof,
(i) the Administrative Agent determines that (A) Dollar deposits (whether in Dollars or an Alternative Currency) are not being offered to banks in the London interbank market for such currency for the applicable amount and Interest Period
of such Eurocurrency Rate Loan, (B) adequate and reasonable means do not exist for determining the Eurocurrency Rate for any requested Interest Period with respect to a proposed Eurocurrency Rate Loan (whether denominated in Dollars or an
Alternative Currency) or in connection with an existing or proposed Base Rate Loan or (C) a fundamental change has occurred in the foreign exchange or interbank markets with respect to such Alternative Currency (including, without limitation,
changes in national or international financial, political or economic conditions or currency exchange rates or exchange controls) (in each case with respect to clause (i), “Impacted Loans”), or (ii) the Administrative Agent or
the Required Lenders determine that for any reason Eurocurrency Rate for any requested Interest Period with respect to a proposed Eurocurrency Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the
Administrative Agent will promptly so notify the Borrower and each Lender. Thereafter, (x) the obligation of the Lenders to make or maintain Eurocurrency Rate Loans in the affected currency or currencies shall be suspended (to the extent of the
affected Eurocurrency Rate Loans or Interest Periods), and (y) in the event of a determination described in the preceding sentence with respect to the Eurocurrency Rate component of the Base Rate, the utilization of the Eurocurrency Rate
component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, the Borrower may revoke any pending request for a
Borrowing of, conversion to or continuation of Eurocurrency Rate Loans in the affected currency or currencies (to the extent of the affected Eurocurrency Rate Loans or Interest Periods) or, failing that, will be deemed to have converted such request
into a request for a Borrowing of Base Rate Loans in Dollars in the amount specified therein. 

  
 70 

 (b) Notwithstanding the foregoing, if the Administrative Agent
has made the determination described in clause (a)(i) of this Section, the Administrative Agent in consultation with the Borrower and the Required Lenders, may establish an alternative interest rate for the Impacted Loans, in which case, such
alternative rate of interest shall apply with respect to the Impacted Loans until (1) the Administrative Agent revokes the notice delivered with respect to the Impacted Loans under clause (a)(i) of this Section, (2) the Administrative
Agent or the Required Lenders notify the Administrative Agent and the Borrower that such alternative interest rate does not adequately and fairly reflect the cost to the Lenders of funding the Impacted Loans, or (3) any Lender determines that
any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for such Lender or its applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to such alternative rate of
interest or to determine or charge interest rates based upon such rate or any Governmental Authority has imposed material restrictions on the authority of such Lender to do any of the foregoing and provides the Administrative Agent and the Borrower
written notice thereof. 
  

	 3.04
	 Increased Costs; Reserves on Eurocurrency Rate Loans. 

(a) Increased Costs Generally. If any Change in Law shall: 

(i) impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or
similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the Eurocurrency Rate) or the L/C Issuer; or 

(ii) impose on any Lender or the L/C Issuer or the London interbank market any other condition, cost or
expense affecting this Agreement or Eurocurrency Rate Loans made by such Lender or any Letter of Credit or participation therein; 

and the result of any of the foregoing shall be to increase the cost to such Lender of making, converting to, continuing or
maintaining any Loan (or of maintaining its obligation to make any such Loan), or to increase the cost to such Lender or the L/C Issuer of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate
in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender or the L/C Issuer hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or the L/C Issuer, the
Borrower will pay to such Lender or the L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L/C Issuer, as the case may be, for such additional costs incurred or reduction suffered; provided
that this Section 3.04(a) shall not apply to Taxes, which shall be governed solely by Section 3.01. 

(b) Capital Requirements. If any Lender or the L/C Issuer determines that any Change in Law affecting
such Lender or the L/C Issuer or any Lending Office of such Lender or such Lender’s or the L/C Issuer’s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on
such Lender’s or the L/C Issuer’s capital or on the capital of such Lender’s or the L/C Issuer’s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by, or participations
in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by the L/C Issuer, to a level below that which such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding company could have
achieved but for such Change in Law (taking into consideration such Lender’s or the L/C Issuer’s policies and the policies of such Lender’s or the L/C Issuer’s holding company with respect to capital adequacy), then from time to
time the Borrower will pay to such Lender or the L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding company for any such reduction
suffered. 

  
 71 

 (c) Certificates for Reimbursement. A certificate of a
Lender or the L/C Issuer setting forth the amount or amounts necessary to compensate such Lender or the L/C Issuer or its holding company, as the case may be, as specified in subsection (a) or (b) of this Section and delivered to the
Borrower shall be conclusive absent manifest error. The Borrower shall pay such Lender or the L/C Issuer, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof. 

(d) Delay in Requests. Failure or delay on the part of any Lender or the L/C Issuer to demand
compensation pursuant to the foregoing provisions of this Section 3.04 shall not constitute a waiver of such Lender’s or the L/C Issuer’s right to demand such compensation, provided that the Borrower shall not be required to
compensate a Lender or the L/C Issuer pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than nine (9) months prior to the date that such Lender or the L/C Issuer, as the case may
be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s or the L/C Issuer’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such
increased costs or reductions is retroactive, then the nine (9) month period referred to above shall be extended to include the period of retroactive effect thereof). 
  

	 3.05
	 Compensation for Losses. 

Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrower shall promptly compensate
such Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of: 

(a) any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other
than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise); 

(b) any failure by the Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay,
borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by the Borrower; 

(c) any assignment of a Eurocurrency Rate Loan on a day other than the last day of the Interest Period therefor
as a result of a request by the Borrower pursuant to Section 11.13; or 
 (d) any failure by the
Borrower to make payment of any Loan (or interest due thereon) denominated in an Alternative Currency on its scheduled due date or any payment thereof in a different currency; 

including any loss of anticipated profits, any foreign exchange losses and any loss or expense arising from the liquidation or reemployment of
funds obtained by it to maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained or from the performance of any foreign exchange contract. The Borrower shall also pay any customary administrative fees
charged by such Lender in connection with the foregoing. 
 For purposes of calculating amounts payable by the Borrower to the Lenders under
this Section 3.05, each Lender shall be deemed to have funded each Eurocurrency Rate Loan made by it at the Eurocurrency Rate for such Loan by a matching deposit or other borrowing in the London interbank eurodollar market for such currency for
a comparable amount and for a comparable period, whether or not such Eurocurrency Rate Loan was in fact so funded. 

  
 72 

	 3.06
	 Mitigation Obligations; Replacement of Lenders. 

(a) Designation of a Different Lending Office. If any Lender requests compensation under
Section 3.04, or requires the Borrower to pay any Indemnified Taxes or additional amounts to any Lender, the L/C Issuer, or any Governmental Authority for the account of any Lender or the L/C Issuer pursuant to Section 3.01, or if any
Lender gives a notice pursuant to Section 3.02, then at the request of the Borrower, such Lender or the L/C Issuer shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder
or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender or the L/C Issuer, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to
Section 3.01 or 3.04, as the case may be, in the future, or eliminate the need for the notice pursuant to Section 3.02, as applicable, and (ii) in each case, would not subject such Lender or the L/C Issuer, as the case may be, to any
unreimbursed cost or expense and would not otherwise be materially disadvantageous to such Lender or the L/C Issuer, as the case may be. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender or the L/C Issuer in
connection with any such designation or assignment. 
 (b) Replacement of Lenders. If any Lender
requests compensation under Section 3.04, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01 and, in each
case, such Lender has declined or is unable to designate a different lending office in accordance with Section 3.06(a), the Borrower may replace such Lender in accordance with Section 11.13. 

 

	 3.07
	 Survival. 

All of the Borrower’s obligations under this Article III shall survive termination of the Aggregate Commitments, repayment
of all other Obligations hereunder, resignation of the Administrative Agent and the Facility Termination Date. 
 ARTICLE IV 

CONDITIONS PRECEDENT TO CREDIT EXTENSIONS 
  

	 4.01
	 Conditions of Initial Credit Extension. 

The obligation of the L/C Issuer and each Lender to make its initial Credit Extension hereunder is subject to satisfaction of
the following conditions precedent: 
 (a) Execution of Credit Agreement; Loan Documents. The
Administrative Agent shall have received (i) counterparts of this Agreement, executed by a Responsible Officer of each Loan Party and a duly authorized officer of each Lender, (ii) for the account of each Lender requesting a Note, a Note
executed by a Responsible Officer of the Borrower, (iii) counterparts of the Security Agreement and each other Collateral Document required to be delivered on the Closing Date, executed by a Responsible Officer of the applicable Loan Parties
and a duly authorized officer of each other Person party thereto, as applicable and (iv) counterparts of any other Loan Document required to be delivered on the Closing Date, executed by a Responsible Officer of the applicable Loan Party and a
duly authorized officer of each other Person party thereto. 

  
 73 

 (b) Secretary’s Certificate. The Administrative Agent
shall have received a Secretary’s Certificate dated the Closing Date, certifying as to the Organization Documents of each Loan Party (which, to the extent filed with a Governmental Authority, shall be certified as of a recent date by such
Governmental Authority), the resolutions of the governing body of each Loan Party, the good standing, existence or its equivalent of each Loan Party and of the incumbency (including specimen signatures) of the Responsible Officers of each Loan
Party. 
 (c) Legal Opinions of Counsel. The Administrative Agent shall have received an opinion or
opinions (including, if requested by the Administrative Agent, local counsel opinions) of counsel for the Loan Parties, dated the Closing Date and addressed to the Administrative Agent and the Lenders, in form and substance reasonably acceptable to
the Administrative Agent. 
 (d) Financial Statements. The Administrative Agent and the Lenders shall
have received copies of the financial statements referred to in Section 5.05. 
 (e) Personal
Property Collateral. The Administrative Agent shall have received, in form and substance reasonably satisfactory to the Administrative Agent: 

(i) (A) searches of UCC filings in the jurisdiction of incorporation or formation, as applicable, of each
Loan Party, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist other than Permitted Liens and (B) tax lien, judgment and bankruptcy searches; 

(ii) searches of ownership of material Intellectual Property in the appropriate governmental offices and such
patent/trademark/copyright filings as reasonably requested by the Administrative Agent in order to perfect the Administrative Agent’s security interest in the Intellectual Property; 

(iii) completed UCC financing statements for each jurisdiction required by Law to perfect the Administrative
Agent’s security interest in the Collateral; 
 (iv) stock or membership certificates, if any,
evidencing the Pledged Equity and undated stock or transfer powers duly executed in blank; in each case to the extent such Pledged Equity is certificated; and 

(v) to the extent required to be delivered, filed, registered or recorded pursuant to the terms and conditions
of the Collateral Documents, all instruments, documents and chattel paper in the possession of any of the Loan Parties, together with allonges or assignments as may be necessary or appropriate to create and perfect the Administrative Agent’s
and the Lenders’ security interest in the Collateral; 
 (f) Material Adverse Effect. Since
September 30, 2015, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect. 

(g) Solvency Certificate. The Administrative Agent shall have received a Solvency Certificate signed by
a Responsible Officer of the Borrower as to the financial condition, solvency and related matters of the Borrower and its Subsidiaries, after giving effect to the initial borrowings under the Loan Documents and the other transactions contemplated
hereby. 
 (h) Officer’s Certificate. The Administrative Agent shall have received a certificate
or certificates executed by a Responsible Officer of the Borrower as of the Closing Date, as to certain financial matters, in form and substance satisfactory to Administrative Agent. 

  
 74 

 (i) Loan Notice. The Administrative Agent shall have
received a Loan Notice with respect to the Loans to be made on the Closing Date. 
 (j) Existing
Indebtedness of the Loan Parties. All of the existing Indebtedness for borrowed money of the Borrower and its Subsidiaries (other than Indebtedness permitted to exist pursuant to Section 7.02) shall be repaid in full and all security
interests related thereto shall be terminated on or prior to the Closing Date. 
 (k) Consents. The
Administrative Agent shall have received evidence that all members, boards of directors, governmental, shareholder and material third party consents and approvals necessary in connection with the entering into of this Agreement have been obtained.

 (l) Fees and Expenses. The Administrative Agent and the Lenders shall have received all fees and
expenses, if any, owing pursuant to Section 2.09. 
 Without limiting the generality of the provisions of the last paragraph of
Section 9.03, for purposes of determining compliance with the conditions specified in this Section, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or
other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection
thereto. 
  

	 4.02
	 Conditions to all Credit Extensions. 

The obligation of each Lender and the L/C Issuer to honor any Request for Credit Extension is subject to the following
conditions precedent: 
 (a) Representations and Warranties. The representations and
warranties of the Borrower and each other Loan Party contained in Article II, Article V or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct
in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty shall be true and correct in all respects) on and as of the date of such Credit
Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse
Effect or a similar concept applies, such representation or warranty shall be true and correct in all respects) as of such earlier date, and except that for purposes of this Section 4.02, the representations and warranties contained in
Sections 5.05(a) and (b) shall be deemed to refer to the most recent statements furnished pursuant to Sections 6.01(a) and (b), respectively, subject in the case of Incremental Commitments to
Section 2.16(b)(ii). 
 (b) Default. No Default or Event of Default shall exist, or would
result from such proposed Credit Extension or from the application of the proceeds thereof, subject in the case of Incremental Term Loans to Section 2.16(i). 

(c) Request for Credit Extension. The Administrative Agent and, if applicable, the L/C Issuer or the
Swingline Lender shall have received a Request for Credit Extension in accordance with the requirements hereof. 

  
 75 

 (d) Alternative Currency. In the case of a Credit
Extension to be denominated in an Alternative Currency, there shall not have occurred any change in national or international financial, political or economic conditions or currency exchange rates or exchange controls which in the reasonable opinion
of the Administrative Agent, the Required Lenders (in the case of any Loans to be denominated in an Alternative Currency) or the L/C Issuer (in the case of any Letter of Credit to be denominated in an Alternative Currency) would make it
impracticable for such Credit Extension to be denominated in the relevant Alternative Currency. 
 Each Request for Credit Extension
submitted by the Borrower shall be deemed to be a representation and warranty that the conditions specified in Sections 4.02(a) and (b) have been satisfied on and as of the date of the applicable Credit Extension. 

ARTICLE V 

REPRESENTATIONS AND WARRANTIES 

Each Loan Party represents and warrants to the Administrative Agent and the Lenders, as of the date made or deemed made, that:

  

	 5.01
	 Existence, Qualification and Power. 

Each Loan Party and each of its Subsidiaries (a) is duly organized or formed, validly existing and, as applicable, in good
standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and
carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, and (c) is duly qualified and is licensed and, as applicable, in good standing under the Laws of each jurisdiction
where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in each case referred to in clause (b)(i) or (c), to the extent that failure to do so could not reasonably be
expected to have a Material Adverse Effect. 
  

	 5.02
	 Authorization; No Contravention. 

The execution, delivery and performance by each Loan Party of each Loan Document to which such Person is or is to be a party
have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of such Person’s Organization Documents; (b) conflict with or result in any material breach
or contravention of, or the creation of any Lien under, or require any payment to be made under (i) any material Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its
Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (c) violate any material Law. 

 

	 5.03
	 Governmental Authorization; Other Consents. 

No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or
any other Person is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, (b) the grant by any Loan Party of the Liens
granted by it pursuant to the Collateral Documents, (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the first priority nature thereof, subject to Permitted Liens) or (d) the exercise by the
Administrative Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Collateral Documents, other than (i) authorizations, approvals, actions, notices and filings which have been
duly obtained and (ii) filings to perfect the Liens created by the Collateral Documents. 

  
 76 

	 5.04
	 Binding Effect. 

This Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by
each Loan Party that is party thereto. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a legal, valid and binding obligation of such Loan Party, enforceable against each Loan Party that is party thereto in
accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principals of equity. 

 

	 5.05
	 Financial Statements; No Material Adverse Effect. 

(a) Audited Financial Statements. The Audited Financial Statements (i) were prepared in accordance
with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; and (ii) fairly present the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of
operations, cash flows and changes in shareholder’s equity for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein. 

(b) Quarterly Financial Statements. The unaudited Consolidated balance sheets of the Borrower and its
Subsidiaries dated September 30, 2015, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for the fiscal quarter ended on that date (i) were prepared in accordance with GAAP
consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of
operations, cash flows and changes in shareholders’ equity for the period covered thereby, subject, in the case of clauses (i) and (ii), to the absence of footnotes and to normal year-end audit adjustments. 

(c) Material Adverse Effect. Since September 30, 2015, there has been no event or circumstance,
either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect. 
  

	 5.06
	 Litigation. 

Other than as set forth on Schedule 5.06 to the Disclosure Letter, there are no actions, suits, proceedings, claims or
disputes pending or, to the knowledge of the Borrower, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against any Loan Party or any Subsidiary or against any of their properties or revenues
that (a) purport to affect or pertain to this Agreement or any other Loan Document or any of the transactions contemplated hereby, or (b) either individually or in the aggregate would reasonably be expected to have a Material Adverse
Effect. 
  

	 5.07
	 No Default. 

Neither any Loan Party nor any Subsidiary thereof is in default under or with respect to, or a party to, any Contractual
Obligation that could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this
Agreement or any other Loan Document. 

  
 77 

	 5.08
	 Ownership of Property. 

Each Loan Party and each of its Subsidiaries has good record and marketable title in fee simple to, or valid leasehold
interests in, all real property necessary or used in the ordinary conduct of its business, except for such defects in title as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

 

	 5.09
	 Environmental Compliance. 

(a) The Loan Parties and their respective Subsidiaries conduct in the ordinary course of business a review of
the effect of existing Environmental Laws and claims alleging potential liability or responsibility for violation of any Environmental Law on their respective businesses, operations and properties, and as a result thereof the Loan Parties have
reasonably concluded that such Environmental Laws and claims could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(b) Neither any Loan Party nor any of its Subsidiaries is undertaking, and has not completed, either
individually or together with other potentially responsible parties, any investigation or assessment or remedial or response action relating to any actual or threatened release, discharge or disposal of Hazardous Materials (that could, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect) at any site, location or operation, either voluntarily or pursuant to the order of any Governmental Authority or the requirements of any Environmental Law; and all
Hazardous Materials generated, used, treated, handled or stored at, or transported to or from, any property currently or formerly owned or operated by any Loan Party or any of its Subsidiaries have been disposed of in a manner not, individually or
in the aggregate, reasonably be expected to result in a Material Adverse Effect. 
  

	 5.10
	 Insurance. 

The properties of the Borrower and its Subsidiaries are insured with financially sound and reputable insurance companies not
Affiliates of the Borrower, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the applicable Loan Party or the
applicable Subsidiary operates. A true and complete listing of such insurance, including issuers, coverages and deductibles, as of the Closing Date has been provided to the Administrative Agent. 

 

	 5.11
	 Taxes. 

Each Loan Party and its Subsidiaries have filed all federal, and all material state and other tax returns and reports required
to be filed, and have paid all federal, and all material state and other taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are
being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP. There is no proposed tax assessment against any Loan Party or any Subsidiary that would, if
made, have a Material Adverse Effect. 

  
 78 

	 5.12
	 ERISA Compliance. 

(a) Except as would not reasonably be expected to result in a Material Adverse Effect, each Plan is in
compliance in all respects with the applicable provisions of ERISA, the Code and other federal or state laws. Each Pension Plan that is intended to be a qualified plan under Section 401(a) of the Code has received a favorable determination
letter or is subject to a favorable opinion letter from the IRS to the effect that the form of such Plan is qualified under Section 401(a) of the Code and the trust related thereto has been determined by the IRS to be exempt from federal income
tax under Section 501(a) of the Code, or an application for such a letter is currently being processed by the IRS. To the best knowledge of the Loan Parties, nothing has occurred that would prevent or cause the loss of such tax-qualified
status. 
 (b) There are no pending or, to the best knowledge of the Loan Parties, threatened claims, actions
or lawsuits, or action by any Governmental Authority, with respect to any Plan that would reasonably be expected to have a Material Adverse Effect. There has been no prohibited transaction or violation of the fiduciary responsibility rules with
respect to any Plan that has resulted or would reasonably be expected to result in a Material Adverse Effect. 

(c) (i) Except as would not reasonably be expected to result in a Material Adverse Effect, no ERISA Event
has occurred, and no Loan Party nor any ERISA Affiliate is aware of any fact, event or circumstance that would reasonably be expected to constitute or result in an ERISA Event with respect to any Pension Plan or Multiemployer Plan; (ii) as of
the most recent valuation date for any Pension Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is 60% or higher and no Loan Party nor any ERISA Affiliate knows of any facts or circumstances that
would reasonably be expected to cause the funding target attainment percentage for any such plan to drop below 60% as of the most recent valuation date; (iii) no Loan Party nor any ERISA Affiliate has incurred any liability to the PBGC other
than for the payment of premiums, and there are no premium payments which have become due that are unpaid; (iv) neither the Borrower nor any ERISA Affiliate has engaged in a transaction that could be subject to Section 4069 or
Section 4212(c) of ERISA; and (v) no Pension Plan has been terminated by the plan administrator thereof nor by the PBGC, and no event or circumstance has occurred or exists that would reasonably be expected to cause the PBGC to institute
proceedings under Title IV of ERISA to terminate any Pension Plan. 
 (d) Neither the Borrower nor any ERISA
Affiliate maintains or contributes to, or has any unsatisfied obligation to contribute to, or liability under, any active or terminated Pension Plan other than on the Closing Date, those listed on Schedule 5.12 to the Disclosure Letter.

  

	 5.13
	 Margin Regulations; Investment Company Act. 

(a) Margin Regulations. The Borrower is not engaged and will not engage, principally or as one of its
important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock. Following the application of the
proceeds of each Borrowing or drawing under each Letter of Credit, not more than twenty-five percent (25%) of the value of the assets (either of the Borrower only or of the Borrower and its Subsidiaries on a Consolidated basis) subject to the
provisions of Section 7.01 or Section 7.05 or subject to any restriction contained in any agreement or instrument between the Borrower and any Lender or any Affiliate of any Lender relating to Indebtedness and within the scope of
Section 8.01(e) will be margin stock. 
 (b) Investment Company Act. No Loan Party is an
“investment company” within the meaning of the Investment Company Act of 1940. 

  
 79 

	 5.14
	 Disclosure. 

The written reports, financial statements, certificates or other information furnished by or on behalf of any Loan Party to the
Administrative Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Loan Document (in each case as modified or supplemented by other information
so furnished) do not contain, when taken as a whole, any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time made or delivered. 

 

	 5.15
	 Compliance with Laws. 

Each Loan Party and each Subsidiary thereof is in compliance with the requirements of all Laws and all orders, writs,
injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted
or (b) the failure to comply therewith, either individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. 
  

	 5.16
	 Solvency. 

The Loan Parties and their Subsidiaries, taken as a whole, are Solvent. 

 

	 5.17
	 Reserved. 

  

	 5.18
	 Sanctions Concerns and Anti-Corruption Laws. 

(a) Sanctions Concerns. No Loan Party, nor any Subsidiary, nor any director or officer thereof, nor, to
the knowledge of the Loan Parties and their Subsidiaries, any employee, agent, affiliate or representative thereof, is an individual or entity that is, or is owned or controlled by any individual or entity that is (i) currently the subject or
target of any Sanctions or (ii) located, organized or resident in a Designated Jurisdiction. 
 (b)
Anti-Corruption Laws. The Loan Parties and their Subsidiaries have conducted their business in compliance in all material respects with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar,
applicable anti-corruption legislation in other jurisdictions, and have instituted and maintained policies and procedures designed to promote and achieve compliance with such laws. 

 

	 5.19
	 [Reserved]. 

  

	 5.20
	 Subsidiaries; Equity Interests; Loan Parties. 

Except as set forth in Schedule 5.20(a) to the Disclosure Letter, as of the Closing Date, no Loan Party and no
Subsidiary of any Loan Party (a) has any Subsidiaries, or (b) is engaged in any joint venture or partnership with any other Person. All issued and outstanding Equity Interests of each of the Loan Parties and each of their respective
Subsidiaries are, as applicable, duly authorized and validly issued, fully paid, non-assessable, and free and clear of all Liens other than, with respect to the Equity Interests of the Borrower and Subsidiaries of the Borrower, those in favor of
Administrative Agent, for the benefit of the Secured Parties. All such securities were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 

  
 80 

	 5.21
	 Healthcare Regulatory Matters. 

(a) The Loan Parties hold, and are operating in compliance with, such material permits, registrations,
licenses, franchises, approvals, authorizations and clearances of the FDA, if any, required for the conduct of their business as currently conducted (collectively, the “FDA Permits”), and all such FDA Permits, if any, are in full
force and effect. The Loan Parties have fulfilled and performed, in all material respects, all of their obligations with respect to the FDA Permits, and no event has occurred which allows, or after notice or lapse of time would allow, revocation or
termination thereof or results in any other impairment of the rights of the holder of any FDA Permit. 
 (b)
The Loan Parties, and to the knowledge of the Loan Parties, each of their licensed employees and contractors, are in compliance with all applicable Healthcare Laws, to the extent failure to do so could not reasonably be expected to have a Material
Adverse Effect. Except as disclosed to the Administrative Agent from time to time pursuant to Section 6.03, the Loan Parties have not received notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit,
inspection, investigation, arbitration or other action from the FDA or any other applicable Governmental Authority or applicable foreign regulatory agency with jurisdiction over the Loan Parties, alleging that any operation or activity of the Loan
Parties is in violation of any applicable Healthcare Law, in each case, which would reasonably be expected to have a Material Adverse Effect on the Borrower and its Subsidiaries taken as a whole. 

(c) All applications, notifications, submissions, information, claims, reports and statistics, and other data
and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a FDA Permit or other permit or license from the FDA or other Governmental Authority with jurisdiction over the Loan Parties and
relating to the Loan Parties, their business and their products, when submitted to the FDA or other Governmental Authority were true, complete and correct in all material respects as of the date of submission and any necessary or required material
updates, changes, corrections or modification to such applications, submissions, information and data have been timely submitted to the FDA or other Governmental Authority. 

(d) Except as set forth on Schedule 5.21 to the Disclosure Letter, since September 30, 2015, the
Loan Parties have not had any product or manufacturing site (whether owned by the Loan Parties or that of a contract manufacturer) subject to a Governmental Authority (including FDA) shutdown or import or export prohibition, nor received any FDA
Form 483 or other Governmental Authority notice of inspectional observations (other than with respect to routine inspections that are not related to any actual or potential violation of any applicable Law), “warning letters,”
“untitled letters” or requests or requirements to make material changes to any of the Loan Parties’ products, or similar correspondence or notice from the FDA or other Governmental Authority with jurisdiction over the Loan Parties in
respect of the Loan Parties’ business and alleging or asserting noncompliance with any applicable law, permit or such requests or requirements of such Governmental Authority, and, to the knowledge of the Loan Parties, neither the FDA nor any
such Governmental Authority is considering such action, in each case, which would reasonably be expected to have a Material Adverse Effect on the Borrower and its Subsidiaries taken as a whole. 

  
 81 

 (e) Except as set forth on Schedule 5.21 to the Disclosure
Letter, there are no recalls, field notifications, field corrections, field safety corrective actions, market withdrawals or replacements, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory
compliance of the Loan Parties’ products (“Safety Notices”) or, to the Loan Parties’ knowledge, material product complaints with respect to the Loan Parties’ products, and to the Loan Parties’ knowledge, there
are no facts that would be reasonably likely to result in (i) a material Safety Notice with respect to the Loan Parties’ products, (ii) a material change in labeling of any of the Loan Parties’ products; or (iii) a
termination or suspension of marketing or testing of any of the Loan Parties’ products, in each case, which would reasonably be expected to have a Material Adverse Effect on the Borrower and its Subsidiaries taken as a whole. 

(f) None of the Loan Parties is the subject of any pending or, to the Loan Parties’ knowledge, threatened
investigation in respect of the Loan Parties or their products, by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and
any amendments thereto and neither the Loan Parties nor any of their officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a material debarment or exclusion (i) under 21 U.S.C.
Section 335a, or (ii) under any similar law applicable to the Loan Parties, in each case, which would reasonably be expected to have a Material Adverse Effect on the Borrower and its Subsidiaries taken as a whole. As of the Closing Date,
no claims, actions, proceedings or investigations that would reasonably be expected to result in such a material debarment or exclusion are pending or threatened against the Loan Parties or any of their officers, employees or agents. 

(g) As of the Closing Date, except as set forth on Schedule 5.21 to the Disclosure Letter, the Loan
Parties, and the managers, officers, employees and, to the knowledge of the Loan Parties, agents of the Loan Parties, have not been convicted of any crime or engaged in any conduct that could result in a material debarment or exclusion
(i) under 21 U.S.C. § 335a, or (ii) any similar state law, rule or regulation. As of the Closing Date, no claims, actions, proceedings or investigations that would reasonably be expected to result in such a material debarment or
exclusion are pending or threatened against the Loan Parties, or the managers, officers, employees or, to the knowledge of the Loan Parties, agents of the Loan Parties. 
  

	 5.22
	 Intellectual Property; Licenses, Etc.  

Except as set forth on Schedule 5.22 to the Disclosure Letter, the Borrower and each of its Subsidiaries own and
possess, or have a license or other right to use in all respects all Intellectual Property as is reasonably necessary for the conduct of their respective businesses, without conflict with the rights of any other Person, other than as would not
reasonably be expected to have a Material Adverse Effect. Except as set forth on Schedule 5.22 to the Disclosure Letter, the knowledge of the Borrower, no slogan or other advertising device, product, process, method, substance, part or other
material now employed, or now contemplated to be employed, by the Borrower or any of its Subsidiaries infringes upon any Intellectual Property rights held by any other Person, other than as would not reasonably be expected to have a Material Adverse
Effect. Except as set forth on Schedule 5.22 to the Disclosure Letter, no claim or litigation regarding any of the foregoing is pending or, to the knowledge of the Borrower, threatened in writing, which, either individually or in the
aggregate, would reasonably be expected to have a Material Adverse Effect. 
  

	 5.23
	 EEA Financial Institutions. Neither the Borrower nor any Guarantor is an EEA Financial Institution. 

  
 82 

 ARTICLE VI 

AFFIRMATIVE COVENANTS 

Each of the Loan Parties hereby covenants and agrees that on the Closing Date and thereafter until the Facility Termination
Date, such Loan Party shall, and shall cause each of its Subsidiaries to: 
  

	 6.01
	 Financial Statements. 

Deliver to the Administrative Agent and each Lender: 

(a) Audited Financial Statements. As soon as available, but in any event within ninety (90) days
after the end of each fiscal year of the Borrower, a Consolidated balance sheet of the Borrower and its Subsidiaries as at the end of such fiscal year, and the related Consolidated statements of income or operations, changes in shareholders’
equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such Consolidated statements to be audited and
accompanied by a report and opinion of any “Big Four” or any other independent certified public accountant of nationally recognized standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in
accordance with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit. 

(b) Quarterly Financial Statements. As soon as available, but in any event within forty-five
(45) days after the end of each of the first three (3) fiscal quarters of each fiscal year of the Borrower, a Consolidated balance sheet of the Borrower and its Subsidiaries as at the end of such fiscal quarter, and the related
Consolidated statements of income or operations, changes in shareholders’ equity and cash flows for such fiscal quarter and for the portion of the Borrower’s fiscal year then ended, setting forth in each case in comparative form the
figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, such Consolidated statements to be certified by the
chief executive officer, chief financial officer, treasurer or controller who is a Responsible Officer of the Borrower as fairly presenting the financial condition, results of operations, shareholders’ equity and cash flows of the Borrower and
its Subsidiaries, subject only to normal year-end audit adjustments and the absence of footnotes. 
 (c)
Business Plan and Budget. As soon as available, but in any event within ninety (90) days after the end of each fiscal year of the Borrower, an annual business plan and budget of the Borrower and its Subsidiaries on a Consolidated basis,
including forecasts prepared by management of the Borrower, in form reasonably satisfactory to the Administrative Agent (it being understood that the form of business plan and budget of the Borrower and its Subsidiaries provided by the Borrower
prior to the Closing Date is reasonably satisfactory to the Administrative Agent), of Consolidated balance sheets and statements of income or operations and cash flows of the Borrower and its Subsidiaries on a quarterly basis for the immediately
following fiscal year . 
 As to any information contained in materials furnished pursuant to Section 6.02(d), the Borrower
shall not be separately required to furnish such information under Section 6.01(a) or (b) above, but the foregoing shall not be in derogation of the obligation of the Borrower to furnish the information and materials described in Sections
6.01(a) and (b) above at the times specified therein. 

  
 83 

	 6.02
	 Certificates; Other Information. 

Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the
Required Lenders: 
 (a) Compliance Certificate. Commencing with the fiscal quarter ending
December 31, 2015, concurrently with the delivery of the financial statements referred to in Sections 6.01(a) and (b), a duly completed Compliance Certificate signed by the chief executive officer, chief financial officer,
treasurer or controller which is a Responsible Officer of the Borrower. Unless the Administrative Agent or a Lender requests executed originals, delivery of the Compliance Certificate may be by electronic communication including fax or email and
shall be deemed to be an original and authentic counterpart thereof for all purposes. 
 (b) Changes in
Entity Structure. With respect to each fiscal quarter during which there is a change to the organizational structure of the Borrower or its Subsidiaries, a true and complete organizational chart of the Borrower and all of its Subsidiaries shall
be delivered concurrently with the delivery of the Compliance Certificate referred to in Section 6.02(a). 

(c) Management Letters. Promptly after receipt thereof by the Borrower or any of its Subsidiaries, a
copy of any management letter received by such Person from its certified public accountants and the management’s response thereto. 

(d) Annual Reports; Etc. Promptly after the same are available, copies of each annual report, proxy or
financial statement or other report or communication sent to the stockholders of the Borrower, and copies of all annual, regular, periodic and special reports and registration statements which the Borrower may file or be required to file with the
SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, or with any national securities exchange, and in any case not otherwise required to be delivered to the Administrative Agent pursuant hereto. 

(e) Debt Securities Statements and Reports. Promptly after the furnishing thereof, copies of any
statement or report furnished to any holder of debt securities of any Loan Party or of any of its Subsidiaries in excess of the Threshold Amount pursuant to the terms of any indenture, loan or credit or similar agreement and not otherwise required
to be furnished to the Lenders pursuant to Section 6.01 or any other clause of this Section. 
 (f)
SEC Notices. Promptly, and in any event within ten (10) Business Days after receipt thereof by any Loan Party or any Subsidiary thereof, copies of each notice or other correspondence received from the SEC (or comparable agency in any
applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of any Loan Party or any Subsidiary thereof. 

(g) Notices. Not later than ten (10) Business Days after receipt thereof by any Loan Party or any
Subsidiary thereof, copies of all notices, requests and other documents (including amendments, waivers and other modifications) so received under or pursuant to any instrument, indenture, loan or credit or similar agreement having an outstanding
principal amount equal to or greater than the Threshold Amount regarding or related to any breach or default by any party thereto or any other event that could materially impair the value of the interests or the rights of any Loan Party or otherwise
have a Material Adverse Effect and, from time to time upon request by the Administrative Agent, such information and reports regarding such instruments, indentures and loan and credit and similar agreements as the Administrative Agent may reasonably
request. 

  
 84 

 (h) Environmental Notice. Promptly after any Loan Party or
any Subsidiary becomes aware of the assertion or occurrence thereof, notice of any action or proceeding against or of any noncompliance by any Loan Party or any of its Subsidiaries with any Environmental Law or Environmental Permit that
would reasonably be expected to have a Material Adverse Effect. 
 (i) Additional Information.
Promptly, such additional information regarding the business, financial, legal or corporate affairs of any Loan Party or any Subsidiary thereof, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender may from
time to time reasonably request. 
 Documents required to be delivered pursuant to Section 6.01(a) or (b) or
Section 6.02(d), (e), (f) or (g) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on
the date (a) on which the Borrower posts such documents, or provides a link thereto on the Borrower’s website on the Internet at the website address listed on Schedule 1.01(a); or (b) on which such documents are posted on the
Borrower’s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent). The Administrative Agent
shall have no obligation to request the delivery of or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any such request by a Lender for delivery, and
each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents. 
 The Borrower hereby
acknowledges (A) if there is more than one Lender, the Administrative Agent will, at the reasonable request of the Borrower, make available to the Lenders and the L/C Issuer materials and/or information provided by or on behalf of the Borrower
hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks, Syndtrak, ClearPar or a substantially similar electronic transmission system (the “Platform”) and (B) certain of
the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive material non-public information with respect to the Borrower or its Affiliates, or the respective securities of any of the foregoing, and who may be
engaged in investment and other market-related activities with respect to such Persons’ securities. The Borrower hereby agrees that it will use commercially reasonable efforts to identify that portion of the Borrower Materials that may be
distributed to the Public Lenders and that (1) all such Borrower Materials shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page
thereof; (2) by marking Borrower Materials “PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent, any Affiliate thereof, the Arranger, the L/C Issuer and the Lenders to treat such Borrower Materials as not
containing any material non-public information (although it may be sensitive and proprietary) with respect to the Borrower or its securities for purposes of United States federal and state securities laws (provided, however, that to the extent such
Borrower Materials constitute Information, they shall be treated as set forth in Section 11.07); (3) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated
“Public Side Information;” and (4) the Administrative Agent any Affiliate thereof and the Arranger shall be entitled to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a
portion of the Platform not designated “Public Side Information.” 

  
 85 

	 6.03
	 Notices. 

Promptly, but in any event within four (4) Business Days after a Responsible Officer becomes aware thereof, notify the
Administrative Agent and each Lender: 
 (a) of the occurrence of any Default or Event of Default that is
continuing; 
 (b) any breach or non-performance of, or any default
under, any Contractual Obligation of any Loan Party or any Subsidiary of any Loan Party, or any violation of, or non-compliance with, any applicable Law, in each case which would reasonably be expected to result, either individually or in the
aggregate, in a Material Adverse Effect; 
 (c) of the occurrence of any ERISA Event to the extent such ERISA
Event has resulted or would reasonably be expected to result in a liability of any Loan Party in an aggregate amount in excess of the Threshold Amount; 

(d) of any material change in accounting policies or financial reporting practices by any Loan Party or any
Subsidiary thereof, including any determination by the Borrower referred to in Section 2.10(b); 
 (e)
the commencement of, or any material development in, any litigation or proceeding affecting any Loan Party or any Subsidiary of any Loan Party (i) in which the amount of damages claimed exceeds the Threshold Amount, (ii) in which
injunctive or similar relief is sought and which, if adversely determined, would reasonably be expected to have a Material Adverse Effect, or (iii) in which the relief sought is an injunction or other stay of the performance of this Agreement,
any other Loan Document; and 
 (f) (i) the receipt by any Loan Party of any notice of violation of, or
potential liability under, any Environmental Law or similar notice, which would reasonably be expected to result in Environmental Liabilities exceeding the Threshold Amount, and (ii)(A) the occurrence of unpermitted Releases, (B) the existence
of any condition that would reasonably be expected to result in violations of or Liabilities under, any Environmental Law or (C) the commencement of, or any material change to, any action, investigation, suit, proceeding, audit, claim, demand,
dispute alleging a violation of or Liability under any Environmental Law which, in the case of clauses (A), (B) and (C) above, in the aggregate for all such clauses, would reasonably be expected to result in Environmental Liabilities
exceeding the Threshold Amount. 
 Each notice pursuant to this Section 6.03 shall be accompanied by a statement of a
Responsible Officer of the Borrower setting forth details of the occurrence referred to therein and to the extent applicable, stating what action the Borrower has taken and proposes to take with respect thereto. Each notice pursuant to
Section 6.03(a) shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached. 
  

	 6.04
	 Payment of Obligations. 

Pay and discharge as the same shall become due and payable, (a) all material tax liabilities, assessments and governmental
charges or levies upon it or its properties or assets, except those which are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Borrower or such
Subsidiary; (b) all lawful claims which, if unpaid, would by law become a Lien (other than Liens permitted pursuant to Section 7.01) upon its property; and (c) all Indebtedness having an aggregate outstanding principal amount
of more than the Threshold Amount, as and when due and payable, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness. 

  
 86 

	 6.05
	 Preservation of Existence, Etc.  

(a) Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws
of the jurisdiction of its organization except in a transaction permitted by Section 7.04 or 7.05; 

(b) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary
or desirable in the normal conduct of its business, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; and 

(c) preserve or renew all of its registered patents, trademarks, trade names and service marks, the
non-preservation of which would reasonably be expected to have a Material Adverse Effect. 
  

	 6.06
	 Maintenance of Properties.  

(a) Maintain, preserve and protect all of its material properties and equipment necessary in the operation of
its business in good working order and condition, ordinary wear and tear excepted; and 
 (b) make all
necessary repairs thereto and renewals and replacements thereof except where the failure to do so could not reasonably be expected to have a Material Adverse Effect. 
  

	 6.07
	 Maintenance of Insurance.  

(a) Maintenance of Insurance. Maintain with financially sound and reputable insurance companies not
Affiliates of the Borrower, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are
customarily carried under similar circumstances by such other Persons. 
 (b) Evidence of Insurance.
Cause the Administrative Agent to be named as lenders’ loss payable, loss payee or mortgagee, as its interest may appear, and/or additional insured with respect of any such insurance providing liability coverage or coverage in respect of any
Collateral, and cause, unless otherwise agreed to by the Administrative Agent, each provider of any such insurance to agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Administrative Agent
that it will give the Administrative Agent thirty (30) days prior written notice before any such policy or policies shall be altered or cancelled (or ten (10) days prior notice in the case of cancellation due to the nonpayment of
premiums). Upon the Administrative Agent’s reasonable request, the Loan Parties shall provide, or cause to be provided, to the Administrative Agent, such evidence of insurance as required by the Administrative Agent hereunder; provided, that
unless an Event of Default has occurred and is continuing, the Administrative Agent shall make no more than one (1) such request per fiscal year. 

  
 87 

	 6.08
	 Compliance with Laws.  

Comply with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or
property, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (b) the failure to comply therewith could not
reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, each Loan Party and its Subsidiaries shall comply with all applicable Healthcare Laws and their implementation by any applicable Governmental
Authority and all lawful requests of any Governmental Authority applicable to its products except in each case where such failure could not reasonably be expected to have a Material Adverse Effect. All products developed, manufactured, tested,
distributed or marketed by or on behalf of any Loan Party or any of its Subsidiaries that are subject to the jurisdiction of the FDA or comparable Governmental Authority shall be developed, tested, manufactured, distributed and marketed in
compliance with all applicable Healthcare Laws and any other requirements of Law, including, without limitation, product approval or premarket notification, good manufacturing practices, labeling, advertising,
record-keeping, and adverse event reporting, and have been and are being tested, investigated, distributed, marketed, and sold in compliance with all applicable Healthcare Laws and all other requirements of
Law in each case where such failure could not reasonably be expected to have a Material Adverse Effect. 
  

	 6.09
	 Books and Records. 

Maintain proper books of record and account, in which in all material respects full, true and correct entries in conformity
with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of such Loan Party or such Subsidiary, as the case may be. 

 

	 6.10
	 Inspection Rights. 

Permit representatives and independent contractors of the Administrative Agent to visit and inspect any of its properties, to
examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at the expense of the
Borrower and at such reasonable times during normal business hours and as often as may be reasonably desired, upon reasonable advance notice to the Borrower; provided, however, that when an Event of Default exists the Administrative
Agent or any Lender (or any of their representatives or independent contractors) may do any of the foregoing at the expense of the Borrower at any time during normal business hours and without advance notice; provided further, that
unless an Event of Default has occurred and is continuing, only one such visit per fiscal year shall be at the Borrower’s expense. 
  

	 6.11
	 Use of Proceeds. 

Use the proceeds of the Credit Extensions to provide ongoing working capital and for general corporate purposes (including the
Ellipse Acquisition and other Permitted Acquisitions) not in contravention of any Law or of any Loan Document. 
  

	 6.12
	 Material Contracts. 

Perform and observe all the terms and provisions of each Material Contract to be performed or observed by it, maintain each
such Material Contract in full force and effect, enforce each such Material Contract in accordance with its terms, take all such action to such end as may be from time to time requested by the Administrative Agent and, upon request of the
Administrative Agent, make to each other party to each such Material Contract such demands and requests for information and reports or for action as any Loan Party or any of its Subsidiaries is entitled to make under such Material Contract, and
cause each of its Subsidiaries to do so, except, in any case, where the failure to do so, either individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. 

  
 88 

	 6.13
	 Covenant to Guarantee Obligations. 

The Loan Parties will cause each of their Subsidiaries (other than Excluded Subsidiaries) whether newly formed, after acquired
or otherwise existing to promptly (and in any event within thirty (30) days after such Subsidiary is formed or acquired (or such longer period of time as agreed to by the Administrative Agent in its reasonable discretion)) become a Guarantor
hereunder by way of execution of a Joinder Agreement. In connection therewith, the Loan Parties shall give notice to the Administrative Agent not more than thirty (30) days after creating a Subsidiary or acquiring the Equity Interests of any
other Person (or such longer period of time as agreed to by the Administrative Agent in its reasonable discretion). In connection with the foregoing, the Loan Parties shall deliver to the Administrative Agent, with respect to each new Guarantor to
the extent applicable, substantially all the same documentation required pursuant to Section 4.01(b) through (c) and such other documents or agreements as the Administrative Agent may reasonably require. 

 

	 6.14
	 Covenant to Give Security. 

Except with respect to Excluded Property: 

(a) Equity Interests and Personal Property. Each Loan Party will cause the Pledged Equity and all of its
tangible and intangible personal property, in each case other than Excluded Property, now owned or hereafter acquired by it to be subject at all times to a first priority, perfected Lien (subject to Permitted Liens to the extent permitted by the
Loan Documents) in favor of the Administrative Agent for the benefit of the Secured Parties to secure the Secured Obligations pursuant to the terms and conditions of the Collateral Documents. Each Loan Party shall provide opinions of counsel and any
filings and deliveries reasonably necessary in connection therewith to perfect the security interests therein to the extent required by the Collateral Documents, all in form and substance reasonably satisfactory to the Administrative Agent. 

(b) Account Control Agreements. Subject to Section 6.18 (which will provide for an
agreed-upon post-closing period to comply with this Section 6.14(b)), each of the Loan Parties shall not open, maintain or otherwise have any deposit or other accounts (including securities accounts) at any bank or other financial
institution, or any other account where money or securities are or may be deposited or maintained with any Person, other than (a) deposit accounts that are maintained at all times with depositary institutions as to which the Administrative
Agent shall have received a Qualifying Control Agreement, (b) securities accounts that are maintained at all times with financial institutions as to which the Administrative Agent shall have received a Qualifying Control Agreement, (c) any
payroll and other zero balance accounts, (d) petty cash accounts, amounts on deposit in which do not exceed $1,000,000 in the aggregate on a rolling 30-day average basis, (e) other deposit accounts and/or securities accounts, amounts on
deposit in which do not exceed $2,000,000 in the aggregate on a rolling 30-day average basis, (f) deposit accounts and securities accounts of Foreign Subsidiaries and (g) deposit accounts and securities accounts located outside of the
United States; provided that, with respect to any deposit accounts and securities accounts acquired in connection with a Permitted Acquisition, the Loan Parties shall have 60 days following the consummation of such Permitted Acquisition to comply
with this Section 6.14(b). 
 (c) Landlord Waivers. Subject to Section 6.18 (which
will provide for an agreed-upon post-closing period to comply with this Section 6.14(c)), in the case of each headquarter location of the Loan Parties, each other location where any significant administrative or governmental functions
are performed and each other location where the Loan Parties maintain any books or records (electronic or otherwise), the Loan Parties will provide the Administrative Agent with such estoppel letters, consents and waivers from the landlords on such
real property to the extent (A) requested by the Administrative Agent and (B) the Loan Parties are able to secure such letters, consents and waivers after using commercially reasonable efforts (such letters, consents and waivers shall be
in form and substance satisfactory to the Administrative Agent, it being acknowledged and agreed that any such estoppel letter, consent and waiver from the landlords is satisfactory to the Administrative Agent). 

  
 89 

 (d) Further Assurances. At any time upon reasonable
request of the Administrative Agent, promptly execute and deliver any and all further instruments and documents and take all such other action as the Administrative Agent may reasonably deem necessary or advisable to maintain in favor of the
Administrative Agent, for the benefit of the Secured Parties, Liens and insurance rights on the Collateral that are duly perfected in accordance with the requirements of, or the obligations of the Loan Parties under, the Loan Documents and all
applicable Laws. 
  

	 6.15
	 Further Assurances. 

(a) Promptly upon reasonable request by the Administrative Agent, or any Lender through the Administrative
Agent, (a) correct any material defect or error that may be discovered in any Loan Document or in the execution, acknowledgment, filing or recordation thereof, and (b) do, execute, acknowledge, deliver, record, re-record, file, re-file,
register and re-register any and all such further acts, deeds, certificates, assurances and other instruments as the Administrative Agent, or any Lender through the Administrative Agent, may reasonably require from time to time in order to
(i) carry out more effectively the purposes of the Loan Documents, (ii) to the fullest extent permitted by applicable Law, subject any Loan Party’s or any of its Subsidiaries’ properties, assets, rights or interests to the Liens
now or hereafter intended to be covered by any of the Collateral Documents, (iii) perfect and maintain the validity, effectiveness and priority of any of the Collateral Documents and any of the Liens intended to be created thereunder and
(iv) assure, convey, grant, assign, transfer, preserve, protect and confirm more effectively unto the Secured Parties the rights granted or now or hereafter intended to be granted to the Secured Parties under any Loan Document or under any
other instrument executed in connection with any Loan Document to which any Loan Party or any of its Subsidiaries is or is to be a party, and cause each of its Subsidiaries to do so. 

(b) Without limiting the generality of the foregoing and except as otherwise approved in writing by the
Required Lenders, each Loan Party shall pledge all of the Equity Interests of each of its Domestic Subsidiaries (other than Excluded Foreign Subsidiaries) and First Tier Foreign Subsidiaries; provided that with respect to any First Tier Foreign
Subsidiary that is an Excluded Foreign Subsidiary, such pledge shall be limited to sixty-five percent (65%) of such First Tier Foreign Subsidiary’s outstanding Voting Stock and one hundred percent (100%) of such First Tier Foreign
Subsidiary’s outstanding non-voting Equity Interests), in each instance, to the Administrative Agent for the benefit of the Secured Parties, to secure the Obligations. In connection with each pledge of Equity Interests, the Loan Parties shall
deliver, or cause to be delivered, to the Administrative Agent, irrevocable proxies and stock powers and/or assignments, as applicable, duly executed in blank. 

(c) Notwithstanding anything to the contrary contained in the Loan Documents, the Administrative Agent shall
not obtain or perfect a security interest in any assets of any Loan Party as to which the Administrative Agent shall determine, in its reasonable discretion, that the cost of obtaining or perfecting such security interest is excessive in relation to
the benefit to the Lenders of the security afforded thereby or would otherwise violate applicable Law. 

  
 90 

	 6.16
	 Compliance with Environmental Laws. 

Comply, and cause all lessees and other Persons operating or occupying its properties to comply, with all applicable
Environmental Laws and Environmental Permits; (b) obtain and renew all Environmental Permits necessary for its operations and properties; and (c) conduct any investigation, study, sampling and testing, and undertake any cleanup, removal,
remedial or other action necessary to remove and clean up all Hazardous Materials from any of its properties, in accordance with the requirements of all Environmental Laws, in the case of clauses (a), (b) and
(c) above, except where such failure could not reasonably be expected to have a Material Adverse Effect; provided, however, that neither the Borrower nor any of its Subsidiaries shall be required to undertake any such
cleanup, removal, remedial or other action to the extent that its obligation to do so is being contested in good faith and by proper proceedings and appropriate reserves are being maintained with respect to such circumstances in accordance with
GAAP. 
  

	 6.17
	 Anti-Corruption Laws. 

Conduct its business in material compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act
2010 and other similar anti-corruption legislation in other jurisdictions and maintain policies and procedures designed to promote and achieve compliance with such laws. 
  

	 6.18
	 Post-Closing Covenants. 

The Borrower agrees to deliver, or cause to be delivered, to the Administrative Agent, the items described in Schedule
6.18 to the Disclosure Letter on the dates and by the times specified with respect to such items, or such later time as may be agreed to by the Administrative Agent in writing in its reasonable discretion. 

ARTICLE VII 
 NEGATIVE
COVENANTS 
 Each of the Loan Parties hereby covenants and agrees that on the Closing Date and thereafter until the
Facility Termination Date, no Loan Party shall, nor shall it permit any Subsidiary to, directly or indirectly: 
  

	 7.01
	 Liens. 

Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter
acquired, except for the following (the “Permitted Liens”): 
 (a) Liens pursuant to any
Loan Document; 
 (b) Liens existing on the Closing Date and listed on Schedule 7.01 to the Disclosure
Letter and any renewals or extensions thereof, provided that (i) the property covered thereby is not changed, (ii) the amount secured or benefited thereby is not increased except as contemplated by Section 7.02(b),
(iii) obligors with respect thereto are not changed, and (iv) any renewal or extension of the obligations secured or benefited thereby is permitted by Section 7.02(b); 

(c) Liens for Taxes not yet due or which are being contested in good faith and by appropriate proceedings
diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP; 

  
 91 

 (d) Statutory Liens such as carriers’, warehousemen’s,
mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than ninety (90) days or which are being contested in good faith and by appropriate
proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person; 

(e) pledges or deposits in the ordinary course of business in connection with workers’ compensation,
unemployment insurance and other social security legislation, other than any Lien imposed by ERISA; 
 (f)
deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business;

 (g) easements, rights-of-way, restrictions and other similar encumbrances affecting real property which,
in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person; 

(h) Liens securing judgments for the payment of money (or appeal or other surety bonds relating to such
judgments) not constituting an Event of Default under Section 8.01(h); 
 (i) bankers’
Liens, rights of setoff and other similar Liens existing solely with respect to cash and Cash Equivalents on deposit in one or more accounts maintained by the Borrower or any of its Subsidiaries with any Lender, in each case in the ordinary course
of business in favor of the bank or banks with which such accounts are maintained, securing solely the customary amounts owing to such bank with respect to cash management and operating account arrangements; provided, that in no case shall
any such Liens secure (either directly or indirectly) the repayment of any Indebtedness; 
 (j) any interest
or title of a lessor, licensor or sublessor under any lease, license or sublease entered into by any Loan Party or any Subsidiary thereof, including the license (as licensor or sublicensor) of Intellectual Property, in each case in the ordinary
course of business and covering only the assets so leased, licensed or subleased; 
 (k) Liens of a
collection bank arising under Section 4-210 of the UCC on items in the course of collection; 
 (l)
Liens on any property of a Person acquired or held by any Loan Party or any Subsidiary of any Loan Party securing Indebtedness incurred or assumed for the purpose of financing (or refinancing) all or any part of the cost of acquiring such property
and permitted under Section 7.02(c); provided that (i) any such Lien attaches to such property concurrently with or within one-hundred twenty (120) days after the acquisition thereof, (ii) such Lien attaches
solely to the property so acquired in such transaction and the proceeds thereof, and (iii) the principal amount of the debt secured thereby does not exceed 100% of the cost of such property (including, without limitation, reasonable fees and
expenses); 
 (m) any interest or title of a lessor or sublessor under any lease permitted by this Agreement;

  
 92 

 (n) Liens arising from the filing of precautionary uniform
commercial code financing statements with respect to any lease permitted by this Agreement; 
 (o) Liens
arising out of consignment or similar arrangements for the sale of goods entered into by the Borrower or any Subsidiary of the Borrower in the ordinary course of business; 

(p) Liens in favor of customs and revenue authorities arising as a matter of law which secure payment of
customs duties in connection with the importation of goods in the ordinary course of business; 
 (q) any
Lien existing on any property or asset prior to the acquisition thereof by the Borrower or any Subsidiary or existing on any property or asset of such Person that becomes a Subsidiary after the date hereof (including pursuant to a Permitted
Acquisition) prior to the time such Person becomes a Subsidiary; provided that (i) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be,
(ii) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary (other than the proceeds or products thereof and after-acquired property subjected to a Lien pursuant to terms existing at the time of such
acquisition, it being understood that such requirement shall not be permitted to apply to any property to which such requirement would not have applied but for such acquisition) and (iii) such Lien shall only secure Indebtedness permitted
pursuant to Sections 7.02(h) and (n); 
 (r) pledges of cash or Cash Equivalents in the ordinary
course of business securing insurance premiums under insurance policies, in each case, payable to insurance carriers that provide insurance to the Borrower and its Subsidiaries in an aggregate amount not to exceed the amount of insurance premiums
secured by such pledges; 
 (s) Liens arising out of conditional sale, title retention, consignment or
similar arrangements for sale of goods entered into by the Borrower or any Subsidiary in the ordinary course of business and not prohibited by this Agreement; 

(t) Liens on assets of Excluded Subsidiaries; provided that (i) such Liens do not extend to, or encumber,
assets that constitute Collateral or the Equity Interest of the Borrower or any other Loan Party, and (ii) such Liens extending to the assets of any Excluded Subsidiary secure only Indebtedness of Excluded Subsidiaries otherwise permitted under
Section 7.02(g); 
 (u) Liens securing Indebtedness outstanding permitted pursuant to
Section 7.02 or other obligations not exceeding $10,000,000 in aggregate principal amount; 
 (v)
Liens securing any Swap Contract permitted pursuant to Section 7.02(l); 
 (w) Liens securing any
Capitalized Lease Obligations and Synthetic Lease Obligations permitted pursuant to Section 7.02(c); and 

(x) non-exclusive licenses and sublicenses granted by a Loan Party or any Subsidiary of a Loan Party and leases
and subleases (by a Loan Party or any Subsidiary of a Loan Party as lessor or sublessor) to third parties in the ordinary course of business not interfering with the business of the Loan Parties or any of their Subsidiaries. 

  
 93 

	 7.02
	 Indebtedness. 

Create, incur, assume or suffer to exist any Indebtedness, except: 

(a) Indebtedness under the Loan Documents; 

(b) Indebtedness outstanding on the date hereof and listed on Schedule 7.02(b) to the Disclosure
Letter and any refinancings, refundings, renewals or extensions thereof; provided that the amount of such Indebtedness is not increased at the time of such refinancing, refunding, renewal or extension except by an amount equal to a reasonable
premium or other reasonable amount paid, and fees and expenses reasonably incurred, in connection with such refinancing and by an amount equal to any existing commitments unutilized thereunder and the direct or any contingent obligor with respect
thereto is not changed, as a result of or in connection with such refinancing, refunding, renewal or extension; 

(c) Indebtedness in respect of (x) Capitalized Leases and Synthetic Lease Obligations and
(y) purchase money obligations for fixed or capital assets within the limitations set forth in Section 7.01(l); provided, however, that the aggregate amount of all such Indebtedness under this clause (c) at any
one time outstanding shall not exceed $50,000,000; 
 (d) unsecured Indebtedness of a Subsidiary of the
Borrower owed to the Borrower or a wholly-owned Subsidiary of the Borrower, which Indebtedness shall (i) to the extent required by the Administrative Agent, be evidenced by promissory notes which shall be pledged to the Administrative Agent as
Collateral for the Secured Obligations in accordance with the terms of the Security Agreement, (ii) be on terms (including subordination terms) reasonably acceptable to the Administrative Agent and (iii) be otherwise permitted under the
provisions of Section 7.03 (“Intercompany Debt”); 
 (e) Guarantees of the
Borrower or any Guarantor in respect of Indebtedness otherwise permitted hereunder of the Borrower or any other Loan Party; 

(f) (i) the unsecured Convertible Notes outstanding on the date hereof and listed on Schedule
7.02(f) to the Disclosure Letter and any Permitted Convertible Note Refinancing thereof, and (ii) unsecured Indebtedness in the form of the Convertible Notes not to exceed $400,000,000 in the aggregate at any time outstanding (which
aggregate amount shall be reduced to $250,000,000 on or prior to July 14, 2017) and any Permitted Convertible Note Refinancing thereof; provided, that, with respect to this clause (f), as part of the consummation of a Permitted
Convertible Note Refinancing or a repayment of a Convertible Note, the aggregate principal amount of such Indebtedness shall be permitted to be greater than the amounts set forth in this clause (f) for a period of not more than three
(3) Business Days subsequent to the refinancing or repayment of such Indebtedness and by an amount not greater than required to consummate such refinancing or repayment; 

(g) guarantees (i) by any Loan Party of Indebtedness of any Excluded Subsidiary to the extent such
guarantees constitute Investments subject to the limitations of Section 7.03, (ii) by any Excluded Subsidiary of Indebtedness of any other Excluded Subsidiary, and (iii) by any Subsidiary of the Borrower of Indebtedness of the
Borrower or any other Loan Party; 
 (h) Indebtedness of any Person that becomes a Subsidiary of the Borrower
after the date hereof in a transaction permitted hereunder in an aggregate principal amount not to exceed $20,000,000; provided that such Indebtedness is existing at the time such Person becomes a Subsidiary of the Borrower and was not incurred
solely in contemplation of such Person’s becoming a Subsidiary of the Borrower); 

  
 94 

 (i) Indebtedness, whether secured or unsecured, incurred by
Foreign Subsidiaries in an aggregate principal amount not to exceed $10,000,000 at any time outstanding so long as no Loan Party is liable or obligated with respect thereto; 

(j) Indebtedness owed to insurance carriers at any time incurred in connection with financing insurance
premiums in the ordinary course of business; 
 (k) indemnification, purchase price adjustment or similar
obligations incurred in connection with Permitted Acquisitions, other acquisitions permitted by Section 7.03 or dispositions permitted under Section 7.05; 

(l) Indebtedness in respect of Swap Contracts not entered into for speculative purposes; 

(m) unsecured Indebtedness of the Borrower consisting of (i) repurchase obligations in respect of Equity
Interests of the Borrower issued to directors, consultants, managers, officers and employees of the Borrower and its Subsidiaries arising upon the death, disability or termination of employment of such director, consultant, manager, officer or
employee to the extent such repurchase is permitted by Section 7.06(h) and (ii) promissory notes issued by the Borrower to directors, consultants, managers, officers or employees (or their spouses or estates) of the Borrower and its
Subsidiaries to purchase or redeem Equity Interests of the Borrower issued to such director, consultant, manager, officer or employee to the extent such purchase or redemption is permitted under Section 7.06(h); and 

(n) other Indebtedness not exceeding in the aggregate at any time outstanding $25,000,000; provided,
that, not more than $15,000,000 in the aggregate at any time for all such Indebtedness under this clause (n) shall be secured Indebtedness (excluding letters of credit that have been fully cash collateralized). 

 

	 7.03
	 Investments. 

Make or hold any Investments, except: 

(a) Investments held by the Borrower and its Subsidiaries in the form of cash or Cash Equivalents; 

(b) advances to officers, directors and employees of the Borrower and Subsidiaries in an aggregate amount not
to exceed (x) $3,000,000 at any time outstanding, for relocation and analogous ordinary business purposes and (y) $500,000 for travel, entertainment and analogous ordinary business purposes; 

(c) (i) (A) Investments by the Borrower in any Loan Party, (B) additional Investments by any
Loan Party in any other Loan Party, (C) additional Investments by Subsidiaries of the Borrower that are not Loan Parties in other Subsidiaries that are not Loan Parties, and (D) so long as no Default has occurred and is continuing or would
result from such Investment, additional Investments by the Loan Parties in Subsidiaries that are not Loan Parties, in each case of clauses (A), (B), (C) and (D), in an aggregate amount invested at any time from the date hereof not to exceed 15%
of the Total Assets of the Borrower and its Subsidiaries as of the end of the any Measurement Period; (ii) so long as no Default has occurred and is continuing or would result from such Investment, Investment or Disposition by the Loan Parties
of intellectual property to Foreign Subsidiaries to the extent that (A) the aggregate market value of all such intellectual property transferred to such Foreign Subsidiaries as of the Closing Date does not exceed 50% of the market value of the
intellectual property of the Loan Parties, and (B) the Equity Interest of each such Foreign Subsidiary shall have been pledged to the Administrative Agent pursuant to Section 6.15(b); 

  
 95 

 (d) Investments consisting of extensions of credit in the nature
of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business, and Investments received in satisfaction or partial satisfaction thereof from financially troubled account debtors to the extent
reasonably necessary in order to prevent or limit loss; 
 (e) Guarantees permitted by
Section 7.02; 
 (f) Investments existing on the date hereof (other than those referred to in
Section 7.03(c)) and set forth on Schedule 7.03 to the Disclosure Letter; 
 (g) Permitted
Acquisitions (other than of CFCs and Subsidiaries held directly or indirectly by a CFC which Investments are covered by Section 7.03(c)(iv)); 

(h) Investments (including debt obligations) received or acquired as the non-cash portion of consideration
received in connection with transactions permitted pursuant to Section 7.05(f); 
 (i)
Investments consisting of any transaction expressly permitted under the terms and conditions of Section 7.04; 

(j) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of
suppliers and customers and in settlement of delinquent obligations of, and other disputes with, customers and suppliers arising in the ordinary course of business; 

(k) Investments arising from deposits made in the ordinary course of business securing obligations or
performance under real estate or personal property leases; 
 (l) Investments consisting of deposit,
securities or commodities accounts that are subject to a Qualifying Control Agreement, in each case, to the extent required hereunder; 

(m) Investments consisting of non-cash loans made by the Borrower to officers, directors, employees and
consultants of a Loan Party which are used by such Persons to purchase simultaneously Equity Interests of the Borrower; 

(n) Investments in an aggregate amount invested at any time from the date hereof not to exceed 10% of the Total
Assets of the Borrower and its Subsidiaries as of the end of the any Measurement Period; and 
 (o)
Investments by the Borrower in Swap Contracts permitted under Section 7.02(l). 

  
 96 

	 7.04
	 Fundamental Changes. 

Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one transaction or in a series
of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, except that: 

(a) any Subsidiary may merge with (i) the Borrower; provided that the Borrower shall be the
continuing or surviving Person, or (ii) any one or more other Subsidiaries, provided that when any Loan Party is merging with another Subsidiary, such Loan Party shall be the continuing or surviving Person; 

(b) any Excluded Subsidiary may merge with another Excluded Subsidiary; provided that if a First Tier
Foreign Subsidiary is merging with an Excluded Subsidiary, such First Tier Foreign Subsidiary shall be the continuing or surviving Person; 

(c) any Loan Party may Dispose of all or substantially all of its assets (upon voluntary liquidation or
otherwise) to the Borrower or to another Loan Party; 
 (d) any Subsidiary that is not a Loan Party may
dispose of all or substantially all its assets (including any Disposition that is in the nature of a liquidation) to (i) another Subsidiary that is not a Loan Party or (ii) to a Loan Party; 

(e) in connection with any Permitted Acquisition, any Subsidiary of the Borrower may merge into or consolidate
with any other Person or permit any other Person to merge into or consolidate with it; provided that (i) the Person surviving such merger shall be a wholly-owned Subsidiary of the Borrower and (ii) in the case of any such merger to
which any Loan Party (other than the Borrower) is a party, such Loan Party is the surviving Person; 
 (f) so
long as no Default has occurred and is continuing or would result therefrom, each of the Borrower and any of its Subsidiaries may merge into or consolidate with any other Person or permit any other Person to merge into or consolidate with it;
provided, however, that in each case, immediately after giving effect thereto (i) in the case of any such merger to which the Borrower is a party, the Borrower is the surviving Person and (ii) in the case of any such merger
to which any Loan Party (other than the Borrower) is a party, such Loan Party is the surviving Person; 
 (g)
Permitted Acquisitions and other Acquisitions permitted under Section 7.03 shall be permitted; and 

(h) Dispositions to a third party permitted under Section 7.05 shall be permitted. 

 

	 7.05
	 Dispositions. 

Make any Disposition or enter into any agreement to make any Disposition, except: 

(a) Permitted Transfers; 

(b) Dispositions of obsolete or worn out property, whether now owned or hereafter acquired, in the ordinary
course of business, including the abandonment or other Disposition of Intellectual Property, in each case, which, in the reasonable judgment of the Borrower, is no longer economically practicable to maintain or useful in the conduct of the business
of the Borrower and its Subsidiaries, taken as a whole; 
 (c) Dispositions of equipment or real property to
the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such Disposition are reasonably promptly applied to the purchase price of such replacement
property; 

  
 97 

 (d) Dispositions permitted by Sections 7.03 and 7.04; 

(e) Dispositions of accounts receivables to a third party in connection with the compromise, settlement or
collection thereof in the ordinary course of business exclusive of factoring or similar arrangements so long as all such Dispositions do not exceed $5,000,000 in the aggregate in any fiscal year (determined on a net basis by reducing such accounts
receivable by related reserves); 
 (f) Dispositions of assets so long as (i) at the time of such
Disposition, no Event of Default shall exist or shall result from therefrom, (ii) at least 75% of the consideration paid in connection therewith shall be cash or Cash Equivalents and shall be in an amount not less than the fair market value of
the property disposed of, and (iii) the aggregate consideration paid for all of the assets sold or otherwise disposed of by the Loan Parties and their Subsidiaries in all such transactions during the term of this Agreement shall not exceed
$50,000,000; and 
 (g) the entry into any agreement providing for any of the foregoing dispositions;
provided such disposition is permitted as of the date of such agreement. 
  

	 7.06
	 Restricted Payments. 

Declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so,
except that, so long as no Default shall have occurred and be continuing at the time of any action described below or would result therefrom: 

(a) each Subsidiary may make Restricted Payments to any Person that owns Equity Interests in such Subsidiary,
ratably according to their respective holdings of the type of Equity Interest in respect of which such Restricted Payment is being made; 

(b) the Borrower and each Subsidiary may declare and make Restricted Payments payable solely in common Equity
Interests of such Person; 
 (c) the Borrower and each Subsidiary may make Restricted Payments, provided all
of the following conditions are satisfied: 
 (i) no Default or Event of Default has occurred and is
continuing or would arise as a result of such Restricted Payment, and 
 (ii) at the time of such Restricted
Payment, the Loan Parties shall be in Pro Forma Compliance; 
 (d) reserved; 

(e) the Loan Parties may pay, as and when due and payable, interest payments required with respect to the
Convertible Notes and any Permitted Convertible Note Refinancings; 
 (f) subject to the terms of any
applicable subordination agreement, the Loan Parties may pay, as and when due and payable, interest payments required with respect to any Subordinated Debt permitted hereunder; 

  
 98 

 (g) the Borrower may repurchase Equity Interests issued by it,
which redemption is deemed to occur upon (i) the exercise of stock options if the Equity Interests represent a portion of the exercise price thereof or (ii) the withholding of a portion of Equity Interests issued to employees and other
participants under an equity compensation program of the Borrower or its Subsidiaries, in each case to cover tax obligations of such persons in respect of such issuance; 

(h) the Borrower may redeem from officers, directors, employees and consultants Equity Interests provided all
of the following conditions are satisfied: 
 (i) no Default or Event of Default has occurred and is
continuing or would arise as a result of such Restricted Payment; 
 (ii) after giving effect to such
Restricted Payment, the Loan Parties are in Pro Forma Compliance; 
 (iii) the aggregate Restricted Payments
and notes issued in lieu of any such Restricted Payment permitted (x) in any fiscal year of the Borrower shall not exceed $2,500,000 and (y) during the term of this Agreement shall not exceed $5,000,000; and 

(iv) after giving effect to such Restricted Payment, the aggregate principal amount of Revolving Loans
available to be borrowed under Section 2.01 hereof shall be at least $15,000,000; 
 (i) the
Borrower may (i) to the extent constituting a Restricted Payment, effect the conversion of any Convertible Notes and Permitted Convertible Notes Refinancings into Equity Interests and (ii) may repurchase fractional shares of any Equity
Interests arising out of the conversion of securities convertible (including the Convertible Notes and Permitted Convertible Notes Refinancings) into any such Equity Interests; 

(j) Loan Parties may repurchase or repay any Convertible Notes and Permitted Convertible Notes Refinancings
that the Loan Parties are required to repurchase or repaid in accordance with the applicable Convertible Indebtedness Documents or the documents evidencing the Permitted Convertible Notes Refinancings, as the case may be; and 

(k) The Loan Parties may refinance any Junior Debt with the net cash proceeds of other Junior Debt or Equity
Interests (excluding any Disqualified Stock); provided that the amount of such Junior Debt is not increased at the time of such refinancing to the extent such increase would cause a breach of Section 7.02, except by an amount equal to a
reasonable premium or other reasonable amount paid, and fees and expenses reasonably incurred, in connection with such refinancing and the direct or any contingent obligor with respect thereto is not changed, as a result of or in connection with
such refinancing. 
  

	 7.07
	 Change in Nature of Business. 

Engage in any material line of business substantially different from those lines of business conducted by the Borrower and its
Subsidiaries on the date hereof (orthopedics) or any business substantially related or complementary thereto. 

  
 99 

	 7.08
	 Transactions with Affiliates. 

Enter into or permit to exist any transaction or series of transactions with any officer, director or Affiliate of the Borrower
other than transactions which are: 
 (a) entered into in the ordinary course of such Person’s business
on fair and reasonable terms and conditions substantially as favorable to such Person as would be obtainable by it in a comparable arm’s length transaction with a Person other than an officer, director or Affiliate; 

(b) Restricted Payments permitted by Section 7.06; 

(c) any payment of compensation or fees to employees, officers, directors or shareholders made in the ordinary
course of business or otherwise expressly permitted hereunder; 
 (d) transactions between or among Loan
Parties; 
 (e) Investments in Excluded Subsidiaries subject to the limitations of Section 7.03;
and 
 (f) transactions expressly permitted by this Agreement. 

 

	 7.09
	 Burdensome Agreements. 

Enter into, or permit to exist, any Contractual Obligation (except for this Agreement and the other Loan Documents)
that (a) encumbers or restricts the ability of any such Person to (i) to act as a Loan Party; (ii) make Restricted Payments to any Loan Party, (iii) pay any Indebtedness or other obligation owed to any Loan
Party, (iv) make loans or advances to any Loan Party, or (v) create any Lien to secure the Obligations upon any of their properties or assets, whether now owned or hereafter acquired, except, in the case of clause (a)(v)
only, for any document or instrument governing Indebtedness incurred pursuant to Section 7.02(c), provided that any such restriction contained therein relates only to the asset or assets constructed or acquired in connection
therewith, or (b) requires the grant of any Lien on property for any obligation if a Lien on such property is given as security for the Secured Obligations; provided, however, the foregoing shall not apply to (A) restrictions and
conditions imposed by law, (B) restrictions and conditions existing on the date hereof identified on Schedule 7.09 to the Disclosure Letter (but shall apply to any extension or renewal of, or any amendment or modification expanding the
scope of, any such restriction or condition), (C) Indebtedness of a Subsidiary that is an Excluded Subsidiary or restrictions and conditions contained in agreements or instruments evidencing any Indebtedness of an Excluded Subsidiary permitted
to be incurred under Section 7.02, provided that the income and results of operations of such Excluded Subsidiary shall be excluded from the calculation of the covenants set forth in Section 7.11, (D) any document
or instrument governing Liens permitted pursuant to Sections 7.01(j), 7.01(l), 7.01(m), 7.01(q), 7.01(r) and, as long as the fair market value of assets subject to such permitted Liens does not exceed the amount of
Indebtedness secured, 7.01(u), provided that any such restriction contained therein relates only to the asset or assets subject to such permitted Liens, and (E) customary restrictions that arise solely in connection with any disposition
permitted by Section 7.05 and relate solely to the assets or Person subject to such disposition. Notwithstanding anything in Section 7.09 to the contrary, nothing herein shall restrict the licensing or sublicensing by the
Borrower and its Subsidiaries of Intellectual Property in the ordinary course of business. 
  

	 7.10
	 Use of Proceeds. 

Use the proceeds of any Credit Extension, whether directly or indirectly, and whether immediately, incidentally or ultimately,
to purchase or carry margin stock (within the meaning of Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose. 

  
 100 

	 7.11
	 Financial Covenants. 

(a) Consolidated Interest Coverage Ratio. Permit the Consolidated Interest Coverage Ratio as of the end
of any Measurement Period ending as of the end of any fiscal quarter of the Borrower (commencing with the fiscal quarter ending June 30, 2016) to be less than 3.00 to 1.00. 

(b) Consolidated Leverage Ratio. Permit the Consolidated Leverage Ratio at any time during any
Measurement Period ending as of the end of any fiscal quarter of the Borrower (commencing with the fiscal quarter ending June 30, 2016) set forth below to be greater than the ratio set forth below opposite such period: 

 

			
	 Measurement Period Ending
	  	Maximum Consolidated
Leverage Ratio
	 Closing Date through December 31, 2016
	  	4.50:1.00
	 March 31, 2017 through September 30, 2017
	  	4.25:1.00
	 December 31, 2017 through September 30, 2018
	  	4.00:1.00
	 December 31, 2018 through September 30, 2019
	  	3.75:1.00
	 December 31, 2019 and each fiscal quarter thereafter
	  	3.50:1.00

  

	 7.12
	 Amendments of Organization Documents; Fiscal Year; Legal Name, State of Formation; Form of Entity and Accounting Changes.

 (a) Amend any of its Organization Documents in a manner that is materially adverse to
the Lenders; 
 (b) change its fiscal year; 

(c) without providing ten (10) days prior written notice to the Administrative Agent (or such extended
period of time as agreed to by the Administrative Agent), change its name, state of formation, form of organization or principal place of business; or 

(d) make any change in accounting policies or reporting practices, except as permitted or required by GAAP.

  

	 7.13
	 Sale and Leaseback Transactions. 

Enter into any Sale and Leaseback Transaction (except to the extent permitted under Section 7.05). 

 

	 7.14
	 Amendment, Etc. of Indebtedness. 

No Loan Party shall, and no Loan Party shall permit any of its Subsidiaries directly or indirectly to, change or amend the
terms of any (i) Subordinated Debt, other than as permitted under the Subordinated Debt Documents or (ii) Convertible Indebtedness Documents if the effect of such change or amendment is to: (A) shorten the maturity date to a date
prior to the Maturity Date or require any payment of principal in respect thereof in any manner materially different from the repayment requirements set forth in the the Convertible Notes, (B) require or permit any cash payment of interest in
respect thereof at a rate in excess of 1.5% per annum of rate set forth in the Convertible Notes, (C) add or change guaranties that are more favorable than the guaranties supporting the Obligations, (d) add or modify representations,
warranties, covenants or events of default that are more restrictive, taken as a whole, than those set forth herein, (e) add a cross-default to any Loan Document and (f) require a security interest. 

  
 101 

	 7.15
	 Sanctions.  

Directly or indirectly, use any Credit Extension or the proceeds of any Credit Extension, or lend, contribute or otherwise make
available such Credit Extension or the proceeds of any Credit Extension to any Person, to fund any activities of or business with any Person, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions, or in
any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as Lender, Arranger, Administrative Agent, L/C Issuer, Swingline Lender, or otherwise) of Sanctions. 

 

	 7.16
	 Anti-Corruption Laws. 

Directly or indirectly, use any Credit Extension or the proceeds of any Credit Extension for any purpose which would breach the
United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar, applicable anti-corruption legislation in other jurisdictions. 

ARTICLE VIII 
 EVENTS OF
DEFAULT AND REMEDIES 
  

	 8.01
	 Events of Default. 

Any of the following shall constitute an Event of Default: 

(a) Non-Payment. The Borrower or any other Loan Party fails to pay (i) when and as required to be
paid herein and in the currency required hereunder, any amount of principal of any Loan or any L/C Obligation or deposit any funds as Cash Collateral in respect of L/C Obligations, or (ii) within five (5) Business Days after the same
becomes due, any interest on any Loan or on any L/C Obligation, or any fee due hereunder, or (iii) within five (5) Business Days after the same becomes due, any other amount payable hereunder or under any other Loan Document; or 

(b) Specific Covenants. Any Loan Party fails to perform or observe any term, covenant or agreement
contained in any of Section 6.01, 6.02, 6.03, 6.05, 6.09, 6.10, 6.11, Article VII or Article X; or 

(c) Other Defaults. Any Loan Party fails to perform or observe any other covenant or agreement (not
specified in Section 8.01(a) or (b) above) contained in any Loan Document on its part to be performed or observed and such failure continues for thirty (30) days after the earliest to occur of (i) the date upon which a
Responsible Officer of any Loan Party becomes aware of such default and (ii) the date upon which written notice thereof is given to the Borrower by the Administrative Agent or the Required Lenders; or 

(d) Representations and Warranties. Any representation, warranty, certification or statement of fact
made or deemed made by or on behalf of the Borrower or any other Loan Party herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be incorrect or misleading in any material respect (without
duplication of any materiality qualifiers contained therein) when made or deemed made; or 

  
 102 

 (e) Cross-Default. (i) Any Loan Party or any
Subsidiary thereof (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than Indebtedness hereunder and Indebtedness
under Swap Contracts) having an aggregate outstanding principal amount of more than the Threshold Amount, or (B) fails to observe or perform any other agreement or condition relating to any such Indebtedness or Guarantee or contained in any
instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such
Guarantee (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or
redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded;
provided that this clause (B) shall not apply to Indebtedness that becomes due as a result of a voluntary sale or transfer of assets not prohibited by the applicable agreement or instrument; or (ii) there occurs under any Swap Contract an
Early Termination Date (as defined in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which a Loan Party or any Subsidiary thereof is the Defaulting Party (as defined in such Swap Contract) or
(B) any Termination Event (as so defined) under such Swap Contract as to which a Loan Party or any Subsidiary thereof is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by such Loan Party or such
Subsidiary as a result thereof is greater than the Threshold Amount; or 
 (f) Insolvency Proceedings,
Etc. Any Loan Party or any Subsidiary thereof institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any
receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is
appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for sixty (60) calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material
part of its property is instituted without the consent of such Person and continues undismissed or unstayed for sixty (60) calendar days, or an order for relief is entered in any such proceeding; or 

(g) Inability to Pay Debts; Attachment. (i) Any Loan Party or any Subsidiary thereof becomes unable
or admits in writing its inability or fails generally to pay its debts as they become due, subject to applicable grace periods, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any
material part of the property of any such Person and is not released, vacated or fully bonded within sixty (60) days after its issue or levy; or 

(h) Judgments. There is entered against any Loan Party or any Subsidiary thereof (i) one or more
final judgments or orders for the payment of money (other than in connection with the Medtronic Litigation) in an aggregate amount (as to all such judgments and orders) exceeding the Threshold Amount (to the extent not covered by independent
third-party insurance as to which the insurer is rated at least “A” by A.M. Best Company, has been notified of the potential claim and does not dispute coverage), or (ii) any one or more non-monetary final judgments that have, or
would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and, in either case, (A) enforcement proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of
thirty (30) consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect; or 

  
 103 

 (i) ERISA. (i) an ERISA Event occurs with respect to
a Pension Plan or Multiemployer Plan which has resulted or would reasonably be expected to result in liability of any Loan Party under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of the
Threshold Amount, or (ii) the Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a
Multiemployer Plan in an aggregate amount in excess of the Threshold Amount; or 
 (j) Invalidity of Loan
Documents. Any material provision of any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all Obligations arising under the Loan
Documents, ceases to be in full force and effect; or any Loan Party or any other Person contests in any manner the validity or enforceability of any provision of any Loan Document; or any Loan Party denies in writing that it has any or further
liability or obligation under any provision of any Loan Document, or purports to revoke, terminate or rescind any provision of any Loan Document; or 

(k) Collateral Documents. Any Collateral Document after delivery thereof pursuant to the terms of the
Loan Documents shall for any reason cease to create a valid and perfected first priority Lien (subject to Permitted Liens) on any material portion of the Collateral purported to be covered thereby, or any Loan Party shall assert the invalidity of
such Liens; or 
 (l) Change of Control. There occurs any Change of Control. 

 

	 8.02
	 Remedies upon Event of Default. 

If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent
of, the Required Lenders, take any or all of the following actions: 
 (a) declare the Commitment of each
Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated; 

(b) declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and
all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Borrower; 

(c) require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the Minimum
Collateral Amount with respect thereto); and 
 (d) exercise on behalf of itself, the Lenders and the L/C
Issuer all rights and remedies available to it, the Lenders and the L/C Issuer under the Loan Documents or applicable Law or equity; 

  
 104 

 provided, however, that upon the occurrence of an actual or deemed entry of an
order for relief with respect to the Borrower under the Bankruptcy Code of the United States, the obligation of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid
principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrower to Cash Collateralize the L/C Obligations as aforesaid shall automatically
become effective, in each case without further act of the Administrative Agent or any Lender. 
  

	 8.03
	 Application of Funds. 

After the exercise of remedies provided for in Section 8.02 (or after the Loans have automatically become immediately due
and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso to Section 8.02) or if at any time insufficient funds are received by and available to the Administrative Agent to pay
fully all Secured Obligations then due hereunder, any amounts received on account of the Secured Obligations shall, subject to the provisions of Sections 2.14 and 2.15, be applied by the Administrative Agent in the following order : 

First, to payment of that portion of the Secured Obligations constituting fees, indemnities, expenses
and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) payable to the Administrative Agent in its capacity as such; 

Second, to payment of that portion of the Secured Obligations constituting fees, indemnities and other
amounts (other than principal, interest and Letter of Credit Fees) payable to the Lenders and the L/C Issuer (including fees, charges and disbursements of counsel to the respective Lenders and the L/C Issuer) arising under the Loan Documents and
amounts payable under Article III, ratably among them in proportion to the respective amounts described in this clause Second payable to them; 

Third, to payment of that portion of the Secured Obligations constituting accrued and unpaid Letter of
Credit Fees and interest on the Loans, L/C Borrowings and other Secured Obligations arising under the Loan Documents, ratably among the Lenders and the L/C Issuer in proportion to the respective amounts described in this clause Third payable to
them; 
 Fourth, to payment of that portion of the Secured Obligations constituting unpaid principal
of the Loans, L/C Borrowings and Secured Obligations then owing under Secured Hedge Agreements and Secured Cash Management Agreements and to the to the Administrative Agent for the account of the L/C Issuer, to Cash Collateralize that portion of L/C
Obligations comprised of the aggregate undrawn amount of Letters of Credit to the extent not otherwise Cash Collateralized by the Borrower pursuant to Sections 2.03 and 2.14, in each case ratably among the Administrative Agent, the Lenders, the L/C
Issuer, the Hedge Banks and the Cash Management Banks in proportion to the respective amounts described in this clause Fourth held by them; and 

Last, the balance, if any, after all of the Secured Obligations have been indefeasibly paid in full, to
the Borrower or as otherwise required by Law. 
 Subject to Sections 2.03(c) and 2.14, amounts used to Cash Collateralize the aggregate
undrawn amount of Letters of Credit pursuant to clause Fourth above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either
been fully drawn or expired, such remaining amount shall be applied to the other Secured Obligations, if any, in the order set forth above. Excluded Swap Obligations with respect to any Guarantor shall not be paid with amounts received from such
Guarantor or its assets, but appropriate adjustments shall be made with respect to payments from other Loan Parties to preserve the allocation to Secured Obligations otherwise set forth above in this Section. 

  
 105 

 Notwithstanding the foregoing, Secured Obligations arising under Secured Cash Management
Agreements and Secured Hedge Agreements shall be excluded from the application described above if the Administrative Agent has not received a Secured Party Designation Notice, together with such supporting documentation as the Administrative Agent
may request, from the applicable Cash Management Bank or Hedge Bank, as the case may be. Each Cash Management Bank or Hedge Bank not a party to this Agreement that has given the notice contemplated by the preceding sentence shall, by such notice, be
deemed to have acknowledged and accepted the appointment of the Administrative Agent pursuant to the terms of Article IX for itself and its Affiliates as if a “Lender” party hereto. 

ARTICLE IX 

ADMINISTRATIVE AGENT 
  

	 9.01
	 Appointment and Authority. 

(a) Appointment. Each of the Lenders and the L/C Issuer hereby irrevocably appoints, designates and
authorizes Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the
Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuer,
and neither the Borrower nor any other Loan Party shall have rights as a third party beneficiary of any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other
similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom,
and is intended to create or reflect only an administrative relationship between contracting parties. 
 (b)
Collateral Agent. The Administrative Agent shall also act as the “collateral agent” under the Loan Documents, and each of the Lenders (including in its capacities as a potential Hedge Bank, and a potential Cash Management Bank) and
the L/C Issuer hereby irrevocably appoints and authorizes the Administrative Agent to act as the agent of such Lender and the L/C Issuer for purposes of acquiring, holding and enforcing any and all Liens on Collateral granted by any of the Loan
Parties to secure any of the Secured Obligations, together with such powers and discretion as are reasonably incidental thereto. In this connection, the Administrative Agent, as “collateral agent” and any co-agents, sub-agents and
attorneys-in-fact appointed by the Administrative Agent pursuant to Section 9.05 for purposes of holding or enforcing any Lien on the Collateral (or any portion thereof) granted under the Collateral Documents, or for exercising any rights and
remedies thereunder at the direction of the Administrative Agent), shall be entitled to the benefits of all provisions of this Article IX and Article XI (including Section 11.04(c), as though such co-agents, sub-agents and attorneys-in-fact
were the “collateral agent” under the Loan Documents) as if set forth in full herein with respect thereto. 

  
 106 

	 9.02
	 Rights as a Lender.  

The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as
any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person
serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally
engage in any kind of banking, trust, financial, advisory, underwriting or other business with any Loan Party or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account
therefor to the Lenders or to provide notice to or consent of the Lenders with respect thereto. 
  

	 9.03
	 Exculpatory Provisions. 

The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan
Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent and its Related Parties: 

(a) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred
and is continuing; 
 (b) shall not have any duty to take any discretionary action or exercise any
discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or
percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents), provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may
expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a
forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and 

(c) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty or
responsibility to disclose, and shall not be liable for the failure to disclose, any information relating to any Loan Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its
Affiliates in any capacity. 
 Neither the Administrative Agent nor any of its Related Parties shall be liable for any
action taken or not taken by the Administrative Agent under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby or thereby (i) with the consent or at the request of the Required Lenders (or
such other number or percentage of the Lenders as shall be necessary), or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 11.01 and 8.02) or (ii) in the absence of its
own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such
Default is given in writing to the Administrative Agent by the Borrower, a Lender or the L/C Issuer. 

  
 107 

 Neither the Administrative Agent nor any of its Related Parties have any duty or
obligation to any Lender or participant or any other Person to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any
certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or
the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document, or the creation, perfection or priority of any Lien
purported to be created by the Collateral Documents, (v) the value or the sufficiency of any Collateral, or (vi) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items
expressly required to be delivered to the Administrative Agent. 
  

	 9.04
	 Reliance by Administrative Agent. 

The Administrative Agent shall be entitled to rely upon, and shall be fully protected in relying and shall not incur any
liability for relying upon, any notice, request, certificate, communication, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to
be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and
shall be fully protected in relying and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by
its terms must be fulfilled to the satisfaction of a Lender or the L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L/C Issuer unless the Administrative Agent shall have received notice to
the contrary from such Lender or the L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Loan Parties), independent accountants and
other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. For purposes of determining compliance with the conditions specified in
Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or
satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objections. 
  

	 9.05
	 Delegation of Duties. 

The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other
Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective
Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the
syndication of the Aggregate Commitments as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction
determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents. 

  
 108 

	 9.06
	 Resignation of Administrative Agent. 

(a) Notice. The Administrative Agent may at any time give notice of its resignation to the Lenders, the
L/C Issuer and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a bank with an office in the United States, or an
Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent
gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be obligated to) on behalf of the Lenders
and the L/C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above; provided that in no event shall any successor Administrative Agent be a Defaulting Lender. Whether or not a successor has been appointed,
such resignation shall become effective in accordance with such notice on the Resignation Effective Date. 

(b) Effect of Resignation. With effect from the Resignation Effective Date (i) the retiring
Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any collateral security held by the Administrative Agent on behalf of the Lenders or the L/C Issuer
under any of the Loan Documents, the retiring Administrative Agent shall continue to hold such collateral security until such time as a successor Administrative Agent is appointed) and (ii) except for any indemnity payments or other amounts
then owed to the retiring Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and the L/C Issuer directly, until such
time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all
of the rights, powers, privileges and duties of the retiring Administrative Agent (other than as provided in Section 3.01(g) and other than any rights to indemnity payments or other amounts owed to the retiring Administrative Agent as of the
Resignation Effective Date or the Removal Effective Date, as applicable), and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged
therefrom as provided above in this Section). The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the
retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Article and Section 11.04 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and
their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent. 

 

	 9.07
	 Non-Reliance on Administrative Agent and Other Lenders. 

Each Lender and the L/C Issuer acknowledges that it has, independently and without reliance upon the Administrative Agent or
any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender and the L/C Issuer also acknowledges that
it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own
decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. 

  
 109 

	 9.08
	 No Other Duties, Etc. 

Anything herein to the contrary notwithstanding, none of the titles listed on the cover page hereof shall have any powers,
duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, the Arranger, a Lender or the L/C Issuer hereunder. 

 

	 9.09
	 Administrative Agent May File Proofs of Claim; Credit Bidding. 

In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to any Loan
Party, the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have
made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise: 

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of
the Loans, L/C Obligations and all other Secured Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuer and the Administrative Agent
(including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L/C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuer and
the Administrative Agent under Sections 2.03(h) and (i), 2.09, 2.10(b) and 11.04) allowed in such judicial proceeding; and 

(b) to collect and receive any monies or other property payable or deliverable on any such claims and to
distribute the same; 
 and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such
judicial proceeding is hereby authorized by each Lender and the L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the
L/C Issuer, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under
Sections 2.09, 2.10(b) and 11.04. 
 Nothing contained herein shall be deemed to authorize the Administrative Agent to
authorize or consent to or accept or adopt on behalf of any Lender or the L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Secured Obligations or the rights of any Lender or the L/C Issuer to authorize the
Administrative Agent to vote in respect of the claim of any Lender or the L/C Issuer or in any such proceeding. 
 The
Secured Parties hereby irrevocably authorize the Administrative Agent, at the direction of the Required Lenders, to credit bid all or any portion of the Secured Obligations (including accepting some or all of the Collateral in satisfaction of some
or all of the Secured Obligations pursuant to a deed in lieu of foreclosure or otherwise) and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral (a) at any sale thereof
conducted under the provisions of the Bankruptcy Code of the United States, including under Sections 363, 1123 or 1129 of the Bankruptcy Code of the United States, or any similar Laws in any other jurisdictions to which a Loan Party is subject,
(b) at any other sale or foreclosure or acceptance of collateral in lieu of debt conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with any applicable
Law. In connection with any such credit bid and purchase, the Secured Obligations owed to the Secured Parties shall be entitled to be, and shall be, credit bid on a ratable basis (with Secured Obligations with respect to contingent or
unliquidated claims receiving contingent interests in the acquired assets on a ratable basis that would vest upon the liquidation of such claims in an amount proportional to the liquidated portion of the contingent claim amount used in allocating
the contingent interests) in the asset or assets so purchased (or in the Equity Interests or debt instruments of the acquisition vehicle or vehicles that are used to consummate such purchase). In connection with any such bid (i) the
Administrative Agent shall be authorized to form one or more acquisition vehicles to make a bid, (ii) to adopt documents providing for the governance of the acquisition vehicle or vehicles (provided that any actions by the Administrative Agent
with respect to such acquisition vehicle or vehicles, including any disposition of the assets or Equity Interests thereof shall be governed, directly or indirectly, by the vote of the Required Lenders, irrespective of the termination of this
Agreement and without giving effect to the limitations on actions by the Required Lenders contained in clauses (a) through (h) of Section 11.1 of this Agreement, and (iii) to the extent that Secured Obligations that are assigned
to an acquisition vehicle are not used to acquire Collateral for any reason (as a result of another bid being higher or better, because the amount of Secured Obligations assigned to the acquisition vehicle exceeds the amount of debt credit bid by
the acquisition vehicle or otherwise), such Secured Obligations shall automatically be reassigned to the Lenders pro rata and the Equity Interests and/or debt instruments issued by any acquisition vehicle on account of the Secured Obligations that
had been assigned to the acquisition vehicle shall automatically be cancelled, without the need for any Secured Party or any acquisition vehicle to take any further action. 

  
 110 

	 9.10
	 Collateral and Guaranty Matters. 

Each of the Lenders (including in its capacities as a potential Cash Management Bank and a potential Hedge Bank) and the L/C
Issuer irrevocably authorize the Administrative Agent, at its option and in its discretion, 
 (a) to release
any Lien on any property granted to or held by the Administrative Agent under any Loan Document (i) upon the Facility Termination Date, (ii) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in
connection with any sale or other disposition permitted hereunder or under any other Loan Document, or (iii) if approved, authorized or ratified in writing by the Required Lenders in accordance with Section 11.01; 

(b) to subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan
Document to the holder of any Lien on such property that is permitted by Section 7.01(l); and 
 (c) to
release any Guarantor from its obligations under the Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents. 

Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative
Agent’s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Guaranty pursuant to this Section 9.10. In each case as specified in this
Section 9.10, the Administrative Agent will, at the Borrower’s expense, execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such item of Collateral from the
assignment and security interest granted under the Collateral Documents or to subordinate its interest in such item, or to release such Guarantor from its obligations under the Guaranty, in each case in accordance with the terms of the Loan
Documents and this Section 9.10. 
 The Administrative Agent shall not be responsible for or have a duty to ascertain
or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by any Loan Party
in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral. 

  
 111 

	 9.11
	 Secured Cash Management Agreements and Secured Hedge Agreements. 

Except as otherwise expressly set forth herein, no Cash Management Bank or Hedge Bank that obtains the benefit of the
provisions of Section 8.03, the Guaranty or any Collateral by virtue of the provisions hereof or any Collateral Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other
Loan Document or otherwise in respect of the Collateral (including the release or impairment of any Collateral) (or to notice of or to consent to any amendment, waiver or modification of the provisions hereof or of the Guaranty or any Collateral
Document) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Loan Documents. Notwithstanding any other provision of this Article IX to the contrary, the Administrative Agent shall not be required
to verify the payment of, or that other satisfactory arrangements have been made with respect to, Secured Obligations arising under Secured Cash Management Agreements and Secured Hedge Agreements except to the extent expressly provided herein and
unless the Administrative Agent has received a Secured Party Designation Notice of such Secured Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Cash Management Bank or Hedge Bank,
as the case may be. The Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Secured Obligations arising under Secured Cash Management Agreements and Secured
Hedge Agreements in the case of a Facility Termination Date. 
 ARTICLE X 

CONTINUING GUARANTY 
  

	 10.01
	 Guaranty. 

Each Guarantor hereby absolutely and unconditionally, jointly and severally guarantees, as primary obligor and as a guaranty of
payment and performance and not merely as a guaranty of collection, prompt payment when due, whether at stated maturity, by required prepayment, upon acceleration, demand or otherwise, and at all times thereafter, of any and all Secured Obligations
(for each Guarantor, subject to the proviso in this sentence, its “Guaranteed Obligations”); provided that (a) the Guaranteed Obligations of a Guarantor shall exclude any Excluded Swap Obligations with respect to such
Guarantor and (b) the liability of each Guarantor individually with respect to this Guaranty shall be limited to an aggregate amount equal to the largest amount that would not render its obligations hereunder subject to avoidance under
Section 548 of the Bankruptcy Code of the United States or any comparable provisions of any applicable state law. The Administrative Agent’s books and records showing the amount of the Obligations shall be admissible in evidence in any
action or proceeding, and shall be binding upon each Guarantor, and conclusive for the purpose of establishing the amount of the Secured Obligations. This Guaranty shall not be affected by the genuineness, validity, regularity or enforceability of
the Secured Obligations or any instrument or agreement evidencing any Secured Obligations, or by the existence, validity, enforceability, perfection, non-perfection or extent of any collateral therefor, or by any fact or circumstance relating to the
Secured Obligations which might otherwise constitute a defense to the obligations of the Guarantors, or any of them, under this Guaranty, and each Guarantor hereby irrevocably waives any defenses it may now have or hereafter acquire in any way
relating to any or all of the foregoing. 

  
 112 

	 10.02
	 Rights of Lenders. 

Each Guarantor consents and agrees that the Secured Parties may, at any time and from time to time, without notice or demand,
and without affecting the enforceability or continuing effectiveness hereof: (a) amend, extend, renew, compromise, discharge, accelerate or otherwise change the time for payment or the terms of the Secured Obligations or any part thereof;
(b) take, hold, exchange, enforce, waive, release, fail to perfect, sell, or otherwise dispose of any security for the payment of this Guaranty or any Secured Obligations; (c) apply such security and direct the order or manner of sale
thereof as the Administrative Agent, the L/C Issuer and the Lenders in their sole discretion may determine; and (d) release or substitute one or more of any endorsers or other guarantors of any of the Secured Obligations. Without limiting the
generality of the foregoing, each Guarantor consents to the taking of, or failure to take, any action which might in any manner or to any extent vary the risks of such Guarantor under this Guaranty or which, but for this provision, might operate as
a discharge of such Guarantor. 
  

	 10.03
	 Certain Waivers. 

Each Guarantor waives (a) any defense arising by reason of any disability or other defense of the Borrower or any other
guarantor, or the cessation from any cause whatsoever (including any act or omission of any Secured Party) of the liability of the Borrower or any other Loan Party; (b) any defense based on any claim that such Guarantor’s obligations
exceed or are more burdensome than those of the Borrower or any other Loan Party; (c) the benefit of any statute of limitations affecting any Guarantor’s liability hereunder; (d) any right to proceed against the Borrower or any other
Loan Party, proceed against or exhaust any security for the Secured Obligations, or pursue any other remedy in the power of any Secured Party whatsoever; (e) any benefit of and any right to participate in any security now or hereafter held by
any Secured Party; and (f) to the fullest extent permitted by law, any and all other defenses or benefits that may be derived from or afforded by applicable Law limiting the liability of or exonerating guarantors or sureties. Each Guarantor
expressly waives all setoffs and counterclaims and all presentments, demands for payment or performance, notices of nonpayment or nonperformance, protests, notices of protest, notices of dishonor and all other notices or demands of any kind or
nature whatsoever with respect to the Secured Obligations, and all notices of acceptance of this Guaranty or of the existence, creation or incurrence of new or additional Secured Obligations. 

 

	 10.04
	 Obligations Independent. 

The obligations of each Guarantor hereunder are those of primary obligor, and not merely as surety, and are independent of the
Secured Obligations and the obligations of any other guarantor, and a separate action may be brought against each Guarantor to enforce this Guaranty whether or not the Borrower or any other person or entity is joined as a party. 

 

	 10.05
	 Subrogation. 

No Guarantor shall exercise any right of subrogation, contribution, indemnity, reimbursement or similar rights with respect to
any payments it makes under this Guaranty until all of the Secured Obligations and any amounts payable under this Guaranty have been indefeasibly paid and performed in full and the Aggregate Commitments are terminated. If any amounts are paid to a
Guarantor in violation of the foregoing limitation, then such amounts shall be held in trust for the benefit of the Secured Parties and shall forthwith be paid to the Secured Parties to reduce the amount of the Secured Obligations, whether matured
or unmatured. 

  
 113 

	 10.06
	 Termination; Reinstatement. 

This Guaranty is a continuing and irrevocable guaranty of all Secured Obligations now or hereafter existing and shall remain in
full force and effect until the Facility Termination Date. Notwithstanding the foregoing, this Guaranty shall continue in full force and effect or be revived, as the case may be, if any payment by or on behalf of the Borrower or a Guarantor is made,
or any of the Secured Parties exercises its right of setoff, in respect of the Secured Obligations and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside
or required (including pursuant to any settlement entered into by any of the Secured Parties in their discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Laws or otherwise,
all as if such payment had not been made or such setoff had not occurred and whether or not the Secured Parties are in possession of or have released this Guaranty and regardless of any prior revocation, rescission, termination or reduction. The
obligations of each Guarantor under this paragraph shall survive termination of this Guaranty. 
  

	 10.07
	 Stay of Acceleration. 

If acceleration of the time for payment of any of the Secured Obligations is stayed, in connection with any case commenced by
or against a Guarantor or the Borrower under any Debtor Relief Laws, or otherwise, all such amounts shall nonetheless be payable by each Guarantor, jointly and severally, immediately upon demand by the Secured Parties. 

 

	 10.08
	 Condition of Borrower. 

Each Guarantor acknowledges and agrees that it has the sole responsibility for, and has adequate means of, obtaining from the
Borrower and any other guarantor such information concerning the financial condition, business and operations of the Borrower and any such other guarantor as such Guarantor requires, and that none of the Secured Parties has any duty, and such
Guarantor is not relying on the Secured Parties at any time, to disclose to it any information relating to the business, operations or financial condition of the Borrower or any other guarantor (each Guarantor waiving any duty on the part of the
Secured Parties to disclose such information and any defense relating to the failure to provide the same). 
  

	 10.09
	 Appointment of Borrower. 

Each of the Loan Parties hereby appoints the Borrower to act as its agent for all purposes of this Agreement, the other Loan
Documents and all other documents and electronic platforms entered into in connection herewith and agrees that (a) the Borrower may execute such documents and provide such authorizations on behalf of such Loan Parties as the Borrower deems
appropriate in its sole discretion and each Loan Party shall be obligated by all of the terms of any such document and/or authorization executed on its behalf, (b) any notice or communication delivered by the Administrative Agent, L/C Issuer or
a Lender to the Borrower shall be deemed delivered to each Loan Party and (c) the Administrative Agent, L/C Issuer or the Lenders may accept, and be permitted to rely on, any document, authorization, instrument or agreement executed by the
Borrower on behalf of each of the Loan Parties. 
  

	 10.10
	 Right of Contribution. 

The Guarantors agree among themselves that, in connection with payments made hereunder, each Guarantor shall have contribution
rights against the other Guarantors as permitted under applicable Law. 

  
 114 

	 10.11
	 Keepwell. 

Each Loan Party that is a Qualified ECP Guarantor at the time the Guaranty or the grant of a Lien under the Loan Documents, in
each case, by any Specified Loan Party becomes effective with respect to any Swap Obligation, hereby jointly and severally, absolutely, unconditionally and irrevocably undertakes to provide such funds or other support to each Specified Loan Party
with respect to such Swap Obligation as may be needed by such Specified Loan Party from time to time to honor all of its obligations under the Loan Documents in respect of such Swap Obligation (but, in each case, only up to the maximum amount of
such liability that can be hereby incurred without rendering such Qualified ECP Guarantor’s obligations and undertakings under this Article X voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for
any greater amount). The obligations and undertakings of each Qualified ECP Guarantor under this Section shall remain in full force and effect until the Secured Obligations have been indefeasibly paid and performed in full. Each Loan Party intends
this Section to constitute, and this Section shall be deemed to constitute, a guarantee of the obligations of, and a “keepwell, support, or other agreement” for the benefit of, each Specified Loan Party for all purposes of the Commodity
Exchange Act. 
 ARTICLE XI 

MISCELLANEOUS 
  

	 11.01
	 Amendments, Etc. 

No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the
Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders (or by the Administrative Agent with the consent of the Required Lenders) and the Borrower or the applicable Loan Party, as the case may
be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or
consent shall: 
 (a) extend or increase the Commitment of any Lender (or reinstate any Commitment terminated
pursuant to Section 8.02) without the written consent of such Lender (it being understood and agreed that a waiver of any condition precedent in Section 4.02 or of any Default or a mandatory reduction in Commitments is not considered an
extension or increase in Commitments of any Lender); 
 (b) postpone any date fixed by this Agreement or any
other Loan Document for any payment (excluding mandatory prepayments) of principal, interest, fees or other amounts due to the Lenders (or any of them) hereunder or under such other Loan Document without the written consent of each Lender
entitled to such payment; 
 (c) reduce the principal of, or the rate of interest specified herein on, any
Loan or L/C Borrowing, or (subject to clause (iv) of the second proviso to this Section 11.01) any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender entitled to such amount;
provided, however, that only the consent of the Required Lenders shall be necessary (i) to amend the definition of “Default Rate” or to waive any obligation of the Borrower to pay interest or Letter of Credit Fees at the
Default Rate or (ii) to amend any financial covenant hereunder (or any defined term used therein) even if the effect of such amendment would be to reduce the rate of interest on any Loan or L/C Borrowing or to reduce any fee payable hereunder;

 (d) change Section 8.03 in a manner that would alter the pro rata sharing of payments required
thereby without the written consent of each Lender; 

  
 115 

 (e) change any provision of this Section 11.01 or the
definition of “Required Lenders” or any other provision of any Loan Document specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or thereunder or make any determination or grant
any consent hereunder, without the written consent of each Lender; 
 (f) release all or substantially all of
the Collateral in any transaction or series of related transactions, without the written consent of each Lender; or 

(g) release all or substantially all of the value of the Guaranty, without the written consent of each Lender,
except to the extent the release of any Subsidiary from the Guaranty is permitted pursuant to Section 9.10 (in which case such release may be made by the Administrative Agent acting alone); or 

(h) amend Section 1.09 or the definition of “Alternative Currency” without the written
consent of each Lender directly affected thereby; 
 and provided, further, that (i) no amendment, waiver or consent
shall, unless in writing and signed by the L/C Issuer in addition to the Lenders required above, affect the rights or duties of the L/C Issuer under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it;
(ii) no amendment, waiver or consent shall, unless in writing and signed by the Swingline Lender in addition to the Lenders required above, affect the rights or duties of the Swingline Lender under this Agreement; and (iii) no amendment,
waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document. Notwithstanding
anything to the contrary herein, (A) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or
each affected Lender, or all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (1) the Commitment of any Defaulting Lender may not be increased or extended
without the consent of such Lender and (2) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender, or all Lenders or each affected Lender that by its terms affects any Defaulting Lender
disproportionately adversely relative to other affected Lenders shall require the consent of such Defaulting Lender; (B) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and
each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code of the United States supersedes the unanimous consent provisions set forth herein and (C) the Required Lenders shall determine whether or not to allow a
Loan Party to use cash collateral in the context of a bankruptcy or insolvency proceeding and such determination shall be binding on all of the Lenders. 

Notwithstanding anything to the contrary herein the Administrative Agent may, with the prior written consent of the Borrower only, amend,
modify or supplement this Agreement or any of the other Loan Documents to cure any ambiguity, omission, mistake, defect or inconsistency. 

  
 116 

	 11.02
	 Notices; Effectiveness; Electronic Communications. 

(a) Notices Generally. Except in the case of notices and other communications expressly permitted to be
given by telephone (and except as provided in subsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered
mail or sent by fax transmission or e-mail transmission as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: 

(i) if to the Borrower or any other Loan Party, the Administrative Agent, the L/C Issuer or the Swingline
Lender, to the address, fax number, e-mail address or telephone number specified for such Person on Schedule 1.01(a); and 

(ii) if to any other Lender, to the address, fax number, e-mail address or telephone number specified in its
Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public information
relating to the Borrower). 
 Notices and other communications sent by hand or overnight courier service, or
mailed by certified or registered mail, shall be deemed to have been given when received; notices and other communications sent by fax transmission shall be deemed to have been given when sent (except that, if not given during normal business hours
for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices and other communications delivered through electronic communications to the extent provided in subsection
(b) below shall be effective as provided in such subsection (b). 
 (b) Electronic
Communications. Notices and other communications to the Administrative Agent, the Lenders, the Swingline Lender and the L/C Issuer hereunder may be delivered or furnished by electronic communication (including e-mail, FPML messaging and Internet
or intranet websites) pursuant to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices to any Lender, the Swingline Lender or the L/C Issuer pursuant to Article II if such Lender,
Swingline Lender or the L/C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent, the Swingline Lender, the L/C Issuer or the
Borrower may each, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices
or communications. 
 Unless the Administrative Agent otherwise prescribes, (i) notices and other
communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgment from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other
written acknowledgement) and (ii) notices and other communications posted to an Internet or intranet website shall be deemed received by the intended recipient upon the sender’s receipt of an acknowledgement from the intended recipient
(such as by the “return receipt requested” function, as available, return e-mail address or other written acknowledgement) indicating that such notice or communication is available and identifying the website address therefor;
provided that for both clauses (i) and (ii), if such notice or other communication is not sent during the normal business hours of the recipient, such notice, email or communication shall be deemed to have been sent at the opening of
business on the next Business Day for the recipient. 

  
 117 

 (c) The Platform. THE PLATFORM IS PROVIDED “AS
IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE
BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY
ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrower, any Lender,
the L/C Issuer or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Borrower’s, any Loan Party’s or the Administrative Agent’s transmission of
Borrower Materials or notices through the Platform, any other electronic platform or electronic messaging service, or through the Internet. 

(d) Change of Address, Etc. Each of the Borrower, the Administrative Agent, the L/C Issuer and the
Swingline Lender may change its address, fax number or telephone number or e-mail address for notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, fax number or telephone number
or e-mail address for notices and other communications hereunder by notice to the Borrower, the Administrative Agent, the L/C Issuer and the Swingline Lender. In addition, each Lender agrees to notify the Administrative Agent from time to time to
ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, fax number and e-mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such
Lender. Furthermore, each Public Lender agrees to cause at least one (1) individual at or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on the content declaration
screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public Lender’s compliance procedures and applicable Law, including United States federal and state securities Laws, to make reference to
Borrower Materials that are not made available through the “Public Side Information” portion of the Platform and that may contain material non-public information with respect to the Borrower or its securities for purposes of United States
federal or state securities laws. 
 (e) Reliance by Administrative Agent, L/C Issuer and Lenders. The
Administrative Agent, the L/C Issuer and the Lenders shall be entitled to rely and act upon any notices (including, without limitation, telephonic or electronic notices, Loan Notices, Letter of Credit Applications, Notice of Loan Prepayment and
Swingline Loan Notices) purportedly given by or on behalf of any Loan Party even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or
(ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Loan Parties shall indemnify the Administrative Agent, the L/C Issuer, each Lender and the Related Parties of each of them from all losses, costs,
expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of a Loan Party. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the
Administrative Agent, and each of the parties hereto hereby consents to such recording. 
  

	 11.03
	 No Waiver; Cumulative Remedies; Enforcement. 

No failure by any Lender, the L/C Issuer or the Administrative Agent to exercise, and no delay by any such Person in
exercising, any right, remedy, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or under any other Loan
Document preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not
exclusive of any rights, remedies, powers and privileges provided by law. 

  
 118 

 Notwithstanding anything to the contrary contained herein or in any other Loan
Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement
shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 8.02 for the benefit of all the Lenders and the L/C Issuer; provided, however, that the foregoing shall not prohibit
(a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) the L/C Issuer or the
Swingline Lender from exercising the rights and remedies that inure to its benefit (solely in its capacity as L/C Issuer or Swingline Lender, as the case may be) hereunder and under the other Loan Documents, (c) any Lender from exercising
setoff rights in accordance with Section 11.08 (subject to the terms of Section 2.13), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to
any Loan Party under any Debtor Relief Law; and provided, further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the
rights otherwise ascribed to the Administrative Agent pursuant to Section 8.02 and (ii) in addition to the matters set forth in clauses (b), (c) and (d) of the preceding proviso and subject to Section 2.13, any Lender may,
with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders. 
  

	 11.04
	 Expenses; Indemnity; Damage Waiver. 

(a) Costs and Expenses. The Loan Parties shall pay (i) all reasonable out-of-pocket expenses
incurred by the Administrative Agent and its Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein, the
preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or
thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the L/C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and
(iii) all out-of-pocket expenses incurred by the Administrative Agent, any Lender or the L/C Issuer (including the fees, charges and disbursements of any counsel for the Administrative Agent, any Lender or the L/C Issuer), in connection with
the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section, or (B) in connection with Loans made or Letters of Credit issued hereunder, including
all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit. 

  
 119 

 (b) Indemnification by the Loan Parties. The Loan Parties
shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and the L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each
Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), incurred by any Indemnitee or asserted against any Indemnitee by any
Person (including the Borrower or any other Loan Party) arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or
thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof)
and its Related Parties only, the administration of this Agreement and the other Loan Documents (including in respect of any matters addressed in Section 3.01), (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds
therefrom (including any refusal by the L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any
actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by a Loan Party or any of its Subsidiaries, or any Environmental Liability related in any way to a Loan Party or any of its Subsidiaries (except
to the extent such Environmental Liabilities (i) are incurred following foreclosure by the Administrative Agent or following the Administrative Agent or any Lender having become the successor-in-interest to any Loan Party or any of their
Subsidiaries and (ii) are attributable to acts of such Indemnitee), or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory,
whether brought by a third party or by the Borrower or any other Loan Party, and regardless of whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such
losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or
(y) result from a claim brought by the Borrower or any other Loan Party against an Indemnitee for breach in bad faith, if the Borrower or such other Loan Party has obtained a final and non-appealable judgment in favor of such claim by a court
of competent jurisdiction. Without limiting the provisions of Section 3.01(c), this Section 11.04(b) shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.

 (c) Reimbursement by Lenders. To the extent that the Loan Parties for any reason fail to
indefeasibly pay any amount required under subsection (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L/C Issuer, the Swingline Lender or any Related Party of any of the foregoing,
each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L/C Issuer, the Swingline Lender or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable
unreimbursed expense or indemnity payment is sought based on each Lender’s share of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to
be made severally among them based on such Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought), provided, further that, the unreimbursed expense or
indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent), the L/C Issuer or the Swingline Lender in its capacity as such, or against any
Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent), the L/C Issuer or the Swingline Lender in connection with such capacity. The obligations of the Lenders under this subsection (c) are subject to
the provisions of Section 2.12(d). 
 (d) Waiver of Consequential Damages, Etc. To the fullest
extent permitted by applicable Law, no Loan Party shall assert, and each Loan Party hereby waives, and acknowledges that no other Person shall have, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential
or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or
thereby, any Loan or Letter of Credit or the use of the proceeds thereof. No Indemnitee referred to in subsection (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials
distributed to such unintended recipients by such Indemnitee through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or
thereby. 

  
 120 

 (e) Payments. All amounts due under this Section shall be
payable not later than ten (10) Business Days after demand therefor. 
 (f) Survival. The
agreements in this Section and the indemnity provisions of Section 11.02(e) shall survive the resignation of the Administrative Agent, the L/C Issuer and the Swingline Lender, the replacement of any Lender, the termination of the Aggregate
Commitments and the repayment, satisfaction or discharge of all the other Obligations. 
 (g) One
Counsel. Notwithstanding anything contained in the Loan Documents to the contrary, fees and expenses of legal counsel due and owing under the Loan Documents shall be limited to reasonable fees, disbursements and other charges of one counsel and
if reasonably necessary or advisable, of a single local counsel in each appropriate jurisdiction and, in the case of an actual or perceived conflict of interest, one additional counsel for each affected party. 

 

	 11.05
	 Payments Set Aside. 

To the extent that any payment by or on behalf of the Borrower is made to the Administrative Agent, the L/C Issuer or any
Lender, or the Administrative Agent, the L/C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or
required (including pursuant to any settlement entered into by the Administrative Agent, the L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor
Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had
not occurred, and (b) each Lender and the L/C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest
thereon from the date of such demand to the date such payment is made at a rate per annum equal to the applicable Overnight Rate from time to time in effect. The obligations of the Lenders and the L/C Issuer under clause (b) of the preceding
sentence shall survive the payment in full of the Obligations and the termination of this Agreement. 
  

	 11.06
	 Successors and Assigns. 

(a) Successors and Assigns Generally. The provisions of this Agreement and the other Loan Documents
shall be binding upon and inure to the benefit of the parties hereto and thereto and their respective successors and assigns permitted hereby, except neither the Borrower nor any other Loan Party may assign or otherwise transfer any of its rights or
obligations hereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the
provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section, or (iii) by way of pledge or assignment of a security interest subject to the
restrictions of subsection (e) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other
than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the
Administrative Agent, the L/C Issuer and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. 

  
 121 

 (b) Assignments by Lenders. Any Lender may at any time
assign to one or more assignees all or a portion of its rights and obligations under this Agreement and the other Loan Documents (including all or a portion of its Commitment(s) and the Loans (including for purposes of this subsection (b),
participations in L/C Obligations and in Swingline Loans) at the time owing to it); provided that any such assignment shall be subject to the following conditions: 

(i) Minimum Amounts. 

(A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment
and/or the Loans at the time owing to it or contemporaneous assignments to related Approved Funds (determined after giving effect to such Assignments) that equal at least the amount specified in paragraph (b)(i)(B) of this Section in the aggregate
or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and 

(B) in any case not described in subsection (b)(i)(A) of this Section, the aggregate amount of the Commitment
(which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment, determined as of the date the
Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $5,000,000, unless each of
the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed). 

(ii) Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate
part of all the assigning Lender’s rights and obligations under this Agreement and the other Loan Documents with respect to the Loans and/or the Commitment assigned, except that this clause (ii) shall not apply to the Swingline
Lender’s rights and obligations in respect of Swingline Loans. 
 (iii) Required Consents. No
consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition: 

(A) the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required
unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that the Borrower shall be deemed to have
consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received notice thereof; 

(B) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be
required for assignments if such assignment is to a Person that is not a Lender with a Commitment, an Affiliate of such Lender or an Approved Fund with respect to such Lender; and 

  
 122 

 (C) the consent of the L/C Issuer and the Swingline Lender shall
be required for any assignment. 
 (iv) Assignment and Assumption. The parties to each assignment
shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500; provided, however, that the Administrative Agent may, in its sole discretion,
elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. 

(v) No Assignment to Certain Persons. No such assignment shall be made (A) to the Borrower or any
of the Borrower’s Affiliates or Subsidiaries, (B) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (B), or
(C) to a natural Person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of a natural person). 

(vi) Certain Additional Payments. In connection with any assignment of rights and obligations of any
Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an
aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the
Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (A) pay and
satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent, the L/C Issuer or any Lender hereunder (and interest accrued thereon) and (B) acquire (and fund as appropriate) its full pro rata share of
all Loans and participations in Letters of Credit and Swingline Loans in accordance with its Applicable Percentage. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall
become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs. 

Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the
effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under
this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all
of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05 and 11.04 with respect to facts and circumstances
occurring prior to the effective date of such assignment); provided, that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any
party hereunder arising from that Lender’s having been a Defaulting Lender. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender. Any assignment or transfer by a Lender of rights or obligations
under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section. 

  
 123 

 (c) Register. The Administrative Agent, acting solely for
this purpose as an agent of the Borrower (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic
form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to
time (the “Register”). The entries in the Register shall be conclusive, absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the
terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. 

(d) Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower or
the Administrative Agent, sell participations to any Person (other than a natural Person, or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of a natural Person, a Defaulting Lender or the Borrower
or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the
Loans (including such Lender’s participations in L/C Obligations and/or Swingline Loans) owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain
solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent, the Lenders and the L/C Issuer shall continue to deal solely and directly with such Lender in connection
with such Lender’s rights and obligations under this Agreement. For the avoidance of doubt, each Lender shall be responsible for the indemnity under Section 11.04(c) without regard to the existence of any participations. 

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such
Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without
the consent of the Participant, agree to any amendment, waiver or other modification described in the first proviso to Section 11.01 that affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of
Sections 3.01, 3.04 and 3.05 (subject to the requirements and limitations therein, including the requirements under Section 3.01(e) (it being understood that the documentation required under Section 3.01(e) shall be delivered to the Lender
who sells the participation)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions
of Sections 3.06 and 11.13 as if it were an assignee under paragraph (b) of this Section and (B) shall not be entitled to receive any greater payment under Sections 3.01 or 3.04, with respect to any participation, than the Lender from whom
it acquired the applicable participation would have been entitled to receive. Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the
provisions of Section 3.06 with respect to any Participant. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 11.08 as though it were a Lender; provided that such Participant agrees
to be subject to Section 2.13 as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each
Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any
obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under
any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury
Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this
Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. 

  
 124 

 (e) Certain Pledges. Any Lender may at any time pledge or
assign a security interest in all or any portion of its rights under this Agreement (including under its Note or Notes, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank;
provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 

(f) Resignation as L/C Issuer or Swingline Lender after Assignment. Notwithstanding anything to the
contrary contained herein, if at any time Bank of America assigns all of its Commitment and Revolving Loans pursuant to subsection (b) above, Bank of America may, (i) upon thirty (30) days’ notice to the Borrower and the Lenders,
resign as L/C Issuer and/or (ii) upon thirty (30) days’ notice to the Borrower, resign as Swingline Lender. In the event of any such resignation as L/C Issuer or Swingline Lender, the Borrower shall be entitled to appoint from among
the Lenders a successor L/C Issuer or Swingline Lender hereunder; provided, however, that no failure by the Borrower to appoint any such successor shall affect the resignation of Bank of America as L/C Issuer or Swingline Lender, as
the case may be. If Bank of America resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L/C
Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.03(c)). If Bank of America resigns as Swingline
Lender, it shall retain all the rights of the Swingline Lender provided for hereunder with respect to Swingline Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Base
Rate Loans or fund risk participations in outstanding Swingline Loans pursuant to Section 2.04(c). Upon the appointment of a successor L/C Issuer and/or Swingline Lender, (A) such successor shall succeed to and become vested with all of
the rights, powers, privileges and duties of the retiring L/C Issuer or Swingline Lender, as the case may be, and (B) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the
time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit. 

  
 125 

	 11.07
	 Treatment of Certain Information; Confidentiality. 

(a) Treatment of Certain Information. Each of the Administrative Agent, the Lenders and the L/C Issuer
agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its Affiliates and to its Related Parties (it being understood that the Persons to whom such disclosure is made will
be informed of the confidential nature of such Information and instructed to keep such Information confidential), (ii) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person or its
Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (iii) to the extent required by applicable Laws or regulations or by any subpoena or similar legal process, (iv) to any
other party hereto, (v) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or
thereunder, (vi) subject to an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations
under this Agreement or any Eligible Assignee invited to be a Lender pursuant to Section 2.16(c) or (B) any actual or prospective party (or its Related Parties) to any swap, derivative or other transaction under which payments are
to be made by reference to the Borrower and its obligations, this Agreement or payments hereunder, (vii) on a confidential basis to (A) any rating agency in connection with rating the Borrower or its Subsidiaries or the credit facilities
provided hereunder or (B) the provider of any Platform or other electronic delivery service used by the Administrative Agent, the L/C Issuer and/or the Swingline Lender to deliver Borrower Materials or notices to the Lenders or (C) the
CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, or (viii) with the consent of the Borrower or to
the extent such Information (1) becomes publicly available other than as a result of a breach of this Section or (2) becomes available to the Administrative Agent, any Lender, the L/C Issuer or any of their respective Affiliates on a
nonconfidential basis from a source other than the Borrower. For purposes of this Section, “Information” means all information received from the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their
respective businesses, other than any such information that is available to the Administrative Agent, any Lender or the L/C Issuer on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary, provided that, in the case of
information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this
Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. In
addition, the Administrative Agent and the Lenders may disclose the existence of this Agreement and information about this Agreement to market data collectors, similar service providers to the lending industry and service providers to the Agents and
the Lenders in connection with the administration of this Agreement, the other Loan Documents and the Commitments. 

(b) Non-Public Information. Each of the Administrative Agent, the Lenders and the L/C Issuer
acknowledges that (i) the Information may include material non-public information concerning a Loan Party or a Subsidiary, as the case may be, (ii) it has developed compliance procedures regarding the use of material non-public information
and (iii) it will handle such material non-public information in accordance with applicable Law, including United States federal and state securities Laws. 

  
 126 

 (c) Press Releases. The Loan Parties and their Affiliates
agree that they will not in the future issue any press releases or other public disclosure (other than any document filed with any Governmental Authority relating to a public offering of any securities of any Loan Party or reports filed by any Loan
Party in accordance with the Securities Exchange Act of 1934) using the name of the Administrative Agent or its Affiliates or referring to this Agreement or any of the Loan Documents without the prior written consent of the Administrative Agent,
except to the extent the Loan Parties or such Affiliate is required to do so under applicable Law and then, to the extent not prohibited by applicable law, only after consulting with the Administrative Agent. 

(d) Customary Advertising Material. The Loan Parties consent to the publication by the Administrative
Agent or any Lender of customary advertising material relating to the transactions contemplated hereby using the name, product photographs, logo or trademark of the Loan Parties. 

 

	 11.08
	 Right of Setoff. 

If an Event of Default shall have occurred and be continuing, each Lender, the L/C Issuer and each of their respective
Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any
time held and other obligations (in whatever currency) at any time owing by such Lender, the L/C Issuer or any such Affiliate to or for the credit or the account of the Borrower or any other Loan Party against any and all of the obligations of the
Borrower or such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender or the L/C Issuer or their respective Affiliates, irrespective of whether or not such Lender, the L/C Issuer or Affiliate shall have
made any demand under this Agreement or any other Loan Document and although such obligations of the Borrower or such Loan Party may be contingent or unmatured, secured or unsecured, or are owed to a branch, office or Affiliate of such Lender or the
L/C Issuer different from the branch, office or Affiliate holding such deposit or obligated on such indebtedness; provided that in the event that any Defaulting Lender shall exercise any such right of setoff, (a) all amounts so set off
shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.15 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held
in trust for the benefit of the Administrative Agent, the L/C Issuer and the Lenders, and (b) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Secured Obligations owing to
such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender, the L/C Issuer and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that
such Lender, the L/C Issuer or their respective Affiliates may have. Each Lender and the L/C Issuer agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application, provided that the failure to give such
notice shall not affect the validity of such setoff and application. 
  

	 11.09
	 Interest Rate Limitation. 

Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan
Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the
excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender
exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects
thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder. 

  
 127 

	 11.10
	 Counterparts; Integration; Effectiveness. 

This Agreement and each of the other Loan Documents may be executed in counterparts (and by different parties hereto in
different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, the other Loan Documents, and any separate letter agreements with respect to fees payable
to the Administrative Agent or the L/C Issuer, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter
hereof. Except as provided in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together,
bear the signatures of each of the other parties hereto. Delivery of an executed counterpart of a signature page of this Agreement or any other Loan Document, or any certificate delivered thereunder, by fax transmission or e-mail transmission (e.g.
“pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement or such other Loan Document or certificate. Without limiting the foregoing, to the extent a manually executed counterpart is not
specifically required to be delivered under the terms of any Loan Document, upon the request of any party, such fax transmission or e-mail transmission shall be promptly followed by such manually executed counterpart. 

 

	 11.11
	 Survival of Representations and Warranties. 

All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or
thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any
investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue
in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding. 
  

	 11.12
	 Severability. 

If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the
legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal,
invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction. Without limiting the foregoing provisions of this Section, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders
shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, the L/C Issuer or the Swingline Lender, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited. 

  
 128 

	 11.13
	 Replacement of Lenders. 

If the Borrower is entitled to replace a Lender pursuant to the provisions of Section 3.06, or if any Lender is a
Defaulting Lender or a Non-Consenting Lender or if any other circumstance exists hereunder that gives the Borrower the right to replace a Lender as a party hereto, then the Borrower may, at its sole expense and effort, upon notice to such Lender and
the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 11.06), all of its interests, rights (other than its
existing rights to payments pursuant to Sections 3.01 and 3.04) and obligations under this Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender
accepts such assignment), provided that: 
 (a) the Borrower shall have paid to the Administrative
Agent the assignment fee (if any) specified in Section 11.06(b); 
 (b) such Lender shall have received
payment of an amount equal to 100% of the outstanding principal of its Loans and L/C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under
Section 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); 

(c) in the case of any such assignment resulting from a claim for compensation under Section 3.04 or
payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter; 

(d) such assignment does not conflict with applicable Laws; and 

(e) in the case of an assignment resulting from a Lender becoming a Non-Consenting Lender, the applicable
assignee shall have consented to the applicable amendment, waiver or consent. 
 A Lender shall not be required to make any
such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. 

 

	 11.14
	 Governing Law; Jurisdiction; Etc. 

(a) GOVERNING LAW. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (EXCEPT, AS TO ANY OTHER LOAN DOCUMENT,
AS EXPRESSLY SET FORTH THEREIN) AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT (EXCEPT, AS TO ANY OTHER LOAN
DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

  
 129 

 (b) SUBMISSION TO JURISDICTION. THE BORROWER AND EACH
OTHER LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT IT WILL NOT COMMENCE ANY ACTION, LITIGATION OR PROCEEDING OF ANY KIND OR DESCRIPTION, WHETHER IN LAW OR EQUITY, WHETHER IN CONTRACT OR IN TORT OR OTHERWISE, AGAINST THE ADMINISTRATIVE
AGENT, ANY LENDER, THE L/C ISSUER, OR ANY RELATED PARTY OF THE FOREGOING IN ANY WAY RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS RELATING HERETO OR THERETO, IN ANY FORUM OTHER THAN THE COURTS OF THE STATE OF NEW YORK
SITTING IN NEW YORK COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE JURISDICTION OF SUCH
COURTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION, LITIGATION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES
HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION, LITIGATION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER
LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER OR THE L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE BORROWER OR ANY OTHER LOAN PARTY
OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. 
 (c) WAIVER OF VENUE. THE BORROWER AND EACH
OTHER LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE
MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. 
 (d) SERVICE OF PROCESS. EACH PARTY
HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 11.02. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW. 

 

	 11.15
	 Waiver of Jury Trial. 

EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A
TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY
HERETO (a) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND
(b) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

  
 130 

	 11.16
	 Subordination. 

Each Loan Party (a “Subordinating Loan Party”) hereby subordinates the payment of all obligations and
indebtedness of any other Loan Party owing to it, whether now existing or hereafter arising, including but not limited to any obligation of any such other Loan Party to the Subordinating Loan Party as subrogee of the Secured Parties or resulting
from such Subordinating Loan Party’s performance under this Guaranty, to the indefeasible payment in full in cash of all Obligations. If the Secured Parties so request, any such obligation or indebtedness of any such other Loan Party to the
Subordinating Loan Party shall be enforced and performance received by the Subordinating Loan Party as trustee for the Secured Parties and the proceeds thereof shall be paid over to the Secured Parties on account of the Secured Obligations, but
without reducing or affecting in any manner the liability of the Subordinating Loan Party under this Agreement. Without limitation of the foregoing, so long as no Default has occurred and is continuing, the Loan Parties may make and receive payments
with respect to Intercompany Debt; provided, that in the event that any Loan Party receives any payment of any Intercompany Debt at a time when such payment is prohibited by this Section, such payment shall be held by such Loan Party, in
trust for the benefit of, and shall be paid forthwith over and delivered, upon written request, to the Administrative Agent. 
  

	 11.17
	 No Advisory or Fiduciary Responsibility. 

In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or
other modification hereof or of any other Loan Document), the Borrower and each other Loan Party acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (a) (i) the arranging and other services regarding this
Agreement provided by the Administrative Agent and any Affiliate thereof, the Arranger and the Lenders are arm’s-length commercial transactions between the Borrower, each other Loan Party and their respective Affiliates, on the one hand, and
the Administrative Agent and, as applicable, its Affiliates (including the Arranger) and the Lenders and their Affiliates (collectively, solely for purposes of this Section, the “Lenders”), on the other hand, (ii) each of the
Borrower and the other Loan Parties has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (iii) the Borrower and each other Loan Party is capable of evaluating, and understands and
accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (b) (i) the Administrative Agent and its Affiliates (including the Arranger) and each Lender each is and has been acting
solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary, for Borrower, any other Loan Party or any of their respective Affiliates, or
any other Person and (ii) neither the Administrative Agent, any of its Affiliates (including the Arranger) nor any Lender has any obligation to the Borrower, any other Loan Party or any of their respective Affiliates with respect to the
transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (c) the Administrative Agent and its Affiliates (including the Arranger) and the Lenders may be engaged in a broad range
of transactions that involve interests that differ from those of the Borrower, the other Loan Parties and their respective Affiliates, and neither the Administrative Agent, any of its Affiliates (including the Arranger) nor any Lender has any
obligation to disclose any of such interests to the Borrower, any other Loan Party or any of their respective Affiliates. To the fullest extent permitted by law, each of the Borrower and each other Loan Party hereby waives and releases any claims
that it may have against the Administrative Agent, any of its Affiliates (including the Arranger) or any Lender with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transactions contemplated
hereby. 

  
 131 

	 11.18
	 Electronic Execution.  

(a) The words “delivery,” “execute,” “execution,” “signed,”
“signature,” and words of like import in any Loan Document or any other document executed in connection herewith shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on
electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the
use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and
Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept
electronic signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it; provided further without limiting the foregoing, upon the request of the Administrative Agent,
any electronic signature shall be promptly followed by such manually executed counterpart. 
  

	 11.19
	 USA PATRIOT Act Notice.  

Each Lender that is subject to the Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of
any Lender) hereby notifies the Borrower and the other Loan Parties that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it is required to
obtain, verify and record information that identifies each Loan Party, which information includes the name and address of each Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify each
Loan Party in accordance with the Act. The Borrower and the Loan Parties agree to, promptly following a request by the Administrative Agent or any Lender, provide all such other documentation and information that the Administrative Agent or such
Lender requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Act. 

 

	 11.20
	 Judgment Currency.  

If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder or any other Loan
Document in one currency into another currency, the rate of exchange used shall be that at which in accordance with normal banking procedures the Administrative Agent could purchase the first currency with such other currency on the Business Day
preceding that on which final judgment is given. The obligation of each Loan Party in respect of any such sum due from it to the Administrative Agent or any Lender hereunder or under the other Loan Documents shall, notwithstanding any judgment in a
currency (the “Judgment Currency”) other than that in which such sum is denominated in accordance with the applicable provisions of this Agreement (the “Agreement Currency”), be discharged only to the extent that on
the Business Day following receipt by the Administrative Agent or such Lender, as the case may be, of any sum adjudged to be so due in the Judgment Currency, the Administrative Agent or such Lender, as the case may be, may in accordance with normal
banking procedures purchase the Agreement Currency with the Judgment Currency. If the amount of the Agreement Currency so purchased is less than the sum originally due to the Administrative Agent or any Lender from any Loan Party in the Agreement
Currency, such Loan Party agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent or such Lender, as the case may be, against such loss. If the amount of the Agreement Currency so purchased is
greater than the sum originally due to the Administrative Agent or any Lender in such currency, the Administrative Agent or such Lender, as the case may be, agrees to return the amount of any excess to such Loan Party (or to any other Person who may
be entitled thereto under applicable law). 

  
 132 

	 11.21
	 Acknowledgement and Consent to Bail-In of EEA Financial Institutions.  

Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any
such parties, each party hereto acknowledges that any liability of any Lender that is an EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of
an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by: 
 (a)
the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender that is an EEA Financial Institution; and 

(b) the effects of any Bail-in Action on any such liability, including, if applicable: 

(i) a reduction in full or in part or cancellation of any such liability; 

(ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such
EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any
such liability under this Agreement or any other Loan Document; or 
 (iii) the variation of the terms of
such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority. 
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK.] 

  
 133 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed as of the date first above written. 
  

							
	 BORROWER:
	 		 	 NUVASIVE, INC

				
		 		 	 By:
	 	 /s/ Jereme Sylvain

		 		 	 Name:
	 	 Jereme Sylvain

		 		 	 Title:
	 	 Authorized Signatory

			
	 GUARANTORS:
	 		 	 IMPULSE MONITORING, INC.

				
		 		 	 By:
	 	 /s/ Jereme Sylvain

		 		 	 Name:
	 	 Jereme Sylvain

		 		 	 Title:
	 	 Authorized Signatory

 CREDIT AGREEMENT (NuVasive) 

Signature Page 

							
	 ADMINISTRATIVE AGENT:
	 		 	 BANK OF AMERICA, N.A.,

		 		 	 as Administrative Agent

				
		 		 	 By:
	 	 /s/ Tiffany Shin

		 		 	 Name:
	 	 Tiffany Shin

		 		 	 Title:
	 	 Assistant Vice President

			
	 LENDER(S):
	 		 	 BANK OF AMERICA, N.A.,

		 		 	 as a Lender, L/C Issuer and Swingline Lender

				
		 		 	 By:
	 	 /s/ John C. Plecque

		 		 	 Name:
	 	 John C. Plecque

		 		 	 Title:
	 	 Senior Vice President

 CREDIT AGREEMENT (NuVasive) 

Signature Page 

 EXHIBIT A 

[Form of] 

Administrative Questionnaire 

See attached. 

 ADMINISTRATIVE QUESTIONNAIRE 

 

									
	 Agent Address:
	 	  
	 		 	 Return form to:
	 	  

					
		 	  
	 		 	 Telephone:
	 	  

					
		 	  
	 		 	 Facsimile:
	 	  

					
		 	  
	 		 	 E-mail:
	 	  

  

It is very important that all of the requested information be completed
accurately and that this questionnaire be returned promptly. If your institution is sub-allocating its allocation, please fill out an administrative questionnaire for each legal entity. 

Legal Name of Lender to appear in Documentation: 
  

			
	  

		
	 Signature Block Information:
	 	  

  

			
	•	    	 Signing Credit Agreement      ̈  Yes     ̈  No

		
	•	    	 Coming in via Assignment     ̈  Yes     ̈  No

  

			
	 Type of Lender:
	 	  

	
	 (Bank, Asset Manager, Broker/Dealer, CLO/CDO, Finance Company, Hedge Fund, Insurance, Mutual Fund, Pension Fund, Other Regulated Investment Fund,
Special Purpose Vehicle, Other-please specify)

		
	 Lender Parent:
	 	  

  

					
	 Domestic Address
	 	 	 	 Eurodollar Address

			
	  
	 		 	  

			
	  
	 		 	  

			
	  
	 		 	  

 Contacts/Notification Methods: Borrowings, Paydowns, Interest, Fees, etc. 

 

							
	 	 	 Primary Credit Contact
	  	 	 	 Secondary Credit Contact

	
	 Syndicate-level information (which may contain material non-public information about the Borrower and its related parties or their respective
securities) will be made available to the Credit Contact(s). The Credit Contacts identified must be able to receive such information in accordance with his/her institution’s compliance procedures and applicable laws, including Federal and state
securities laws.

				
	 Name:
	 	  
	  		 	  

				
	 Company:
	 	  
	  		 	  

				
	 Title:
	 	  
	  		 	  

				
	 Address:
	 	  
	  		 	  

				
		 	  
	  		 	  

				
	 Telephone:
	 	  
	  		 	  

				
	 Facsimile:
	 	  
	  		 	  

				
	 E-Email Address:
	 	  
	  		 	  

				
	 	 	 Primary Operations Contact
	  	 	 	 Secondary Operations Contact

				
	 Name:
	 	  
	  		 	  

				
	 Company:
	 	  
	  		 	  

				
	 Title:
	 	  
	  		 	  

				
	 Address:
	 	  
	  		 	  

				
		 	  
	  		 	  

				
	 Telephone:
	 	  
	  		 	  

				
	 Facsimile:
	 	  
	  		 	  

				
	 E-Email Address:
	 	  
	  		 	  

				
	 	 	 Wire Instruction Callback

Confirmer(s)
	  	 	 	 LC Contact

				
	 Name:
	 		  		 	
				
	 Company:
	 		  		 	
				
	 Title:
	 		  		 	
				
	 Address:
	 		  		 	

  

					
	 Telephone:
	 		 	
			
	 Facsimile:
	 		 	
			
	 E-Email Address:
	 		 	

 Lender’s Domestic Wire Instructions 

 

					
	 Bank Name:
	 	  
	  	
			
	 ABA/Routing No.:
	 	  
	  	
			
	 Account Name:
	 	  
	  	
			
	 Account No.:
	 	  
	  	
			
	 FFC Account Name:
	 	  
	  	
			
	 FFC Account No.:
	 	  
	  	
			
	 Attention:
	 	  
	  	
			
	 Reference:
	 	  
	  	

 Lender’s Foreign Wire Instructions 

 

					
	 Currency:
	 		  	
			
	 Bank Name:
	 	  
	  	
			
	 Swift/Routing No.:
	 	  
	  	
			
	 Account Name:
	 	  
	  	
			
	 Account No.:
	 	  
	  	
			
	 FFC Account Name:
	 	  
	  	
			
	 FFC Account No.:
	 	  
	  	
			
	 Attention:
	 	  
	  	
			
	 Reference:
	 	  
	  	

 Agents Wire Instructions 

 

					
	 Bank Name:
	 	  
	 	
			
	 ABA/Routing No.:
	 	  
	 	
			
	 Account Name:
	 	  
	 	
			
	 Account No.:
	 	  
	 	
			
	 FFC Account Name:
	 	  
	 	
			
	 FFC Account No.:
	 	  
	 	
			
	 Attention:
	 	  
	 	
			
	 Reference:
	 	  
	 	

 Tax Documents 

NON-U.S. LENDER INSTITUTIONS: 

I. Corporations: 

If your institution is incorporated outside of the United States for U.S. federal income tax purposes, and is the beneficial owner of
the interest and other income it receives, you must complete one of the following three tax forms, as applicable to your institution: a.) Form W-8BEN (Certificate of Foreign Status of Beneficial Owner), b.) Form
W-8ECI (Income Effectively Connected to a U.S. Trade or Business), or c.) Form W-8EXP (Certificate of Foreign Government or Governmental Agency). 

A U.S. taxpayer identification number is required for any institution submitting Form W-8ECI. It is also required on Form W-8BEN for certain
institutions claiming the benefits of a tax treaty with the U.S. Please refer to the instructions when completing the form applicable to your institution. In addition, please be advised that U.S. tax regulations do not permit the acceptance of faxed
forms. An original tax form must be submitted.  
 II. Flow-Through Entities: 

If your institution is organized outside the U.S., and is classified for U.S. federal income tax purposes as either a Partnership, Trust,
Qualified or Non-Qualified Intermediary, or other non-U.S. flow-through entity, an original Form W-8IMY (Certificate of Foreign Intermediary, Foreign Flow-Through Entity, or Certain U.S. Branches for United States Tax
Withholding) must be completed by the intermediary together with a withholding statement. Flow-through entities other than Qualified Intermediaries are required to include tax forms for each of the underlying beneficial owners. 

Please refer to the instructions when completing this form. In addition, please be advised that U.S. tax regulations do not permit the
acceptance of faxed forms. Original tax form(s) must be submitted.  
 U.S. LENDER INSTITUTIONS: 

If your institution is incorporated or organized within the United States, you must complete and return Form
W-9 (Request for Taxpayer Identification Number and Certification). Please be advised that we request that you submit an original Form W-9. 

Pursuant to the language contained in the tax section of the Credit Agreement, the applicable tax form for your institution must be
completed and returned prior to the first payment of income. Failure to provide the proper tax form when requested may subject your institution to U.S. tax withholding. 

 EXHIBIT B 

[Form of] 
 Assignment
and Assumption 
 This Assignment and Assumption (this “Assignment and Assumption”) is dated as of the
Effective Date set forth below and is entered into by and between [the][each]1 Assignor identified in item 1 below ([the][each, an] “Assignor”) and [the][each]2 Assignee identified in item 2 below ([the][each, an] “Assignee”). [It is understood and agreed that the rights and obligations of [the Assignors][the Assignees]3 hereunder are several and not joint.]4 Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement
identified below (as amended, restated, supplemented, or otherwise modified from time to time, the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and Conditions (the
“Standard Terms and Conditions”) set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full. 

For an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective
Assignees], and [the][each] Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date
inserted by the Administrative Agent as contemplated below (a) all of [the Assignor’s][the respective Assignors’] rights and obligations in [its capacity as a Lender][their respective capacities as Lenders] under the Credit Agreement
and any other Loan Documents in the amount[s] and equal to the percentage interest[s] identified below of all the outstanding rights and obligations under the respective facilities identified below (including, without limitation, the [Letters of
Credit and the Swingline Loans] included in such facilities5) and (b) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of
[the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other Loan Documents or
the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to
the rights and obligations sold and assigned pursuant to clause (a) above (the rights and obligations sold and assigned by [the][any] Assignor to [the][any] Assignee pursuant to clauses (a) and (b) above being referred to herein
collectively as [the][an] “Assigned Interest”). Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by
[the][any] Assignor. 
  
  

	 1 
	 For bracketed language here and elsewhere in this form relating to the Assignor(s), if the assignment is from a single Assignor, choose the first
bracketed language. If the assignment is from multiple Assignors, choose the second bracketed language. 

	 2 
	 For bracketed language here and elsewhere in this form relating to the Assignee(s), if the assignment is to a single Assignee, choose the first
bracketed language. If the assignment is to multiple Assignees, choose the second bracketed language. 

	 3 
	 Select as appropriate. 

	 4 
	 Include bracketed language if there are either multiple Assignors or multiple Assignees. 

	 5 
	 Include all applicable subfacilities. 

													
	 1.
	  	 Assignor[s]:
	  	  
	  		  	
		  		  	  
	  		  	
					
	 2.
	  	 Assignee[s]:
	  	  
	  		  	
		  		  	  
	  		  	
			
		  		  	 [for each Assignee, indicate if an [Affiliate][Approved Fund]

of [identify Lender] [or if an existing Lender][6]

				
	 3.
	  	 Borrower:
	  	 NuVasive, Inc., a Delaware corporation
	  	
		
	 4.
	  	 Administrative Agent: Bank of America, N.A., as the administrative agent under the Credit Agreement

		
	 5.
	  	 Credit Agreement: Credit Agreement, dated as of February 8, 2016 among the Borrower, the Guarantors from time to time party thereto,
the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer, and Swingline Lender

				
	 6.
	  	 Assigned Interest:
	  		  	

  

																			
	 	  	 Assignor[s]7
	  	
Assignee[s]8
	  	Aggregate
Amount of
Commitment/
Loans for all
Lenders9	 	  	Amount of
Commitment/
Loans Assigned	 	  	Percentage
Assigned of
Commitment/
Loans10	 	 	CUSIP
Number
	  		  		  	$	            	  	  	$	            	  	  	 	    	% 	 	
	  		  		  	$	            	  	  	$	            	  	  	 	    	% 	 	
	  		  		  	$	            	  	  	$	            	  	  	 	    	% 	 	
		
	 [7.
	  	 Trade Date:                     ]11

 Effective Date:
                    , 20     [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF
RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.] 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 
  

	 6 
	 If Applicable. 

	 7 
	 List each Assignor, as appropriate. 

	 8 
	 List each Assignee, as appropriate. 

	 9 
	 Amounts in this column and in the column immediately to the right to be adjusted by the counterparties to take into account any payments or
prepayments made between the Trade Date and the Effective Date. 

	 10 
	 Set forth, to at least 9 decimals, as a percentage of the Commitment/Loans of all Lenders thereunder. 

	 11 
	 To be completed if the Assignor and the Assignee intend that the minimum assignment amount is to be determined as of the Trade Date.

 The terms set forth in this Assignment and Assumption are hereby agreed to: 

 

			
	 ASSIGNOR:

	
	 [NAME OF ASSIGNOR]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 ASSIGNEE:

	
	 [NAME OF ASSIGNEE]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  

			
	 Consented to and Accepted:

	
	 BANK OF AMERICA, N.A., as
Administrative Agent

		 	
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 [Consented to:][12]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  
  

	 12 
	 To be added only if the consent of the Borrower and/or other parties (e.g. Swingline Lender, L/C Issuer) is required by the terms of the Credit
Agreement. 

 ANNEX 1 TO ASSIGNMENT AND ASSUMPTION 

Standard Terms and Conditions for Assignment and Assumption 

1. Representations and Warranties. 

1.1. Assignor. [The][Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner
of [the][the relevant] Assigned Interest, (ii) [the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and
deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit
Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its
Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any other Person of any of their respective obligations
under any Loan Document. 
 1.2. Assignee. [The][Each] Assignee (a) represents and warrants that (i) it has
full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the
requirements to be an assignee under the terms of the Credit Agreement (subject to such consents, if any, as may be required under the terms of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions
of the Credit Agreement and the other Loan Documents as a Lender thereunder and, to the extent of [the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to
acquire assets of the type represented by [the][such] Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire [the][such] Assigned Interest, is experienced in acquiring assets of such type, (v) it
has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to the terms of the Credit Agreement, and such other documents and
information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, (vi) it has, independently and without reliance upon the Administrative
Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, and
(vii) if it is a Foreign Lender, attached hereto is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by [the][such] Assignee; and (b) agrees that (i) it will,
independently and without reliance upon the Administrative Agent, [the][any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or
not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender. 

2. Payments. From and after the Effective Date, the Administrative Agent shall make all payments in respect of
[the][each] Assigned Interest (including payments of principal, interest, fees and other amounts) to [the][the relevant] Assignor for amounts which have accrued to but excluding the Effective Date and to [the][the relevant] Assignee for amounts
which have accrued from and after the Effective Date. 

 3. General Provisions. This Assignment and Assumption shall be binding
upon, and inure to the benefit of, the parties hereto and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of an executed
counterpart of a signature page of this Assignment and Assumption by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this
Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York. 

 EXHIBIT C 

[Form of] 
 Compliance
Certificate 
 Financial Statement Date: [            ,
        ] 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 The undersigned
Responsible Officer13 hereby certifies as of the date hereof that [he/she] is the [Chief Executive Officer] [Chief Financial Officer] [treasurer] of the Borrower, and that, as such, [he/she] is
authorized to execute and deliver this Compliance Certificate to the Administrative Agent on the behalf of the Borrower and the other Loan Parties, and that: 

[Use following paragraph 1 for fiscal year-end financial statements] 

1. The Borrower has delivered the year-end audited financial statements required by Section 6.01(a) of the Credit
Agreement for the fiscal year of the Borrower ended as of the above financial statement date, together with the report and opinion of an independent certified public accountant required by such section. 

[Use following paragraph 1 for fiscal quarter-end financial statements] 

1. The Borrower has delivered the unaudited financial statements required by Section 6.01(b) of the Credit Agreement for
the fiscal quarter of the Borrower ended as of the above financial statement date. Such financial statements fairly present the financial condition, results of operations, shareholders’ equity and cash flows of the Borrower and its Subsidiaries
in accordance with GAAP as at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes. 

2. The undersigned has reviewed and is familiar with the terms of the Credit Agreement and has made, or has caused to be made
under [his/her] supervision, a detailed review of the transactions and condition (financial or otherwise) of the Borrower and its Subsidiaries during the accounting period covered by such financial statements. 

3. A review of the activities of the Borrower and its Subsidiaries during such fiscal period has been made under the
supervision of the undersigned with a view to determining whether during such fiscal period the Borrower and each of the other Loan Parties performed and observed all its obligations under the Loan Documents, and 

 
  

	 13 
	 This certificate should be from the chief executive officer, chief financial officer or treasurer of the Borrower. 

 [select one:] 

[to the best knowledge of the undersigned, during such fiscal period each of the Loan Parties performed and observed each
covenant and condition of the Loan Documents applicable to it, and no Default has occurred and is continuing.] 
 —or— 

[to the best knowledge of the undersigned, the following covenants or conditions have not been performed or observed and the
following is a list of each such Default and its nature and status:] 
 4. The representations and warranties of the
Borrower and each other Loan Party contained in Article V of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith are (i) with respect to representations
and warranties that contain a materiality qualification, true and correct on and as of the date hereof and (ii) with respect to representations and warranties that do not contain a materiality qualification, true and correct in all material
respects on and as of the date hereof, and except that for purposes of this Compliance Certificate, the representations and warranties contained in subsections (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to
refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement, including the statements in connection with which this Compliance Certificate is delivered. 

5. The financial covenant analyses and information set forth on Schedule A attached hereto are true and accurate on and
as of the date of this Compliance Certificate. 
 Delivery of an executed counterpart of a signature page of this Compliance
Certificate by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Compliance Certificate. 

 

			
	 NUVASIVE, INC.,

	 a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 Schedule A[14] 

Financial Statement Date: [            ,
        ] (“Statement Date”) 
  

									
	 I.          Section 7.11(a) –
Consolidated Interest Coverage Ratio

			
		 	 A.
	  	 Consolidated EBITDA for the Measurement Period ending on the Statement Date (“Subject Period”):

					
		 		  	 i.
	    	 Consolidated Net Income for Subject Period:
	    	 $            

					
		 		  	 ii.
	    	 Consolidated Interest Charges for Subject Period:
	    	 $            

					
		 		  	 iii.
	    	 Federal, state, local and foreign income taxes payable for Subject Period:
	    	 $            

					
		 		  	 iv.
	    	 depreciation and amortization expense for Subject Period:
	    	 $            

					
		 		  	 v.
	    	 all losses (less gains) in respect of Swap Contracts for Subject Period:
	    	 $            

					
		 		  	 vi.
	    	 fees and expenses incurred in connection with the negotiation, execution and delivery on the Closing Date of the Loan Documents to the extent such fees and
expenses in the aggregate do not exceed $500,000 and were incurred on or prior to the Closing Date or within 60 days after the Closing Date:
	    	 $            

					
		 		  	 vii
	    	 A) fees and expenses incurred in connection with any Acquisition and Disposition permitted under the Credit Agreement, whether or not consummated, (B) fees
and expenses incurred in connection with severance costs, relocation costs, integration and facilities opening and closing costs, signing costs, retention or completion bonuses, transition costs and restructuring charges or reserves (including
restructuring costs related to Acquisitions after the date hereof and to closure and/or consolidation of facilities), and (C) fees, settlement costs and expenses paid in connection with ligation involving a Loan Party, including without limitation,
all reasonable out-of-pocket legal fees and expenses, to the extent all such fees, costs and expenses under clauses (A), (B) and (C) do not exceed 15% of Consolidated EBITDA in the aggregate for Subject Period:
	    	 $            

					
		 		  	 viii.
	    	 fees, costs, expenses, charges and losses incurred in connection with the Medtronic Litigation, including, without limitation, reasonable out-of-pocket legal
fees and expenses, provided that the aggregate amount added back pursuant to the Credit Agreement shall not exceed $85,000,000 in the aggregate
	    	 $            

 
  

	 14 
	 The descriptions of the calculations set forth in this certificate are sometimes abbreviated for simplicity, but are qualified in their entirety by
reference to the full text of the calculations provided in the Credit Agreement. 

									
					
		 		  	 ix.
	    	 fees and expenses related to the issuance of Equity Interests or Indebtedness or any other capital markets transactions, including the termination,
repurchase, redemption or refinancing of any of the foregoing for such Subject Period:
	    	 $            

					
		 		  	 x.
	    	 without duplication of any amounts included in calculating Acquired EBITDA, “run rate” synergies, operating expense reductions and other operating
improvements and cost savings in Acquisitions that are reasonably identifiable, factually supportable, expected to have a continuing impact on the operations of the Borrower and its Subsidiaries and certified by a Responsible Officer of the Borrower
as having been determined in good faith to be reasonably anticipated to be realizable within twelve (12) months following any such Acquisition, net of actual benefits realized; provided that the aggregate amount added back pursuant to this clause
(ix) shall not exceed 10% of Consolidated EBITDA in the aggregate for such Subject Period:
	    	 $            

					
		 		  	 xi.
	    	 proceeds of business interruption insurance actually received in cash during such Subject Period:
	    	 $            

					
		 		  	 xii.
	    	 charges, losses and expenses to the extent indemnified or insured or reimbursed by a third party to the extent such indemnification, insurance or
reimbursement is actually received in cash for such Subject Period:
	    	 $            

					
		 		  	 xiii.
	    	 non-cash charges and losses, including, without limitation, any non-cash loss or expense (or income or gain) due to the application of FASB ASC 815-10
regarding hedging activity, FASB ASC-350 regarding impairment of goodwill, FASB ASC 480-10 regarding accounting for financial instruments with debt and equity characteristics, non-cash foreign currency exchange losses (or minus gains), the
refinancing of convertible indebtedness and non-cash expenses deducted as a result of any grant of Equity Interests to employees, officers or directors (excluding any such non-cash charges or losses to the extent there were cash charges with respect
to such charges and losses in past accounting periods
	    	 $            

									
					
		 		  	 xiv.
	    	 to the extent reflected as a gain or otherwise included in the calculation of Consolidated Net Income (i) non-cash gains (excluding any such non-cash gains
to the extent (A) there were cash gains with respect to such gains in past accounting periods or (B) there is a reasonable expectation that there will be cash gains with respect to such gains in future accounting periods) or (ii) all cash charges
and losses incurred in such Subject Period to the extent that such charges and losses were included in the calculation of Consolidated EBITDA under clause (xiii) above in a prior Subject Period.
	    	 $            

					
		 		  	 xv.
	    	 Consolidated EBITDA (Lines I.A.i + ii + iii + iv + v + vi + vii + viii + ix + x + xi + xii + xiii -
xiv)[15]:
	    	 $            

				
		 	 B.
	  	 Consolidated Interest Charges for Subject Period[16]:
	    	 $            

				
		 	 C.
	  	 Consolidated Interest Coverage Ratio (Line I.A.xi ÷ Line I.B):
	    	              to 1.00

			
		 	 Minimum required:
	    	 3.00 to 1.00

			
	 II.     
	 	 Section 7.11(b) – Consolidated Leverage Ratio
	    	
				
		 	 A.
	  	 Consolidated Funded Indebtedness at Statement Date:
	    	 $            

				
		 	 B.
	  	 Consolidated EBITDA for Subject Period (Line I.A.xi above):
	    	 $            

				
		 	 C.
	  	 Consolidated Leverage Ratio (Line II.A ÷ Line II.B):
	    	              to 1.00

			
		 	 Maximum permitted:
	    	

  

			
	 Measurement Period Ending
	  	Maximum Consolidated
Leverage Ratio
	 Closing Date through December 31, 2016
	  	4.50:1.00
	 March 31, 2017 through September 30, 2017
	  	4.25:1.00
	 December 31, 2017 through September 30, 2018
	  	4.00:1.00
	 December 31, 2018 through September 30, 2019
	  	3.75:1.00
	 December 31, 2019 and each fiscal quarter thereafter
	  	3.50:1.00

  

	 15 
	 There shall be included in determining Consolidated EBITDA for any Measurement Period, without duplication, (i) the Acquired EBITDA of any Target
owned, directly or indirectly, by the Loan Parties for which the total consideration paid or payable (including without limitation, all transaction costs, assumed Indebtedness and liabilities incurred, assumed or reflected on a consolidated balance
sheet of the Loan Parties and their Subsidiaries after giving effect to such Acquisition and the maximum amount of all deferred payments, including earnouts but excluding any Equity Interests of the Borrower) was greater than or equal to $15,000,000
(each, a “Material Acquisition”) and for which the Administrative Agent has received financial statements pursuant to Section 6.01(b) for less than four (4) fiscal quarters, Acquired EBITDA allocated to each quarter prior to
the acquisition thereof included in the trailing four (4) fiscal quarter period for which Acquired EBITDA is being calculated minus (ii) with respect to any Material Disposition consummated within the Measurement Period, Consolidated EBITDA
(if any) attributable to the Subsidiary, profit centers or other asset which is the subject of such Material Disposition from the beginning of such period until the date of consummation of such Material Disposition. 

	 16 
	 For purposes of calculating Consolidated Interest Charges for any Measurement Period, (i) if during such Measurement Period the Loan Parties shall
have made a Material Acquisition, Consolidated Interest Charges for such Measurement Period shall be calculated to include an amount equal to the Consolidated Interest Charges accrued on any Indebtedness incurred in connection with such Material
Acquisition after giving pro forma effect thereto as if such Material Acquisition occurred on the first day of such Measurement Period, and (ii) if at any time during such Measurement Period the Loan Parties shall have made any Material Disposition,
the Consolidated Interest Charges for such Measurement Period shall be reduced by an amount equal to the Consolidated Interest Charges accrued during the relevant Measurement Period on any Indebtedness repaid or refinanced in connection with such
Material Disposition after giving pro forma effect thereto as if such Material Disposition occurred on the first day of such Measurement Period. 

 EXHIBIT D 

[Form of] 
 Joinder
Agreement 
 THIS JOINDER AGREEMENT (this “Agreement”), dated as of
[            ,         ], is by and among
[                    , a                     ]
(the “Subsidiary Guarantor”), NuVasive, Inc., a Delaware corporation (the “Borrower”), and Bank of America, N.A., in its capacity as administrative agent (in such capacity, the “Administrative
Agent”) under that certain Credit Agreement, dated as of February 8, 2016 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”), by and among the Borrower, the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and the Administrative Agent. Capitalized terms used herein but not otherwise defined shall have the meanings provided in the Credit Agreement. 

The Subsidiary Guarantor is an additional Loan Party, and, consequently, the Loan Parties are required by
Section 6.13 of the Credit Agreement to cause the Subsidiary Guarantor to become a “Guarantor” thereunder. 

Accordingly, the Subsidiary Guarantor and the Borrower hereby agree as follows with the Administrative Agent, for the benefit
of the Lenders: 
 1. The Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this
Agreement, the Subsidiary Guarantor will be deemed to be a party to and a “Guarantor” under the Credit Agreement and shall have all of the obligations of a Guarantor thereunder as if it had executed the Credit Agreement. The Subsidiary
Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the applicable Loan Documents, including, without limitation (a) all of the representations and warranties set
forth in Article V of the Credit Agreement and (b) all of the affirmative and negative covenants set forth in Articles VI and VII of the Credit Agreement. Without limiting the generality of the foregoing terms of this
Paragraph 1, the Subsidiary Guarantor hereby guarantees, jointly and severally together with the other Guarantors, the prompt payment of the Secured Obligations in accordance with Article X of the Credit Agreement. 

2. Each of the Subsidiary Guarantor and the Borrower hereby agree that all of the representations and warranties contained in
Article V of the Loan Agreement and each other Loan Document are true and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty shall
be true and correct in all respects) as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (except, if a
qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty shall be true and correct in all respects) as of such earlier date. 

3. The Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this Agreement, the Subsidiary
Guarantor will be deemed to be a party to the Security Agreement, and shall have all the rights and obligations of a “Grantor” (as such term is defined in the Security Agreement) thereunder as if it had executed the Security Agreement. The
Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Security Agreement. Without limiting the generality of the foregoing terms of this Paragraph 3,
the Subsidiary Guarantor hereby grants, pledges and assigns to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in, and a right of set off, to the extent applicable, against any and all right, title
and interest of the Subsidiary Guarantor in and to the Collateral (as such term is defined in Section 2 of the Security Agreement) of the Subsidiary Guarantor. 

 4. The Subsidiary Guarantor acknowledges and confirms that it has received a copy
of the Credit Agreement and the schedules and exhibits thereto and each Collateral Document and the schedules and exhibits thereto. The information on the schedules to the Credit Agreement and the Collateral Documents are hereby supplemented (to the
extent permitted under the Credit Agreement or Collateral Documents) to reflect the information shown on the attached Schedule A. 

5. The Borrower confirms that the Credit Agreement is, and upon the Subsidiary Guarantor becoming a Guarantor, shall continue
to be, in full force and effect. The parties hereto confirm and agree that immediately upon the Subsidiary Guarantor becoming a Guarantor the term “Obligations,” as used in the Credit Agreement, shall include all obligations of the
Subsidiary Guarantor under the Credit Agreement and under each other Loan Document. 
 6. Each of the Borrower and the
Subsidiary Guarantor agrees that at any time and from time to time, upon the written request of the Administrative Agent, it will execute and deliver such further documents and do such further acts as the Administrative Agent may reasonably request
in accordance with the terms and conditions of the Credit Agreement and the other Loan Documents in order to effect the purposes of this Agreement. 

7. This Agreement may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of
an executed counterpart of a signature page of this Agreement by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement.

 8. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York.
The terms of Sections 11.14 and 11.15 of the Credit Agreement are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms. 

IN WITNESS WHEREOF, each of the Borrower and the Subsidiary Guarantor has caused this Agreement to be duly executed by its
authorized officer, and the Administrative Agent, for the benefit of the Lenders, has caused the same to be accepted by its authorized officer, as of the day and year first above written. 

 

									
	 SUBSIDIARY GUARANTOR:
	 		 	 [SUBSIDIARY GUARANTOR]

					
		 		 		 	 By:
	 	  

		 		 		 	 Name:
	 	  

		 		 		 	 Title:
	 	  

			
	 BORROWER:
	 		 	 NUVASIVE, INC.,

a Delaware corporation

					
		 		 		 	 By:
	 	  

		 		 		 	 Name:
	 	  

		 		 		 	 Title:
	 	  

			
	 Acknowledged, accepted and agreed:

	
	 BANK OF AMERICA, N.A.,
as Administrative Agent

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 Schedule A 

Schedules to Credit Agreement and Collateral Documents 

[TO BE COMPLETED BY BORROWER] 

 EXHIBIT E 

[Form of] 
 Loan Notice

 Date: [            ,
        ] 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors party thereto from time to time, the Lenders party thereto from time to time and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 The undersigned
hereby requests (select one): 
  

							
	  ̈
	  	 A Borrowing of Revolving Loans

		
	  ̈
	  	 A [conversion] or [continuation] of Revolving Loans

		
	 1.
	  	 On                      (the
“Credit Extension Date”)

		
	 2.
	  	 In the amount of $             

				
	 3.
	  	 Comprised of:
	 	  ̈
	  	 Base Rate Loans

				
		  		 	  ̈
	  	 Eurocurrency Rate Loans

		
	 4.
	  	 For Eurocurrency Rate Loans: with an Interest Period of
                     months

 [The Revolving Borrowing requested herein complies with the proviso to the first sentence of
Section 2.02(a) of the Credit Agreement.]17 
 The Borrower hereby
represents and warrants that the conditions specified in Section [4.01 and][18] 4.02 of the Credit Agreement shall be satisfied on and as of the Credit Extension Date. 

[The Borrower anticipates that all conditions precedent to the effectiveness of the Credit Agreement will be satisfied on
the Closing Date. The Borrower wishes to borrow the initial Revolving Loans described herein as Eurocurrency Rate Loans (the “Effective Date Eurocurrency Rate Loans”). 

 
  

	 17 
	 Include this sentence in the case of a Revolving Borrowing. 

	 18 
	 To include for the initial funding on the Closing Date. 

 The Borrower acknowledges that (a) in order to accommodate the foregoing
request, the Lenders are making funding arrangements for value on the Credit Extension Date, (b) there can be no assurance that the Credit Agreement will become effective as of the Credit Extension Date, (c) the Lenders will not make such
Effective Date Eurocurrency Rate Loans unless the Credit Agreement has been fully executed and the requirements set forth in Article IV of the Credit Agreement are satisfied (the “Funding Requirements”), and (d) if the Funding
Requirements are not satisfied on or before the Credit Extension Date, the Lenders may sustain funding losses as a result of such failure to close on such date. 

In order to induce the Lenders to make the funding arrangements necessary to make the Effective Date Eurocurrency Rate
Loans on the Credit Extension Date, the Borrower agrees promptly upon demand to compensate each Lender and hold each Lender harmless from any loss, cost or expense (including the cost of counsel) which such Lender may incur (a) as a consequence
of any failure to (i) satisfy the Funding Requirements or (ii) borrow the Effective Date Eurocurrency Rate Loans on the Credit Extension Date from such Lender for any reason whatsoever (including the failure of the Credit Agreement to
become effective) or (b) in connection with the preparation, administration or enforcement of, or any dispute arising under, this Funding Indemnity Letter. For purposes of calculating amounts payable by the Borrower to any Lender under this
paragraph, the provisions of Section 3.05 of the Credit Agreement shall apply as if the Credit Agreement were in effect with respect to the Effective Date Eurocurrency Rate Loans (regardless of whether the Credit Agreement ever
becomes effective).][19] 
 Delivery of an executed
counterpart of a signature page of this notice by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this notice. 

 

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

  
  

	 19 
	 To include if initial funding on the Closing Date is a Eurocurrency Rate Loan. 

 EXHIBIT F 

[Form of] 
 Permitted
Acquisition Certificate 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Lenders and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used
herein and not otherwise defined shall have the meanings set forth in the Credit Agreement) 

  

	 DATE:
	 [Date] 

  

 
 [Loan Party] intends
to make an Acquisition of [                    ] (the “Target”). The undersigned Responsible Officer of [Loan Party], hereby
certifies that: 
 (a) The Acquisition is an acquisition of a type of business (or assets used in a type of
business) permitted to be engaged in by the Borrower and its Subsidiaries pursuant to the terms of the Credit Agreement. 

(b) no Default or Event of Default shall then exist or would exist after giving effect thereto. 

(c) After giving effect to the Acquisition on a Pro Forma Basis, the Loan Parties are in Pro Forma Compliance
with each of the financial covenants set forth in Section 7.11 of the Credit Agreement. 
 (d) The Loan
Parties [have complied/shall comply] with Sections 6.13 and 6.14 of the Credit Agreement, to the extent and within the time periods required to do so thereby. 

(e) Attached hereto as Schedule B is a description of the material terms of the Acquisition
(including a description of the business and the form of consideration). 
 (f) the Target shall have
Acquired EBITDA in an amount greater than $0, provided, however, that the Target may have an Acquired EBITDA that is $0 or less (each a “Negative EBITDA Target”) so long as (i) such Negative EBITDA Target’s
Acquired EBITDA is not less than negative $10,000,000 and (ii) the aggregate Acquired EBITDA for all Negative EBITDA Targets acquired shall not be less than negative $15,000,000; 

(g) The Acquisition is not a “hostile” acquisition and has been approved by the board of directors
(or equivalent) and/or shareholders (or equivalents) of the applicable Loan Party and the Target. 
 (h)
After giving effect to the Acquisition and any Borrowings made in connection therewith, the aggregate principal amount of Revolving Loans available to be borrowed under Section 2.01 of the Credit Agreement is at least $5,000,000. 

 (i) the Cost of Acquisition paid by the Loan Parties and their
Subsidiaries is less than or equal to 50% of Consolidated EBITDA and the total Cost of all Acquisitions made during the term of Credit Agreement is less than or equal to 125% of Consolidated EBITDA. 

Delivery of an executed counterpart of a signature page of this Certificate by fax transmission or other electronic mail
transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Certificate. 
  

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 Schedule A 

Financial Covenant Calculations 

[TO BE COMPLETED BY BORROWER] 

 Schedule B 

Description of Material Terms 

[TO BE COMPLETED BY BORROWER] 

 EXHIBIT G 

[Form of] 
 Note 

[            ,         ] 

FOR VALUE RECEIVED, the undersigned (the “Borrower”), hereby promises to pay to
[                    ] or its registered assigns (the “Lender”), in accordance with the provisions of the Credit Agreement (as
hereinafter defined), the principal amount of each Revolving Loan from time to time made by the Lender to the Borrower under that certain Credit Agreement, dated as of February 8, 2016 (as amended, restated, extended, supplemented or otherwise
modified in writing from time to time, the “Credit Agreement;” the terms defined therein being used herein as therein defined), among the Borrower, the Guarantors from time to time party thereto, the Lenders from time to time party
thereto, and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender. 
 The Borrower promises to
pay interest on the unpaid principal amount of each Revolving Loan from the date of such Revolving Loan until such principal amount is paid in full, at such interest rates and at such times as provided in the Credit Agreement. Except as otherwise
provided in Section 2.04(f) of the Credit Agreement with respect to Swingline Loans, all payments of principal and interest shall be made to the Administrative Agent for the account of the Lender in Dollars in immediately available funds at the
Administrative Agent’s Office. If any amount is not paid in full when due hereunder, such unpaid amount shall bear interest, to be paid upon demand, from the due date thereof until the date of actual payment (and before as well as after
judgment) computed at the per annum rate set forth in the Credit Agreement. 
 This Note is one of the Notes referred to in
the Credit Agreement, and the holder is entitled to the benefits thereof. Revolving Loans made by the Lender shall be evidenced by one or more loan accounts or records maintained by the Lender in the ordinary course of business. The Lender may also
attach schedules to this Note and endorse thereon the date, amount and maturity of its Revolving Loans and payments with respect thereto. 

The Borrower, for itself, its successors and assigns, hereby waives diligence, presentment, protest and demand and notice of
protest, demand, dishonor and non-payment of this Note. 
 Delivery of an executed counterpart of a signature page of this
Note by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Note. 

THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 

 

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 EXHIBIT H 

[Form of] 
 Secured Party
Designation Notice 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 [Name of Cash
Management Bank/Hedge Bank] (the “Secured Party”) hereby notifies you, pursuant to the terms of the Credit Agreement, that the Secured Party meets the requirements of a [Cash Management Bank] [Hedge Bank] under the terms of the
Credit Agreement and is a [Cash Management Bank] [Hedge Bank] under the Credit Agreement and the other Loan Documents. 

Delivery of an executed counterpart of a signature page of this notice by fax transmission or other electronic mail
transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this notice. 

A duly authorized officer of the undersigned has executed this notice as of the day and year set forth above. 

 

					
	  
	 	 ,

	 as a [Cash Management Bank] [Hedge Bank]
	 	
			
	 By:
	 	  
	 	
	 Name:
	 	  
	 	
	 Title:
	 	  
	 	

 EXHIBIT I 

[Form of] 
 Solvency
Certificate 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 The undersigned
Responsible Officer of the Borrower is familiar with the properties, businesses, assets and liabilities of the Loan Parties and is duly authorized to execute this certificate on behalf of the Borrower and the other Loan Parties. 

The undersigned certifies that [he/she] has made such investigation and inquiries as to the financial condition of the Loan
Parties and their Subsidiaries as the undersigned deems necessary and prudent for the purpose of providing this Certificate. The undersigned acknowledges that the Administrative Agent and the Lenders are relying on the truth and accuracy of this
Certificate in connection with the making of Credit Extensions and the other transactions contemplated under the Credit Agreement. 

The undersigned certifies that the financial information, projections and assumptions which underlie and form the basis for
the representations made in this Certificate were reasonable when made and were made in good faith and continue to be reasonable as of the date hereof. 

BASED ON THE FOREGOING, the undersigned certifies that, both before and after giving effect to the transactions contemplated
by the Credit Agreement: 
 (a) The fair value of the property of the Borrower and its Subsidiaries on a
Consolidated basis, is greater than the total amount of liabilities, including contingent liabilities, of the Borrower and its Subsidiaries on a Consolidated basis. 

(b) The present fair salable value of the assets of the Borrower and its Subsidiaries on a Consolidated basis,
is not less than the amount that will be required to pay the probable liability of the Borrower and its Subsidiaries on a Consolidated basis, on their debts as they become absolute and matured. 

(c) The Borrower and its Subsidiaries on a Consolidated basis, do not intend to, and do not believe that they
will, incur debts or liabilities beyond their ability to pay such debts and liabilities as they mature. 

 (d) The Borrower and its Subsidiaries on a Consolidated basis,
are not engaged in business or a transaction, and are not about to engage in business or a transaction, for which they have unreasonably small capital. 

(e) The Borrower and its Subsidiaries on a Consolidated basis, are able to pay their debts and liabilities,
contingent obligations and other commitments as they mature in the ordinary course of business. 
 (f) The
amount of contingent liabilities at any time have been computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured
liability. 
 Delivery of an executed counterpart of a signature page of this Certificate by fax transmission or other
electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Certificate. 

 

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 EXHIBIT J 

[Form of] 
 Swingline
Loan Notice 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent and Swingline Lender 

 

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 The undersigned
hereby requests a Swingline Loan: 
  

	 	 1.
	 On                      (the
“Credit Extension Date”) 

  

	 	 2.
	 In the amount of $        . 

The Swingline Borrowing requested herein complies with the requirements of the provisos contained in Section 2.04(a) of
the Credit Agreement. 
 The Borrower hereby represents and warrants that the conditions specified in Section 4.02
shall be satisfied on and as of the date of the Credit Extension Date. 
 Delivery of an executed counterpart of a signature
page of this notice by fax transmission or other electronic mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this notice. 

 

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 EXHIBIT L 

[Form of] 

Officer’s Certificate 

NUVASIVE, INC. 

                 , 20     

Reference is hereby made to that certain Credit Agreement, dated as of the date hereof (the “Credit
Agreement”) among NuVasive, Inc. (the “Borrower”), the other persons party thereto that are designated as loan parties (the “Loan Parties”), Bank of America, N.A., as administrative agent (in such capacity,
the “Administrative Agent”), Swingline Lender and L/C Issuer, and the various financial institutions from time to time party thereto as lenders (the “Lenders”). 

Unless otherwise defined herein, capitalized terms used herein shall have the meanings set forth in the Credit Agreement. 

The undersigned hereby certifies that he is a duly appointed or elected, qualified and serving Executive Vice President of the
Borrower and hereby certifies on behalf of the Borrower, in such capacity, and not individually, that: 
  

	 	 1)
	 No Default or Event of Default has occurred and is continuing as of the date hereof; 

 

	 	 2)
	 The representations and warranties of the Borrower and each other Loan Party contained in the Credit Agreement and the other Loan Documents are
true and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty shall be true and correct in all respects) on and as of the date hereof,
except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a
similar concept applies, such representation or warranty shall be true and correct in all respects) as of such earlier date; 

  

	 	 3)
	 No consents, licenses or approvals are required in connection with the execution, delivery and performance by each Loan Party and the validity
against each Loan Party of the Loan Documents to which it is a party; and 

  

	 	 4)
	 Since September 30, 2015, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably
be expected to have a Material Adverse Effect. 

 IN WITNESS WHEREOF, the undersigned has executed this Closing Certificate as of
the date first set forth above. 
  

			
	 NUVASIVE, INC.

	
	  

	 Name:
	 	
	 Title:
	 	

 EXHIBIT M-1 

[Form of] 
 U.S. Tax
Compliance Certificate 
 (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) 

Reference is hereby made to the Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the
“Borrower”), the Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated,
replaced, or supplemented from time to time, the “Credit Agreement”). Pursuant to the provisions of Section 3.01 of the Credit Agreement, the undersigned hereby certifies that (a) it is the sole record and beneficial owner
of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (b) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (c) it is not a ten percent shareholder
of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (d) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. 

The undersigned has furnished the Administrative Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN-E
(or W-8BEN, as applicable). By executing this certificate, the undersigned agrees that (a) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and
(b) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or
in either of the two calendar years preceding such payments. 
 Unless otherwise defined herein, terms defined in the Credit Agreement and
used herein shall have the meanings given to them in the Credit Agreement. 
 [NAME OF FOREIGN LENDER] 

 

			
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 Date:             , 20    

 EXHIBIT M-2 

[Form of] 
 U.S. Tax
Compliance Certificate 
 (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes) 

Reference is hereby made to the Credit Agreement, dated as of February 8, 2016 by and among NuVasive, Inc., a Delaware corporation (the
“Borrower”), the Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated,
replaced, or supplemented from time to time, the “Credit Agreement”). Pursuant to the provisions of Section 3.01 of the Credit Agreement, the undersigned hereby certifies that (a) it is the sole record and beneficial owner
of the participation in respect of which it is providing this certificate, (b) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (c) it is not a ten percent shareholder of the Borrower within the meaning of
Section 871(h)(3)(B) of the Code, and (d) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. 

The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN-E (or W-8BEN, as
applicable). By executing this certificate, the undersigned agrees that (a) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (b) the undersigned shall have at all
times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit
Agreement. 
  

			
	 [NAME OF PARTICIPANT]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 Date:             , 20    

 EXHIBIT M-3 

[Form of] 
 U.S. Tax
Compliance Certificate 
 (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes) 

Reference is hereby made to the Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the
“Borrower”), the Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated,
replaced, or supplemented from time to time, the “Credit Agreement”). Pursuant to the provisions of Section 3.01 of the Credit Agreement, the undersigned hereby certifies that (a) it is the sole record owner of the
participation in respect of which it is providing this certificate, (b) its direct or indirect partners/members are the sole beneficial owners of such participation, (c) with respect such participation, neither the undersigned nor any of
its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (d) none of its direct or
indirect partners/members is a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (e) none of its direct or indirect partners/members is a controlled foreign corporation related to the
Borrower as described in Section 881(c)(3)(C) of the Code. 
 The undersigned has furnished its participating Lender with IRS Form
W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (a) an IRS Form W-8BEN-E (or W-8BEN, as applicable) or (b) an IRS Form W-8IMY accompanied by an IRS Form
W-8BEN-E (or W-8BEN, as applicable) from each of such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (i) if the information provided
on this certificate changes, the undersigned shall promptly so inform such Lender and (ii) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year
in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. 
 Unless otherwise
defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. 
  

			
	 [NAME OF PARTICIPANT]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 Date:             , 20    

 EXHIBIT M-4 

[Form of] 
 U.S. Tax
Compliance Certificate 
 (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes) 

Reference is hereby made to the Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the
“Borrower”), the Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated,
replaced, or supplemented from time to time, the “Credit Agreement”). Pursuant to the provisions of Section 3.01 of the Credit Agreement, the undersigned hereby certifies that (a) it is the sole record owner of the Loan(s)
(as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (b) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any Note(s) evidencing such Loan(s)),
(c) with respect to the extension of credit pursuant to this Credit Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered
into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (d) none of its direct or indirect partners/members is a ten percent shareholder of the Borrower within the meaning of
Section 871(h)(3)(B) of the Code and (e) none of its direct or indirect partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code. 

The undersigned has furnished the Administrative Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from
each of its partners/members that is claiming the portfolio interest exemption: (a) an IRS Form W-8BEN-E (or W-8BEN, as applicable) or (b) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN-E (or W-8BEN, as applicable) from each of such
partner’s/member’s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (i) if the information provided on this certificate changes, the undersigned shall
promptly so inform the Borrower and the Administrative Agent, and (ii) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the
calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit
Agreement. 
  

			
	 [NAME OF LENDER]

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 Date:             , 20    

 EXHIBIT N 

[Form of] 
 Notice of
Loan Prepayment 
  

	 TO:
	 Bank of America, N.A., as Administrative Agent 

  

	 RE:
	 Credit Agreement, dated as of February 8, 2016, by and among NuVasive, Inc., a Delaware corporation (the “Borrower”), the
Guarantors from time to time party thereto, the Lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, L/C Issuer and Swingline Lender (as amended, modified, extended, restated, replaced, or supplemented from
time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement) 

 

	 DATE:
	 [Date] 

  

 
 This Notice of
Prepayment is delivered to you pursuant to Section 2.05 of the Credit Agreement. 
  

	 	 1.
	 The Borrower hereby provides notice to the Administrative Agent that shall prepay the Revolving Loans in the following amount(s):
                    . (Complete with an amount in accordance with Section 2.05 of the Credit Agreement.) 

 

	 	 2.
	 The Loan(s) to be prepaid consist of: 

  

	 	  ̈
	 a Revolving Loan 

  

	 	 3.
	 The Borrower shall repay the above-referenced Loan(s) on the following Business Day:
                    . 

Delivery of an executed counterpart of a signature page of this Certificate by fax transmission or other electronic mail
transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Certificate. 

IN WITNESS WHEREOF, the undersigned has executed this Notice of Prepayment as of the day and year first written above. 

 

			
	 NUVASIVE, INC.,

a Delaware corporation

		
	 By:
	 	  

	 Name:
	 	  

	 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]